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Abstract  iii 
 
Abstract 
 
The use of pre-organized macrocyclic scaffolds to achieve a precise alignment of 
functional elements has proven to be extremely useful over the years in the design of 
artificial receptors and ligands capable of mimicking the supramolecular events occurring 
in living organisms. The cyclic maltooligosaccharide (cyclodextrin, CD) nucleus is 
considered a privileged platform for these channels, as it combines biocompatibility, 
availability and a tubular symmetric framework with well-differentiated faces. CD-based 
architectures can additionally take advantage of their distinctive inclusion capabilities.  
Recently, CDs have found their way into the field of gene delivery, giving rise to a 
plethora of synthetic CD-containing carriers, such as CD-embedding or pendant 
polymers, polyrotaxanes, and CD-centered and coated dendrimers and dendripolymers.1 
Although many of these systems have proven to be efficient vectors,2 their essentially 
disperse nature handicaps both investigational studies and clinical applications. The 
development of monodisperse CD derivatives that are capable to self-organize in the 
presence of nucleic acids and deliver them into cells constitutes an interesting alternative 
that critically depends on the availability of efficient methods to systematically manipulate 
the CD topology in order to attain a precise control of the presentation and orientation of 
functional elements and, thereby, of their supramolecular capabilities. 
In this Ph.D. Thesis, a molecular-diversity-oriented approach has been exploited for 
the preparation of well-defined polycationic amphiphilic cyclodextrins (paCDs) as gene 
delivery systems. The synthetic strategy takes advantage of the differential reactivity of 
primary versus secondary hydroxyl groups on the CD torus to regioselectively decorate 
each rim with cationic and lipophilic tails, respectively. Both the charge density and the  
display and the nature of the hydrophobic domain can be finely tuned by using "click 
chemistry" methodologies, preserving the molecular homogeneity (and architectural 
symmetry), thereby providing an easy-to-use tool for tight control over the 
hydrophilic/hydrophobic balance.  
The monodisperse nature of paCDs and the modularity of the synthetic scheme are 
particularly well suited to correlate molecular structure with self-assembling and gene 
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delivery capabilities in the way that structure-activity relationship (SAR) studies are 
carried out in typical medicinal chemistry programs. Their self-assembling capabilities in 
aqueous environment have been investigated and a progressive decrease of the critical 
aggregation concentration (CAC) with increasing amphiphilicity of the CD conjugates was 
observed. Acid-base titration experiments revealed that in comparison to their non-
amphiphilic analogs amphiphilic CD derivatives showed improved buffering capacities in 
the pH range from 7 to 5. This indicates that paCD-based nanoparticles may exhibit 
proton sponge capabilities upon acidification, which might help to promote endosomal 
escape after cell internalization. Gel electrophoresis and fluorescence quenching assays 
evidenced that paCDs self-assemble in the presence of calf thymus DNA (ctDNA) to 
provide stable nanoparticles (CDplexes) that fully protect nucleic acids from the 
environment. As characterized by DLS measurements, paCDs formed narrow 
populations of compact and ordered nanoparticles with ctDNA, exhibiting small 
hydrodynamic diameters (60-90 nm) and positive zeta (ζ) potentials (40-50 mV). 
Fluorescence tracking of CDplex dissociation promoted by heparin showed that CDplex 
dissociation kinetics is drastically influenced by the hydrophilic/hydrophobic balance. 
Furthermore, the transfection efficiency of the CDplexes was investigated in vitro on 
COS-7 cells in serum-containing medium and was found to be intimately dependent on 
architectural features. 
In the following chapter of this Ph.D. Thesis, the focus has been moved to the 
assessment of the gene delivery potential of paCDs decorated with cyclic oligoamines as 
alternative polar headgroups. In particular, the goal consisted on exploiting cationic 
preorganized scaffolds such as cyclen and cyclam, which exhibit unique DNA-binding 
capabilities. 
With the purpose of rationalizing the role of the cationic element in gene delivery, their 
structure-activity relationships were investigated and compared to acyclic oligoamine-
grafted paCDs. The self-assembling capabilities of cyclen/cyclam-bearing paCDs 
resembled those of paCDs with acyclic polycationic elements and lipophilic tails of the 
same length. Cyclen/cyclam-grafted paCDs exhibited improved pH buffering abilities in 
the range from 7 to 5. Gel electrophoresis shift assays evidenced that paCDs furnished 
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with cyclic polyamines self-assemble in the presence of calf thymus DNA (ctDNA) to 
provide stable nanoparticles (CDplexes) that fully protect ctDNA from the environment. 
Hydrodynamic diameter and zeta (ζ) potential measurements indicated that modifications 
of the molecular structure did influence neither particle size (80-100 nm) nor surface 
charge (40-60mV) significantly. Moreover, the transfection efficiency of the CDplexes 
derived from paCDs decorated with cyclic oligoamines was investigated in vitro on COS-7 
and HeLa cells, both in the absence and in presence of serum and was found to be 
similar to that of CDplexes formulated with paCDs bearing acyclic cationic headgroups. 
The above chapters demonstrate that fine-tuning of CD topology holds a great 
potential to manipulate supramolecular capabilities, including nucleic acid delivery. 
Unfortunately, the actual toolbox for selective CD modification is still limited. The final 
chapter of this Ph.D. Thesis has been devoted to the development of a conceptually 
novel approach to the selective functionalization of cyclodextrins. This novel strategy 
exploits a solid matrix to display the complementary reagent functionalities sufficiently far 
from each other to prevent a single CD species from reacting through more than one site. 
Using a "catch-and-release" process based on the Staudinger reaction, complex CD 
functionalization patterns could be produced in one pot and without any purification step. 
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1. The Gene Therapy Paradigm 
It is hardly conceivable for the pharmaceutical industry nowadays, investing a vast 
amount of resources on high-throughput drug discovery technologies, that the strategy to 
bring up new drugs could simply rely on the design based on a rational set of rules of a 
single candidate programmed to develop the required task. This is precisely what made 
nucleic acids (genes, oligonucleotides, aptamers, ribozymes, DNAzymes, or small 
interfering RNAs) an attractive source of therapeutic agents. The intimate structure-
activity relationship and their highly specific mode of action theoretically permit, when 
using appropriate designs, to exploit cellular machinery in a predictable fashion to either 
stimulate or silence the expression of virtually any protein, with reduced potential for 
toxicity and fewer side effects; the Holy Grail of medicinal chemistry. These issues are the 
foundation of Gene Therapy’s high prospects to develop an alternative therapeutic 
modality to traditional chemotherapy. 
The potential use of genes as therapeutic agents has attracted attention as a novel 
approach to the treatment of severe diseases. In the case of inherited disorders, the 
introduction of a normal copy of the affected gene can effectively restore healthy cell 
functioning. For the treatment of acquired disorders, such as cancer and infectious 
diseases, effective potential strategies involve not only the introduction of a therapeutic 
gene, such as the gene for a cytokine or an antigen, but also the silencing of the 
expression of an abnormal gene, whose expression is enhanced in the diseased tissue or 
cells. 
Although its underlying concepts date back to the 1960s, gene therapy is a relatively 
young field in modern molecular medicine. The first gene transfer clinical trial dates back 
from 1989, consisting on the transfer of a drug resistance gene marker to a patient’s 
lymphocytes.3 This and other early trials, which utilized early generation retroviral vectors, 
provided evidence of safe in vivo gene transfer for potential therapeutic benefit.4 In the 
2000, an experimental gene therapy treatment was put forward against combined severe 
immunodeficiency (SCID).5 More recently, gene therapy has also been satisfactorily 
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applied to β-thalassemia, an inherited autosomal recessive blood disorder.6 In parallel, a 
growing number of clinical trials have been conducted over the last 20 years or are under 
progress, targeting a range of maladies (Figure 1).7 However, these trials have also 
highlighted the need for progress on many fronts, including deeper molecular knowledge 
of disease target pathologies, the development of enhanced therapeutic cargoes, further 
insights into gene delivery mechanisms, engineering of safer carriers, and the 
improvement of vector manipulation processes. Initial over-optimism had to face many 
disappointing roadblocks and safety concerns, including the death of a trial volunteer 
from carrier-associated toxicity8 or several cases of leukemia in children receiving gene 
therapy treatment against SCID for replacing the interleukin-2 receptor γ chain gene.9 
 
 
Figure 1. Gene therapy clinical trials approved worldwide 1989-2012 (left) and the indications 
addressed (right).7 
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The effort developed in the last decades to facilitate manipulation and engineering of 
oligonucleotides, together with the identification and understanding of the genetic 
grounds of a plethora of maladies, transformed the initial concepts into a potentially 
useful technology to develop novel therapeutic alternatives to known diseases. Indeed, 
there already exist a number of therapeutic agents based on different types of nucleic 
acids, which can be roughly divided into protein-coding sequences (e.g. plasmid DNA)10 
and non-coding agents (e.g. oligonucleotides,11 ribozymes,12,13 interfering RNAs,14 or 
aptamers, Table 1).15 Several examples of each category are undergoing clinical trials16 
for the treatment of a range of diseases, including cancer, HIV, and cardiac or 
neurological disorders (e.g. Parkinson and Alzheimer diseases).17 
 
Table 1. Types of therapeutic nucleic acids. 
Protein-coding 
DNA sequences 
Proteins substituting missing or mutated cellular proteins 
Proteins modulating cellular functions 
Secreted growth factors and cytokines 
Proteins regulating cell survival and apoptosis 
Antigens for vaccinations 
Antibodies and intracellular antibodies 
T-cell receptor (TCR) subunits 
Non-coding 
nucleic acids 
Oligonucleotides and 
modified oligonucleotides 
Phosphorothioate 
oligonucleotides 
2’-Ribose modified 
oligonucleotides 
Locked nucleic acids (LNA) and 
ethylene-bridged nucleic acids 
(ENA) 
Morpholinos (PMO) 
Peptide nucleic acids (PNA) 
Catalytic RNAs and DNAs Ribozymes and DNAzymes 
Small regulatory RNAs siRNAs and shRNAs, microRNAs 
Long antisense RNAs 
Decoys 
Aptamers 
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Conventional drugs consist of a formulation of a bioactive species and a carrier, 
accounting the former for most of the sophistication of the design. However, in the case 
of biomolecular drugs such as nucleic acids, the role of the carrier becomes decisive in 
enabling the load to overcome the physiological barriers and reach its target in a fully 
functional form to carry out its designed therapeutic function. This issue was soon 
recognized and still remains a challenge 25 years later. Although naked oligonucleotides 
have been shown to transfect cells both in vitro and in vivo,18 their transfection efficiency 
is generally low because of their limited bioavailability. Nucleic acids are easily degraded 
by nucleases in biological fluids19 and their membrane-crossing abilities and cellular 
uptake are seriously limited by their inherently large size and charge (Figure 2).20 These 
hurdles, evolved over millions of years, are exploited by most organisms to preserve the 
integrity of their genetic material from external contaminations and constitute the major 
impairment for the clinical success of gene therapy. 
 
 
Figure 2. Schematic representation of pharmacokinetic limitations of nucleic acid-based therapeutic 
agents. 
 
The myriad of technologies and strategies envisioned to improve the (therapeutic) 
bioavailability of nucleic acid illustrates the complications behind this challenge. Nucleic 
acid delivery is a multistep process and inefficiencies at any stage result in a dramatic 
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decrease in the pretended effects. Difficulties associated to intracellular delivery of 
nucleic acids are manifold, starting at cell membrane crossing, but also include 
distribution to the proper subcellular compartment and timely release of the cargo. In the 
case of DNA, an additional translocation into the nucleus is necessary, while siRNA, for 
instance, must be targeted to the RNA-induced silencing complex (RISC) elsewhere in 
the cytoplasm. Moreover, systemic delivery encounters additional hurdles, for example 
the unspecific interaction of nucleic acid carriers with biological milieu (e.g. blood 
components), uptake by the reticuloendothelial system or kidney filtration, and 
management of the targeting ability and the off-target toxicity.21 
A major problem associated to extracellular gene delivery is the strong interaction of 
carriers with serum proteins, which leads to structural reorganization, aggregation, and/or 
dissociation of the carrier-nucleic acid assemblies, thereby dramatically lowering the 
transfection efficiency.22 In addition, the presence of nuclease in the serum can also 
degrade nucleic acids if not conveniently protected by the carrier, resulting in a loss of 
biological activity.23 
Cellular uptake of the carrier-nucleic acid assemblies is also major hurdle for gene 
therapy (Figure 3). Internalization of macromolecular entities or their aggregates does not 
occur passively, but exploiting cellular endocytic mechanisms.24 The ability of the carriers 
to associate cell membrane and promote its uptake remarkably determines the efficacy of 
the transfection process. Moreover, timely escape from the internalized endosome to 
release the nucleic acid payload at the right intracellular spot is also crucial of the 
efficiency of the whole process. Unfortunately, attempting to overcome these hurdles 
individually is a delicate effort (often futile), since carrier manipulation usually affects 
several of their features simultaneously. 
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Figure 3. Schematic representation of the hurdles to gene transfer into cells. 
 
Technological and strategic alternatives envisioned to overcome these hurdles are 
overwhelming. The advent of nanotechnologies and the increasing knowledge of the 
molecular basis of many diseases and how they are connected to gene or protein 
dysfunctions has attracted an unparalleled interest from the most varied fields. 
Unfortunately, given the cumbersome size of the challenge, as consensus solution is far 
from being reached. The main alternatives for nucleic acid delivery are succinctly 
overviewed in the following paragraphs. 
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2. Viral vs. Non-viral Gene Carriers 
The simplest way of gene delivery consists on direct treatment of the target with naked 
nucleic acids, but due to their low bioavailability, a number of techniques have been 
developed. These can be roughly classified into two main groups: physical methods and 
carrier-assisted ones. The formers exploit mechanical or electric stimuli to promote 
uptake of the therapeutic nucleic acid into the target cell or tissue. Physical methods 
include microinjection,25 bio-ballistic transfection (gene gun),26 electroporation,27 
ultrasounds, or pressure gradients,28 among others (Figure 4).29 Evidently, the nature of 
most of these techniques makes them quite unsound for in vivo application, though they 
have demonstrated certain success ex vivo.30 
 
 
Figure 4. Physical methods used in gene therapy. 
 
 
2.1. Viral-based gene carriers 
 
Vector-assisted techniques, conversely, aim at mimicking the capabilities of natural 
viruses to transport nucleic acids into different targets. A successful vector should (a) 
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provide nucleic acid protection, (b) enable cellular uptake of its payload and delivery to its 
subcellular target, and (c) promote its biological action (e.g. gene transcription). Along 
millions of years, viruses have evolved the most fascinating mechanisms to fulfill these 
tasks and their capabilities were immediately recognized at the nascence of the gene 
therapy paradigm. Indeed, it is not surprising the recombinant viruses (devoid of 
replicating capabilities) were the first nucleic acid carrier candidates investigated to 
deliver nucleic acids at the right spot.31,32 Unfortunately, engineering of non-replicating 
viruses still is nowadays an unmet challenge. Only relatively simple viruses such as 
retroviruses,33 adenoviruses,34 adeno-associated viruses (AAV),35 the poxvirus,36 the 
vaccinia virus,37 or the simplex herpes38 can be reliably modified (Figure 5). 
 
 
Figure 5. Some viral vectors used in gene therapy. 
 
Despite therapeutically relevant levels of gene expression have been achieved in 
different organs such as kidney,39 ovary,40 eye,41 and muscle tissues,42 and over 70% of 
ongoing gene therapy clinical trials (approximately 1500, Figure 6) are assessing the 
performance of viral vectors, serious risks and limitations still exist concerning the broad 
applicability.43 On one hand, viral vectors are potentially capable of recombining with 
replication-competent viruses. On the other, they can also induce immunogenic or 
inflammatory response, or eventually, undesired insertion on the host genome.43,44 
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Moreover, large scale manufacturing of even the simplest viral carriers still is far from 
obvious. In fact, due to these drawbacks, only one viral-vector-based gene therapy 
treatment has received so far the green light from the European Medicines Agency 
(EMA): Glybera® (UniQure), an AAV vector encoding the human lipoprotein lipase gene 
indicated for the treatment of lipoprotein lipase deficiency (LPLD), a very rare inherited 
condition that is associated with pancreatic inflammation.45 The FDA has not approved 
any formulation yet. The more relaxed Chinese authorities granted Shenzhen 
SiBionoGenTech the use of Gendicine, a modified adenovirus vector encoding the p53 
tumor suppressor gene for treating head and neck cancer in 2003.46 Two years later, 
Sunway Biotech gained approval in China for H101, a recombinant oncolytic adenovirus 
that targets p53-deficient tumor cells.47 Western authorities questioned both decisions 
due to a lack of available information on the two therapies.48 
 
 
Figure 6. Vectors used in gene therapy clinical trials.7 
 
Very recently, Naldini and co-workers published the results of two clinical trials using 
lentiviral vectors for stem cell gene therapy in patients with Wiskott-Aldrich Syndrome,49 
an inherited disease that disables the immune system, and a methachromatic 
leukodystrophy,50 a metabolic disease. Three years after the start of the clinical trials, 
disease progression stopped in all six patients and some of them showed no symptoms 
for 18 to 32 month following the therapy.51 Even after fairly long-term follow up, the 
Adenovirus 23.2% (n = 453)
Retrovirus 19.4% (n = 378)
Naked/Plasmid DNA 18% (n = 351)
Vaccinia virus 7.8% (n = 152)
Lipofection 5.7% (n = 112)
Adeno-associated virus 5.1% (n = 99)
Poxvirus 4.9% (n = 95)
Lentivirus 3.2% (n = 62)
Herpes simplex virus 3.1% (n = 60)
Other categories 6.3% (n = 123)
Unknown 3.3% (n = 64)
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therapy appears to be safe and effective, as the risk of the corrected gene inserting itself 
next to the cancer-activating one could be reduced.52 
However, despite the progress achieved in the treatment of challenging diseases such 
as muscular dystrophy,42 HIV,53 or cancer,54 (two thirds of investigational gene therapies 
are focused at cancer treatment), gene therapy is immature and clinical success is still 
distant. 
 
 
2.2. Non-viral gene carriers 
 
Alternatively, non-viral-based vectors have gathered momentum. In the era of 
nanotechnologies, synthetic materials can be designed and constructed using bottom-up 
approaches to tailor the desired functional features in terms of bioavailability and 
biocompatibility, nucleic acid complexation, protecting and packing capabilities, or 
membrane-crossing and targeting abilities. 
As the understanding of the self-assembling processes involved in aggregate 
formation between nucleic acids and synthetic vectors increases, the range of designed 
biomaterials for this purpose open wider (literally hundreds).55,56 Most of these non-viral 
nucleic acid vectors fall within the category of cationic lipids57 or polymers58 (Figure 7 and 
Figure 8, respectively), featuring functional groups that electrostatically neutralize nucleic 
acids and cooperatively promote compaction into colloidal nanoparticles (termed lipo- and 
polyplexes, respectively) with increased metabolic stability and membrane permeability. 
Nanoparticle stability and transfection efficiency largely depend on the structural features 
of the cationic vector, the type of nucleic acid to be delivered and the relative formulation 
ratio. 
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Figure 7. Illustrative examples of cationic lipids used as non-viral vectors. 
 
Non-viral vectors are, in principle, less prone to elicit the immune system response. 
Moreover, they are more flexible than viral particles regarding the type and size of the 
payload and far easier to produce. However, they still may trigger inflammatory response 
and their delivery efficiency and selectivity, despite few exceptions,2 are far from that of 
their viral counterparts. This is not surprising considering that most of the first generation 
non-viral candidates were not purposely conceived for such task, but just off-the-shelf 
materials, such as poly-L-lysine (PLL) or polyethylenenimine (PEI), for which gene 
delivery capabilities were incidentally discovered. Their densely charged nature does not 
usually furnish them with the optimal biocompatibility and cytotoxicity profiles.59 
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Figure 8. Illustrative examples of cationic polymers used as non-viral vectors. 
 
In the last decade, the efforts in field have been focused on furnishing these off-the-
self non-viral carriers with the functional elements that viruses exploit to overcome the 
physiological barriers to improve their inherently poor efficiency. That is, elaborating 
artificial viruses (Figure 9).58b,60 Either covalent or supramolecular chemical manipulation 
of these carriers has been implemented to interfere in and improve their performance in 
several folds:61 
• improving nucleic acid condensation and protection in the extracellular milieu,62 
• enhancing cellular uptake by specific mechanisms by, for instance, grafting cell 
surface receptor complementary ligands,63 
• promoting endosome release by including membrane destabilizing agents64 or 
pH-sensitive architectures,65 
• exploiting intracellular active transport machineries to selectively move through 
the cytoplasm,66 
• targeting nuclear membrane pores by using nuclear localization antennae,67 
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• or improving biocompatibility and bioavailability (eventually also biodegradability) 
in order to prevent interferences with the immune system or undesired unspecific 
interactions in the biological milieu68 by, for instance, shielding carriers with 
polyethylene glycol (PEG) chains.69,70 
 
 
Figure 9. Schematic representation of the components of an artificial virus for nucleic acid delivery. 
 
Cationic lipids are amphiphilic molecules consisting on a charged head group linked to 
a hydrophobic domain that self-assemble in aqueous media in the presence of nucleic 
acids into more or less defined liposomes. Their use in non-viral gene delivery dates back 
from 1987, when Felgner described an improvement of two orders of magnitude in gene 
expression efficiency by using DOTMA (Figure 7) as compared to other non-viral 
carriers.71 This milestone inspired a number of contributions focused on assessing 
structure-activity relationships (SAR).72 Nucleic acid condensation by cationic lipids is 
supposed to be a two-step process initiated by an initial electrostatic interaction between 
cationic heads and the anionic polyphosphate backbone. Then, entropy-driven 
desolvation by clustering of the hydrophobic domains produces aggregate compaction. It 
has been suggested that, once internalized into cells, cationic lipids in lipoplexes interact 
with anionic lipids of the endosome, causing destabilization of the endosomal membrane 
(Figure 10).73 
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Figure 10. Illustration of the proposed mechanism for endosomal escape of cationic lipids.74 
 
The length of the lipophilic tail(s), nature of the cationic head group (size and charge), 
the linker between both domains, or their susceptibility to changes in the biological media 
have been shown to exert major roles in their performance.75 Several generations of 
cationic lipids have evolved improving the performance of the formers. For instance, N-[1-
(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate (DOTAP, Figure 7) has 
been successfully applied to correct lung endothelial dysfunction via antisense 
oligodeoxynucleotide delivery in mice.76 Huang have shown that the use of cholesterol-
based cationic lipids feature reduced toxicity, allowing them to be the first cationic lipids 
entering clinical trials in humans.77 The well-defined molecular structure of cationic lipids 
has allowed the rational fine-tuning of their self-assembling capabilities. As an illustrative 
case, Behr combined the enhanced nucleotide binding ability of polyamines within the 
cationic lipid framework in dioctadecylamido-glycylspermine (DOGS, Figure 7).78 The 
improved gene transfer capability of DOGS was attributed to the enhanced DNA 
compaction and protection achieved by multipoint cationic lipid-nucleic acid interaction.79 
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Figure 11. Example of a neutral lipopolythiourea described by Herscovici and Leblond.80 
 
 
Figure 12. Structure of some lipidic aminoglycoside derivatives (dioleylsuccinyl kanamycin A, 
DOSK, and dioleylsuccinylparomomycin, DOSP) and a representative Cryo-TEM micrograph of 
their siRNA complexes (Reproduced from ref. 81b). 
 
Other synthetic alternatives have been reported to modulate cationic lipid-nucleic acid 
condensation. For instance, though the vector-nucleic acid interaction in lipoplexes is 
essentially electrostatic, recently Herscovici and Leblond80 have shown that neutral 
lipopolythioureas (Figure 11) may promote DNA condensation and compaction by 
cooperative phosphate-thiourea H-bonding and hydrophobic clustering. Probably due to 
their neutral character, these series of carriers exhibit remarkably low toxicity, though 
their gene transfer efficiency is comparatively lower than that reported for structurally 
related cationic lipids.81 The diversity of cationic lipids architecture has been further 
extended exploiting nucleic acid binding epitopes such as complementary 
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oligonucleotides,82 peptides83 or carbohydrates.81a As illustrative example, Pitard and co-
workers have designed a series of cationic lipids inspired in the structure of RNA-binding 
aminoglycosides (Figure 12), their lipoplexes exhibiting enhanced colloidal stability as 
compared with conventional cationic lipids. Remarkably, lipoplex particle features and 
performance could be related to lipid aminoglycoside structure and siRNA binding 
capabilities, finely illustrating the potential of rational design in nucleic acid delivery.81b 
In a seminal contribution, Zuber and Behr designed a novel family of environmental 
sensitive non-viral vectors consisting undimerizable cationic lipids programmed to protect 
more efficiently the nucleic acid payload in the extracellular milieu while facilitating 
intracellular release (Figure 13). Once formulated with DNA, their thiolated lipids undergo 
air-mediated oxidation producing more stable lipoplexes. In the glutathione-rich 
intracellular environment, disulfide tethers are reduced, facilitating plasmid release.84 
 
 
Figure 13. Dimerizable polycationic lipids reported by Zuber and co-workers.84 
 
Cationic polymers, conversely, have been around much longer. Their nucleic acid 
binding capabilities were already noticed in the 70s’,85 but it was not until Behr reported 
the outstanding gene carrier features polyethyleneimine (PEI, Figure 8)86 that their 
development was initiated. Upon formulation with nucleic acids, cationic polymers form 
positively charged complexes (polyplexes) by purely electrostatic interactions. Cationic 
18 Ph.D. Thesis - Iris Pflueger 
 
 
polymers are more easily manipulated as compared to cationic lipids, though their 
inherently polydisperse nature has consistently limited the thorough assessment of their 
SAR. They are generally regarded as more effective than cationic lipids, though their 
heavy charged structures are usually linked to higher cytotoxicity.87 
Among a continuously growing catalog,55 poly-L-lysine (PLL, Figure 8) was the first 
cationic polymer evaluated as non-viral gene carrier.88 Despite its high DNA-binding 
avidity and excellent cellular uptake efficiency of the corresponding polyplexes, 
expression efficiency is limited due to the poor endosomal escaping capabilities.89 
Conversely, high molecular weight poly[2-(dimethylamino)ethyl methacrylate] 
(pDMAEMA, Figure 8) has shown excellent in vitro gene transfer capabilities,90 probably 
associated to more efficient endosome escaping mechanisms, though in vivo 
performance resulted poor.91 
 
 
Figure 14. Illustration of the proposed mechanism for endosomal escape of cationic polymers by 
virtue of the proton sponge effect.74 
 
Behr’s PEI has considerably eclipsed the success achieved with other polymers.86 
Though the precise mechanism leading to this unparalleled efficiency still is a matter of 
debate, it is widely accepted that the PEI backbone should impart buffering capacity to 
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the polyplexes in the pH range between cytosolic (ca. 7.5) and endosomal (5.5) values. 
Upon endosome acidification, there is a significant increase of protonated amino groups 
in PEI. Such “proton sponge” effect65 leads to endosome swelling and polyplex 
destabilization, thereby facilitating nucleic acid release (Figure 14). Its inherent efficacy 
as gene carrier, together with its architectural flexibility, allowing for a precise control of 
polymer size and dispersity and easiness for chemically introducing additional 
functionalities has pushed the commercialization of investigational vectors such as JetPEI 
or ExGen500. 
A great deal of effort has been devoted to ameliorate its intrinsic toxicity by combining 
PEI and other cationic polymers with biocompatible elements (e.g. shielding from 
undesired interactions), while preserving its nucleic acid carrier capabilities. Evidently, the 
production, characterization and screening of each subtle structural modification is a 
limitation, but high throughput tools to speed up SAR analysis are being developed for 
both cationic lipids92 and polymers.93 Grafting polyethylene glycol chains94 or 
cholesterol,95 together with quaternarization of amino groups,96 are among the most 
investigated PEI modifications.55,94,97 
Biocompatibility and, eventually, biodegradability are precisely at the grounds of the 
incorporation of carbohydrates as constitutive elements in these and other type of 
cationic polymers, a topic that is discussed in the following section. 
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3. Glycotransporters in Gene Delivery 
As above mentioned, most efforts in non-viral carrier development aimed at 
overcoming the physiological barriers to gene delivery while minimizing off-target 
interaction.60b,98 Carbohydrates have proven particularly useful towards these goals. 
Similarly to PEG coating (pegylation),70 glycocoating can sterically shield the positively 
charged surface of colloidal aggregates by improving solvation, thus preventing from non-
specific interactions with intra- and extracellular components. Glycoconjugates can also 
be specifically recognized by cell membrane receptors and intracellular trafficking 
machineries, whose expression depends not only in cell type but also in cell 
developmental state.99,100 Nature already offers many examples illustrating the potential 
of carbohydrate polymers as non-viral nucleic acid vectors, chitosan (Figure 15) being 
probably the most exhaustively investigated,101 though many others have also 
demonstrated remarkable features themselves or after chemical manipulation.102,103 
 
 
Figure 15. Naturally occurring carbohydrate polymers used as gene carriers. 
 
Non-viral gene delivery has benefited from the large structural and functional diversity 
of carbohydrates, offering broad opportunities to interfere and manipulate gene transfer 
capabilities of first generation non-viral vectors. Moreover, the inherent flexibility of 
carbohydrate and glycoconjugate chemistry has enlarged the range of functional 
materials that can be conceived. Systematic studies on SAR of such synthetic materials 
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have shed light on the impact that carrier composition, hydrophobic/hydrophilic balance 
or charge and functional group distribution exert on nucleic acid transfer ability. This 
section will highlight the trending topics on the exploitation of the structural and functional 
features of carbohydrates in the design of non-viral gene delivery systems, focusing on 
two separate aspects: i) the effect of glycosylation in the performance of first generation 
non-viral gene vectors, and ii) the de novo design of carbohydrate-based cationic 
polymers as a tool to tailor nucleic acid shuttling capabilities. In a following section, the 
design of molecularly well-defined conjugates using pre-organized carbohydrate-based 
scaffolds (cyclodextrins, CDs) will be discussed as a mean to correlate molecular 
structure with gene transfer capabilities. 
 
 
3.1. Carbohydrate-grafted cationic polymers and lipids 
 
Despite their investigational utility, the functional features of most of first generation 
non-viral vectors resulted suboptimal. Cationic polymers, while structurally diverse (e.g. 
PEI, pDMAEMA, PLL, or dendrimers; see Figure 8), are usually restrained in terms of 
precise structural modification. The polymer molecular weight, dispersity or branching 
degree are known to determine their physicochemical properties and thereby, delivery 
efficiency or toxicity profiles.90b,104 Improved polymerization technologies have rendered 
low polydisperse materials,105 but finely tuning these parameters is very rarely sufficient 
to achieve clinically useful performances.106 The situation with cationic lipids does not 
significantly differ. Decoration of these scaffolds with functional epitopes, such as 
carbohydrates, however, offers excellent opportunities to manipulate a number of 
features, including their nucleic acid condensation capability, biocompatibility, or extra- 
and intracellular trafficking of the carrier. The utility of this approach is demonstrated by 
the large array of glycosylated non-viral carriers reported to date and the diversity of 
synthetic strategies to prepare them.107 
It has been shown that cationic polymer glycosylation may serve to modulate nucleic 
acid condensation and packing. For instance, Aigner and co-workers108 have recently 
observed that covalent grafting of maltose onto PEI alter pDNA and siRNA condensation 
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thermodynamics and nanoparticle stability, consequently affecting a number of other 
features of the aggregates. On the other hand, Strand and co-workers have found that 
the kinetics of DNA complexation and release can be modulated re-engineering the 
glycosyl residues decorating chitosan backbone.109 Interestingly, glycomodulation of 
nucleic acid-carrier interaction is not limited to cationic polymers. As above commented, 
Pitard and co-workers observed an enhanced colloidal stability of aminoglycoside-based 
cationic lipids (Figure 12) as compared with conventional ones. Remarkably, lipoplex 
particle features and performance could be related to lipid aminoglycoside structure and 
siRNA binding capabilities, finely illustrating the potential of rational design in nucleic acid 
delivery.81 
Structural modification of a gene carrier does not only affect a single property, but 
simultaneously several features. Ascertain the precise effect of each structural change is, 
thus, complicated. For instance, oligomaltosylation of PEI did not only affect nucleic acid 
binding dynamics, but also  render complexes that are largely unaffected by the presence 
of serum proteins, are far less toxic, and exploit  different cell uptake mechanisms as 
compared to naked PEI.108 A number of other polymeric scaffolds have been glycocoated 
in order to modulate their biocompatibility and bioavailability with gene delivery purposes. 
Carbon nanotubes,110 gold nanoparticles,111 quantum dots,112 or (pseudo)rotaxanes113 are 
some relevant examples that further provide peculiar functionalities to the gene carrier. 
From the chronological point of view, carbohydrate specific recognition by biological 
receptors first attracted the attention. In fact, the first ever-reported evidence of specific 
non-viral gene delivery used a galactose-terminated PLL carrier targeted to the 
asialoglycoprotein receptors (ASGPr) on hepatocyte cell membrane.114 The topic has 
received a sustained interest ever since. Galactose (or lactose) and mannose have been 
mostly exploited as glycoligands due to their hepatic and immune system cell targeting 
abilities, respectively. But also glucosamine, targeting vimentin,115 and galactosamine116 
have been recently used. Glycotargeted versions of the most usual cationic polymers 
(including PEI,117 PLL,118 or PAMAM)119 and lipids120 have been described. The increase 
in gene expression when using glycoligands is associated to the improved receptor-
mediated uptake of the carriers, but only to a certain extent. As above outlined, many 
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other features of nucleic acid-carrier interaction and nanoparticle pharmacodynamics can 
be altered upon glycosylation, which makes it difficult to quantify the precise role of the 
saccharide antennae. For instance, Behr and co-workers demonstrated that although the 
ASGPr is involved in the internalization of galactosylated PEI by hepatocytes, this is not 
sufficient to achieve specificity since other uptake mechanisms simultaneously operate 
(Scheme 1). Thus, relevant transfection levels were measured upon addition of ASGPr 
competing agents as well as in ASGPr-devoid cells.117a In other cases it was observed 
that even though the glycosylated carriers were recognized by the target receptors, 
endocytosis did not take place or, if it did, the resulting endosomes were unproductive.121 
 
 
Scheme 1. Synthesis of lactosylated PEI via reductive amination and schematic representation of 
the condensation of lactosylated PEI with plasmid DNA into lactosylated polyplexes. 
 
Glycoligands also exert a function in controlling the fate of the internalized nucleic 
acid-carrier nanocomplexes. Monsigny and co-workers showed that cytosolic and nuclear 
lectins might be involved in intracellular trafficking and nuclear import122 and latter coined 
the term glycofection to refer to transfection strategies based on the glycomodulation of 
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intracellular barriers for gene delivery.123 In a number of cases, lactosylated carriers 
appeared to induce faster escape from the late endosome/lysosome than other 
glycosylated counterparts and more efficiently mediated nuclear import.124 Though these 
observations are still a matter of debate, recent publications by the same group125 and 
others126 highlight the potential benefits of controlling of intracellular trafficking as a 
prerequisite for efficient non-viral gene delivery. 
 
 
3.2. De novo designed carbohydrate polymers 
 
Efficiency and toxicity of polymeric vectors can be largely (and unexpectedly) affected 
by subtle structural changes, for example in counterion nature,127 branching degree128 or 
size,129 which may lead even by batch-to-batch disparities. This undesired variability has 
been overcome to a large extent by the implementation of novel polymerization 
techniques, such as controlled polycondensation, radical polymerization and click 
chemistry reactions, which offer superior control over functional features.130 Through the 
judicious choice of monomer structure and polymerization strategies a number of relevant 
parameters regarding gene delivery capabilities can be tailored. In this context, the de 
novo design of polymeric gene carriers from carbohydrate-derived building blocks has 
been very appealing, given the structural diversity and availability of simple saccharides. 
This section surveys a number of examples that illustrate the nucleic acid delivery 
capabilities of synthetic carbohydrate-based polymers. 
One of the most representative examples of the potential of synthetic glycopolymers at 
tailoring non-viral gene vectors is the case of polyglycoamidoamines (PGAAs).131 The first 
insight into the gene delivery capabilities of PGAAs were almost simultaneously reported 
by Reineke132 and Guan133 (Figure 16). In both cases the diversity, availability and 
biocompatibility of carbohydrates and their readily conversion to polymerizable building 
blocks was the main motivation. Reineke and co-workers focused on imitating the 
structure of linear PEI polymers by co-polymerizing their carbohydrate building blocks 
with a set of short oligoethyleneimine (OEI) chains. Guan’s design aimed at mimicking 
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the structure of poly-L-lysine (PLL) by condensing carbohydrate bricks with lysine 
segments. Both studies revealed significantly reduced cytotoxicity of the resulting PGAAs 
as compared to PEI and PLL, respectively, while maintained comparable pDNA 
transfection efficiencies. 
 
 
Figure 16. Schematic representation of the synthesis of polyglycoamidoamines (A) and building 
blocks used by Reineke’s132 (B) and Guan’s133 (C) groups. 
 
Reineke and co-workers have thoroughly analyzed the influence of architectural 
issues of their PEI-inspired PGAAs on nucleic acid complexation, nanoparticle topology 
and stability, cell uptake, toxicity and gene expression efficiency.134 By screening a library 
of cationic PGAAs, synthesized from a range of linear OEIs and esterified aldaric acid 
and lactone co-monomers (Figure 17), they identified vector candidates that mediated 
high gene expression levels in several cell lines (HeLa, H9c2(2-1), HepG2, or BHK-21). 
pDNA transfer efficiency peaked for the polymers containing the longer OEI chains 
tested.135 Transfection efficiency compares favorably to that achieved with PEI, but with a 
less toxic profile. They hypothesized that the iterative interruption of OEI charge density 
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by carbohydrate blocks was at the origin of the reduced toxicity as compared to PEI, 
though their rapid hydrolysis in biological media might also account for this merit.136 
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Figure 17. General structure of PGAAs studied by Reineke and co-workers (A) with indication of 
their structural diversity (B). 
 
PGAAs with longer OEI segments did not significantly influenced cell uptake and 
overall transgene expression, but significantly improved polyplex stability in serum-
containing media. Unfortunately, increased toxicity was also observed.137 Polymers with 
longer inter-amine spacers (e.g. spermine) also exhibited increased toxicity, highlighting a 
critical relationship between charge density distribution and biocompatibility.138 The 
nature of the saccharide segment, though modestly, also influenced polymer 
performance, apparently by altering the buffering capabilities of the system. Since the 
response of polyplexes at the increase of pH in the endosomes closely relates to the 
pDNA release dynamics, it should be expected certain folding differences upon pDNA-
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PGAA complex formation. Overall, PGAA G4, combining pentaethylenehexaamine and 
galactarate segments (Figure 17), was identified as the best performing candidate. PGAA 
G4, shown to induce long lasting transgene expression (over 7 days) without appreciable 
cytotoxicity,139 was recently licensed to Techulon to be commercialized as GlycofectTM.140 
 
 
Scheme 2. Synthesis of trehalose-based cationic “click” polymers.142 
 
Alternatively, carbohydrate-based cationic polymers with amidine141 or triazole linking 
tethers142 have also been explored. Though polyamidines usually exhibit severe 
cytotoxicity, Reineke and Davis observed that this could be overcome by intercalating 
saccharidic moieties (e.g. trehalose) between the cationic elements while maintaining the 
gene transfer capabilities.141 The closer the amidine and the carbohydrate units are 
located in the polymer chain, the more efficiently the cytotoxicity is reduced. Trehalose, 
moreover, seems to impart additional favorable properties to polymeric gene vectors, 
such as shielding aggregation of the resulting polyplexes with proteins and lipids.143 To 
fully benefit from this, Reineke and co-workers have devised a strategy to build a new 
family of cationic trehalose-embedding polymers that exploits the Cu(I)-catalyzed azide-
alkyne cycloaddition (CuAAC) reaction.144 By coupling diazido-functionalized trehalose 
units with a diverse set of α,ω-dipropargylated OEIs (Scheme 2), a series of polymers 
were obtained that allowed the systematic investigation of architectural effects (OEI size 
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and polymer length) on pDNA complexation, nanoparticle properties, cellular uptake and 
transgene expression. Transfection efficiencies that paralleled that of JetPEI-based 
polyplexes were achieved using trehalose “click” polymers with 3-4 ethylenediamine 
segments.142a Dynamic light scattering (DLS) revealed that polyplexes formulated with 
larger polymers exhibited the best tolerance to serum-containing media, but displayed 
higher toxicity.142b This unfavorable feature was alleviated by the fact that “click” polymers 
required far lower N/P ratios, as compared to PGAAs, to achieve similar gene expression 
levels. 
 
 
Scheme 3. Schematic synthesis of statistical vs. diblock copolymers (A) illustrated with the cationic 
glycopolymers synthesized by Ahmed and Narain (B).146 
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Ahmed and Narain have recently used radical addition-fragmentation chain transfer 
(RAFT) polymerization to synthesize a library of carbohydrate-pendant cationic polymers, 
where carbohydrate and cationic units can be either statistically distributed (random 
polymers) or segregated into separate blocks (diblock polymers, Scheme 3).145  
Precise control on chain length, monomer ratio and polydispersity allowed the authors 
to rationalize the large influence that polymer architecture exerts on gene delivery 
capabilities. Statistical copolymers with high molecular weight produced superior gene 
expression with lower toxicity as compared to the corresponding diblock copolymers, both 
in the presence or absence of serum.146 On the other hand, diblock copolymers resulted 
in nanoparticles that were shielded against non-specific interactions in a similar way of 
pegylated cationic polymers. However, current examples of diblock glycopolymers do not 
perform as other synthetic glycopolymers, the control over polymer structure open new 
opportunities in the field of non-viral gene delivery. Targeted delivery for instance, where 
non-specific interactions have to be shielded at the same time that specific uptake is 
promoted, might be one of those channels. 
 
 
3.3. Cyclodextrins in gene delivery 
 
The above evidences point to significant advantages of using non-viral carriers that 
include carbohydrates in their structure.102 Indeed this is not just restricted to naturally 
occurring carbohydrate polymers or glycocoated cationic vectors. In the last decade, a 
growing awareness has been gathered on the remarkable features of cyclodextrins (CDs) 
for such purpose. First identified from bacterial digests of starch by Villiers147 at the fall of 
19th century and latter isolated by Schardinger during the first decades of the past 
century,148 CDs largely remained as chemical curiosities for over half a century. By the 
mid-20th century, Freudenberg and co-workers unveiled their macrocyclic structure, 
composed of α(1→4)-linked glucopyranose units featuring a basket-shaped topology in 
which glucose hydroxyls orient to the outer space flanking the upper and lower rims, 
while methinic protons (H-5 and H-3) point to the inner cavity (Figure 18),149 and reported 
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on their ability to form inclusion complexes with hydrophobic guests.150 This observation 
represented a milestone that certainly switched the course of CD research history and 
steered it for the second half to the century. Indeed, the academic and (bio)technological 
interest for cyclodextrins has been dominated by this unique feature.151 
 
 
Figure 18. General structure of cyclodextrins (CDs). 
 
CDs have long occupied a prominent position in most pharmaceutical laboratories as 
“off-the-shelve” tools to manipulate the pharmacokinetics and dynamics of a broad range 
of active principles (e.g. drugs).152 But a body of evidence also indicates that CDs might 
be useful for formulation improvement on biomacromolecule delivery in general153 and in 
gene therapy in particular.1,154 In the following paragraphs, selected examples are 
described to illustrate the significant contribution of CDs to the field of non-viral-mediated 
gene therapy. 
The potential of native CDs as transfection enhancers, ascribed at least in part to their 
ability to host cell membrane components such as cholesterol in their hydrophobic cavity, 
has been long known and exploited to improve the gene delivery capabilities of 
polycationic lipidic or polymeric non-viral vectors.155 However, the major breakthrough in 
the field was reported by Davis and co-workers. They conceived a class of cationic 
polymers based on the controlled condensation of bifunctional CD monomers, such as 
bis-(C-6)-cysteaminylated βCD, and cationic co-monomers, in order to yield linear chains 
with alternating CD and cationic segments (CDP, A in Figure 19).2,156 Electrostatically-
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driven complexation of the resulting cationic CDPs and negatively charged pDNA (~5 
kpb) rendered nanometric complexes (polyCDplexes; 100-150 nm) featuring in vitro cell 
transfection efficiency comparable to that obtained with PEI and Lipofectamine™, while 
preserving a reduced toxicity. 
 
 
Figure 19. Schematic representation of the transferrin-targeted nucleic acid-CDP nanoparticles 
(RONDEL™) developed by Davis and co-workers.2 
 
This milestone was followed by a series of reports in which the effect of structural 
modifications of CDPs on the gene delivery capabilities were investigated.141,157 Most 
interestingly, supramolecular host-guest CD chemistry could be put forward to further 
decorate the nanoparticle surface. Thus, inclusion of the adamantane (AD) moiety of AD-
PEG conjugates into CD cavities of polyCDplexes could prevent from non-specific 
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interactions with biological components158 and also biorecognizable ligands could be 
installed at the distal end of these PEG chains to target the polyCDplexes to specific 
tissues (B in Figure 19).159 Using transferrin (Tf) as the peripheral ligand, whose receptor 
is known to be up-regulated in malignant cells, the resulting polyCDplexes were shown to 
selectively target and efficiently transfect different tumor tissues in vivo in mammals 
(murine160 and primates).161 This tripartite therapeutic concept (CDP as nucleic acid 
complexing element/ AD-PEG as surface shielding element / AD-PEG-Tf as targeting 
ligand) is named RONDEL™. In June 2008, CALAA-01 (Arrowhead Research), a version 
of RONDEL™ loaded with a specific oligonucleotide sequence (siRNA) that inhibits tumor 
growth via RNA interference (RNAi), entered phase I clinical trials to determine its safety 
and efficacy towards solid tumors refractory to standard-of-cure therapies.162 
 
 
Figure 20. Examples of molecularly well-defined non-amphiphilic polycationic CDs assayed as 
gene vectors. 
 
At the light of these thrilling results, research on polycationic polymeric gene vectors 
incorporating CDs has flourished, including linear,163 dendritic,119,121a,164 star-shaped,165 or 
rotaxanized structures.166 However, despite a significant success, the above systems still 
suffer from the inconveniences associated to polydispersity. Alternatively, attempts to 
overcome this limitation were made designing monodisperse polycationic clusters taking 
advantage of the molecular scaffolding capabilities of CDs. Using strategies for the 
selective chemical manipulation of CD topology, O’Driscoll and Darcy reported the first 
examples of monodisperse cyclodextrin-centered polycationic clusters intended for DNA 
complexation (A in Figure 20)167 and demonstrated their ability to promote transfection in 
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vitro. Their work inspired other architectural proposals to enhance nucleic acid binding 
(e.g. guanidinylated,168 oligoethyleneimine-grafted,169 and histidine/lysine-decorated170 
CDs, B, C and D in Figure 20, respectively). The highly hydrophilic character of these 
materials does not help self-organization of the monomers at the surface of the 
oligonucleotide chain, however. Consequently, relatively large excesses are necessary to 
achieve full protection from the environment. Notwithstanding, some of the resulting CD-
nucleic acid complexes (CDplexes) exhibited remarkable transfection capabilities. 
The above examples illustrate the suitability of CDs as molecular platforms for the 
incorporation of cationic elements with a precise spatial orientation and the potential of 
the resulting monodisperse polycations as gene vectors. Most interestingly, the rim 
anisotropy of the basket-shaped CD structure further allows accessing compounds with 
segregated cationic and lipophilic domains for which, according to the ”facial 
amphiphilicity” concept,171 biomimetic self-assembly and gene delivery properties could 
be expected. Darcy and co-workers first tested this hypothesis by preparing 
heterogeneous βCD derivatives bearing thioalkyl chains at the primary rim and amine-
terminated oligoethylene branches of variable lengths at the secondary hydroxyl positions 
(A in Figure 21). The resulting polycationic amphiphilic CDs (paCDs) were shown to 
entrap pDNA by forming CDplexes that transfected COS-7 and human hepatocellular 
liver carcinoma (HepG2) cells with efficiencies and toxicity profiles comparable to 
Lipofectamine 2000™-based lipoplexes.172 
 
 
Figure 21. Examples of amphiphilic polycationic CDs assayed as gene vectors. 
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Scheme 4. Illustrative example of the synthesis of 2-aminoethylthioureido paCDs. 
 
A dual face modification methodology has been refined in our laboratory to furnish 
truly monodisperse polycationic amphiphilic CDs (paCDs, B in Figure 21).173 The 
synthetic strategy is based on the sequential installation of a cationic cluster on the 
primary rim of a CD scaffold and acylation of the secondary rim hydroxyls.174 The 
sequence starts with the displacement of the halides in the heptakis(6-bromo-6-
deoxy)cyclomaltoheptaose175 by N-Boc protected cysteamine. Then homogeneous 
acylation of the secondary hydroxyls can be achieved by reaction with hexanoic 
anhydride in DMF using DMAP as base promoter (Scheme 4). Final acid hydrolysis of the 
carbamate groups afforded in excellent yield the first member of the paCD family, already 
featuring self-assembling capabilities in the presence of pDNA but poor gene transfer 
performance (e.g. 100-fold lower as compared to bPEI in BNL-CL2 cells).174 Interestingly, 
the reaction of Boc-protected 2-aminoethyl isothiocyanates with this 1st generation paCD, 
followed by acid promoted carbamate cleavage, furnished βCD derivatives incorporating 
a belt of 2-aminoethylthiourea groups that behave as much more efficient phosphate 
anion binding epitopes.176 The biological results indicated a significant increase in the 
transfection efficiency for polyaminothiourea paCD as compared with polyamine 
counterpart, paralleling that for polyplexes formulated with PEI at its optimal N/P 10 
ratio.174 CDplexes based on paCDs have been shown to be broad range delivery agents, 
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affording high transgene expression efficiencies in a most cell lines investigated and often 
surpassing that of PEI and Lipofectamine™. Moreover, transfection efficiency was not 
affected in serum-containing media, an important requisite for in vivo applications. 
These facial amphiphiles efficiently condensed pDNA into stable nanocomplexes 
(CDplexes) of 40-50 nm diameter with very narrow polydispersity.177 pDNA complexation 
is assumed to take place though a two-steps process involving, first, an electrostatic 
driven-interaction between the anionic polyphosphate chain and the cationic amphiphile 
and, then, a hydrophobic-driven compactation (Figure 22), a mechanism that is 
reminiscent of that operating in viral particle assembly. 
 
 
Figure 22. Schematic illustration of the proposed two-step mechanism for CDplex formation 
between paCDs and pDNA. 
 
The flexibility of this synthetic methodology allowed a thorough assessment of how 
architectural parameters such as cationic density and display,177,178 CD scaffold size179 or 
the type of functional group tethering the cationic cluster to the CD core180 exert on self-
assembling and gene transfer capabilities both, in vitro and in vivo,181 and the 
mechanisms involved in the cellular uptake of these nanoparticles (CDplexes).182 
Most interestingly, this flexibility could be further exploited to modulate the gene 
transfer “promiscuity” of CDplexes. Recently, glycosylated versions of paCDs (pGaCDs) 
have been developed for targeting purposes.183 The artificial glycocalyx-like surface 
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generated after glycoCDplex assembly can be recognized by complementary cell 
membrane receptors and/or intracellular trafficking machineries. As a proof of concept, an 
homogeneously mannosylated candidate was shown to selectively transfect MMR-
positive cells (RAW264.7 macrophages) via MMR-dependent route, exhibiting very low 
transfection efficiency towards cell lines devoid of mannose receptors such as BNL-CL2 
and COS-7 as compared to non-glycosylated CDplexes.183a The strategy has been also 
validated for the transfection of hepatocytes with galactosylated pGaCDs via specific 
recognition of the corresponding glyco-CDplexes by the asialoglycoprotein receptor 
(ASGPr).183b 
The above ensemble of data highlights the advantages a flexible synthetic strategy 
leading to homogeneous gene carriers to facilitate the manipulation and optimization of 
their nucleic acid delivery capabilities. Most interestingly, the incorporation of additional 
functional elements can be undertaken at the vector or at the CDplex level, after nucleic 
acid complexation. Covalent as well as supramolecular ligation chemistries can be 
conceived in order to tailor the properties of the transfectious nanoparticles for a 
particular application. Unfortunately, these features are not as common it would be 
desired in the field of non-viral gene delivery. In most of cases, massive efforts in 
development of non-viral carriers yield minimal insight into the structure–function 
relationship of delivery agents that is relevant to adapt investigational designs to 
particular challenges. 
Many early studies on gene delivery focused on developing tight associations of the 
delivery vehicle with nucleic acids such that nuclease resistance was imparted. However, 
such studies ignored the fact that these delivery systems needed to be capable of 
disassembly within the cell; an issue that still receives insufficient attention. In this Ph.D. 
Thesis, we would like to further exploit the competitive advantages of paCDs to gain a 
deeper insight into their SAR in this particular topic. 
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4. Objectives 
Serving as a general frame, the first chapter of this Ph.D. Thesis aims to give an 
overview of the state of the art in non-viral gene delivery, focusing on carbohydrate-based 
carriers and, more particularly, on those designs based on cyclodextrins. Then, the 
influence of the hydrophilic/hydrophobic balance of paCDs on self-assembling, DNA-
condensing and gene delivery capabilities of paCDs is investigated in the second chapter 
of this Ph.D. Thesis pursuing the following objectives: 
 
• the synthesis of a series of monodisperse polycationic amphiphilic CD 
derivatives (paCDs) differing in their hydrophobic/hydrophilic balance, 
• the investigation of their self-assembling capabilities in aqueous 
environment, 
• the determination of pKa values and pH buffering capabilities of CD-
scaffolded polycations, 
• the assessment of DNA-paCD complex (CDplex) formation and dissociation,  
• and the evaluation of CDplex gene transfer capabilities towards COS-7 cells. 
 
On the other hand, the third chapter of this Ph.D. Thesis is aimed at rationalizing the 
influence of the arrangement of the cationic cluster of paCDs on self-assembling and 
gene delivery capabilities For such purpose, in this chapter a novel series of paCDs 
grafted with cyclic polyamine clusters were elaborated pursuing the following goals: 
 
• the investigation of their self-assembling capabilities in aqueous 
environment, 
• the evaluation of their pH buffering capabilities, 
• the assessment of their DNA-condensing abilities,  
• and the evaluation of the gene transfer capabilities towards HeLa cells of the 
resulting paCD-DNA CDplexes. 
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Finally, despite the usefulness of CDs for engineering gene carriers, only a handful of 
synthetic methodologies are available for selective chemical manipulation in the CD 
framework. Regarding the design of CD-based gene carriers, complementing the array of 
regioselective functionalization strategies with methodologies facilitating installation of 
additional bioactive elements on the CD core would be highly desirable. Thus, in the last 
chapter of this Ph.D. Thesis a novel solid phase-assisted synthetic strategy towards 
selective functionalization of multivalent scaffolds is disclosed. Herein, implementation of 
the “catch-and-release” concept using a solid supported reagent is aimed at furnishing an 
array of regioselectively monofunctionalized CD derivatives in one pot. 
  
 
 
 
CHAPTER 2 - INFLUENCE OF THE 
HYDROPHILIC/HYDROPHOBIC BALANCE ON SELF-
ASSEMBLING, DNA-CONDENSING AND GENE 
DELIVERY CAPABILITIES OF POLYCATIONIC 
AMPHIPHILIC CDS (PACDS) 
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1. Structure-activity relationships in the rational design 
of novel gene carriers 
A prerequisite to better understanding and consequently improving transfection 
efficiency of non-viral gene delivery systems is to get a deeper insight into how nucleic 
acid-carrier interactions and assemblies are established, the cell uptake, endosomal 
escaping and intracellular trafficking mechanisms involved in the process. Hence, 
elucidation of structure-activity relationships (SARs) is a crucial parameter for the rational 
design of efficient novel gene carriers. 
Structure-activity correlations for DNA carrier systems are difficult to establish due to 
intricate cellular events involved in the multistep transfection process. Generally, there is 
a great difference between in vitro and in vivo experiments. Furthermore, different cell 
lines behave very differently when subjected to the same series of transfection 
experiments with a certain vector. Another difficulty is derived from the essentially 
polydisperse nature of many of the most prominent non-viral gene carriers, which 
considerably hampers inferring structure–activity links. Although there are exceptional 
cases, such as CD-based polymers described by Davis,2 this is a problem that breaks 
down many promising designs. To overcome these drawbacks, monodisperse 
multifunctional molecular vectors have emerged as a new generation of gene delivery 
systems. Chemical tailoring and systematic structural modification facilitate a deeper 
insight into their structure-activity relationship. 
As illustrated in the preceding chapter, preorganized macrocyclic structures such as 
CDs could be very helpful for this task, since they can be furnished with functional 
elements endowing them with self-assembling capabilities in the presence of nucleic 
acids. In our laboratories, we have succeeded to produce a series of amphiphilic CDs to 
investigate the role of structural features such as architectural design (skirt174,180b vs. 
jellyfish like),178 CD scaffold size,179 density and display of the cationic cluster,177 type and 
length of the connecting tethers (Figure 23),180a and the presence of selective targeting 
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elements183 on their self-assembling, cellular uptake,182 and transgene expressing 
capabilities have been assessed in vitro and in vivo.181 
 
 
Figure 23. paCDs under investigation in SAR studies with indication of the modified structural 
elements. 
 
SAR analysis on these families taught that the “skirt”-type arrangement in combination 
with multiple aminoethylthiourea segments presented advantages in terms of synthetic 
straightforwardness and architectural flexibility, and moreover, resulted in improved gene 
transfer efficiencies. 
However, there remain a number of questions to be addressed, in special those 
regarding the influence of paCD structure on CDplex formation and dissociation. Towards 
this goal, in this Ph.D. Thesis a series of monodisperse paCDs with a precise 
arrangement of functional elements are prepared and used to insight on how their 
structural features determine their physicochemical properties and, ultimately, whether 
these features can be related to their DNA delivery capabilities. In particular, this chapter 
comprises: 
• the synthesis of library of paCDs featuring subtle differences in their 
hydrophilic/hydrophobic balance, 
• the assessment of self-assembling capabilities in aqueous environment by 
means of critical aggregation concentration measurements, 
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• the determination of pH buffering capabilities of paCD aggregates, 
• the assessment of DNA-paCD complex (CDplex) formation and dissociation 
dynamics, 
• and the determination of their pDNA delivery capabilities towards COS-7 
cells. 
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2. Synthesis of paCDs differing in their 
hydrophilic/hydrophobic balance 
Exploiting in-house-developed synthetic methodologies, a semi-convergent, modular 
strategy towards C7-symmetric βCD derivatives differing in their hydrophobic/hydrophilic 
balance has been implemented for the preparation of two sub-collections of paCDs, 
namely (i) the linear heptacationic family and (ii) the branched 21-cationic subset, 
respectively, each of them containing members differing in secondary rim acyl chain 
lengths (Figure 24). 
 
 
Figure 24. Structure of polycationic CD library members. 
 
The first part of the synthetic pathway comprised the incorporation of a cysteaminyl 
segment into the primary βCD face and acylation of the fourteen secondary hydroxyl 
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groups by employing different acid anhydrides as reagents. In principle, two alternative 
routes can be presented, differing in the order of functionalization of the two βCD faces 
(Scheme 5). Although both can provide polycationic amphiphilic paCDs 18-21 in only four 
steps from commercial βCD, they differ significantly in their performance and efficiency. 
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Scheme 5. Synthesis of compounds 18-21 (1st generation paCDs). Reagents and conditions: a) 
hexanoic anhydride, DMAP, Py, 16 h, 72%; b) BocHN(CH2)2SH, Cs2CO3, DMF, 60 ºC, 48 h, 70%; 
c) BocHN(CH2)2SH, Cs2CO3, DMF, 60 ºC, 48 h, 99%; d) 1:1 Ac2O-Py, rt, 15 h (for R = CH3),80%; 
propionic anhydride (for R = CH2CH3), butanoic anhydride (for R = CH2CH2CH3), or hexanoic 
anhydride (for R = (CH2)4CH3), DMAP, DMF, 70 ºC, 24 h, 73-78%; c) e) i, 1:1 TFA-DCM, 2 h; ii, 
HCl, 99%. 
 
The synthesis of CD derivative 21 was explored using both synthetic pathways. 
Starting from heptakis(6-bromo-6-deoxy)cyclomaltoheptaose 11, obtained from 
commercial βCD according to the procedure described by Defaye,175,184 acylation of the 
secondary hydroxyl groups using hexanoic anhydride and DMAP was accomplished. 
When DMF was used as solvent for the acylation the reaction proceeded slowly. 
Increasing the temperature, in turn, led to concomitant nucleophilic substitution of the 
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halide at C-6. This drawback could be overcome by using pyridine instead, which allowed 
for a complete acylation of secondary hydroxyl groups without formation of side products 
(Scheme 5, route A). Subsequent functionalization of the primary face by nucleophilic 
substitution of halides with N-Boc-protected cysteamine in presence of cesium carbonate 
was achieved in good yield, although requiring purification by silica gel column 
chromatography. 
On the other hand, compound 21 could also be obtained by reversing the order of 
functionalization of the two CD faces (Scheme 5, route B). Nucleophilic substitution of the 
halide on the primary face of 11 by N-Boc-protected cysteamine was carried out to yield 
derivative 13 in virtually quantitative yield. Subsequent acylation of the secondary 
hydroxyl groups in the presence of DMAP was accomplished in DMF to smoothly furnish 
17 in 73% yield. This alternative synthetic route presents considerable advantages, since 
it reveals a more convergent character and requires only a single chromatographic 
purification step, i.e. after acylation of secondary hydroxyl groups. Together with its better 
overall performance these factors clearly privilege this synthetic pathway. Consequently, 
CD derivatives 18-20 were prepared exclusively by this route. 
Under these reactions conditions using the corresponding acid anhydrides, i.e. 
propanoic anhydride (15, 73%) or butanoic anhydride (16, 78%), the formation of 
side products ascribed to over-acylation by the reaction of the acylating agent with 
carbamic nitrogen atoms was not observed in any case. Acetyls were introduced using 
standard conditions (1:1 mixture of Ac2O-Py). After purification by silica gel column 
chromatography, homogeneity of all acylated CD derivatives was confirmed by NMR, 
ESI-MS and combustion analysis (see Figures S1-S4 for NMR spectra and Figures S81-
S84 for MS spectra, Supporting Information). Finally, acid hydrolysis of the carbamate 
groups by treatment with 1:1 TFA-DCM led to paCDs 18-21 in quantitative yield. 
The reason for choosing a 2-aminoethanothiol (cysteamine) segment to link the CD 
core with the cationic moieties is not trivial. Previous results of our research group have 
shown that the nucleophilicity of the amino group in βCD derivatives is significantly 
increased after insertion of the 3-atom (SCH2CH2) spacer in between the nitrogen atom 
and the CD core,185 which in turn should facilitate interactions with phosphate anions in 
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the nucleic acid backbone. Moreover, distancing the amino groups from the CD core 
reduces steric hindrance that may limit reactivity with bulky electrophiles. 
Previous insights into paCD SAR led to the identification of the 2-aminoethylthiourea 
segment as a privileged phosphate-binding motif.177 This structural element has been 
preserved in the architectural diversification of paCDs 18-21. Thus, two isothiocyanate 
synthons (22186 and 23,177 Figure 25) have been coupled to each CD derivative (18-21) to 
furnish the linear or branched paCD subsets, respectively. 
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Figure 25. Isothiocyanate synthons used for the elaboration of the paCD collection. 
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Scheme 6. Synthesis of thioureido paCDs 1-8. Reagents and conditions: a) 22, Et3N, DCM, 15 h, 
75-94%; b) 23, Et3N, DCM, 20 h, 62-95%; c) i, anh. TFA, 5 min; ii, HCl, 99%. 
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As shown in Scheme 6, Et3N-catalyzed coupling of isothiocyanates 22 and 23 to 
polyamino compounds 18-21 in DCM led to the corresponding N-Boc protected linear 
poly(aminoethylthioureido) CD derivatives (24, 94%; 25, 75%; 26, 84% and 27, 
81%) as well as to their respective branched analogs (28, 95%; 29, 62%; 30, 74% 
and 31, 71%), respectively. In all cases the thiourea formation reaction was completed 
in a relatively short time (2 to 3 h), as evidenced by TLC and ESI-MS (see Figures S89-
S96 for MS spectra, Supporting Information) of the reaction mixture, provided pH was 
maintained at 8-9. The formation of products from isothiocyanate self-condensation, 
typically associated with long reaction times or elevated temperatures, was not 
observed.187 All N-Boc protected products were purified by conventional silica gel column 
chromatography and were obtained in remarkable final yields (62-95%) keeping in mind 
that coupling reactions should take place at seven positions simultaneously. 
 
 
Scheme 7. Synthesis of polycationic thioureido CDs 9 and 10. Reagents and conditions: a) 22 
(33), 23 (34), 1:1 Py-H2O, 24 h; b) 24 (33), 28 (34), NaOMe, MeOH, 14 h, 98% (33), 
97% (34); c) i, anh. TFA, 5 min; ii, HCl, quantitative yield in both cases. 
 
In addition to this set of compounds, the non-amphiphilic CD analogs (lacking the 
secondary rim acyl chains) have been synthesized. In principle, chemoselectivity of the 
thiourea formation reaction should allow performing the coupling without the need of 
protecting the secondary hydroxyls, as previously described. However, when CD 
derivative 32185a was coupled to the isothiocyanates 22 and 23, products resulting from 
partial addition precipitated from the reaction mixture, thus preventing reaction 
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completion. Alternatively, advantage was taken of CD derivative 24 prepared previously, 
which exhibits acetyl protected hydroxyl groups on the secondary face of the CD core 
and hence organic solvent solubility (Scheme 7). Zemplén transesterification of the 
acetyls gave N-Boc protected CD derivative 33 in excellent yield (98%). The synthesis of 
the corresponding branched polythioureido CD derivative 34 was performed in an 
analogous manner, as shown in Scheme 7. 
Although all other synthetic steps to obtain the collection of linear and branched 
polycationic amphiphilic CDs as well as their two analogs without acyl chains on the 
secondary face furnished the target compounds with remarkable yields and purities, final 
acidic hydrolysis of the carbamate protecting groups of compounds 24-31, 33 and 34 
proved to be a delicate operation. In particular, two aspects have to be considered in 
order to prevent side reactions during acid-promoted cleavage of carbamate protecting 
groups. On one hand, glycosidic linkages of the βCD core are sensitive to harsh acid-
promoted hydrolysis and may therefore be partially cleaved upon prolonged acidic 
treatment, leading to a mixture of ring opening and transglycosylation products. While CD 
derivatives equipped with long fatty acid ester chains seems to be unaffected, probably 
due to steric inaccessibility to the glycosidic bond, minimizing the reaction time is critical 
to obtain a homogenous products with shorter or none-acyl chains.188 On the other hand, 
ester hydrolysis may take place under acidic conditions. In this regard, long fatty acid 
chains seem to be invulnerable, probably due to either steric crowding or the decreased 
rate of hydrolysis associated to longer acyl chains.189 In any case, it was hypothesized 
that using anhydrous conditions in shorter reaction times should diminish the rate of 
hydrolysis to tolerable levels. In a first attempt, hexanoylated compounds 27 and 31 were 
submitted to standard Boc cleavage conditions (i.e. treatment with 1:1 DCM-TFA at rt for 
two hours, followed by solvent evaporation and freeze-drying from 0.1 N HCl). CDs 
bearing long acyl chains resisted these acid-promoted Boc cleavage conditions, as 
evidenced by the preserved symmetry and homogeneity of the reaction products. 
However, Boc group removal in compounds furnished with shorter acyl chains 
revealed a completely distinct scenario. For example, a similar treatment of 
propanoylated CD derivative 25 furnished a heterogeneous product. As revealed by ESI-
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MS, carbamate groups were completely removed, and the origin of heterogeneity was 
attributed to partial hydrolysis of ester chains (Figure 26). The repetitive spacing of 56 
mass units between adjacent mass peaks clearly indicated the partial cleavage of 
propanoyl esters. However, no products derived from glycosidic bond cleavage were 
detected. 
 
 
Figure 26. ESI-MS spectrum evidencing partial ester hydrolysis of compound 25 when treated with 
1:1 TFA-DCM at rt for 1.5 h. 
 
It is noteworthy that CD derivatives with butanoyl chains experienced ester hydrolysis 
far more slowly than their propanoyl analogs, highlighting the substantial influence of an 
additional carbon atom in the acyl chain. 
Softening reaction conditions (i.e. lower acid proportions and shorter reaction times) 
did not improve the reaction outcome. Neither the use of diluted hydrochloric acid in 
water nor dioxane furnished homogeneous products, though results could be slightly 
improved. 
Conversely, deprotection of amine groups under anhydrous conditions (i.e. neat 
anhydrous TFA at rt for 5 min, immediately followed by reaction mixture freeze-drying 
with a minimum amount of water) turned to be successful, as carbamate protection 
groups were completely removed, whereas esters (including acetyls) remained intact. 
Homogeneity was confirmed by ESI-MS, as depicted exemplarily for paCD 2 in Figure 27 
(see Figures S97-S104 for MS spectra, Supporting Information). To facilitate handling 
and to provide greater stability, the crude paCD derivatives were converted into their 
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respective hydrochloride salts by freeze-drying them from a diluted hydrochloric acid 
solution. 
 
 
Figure 27. ESI-MS spectra of symmetric paCD 2. 
 
Polycationic CD derivatives with free hydroxyl groups on the secondary rim 9 and 10 
could be obtained from their N-Boc protected precursors 33 and 34 efficiently in 
quantitative yields making use of the same reaction conditions as described before.  
Recording NMR spectra of polycationic amphiphilic CD derivatives, some specific 
aspects have to be considered in order to achieve satisfactory resolution. In general, 1H 
and 13C NMR spectra of compounds furnished with thiourea moieties recorded at rt tend 
to show the typical line broadening associated with restricted rotation at the pseudoamide 
NH-C(=S) bonds.190 This inconvenience can usually be overcome by acquiring NMR 
spectra at elevated temperatures (50-70 ºC), thus allowing structure confirmation. 
However, when 1H and 13C NMR spectra of compounds 1-10 were recorded in D2O, 
MeOD or mixtures thereof at 50-60 ºC, resolution was unsatisfactory due to apparent loss 
of symmetry. 
Two possible reasons for symmetry distortion exist, namely counter ion unbalance and 
self-assembly of paCDs, both solvent-dependent and probably interplaying. The self-
assembling capabilities of polycationic amphiphilic compounds may lead to their 
aggregation not only in water but also in other solvents and their mixtures. This could be 
manifested in their respective NMR spectra by apparent loss of symmetry. Among the 
most important factors that affect self-assembling of paCDs, rank the nature of the 
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solvent, i.e. its polarity, sample concentration, its amphiphilicity and temperature.191 Thus, 
selection of an appropriate solvent is a crucial issue. 
Furthermore, we hypothesized that the counter ion species of paCDs may contribute 
to spectral resolution, since the presence of different kinds of counter ions, i.e. 
trifluoroacetate anions as well as hydrochloride anions originating from the freeze-drying 
process, would, depending on the solvent, result in increasingly complex NMR spectra 
accounting for a heterogeneous mixture of compounds. 
In order to confirm this hypothesis, paCD salts were neutralized, thus getting rid of 
counter ions. Compound 4 was treated with a basic anion exchange resin (Dowex® 
Monosphere 550A hydroxide form) and, indeed, the 1H NMR spectrum of the neutral 
amino analog featured the expected C7 symmetry of the paCD derivative, compatible with 
its MS spectrum, as shown in Figure 28. 
 
 
Figure 28. 1H NMR spectra (500 MHz, MeOD, 323 K) of compound 4 before (A) and after (B) 
treatment with basic anion exchange resin. The residual HDO peak was suppressed by 
presaturation. 
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With this encouraging result in hand, the other polycationic CD compounds were 
subsequently treated with basic anion exchange resin. Although all amino moieties could 
be readily neutralized, the basic resin led to partial saponification of the more vulnerable 
short ester chains. In particular, hexanoyl as well as butanoyl chains of both linear and 
branched paCDs resisted basic treatment, whereas shorter chains, i.e. propanoyl and 
acetyl chains, were partially hydrolyzed, as evidenced by ESI-MS. Consequently, it has 
not been possible to obtain compounds 1, 2, 5 and 6 as their neutral amino analogs for 
the purpose of NMR studies. 
 
 
Figure 29. 1H NMR spectra (500 MHz, 323 K) of compound 2 recorded in 2:1 D2O-MeOD (A) and 
DMSO-d6 (B), respectively. 
 
As mentioned before, another reason for the apparent heterogeneity of paCDs 
observed in 1H NMR spectra may be self-assembly. paCDs tend to self-assemble in 
aqueous media, while in most cases they are moderately soluble in MeOD. To strike a 
balance between these opposite characteristics, on first attempt NMR spectra were 
recorded in variable mixtures of D2O-MeOD. However, 1H NMR spectra obtained could 
Chapter 2  53 
 
not prove in all cases the homogeneity of the polycationic amphiphilic compounds 
synthesized before. This was attributed to the fact that compounds self-assembled. When 
NMR spectra were recorded in DMSO-d6, homogeneity of all paCD derivatives could be 
verified, indicating a weaker tendency to self-assemble in this solvent, as shown for paCD 
2 in Figure 29 (see Figures S17-S24, S27 and S28 for NMR spectra, Supporting 
Information). Nevertheless, the self-assembling capabilities of all paCDs as well as their 
non-amphiphilic analogs 9 and 10 will be discussed in detail in the next section. 
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3. Investigation of self-assembling capabilities of paCDs 
in aqueous environment 
For the purpose of gaining a deeper insight into their structure-activity relationship, in 
this Ph.D. Thesis the physicochemical properties of the synthesized paCDs were 
investigated. In the first place, the influence of the hydrophobic/hydrophilic balance on 
their self-assembling capabilities has been examined, as molecular assembly is related 
directly to the oligonucleotide condensing potential.  
The first evidences of self-assembling in amphiphilic CDs date back from  1986,192 
when Kawabata and co-workers observed that alkanethiolated βCD derivatives obtained 
by nucleophilic substitution of the halides of 11,175,184 formed monolayers at the air-water 
interface with the hydroxylated face oriented towards the water (35-38 in Scheme 8). 
However, it was not until 2000 that the self-assembling features of amphiphilic CDs were 
systematically analyzed.193 Inserting oligoethyleneoxide segments in the secondary rim of 
the above amphiphiles (39-42 in Scheme 8), Darcy and Ravoo synthesized βCD 
derivatives rendering different types of vesicles in aqueous environments.194 These 
vesicles consisted on bilayers of CD molecules, in which the hydrophobic “tails” are 
directed inward and the hydrophilic “head groups” are facing water, thereby enclosing an 
aqueous interior (Figure 30). 
 
 
Scheme 8. Synthesis of oligo(ethylene oxide) CD amphiphiles 35-42. Reagents and conditions: a) 
RSH, tBuOK, DMF, 80 ºC, 4 d; b) K2CO3, ethylene carbonate, tetramethylurea, 150 ºC, 4 h. 
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Figure 30. (a) Vesicles formed by amphiphilic CD 42 and (b) nanoparticles formed by amphiphilic 
glycosylated CD 45a (scale bars = 200 nm).195 
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Scheme 9. Synthesis of glycosylated and cationic CD amphiphiles 43-47. Reagents and conditions: 
a) i, acetylated Glyc-NCS, DABCO, toluene, rt; ii, NaOMe, MeOH for 43, NaOMe, MeOH-DMF for 
44 and 45; b) NIS, TPP, DMF, 100 ºC, 4-5 h, 45-70%; c) NaN3, DMF, 100 ºC, 4-5 d, 70%; d) i, TPP, 
DMF, 2 h; ii, NH4OH, then 1 M HCl, 50-65%. 
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The fact that these oligo(ethylene oxide) CDs 39-42 exhibited significantly different 
self-assembling capabilities from 6-thioalkylated CDs 35-38 highlighted the utmost role of 
the hydrophilic/hydrophobic balance determining supramolecular features.196 For 
instance, grafting monosaccharide moieties onto the oligo(ethylene oxide) chains of 
amphiphilic CD derivatives 40-42 directly using glycosyl isothiocyanates197 (Scheme 9) 
eventually tuned amphiphilicity to render nanoparticle formation (Figure 30).198 
In addition to non-ionic CD amphiphiles, supramolecular assemblies composed 
entirely of anionic199 and cationic200 amphiphilic CD have been described. Very recently, 
Darcy and co-workers201 showed that cationic amphiphilic CDs 46 and 47, which could be 
obtained from oligo(ethylene oxide) amphiphiles 41 and 42 by a iodination-azidation-
reduction sequence202 (Scheme 9), feature different self-assembling properties. While 
compound 47 forms bilayer vesicles in aqueous environment, 46, equipped with shorter 
lipid chains tends to form micelles. 
 
 
Figure 31. Library of paCDs and their respective non-amphiphil
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The intimate link between amphiphilic CD structure and self-assembling capabilities 
has also been demonstrated recently in our laboratory. It has been shown that subtle 
modifications in the nature of the functional groups installed on the primary rim of the βCD 
core dramatically affect the size a surface electrostatic (ζ) potential of the resulting 
nanoparticles.203 In turn, these features exert an important influence of nanoparticle 
stability and their molecular encapsulation and release capabilities. 
In a first step to correlate molecular structure of the synthesized paCDs (Figure 31) 
with self-assembling properties, in this section their critical aggregation concentrations 
(CAC) have been measured. 
 
 
Figure 32. Fluorescence excitation spectra of pyrene (λem 375 nm) in water containing compound 4 
at the indicated concentrations. 
 
Experimentally, the critical aggregation concentration can be estimated by correlating 
a suitable physical property to surfactant concentration. Earlier attempts of our research 
group to determine the critical aggregation concentration of amphiphilic CDs by surface 
tension measurements based on the Du Noüy ring method204 failed because 
measurements fell below the detection limit in the low µM range. In order to measure the 
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critical aggregation concentrations of the paCD collection synthesized in this Ph.D. 
Thesis, an established easy-to-use fluorescence technique based on the environment 
polarity-induced change in fluorescence spectra of pyrene205 was applied. In aqueous 
environment, this extremely hydrophobic dye is preferentially incorporated in the interior 
of hydrophobic aggregates, leading to a significant change in its fluorescence spectrum. 
The onset of aggregate formation is detected by a shift of its fluorescence excitation 
spectra at an emission wavelength of 375 nm. A series of aqueous solutions of each 
paCD were prepared (0.256 nM to 500 µM), each of them containing 0.6 µM pyrene. After 
incubation of the samples, the fluorescence excitation spectra were registered at 375 nm 
(λex 310-340 nm, Figure 32) and the fluorescence intensity at 339 nm relative to 335 nm 
(I339/I335) was plotted against Log[CD], yielding for each CD derivative a graphic as shown 
in Figure 33. 
 
 
Figure 33. CAC determination for compound 4 using pyrene fluorescence excitation spectra switch 
at λem 375 nm. 
 
In such representation, two linear data ranges can be distinguished: (i) a section with 
constant I339/I335 ratio corresponded to CD concentrations below CAC (sub) and (ii) 
another with a linear increase in I339/I335 ratio associated with CD concentrations above 
CAC (super). By linear fitting of both data ranges, two linear equations could be obtained: 
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The critical aggregation concentrations were then determined from the intersection of 
both lines according to equation (3): 
 
)*) = 10
+,-./01+,-+
2,-+12,-./0
  (3) 
 
Table 2. Critical aggregation concentrations in aqueous environment of both linear and branched 
paCDs and their non-amphiphilic analogs. 
Acyl chain 
length 
Linear series CAC 
(µM) 
Branched series CAC 
(µM) 
none 9 64.7 10 43.3 
Ac 1 94.4 5 66.5 
Pr 2 26.4 6 49.3 
But 3 5.7 7 21.3 
Hex 4 0.94 8 2.79 
 
 
Table 2 collects the critical aggregation concentrations in aqueous environment of 
both linear and branched paCDs and their non-amphiphilic analogs. The expected 
progressive decrease of CAC with increasing acyl chain length was observed. This was 
in agreement with an increasing hydrophobicity of the acyl chains and thus amphiphilicity 
of the CD conjugates. In general, this trend could be observed in both the linear and the 
branched paCD series, although it was more pronounced in the linear one. CAC 
dispersion for the former group ranged from 1 µM (hexanoylated paCD 4) to 
approximately 100 µM (acetylated paCD 1), while CAC values of branched paCDs varied 
from 3 µM (hexanoyl compound 8) to approximately 70 µM (acetylated compound 5). 
Although an increase in acyl chain length and hence in amphiphilicity of the CD 
conjugate resulted in a decrease of CAC, charge density also plays a major role, 
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evidencing that an appropriate equilibrium between acyl chain length and number of 
polycationic groups is decisive for the self-aggregation tendency of paCDs. The six-
membered acyl chains of CD derivatives 4 and 8 seemed to be able to counterbalance 
arrays of both seven and fourteen cationic groups on the primary rim of the CD scaffolds, 
which led to low CACs in both cases. In contrast, the shorter acyl chain of the set of 
propanoyl compounds 2 and 6 apparently matched up better with a lower charge density. 
Hence, CAC of compound 2 is markedly lower than that of its branched analog 6. 
The CAC values obtained for the non-amphiphilic CD derivatives 9 and 10 are, 
however, unexpectedly lower than those measured for the acetylated conjugates. 1H 
NMR registered in D2O up to low mM concentrations gave no evidence of self-
aggregation behavior for compounds 9 and 10. Thereby, the observed effect must be the 
consequence of the molecular inclusion of the pyrene moiety in the CD cavity, which may 
also potentially lead to fluorescence spectral changes.206 Lacking acyl chains on the 
secondary rim may clear the access to the cavity of compounds 9 and 10. The 
experimental setup of the fluorescence technique used to determine the CACs does not 
allow for distinguishing whether the shift of the fluorescence excitation spectra originates 
from incorporation of pyrene in the interior of micelles or from the formation of inclusion 
complexes between CD and pyrene. As a consequence, it has not been possible to 
define the contribution of inclusion complex formation to the allover fluorescence shift and 
the actual CACs of both derivatives 9 and 10 could not be determined although they are 
expected to be much higher than those of their amphiphilic analogs. 
In order to round investigations of self-assembling capabilities in aqueous environment 
out, the stability of the paCD aggregates has been studied. For such purpose, paCD 4 
was chosen to be surveyed in a more detailed manner. Its pyrene-containing aqueous 
solutions were incubated at rt for one month and fluorescence spectra were registered at 
different times over that period. Measurements revealed that the CAC remained constant; 
hence, aggregates remained unaltered for that time. 
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4. Determination of pKa values and buffering capabilities 
of CD-scaffolded polycations 
It is generally recognized that the major obstacles to efficient gene delivery are cellular 
internalization and intracellular trafficking.207,208 There have been noticed major disparities 
among the mechanisms used by non-viral carriers to overcome these hurdles. For 
instance, lipoplexes have been shown to enter the cells predominately via clathrin-
dependent endocytosis (CDE).209 PEI polyplexes, however, are internalized through 
several routes, being the fraction taken up via clathrin-independent (CIE) mechanisms 
the one that leads to gene expression.210 Similarly to the later, in the case of CDplexes, 
though the largest fraction of gene complexes is taken up via CDE, the smaller fraction 
internalized via CIE is predominately responsible for successful transgene expression.182 
 
 
Figure 34. Schematic representation of the structure of haemagglutin (HA) at neutral pH (A) and at 
low pH (B). 
 
These evidences highlight the utmost relevance of endosomal escape skills in the 
overall efficiency of gene carriers. Understanding of the mechanisms of viral escape from 
endosomes is important for improving non-viral gene delivery systems. For instance, the 
naturally evolved strategies by viruses are incomparably more efficient than those 
envisioned for non-viral vectors. Haemagglutinin (HA) protein, which is pH sensitive and 
membrane destabilizing, helps viral vectors to disrupt the endosome efficiently and enter 
the cytoplasm.211 The escape mechanism of HA and other fusion proteins is that they 
shift from an ionized and hydrophilic conformation to a hydrophobic and membrane-active 
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conformation as the environment changes from neutral to acidic, resulting in 
destabilization of the endosomal membrane and its subsequent leakage (Figure 34).212 
Though still a matter of debate, this is much alike the endosomal escape mechanism 
responsible for the gene transfer efficiency of lipidic vectors. The interaction of cationic 
lipids with anionic phospholipids, a model introduced by Xu and Szoka,213 destabilizes 
endosomal membrane and facilitates its rupture (Figure 35). 214 
 
 
Figure 35. Proposed mechanisms of cationic lipid/nucleic acid complexes after endocytosis along 
the endosomal pathway: (1) cationic lipids interact with anionic lipids in endosomes by forming ion-
pairs; (2) the lipid bilayer is destabilized; (3) the hexagonal phase is formed; (4) the nucleic acid is 
released into the cytoplasm.215 
 
Conversely, the gene transfer efficiency of certain cationic polymers is associated to 
their pH buffering capabilities by virtue of the proton sponge effect.65 Endosomal pH 
gradually drops from physiologic (ca. 7.5) to acidic (ca. 5-5.5) upon maturation, a pH 
range in which nearly half of high-molecular weight PEI nitrogens may protonate. This 
large buffering capacity may be accompanied by extensive swelling to compensate the 
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osmotic pressure and/or conformational changes in the DNA-carrier assembly that leads 
to endosome destabilization and subsequent bursting (Figure 36).86 It is hypothesized 
that the proton sponge mechanism is not only valid for PEI but is more generally 
applicable for compounds containing amino groups with pKa values at or below 
physiological pH. 
 
 
Figure 36. Endosomal rupture is mediated by polymers with a buffering capacity at the endosomal 
pH range that can trigger (a) the proton-sponge effect and (b) polymer swelling according to the 
umbrella hypothesis.65 
 
Considering the similarities regarding the endocytic mechanisms between paCD 
CDplexes and PEI polyplexes, it was of interest to investigate the pH buffering 
capabilities of paCDs and their aggregates. 
In general, the pKa of each amine group in a polyamine is affected by the type of 
amine (primary, secondary, tertiary, or quaternary), electronic factors more than steric 
factors, and especially by the distance between neighboring amines.216,217 A variety of 
methods for the determination of polyamine pKa values exist. The most common is 
potentiometric titration, which is characterized by a high accuracy although a relatively 
large amount of pure compound is required.218 Alternatively, any other property directly or 
indirectly affected by protonation can be used as probe for pKa determination (UV 
absorption, electrophoretic mobility or LC, among others).217 NMR-pH titration is also an 
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excellent technique for determining pKa values as the protonation of a basic site leads to 
deshielding effects on the adjacent NMR-active nuclei, so the average chemical shifts of 
all the measureable NMR-active nuclei, as a function of pH, are expected to reflect the 
fractional protonation of each basic group of a molecule. NMR-pH titration offers the 
advantage of measuring pKa in solutions that are not pure, e.g. in the presence of 
biological fluids or even impurities,219 and may allow the sequence of polyamine 
protonation to be determined or even followed. 
To determine pKa values of a set of CD-scaffolded polycations synthesized in this 
Ph.D. Thesis (Figure 37), and to evaluate their buffering capacity, two different 
techniques were combined. 1H NMR-pH titration of non-amphiphilic polycationic CDs and 
their respective model compounds allowed gaining a first insight into the range of their 
pKa values. An advantage of this technique is that only small amounts of compounds are 
required, but cannot be used for self-aggregating paCDs . Alternatively, potentiometric 
titration was used for amphiphilic CDs instead. 
 
 
Figure 37. Compounds for 1H NMR-pH titration: CD-scaffolded polycations (A) and their 
corresponding monovalent models (B). 
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Thereby, 1H NMR-pH titration experiments were used to measure the pKa values of 
non-amphiphilic CDs 9 and 10, together with more simple cysteaminylated CD derivative 
32185a and the single branch models 50 and 51 (Figure 37). Compound 32 is the simplest 
one, only bearing cysteamine moieties, whereas both compound 9 and 10 additionally 
feature thiourea functionalities identified as the optimal tethers between the CD core and 
cationic cluster for gene delivery and expression. Keeping this element fixed, compound 
10 has an increased density of primary amine groups in a dendritic display and is 
additionally furnished with a tertiary amine group. Structural modifications may have an 
influence on pKa values of the primary amines corresponding to different CD derivatives. 
Furthermore, tertiary amines of compound 10 may have a lower pKa than primary amines 
and thus enable the proton sponge effect. Model compounds 50 and 51 (Figure 37) were 
synthesized by reacting butylamine with isothiocyanates 22 and 23, respectively (see 
Experimental Section for details) to assess the effect of the multivalent display on pKa 
values. 
 
Figure 38. pH-Dependent chemical shifts of polycationic CD 9 (500 MHz, D2O-H2O, 298 K). 
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In each titration the 1H NMR spectra were registered at different pH values (from 1.7 
to 11.7) and the shift of each resonance was plotted vs. pH, as shown for CD derivative 9 
in Figure 38 and Figure 39. 
Obviously, protons adjacent to the amine groups were most influenced by the 
fractional deprotonation of each basic group, though this effect only took place at pH 
above 7.5, thus discarding the any buffering capabilities in the pH window of interest for 
this compound. 
 
 
Figure 39. Sigmoidal curves representing changes in chemical shift (∆δ, ppm) of selected protons 
of compound 9 as a function of pH. The grey-shaded area represents the pH range where effective 
buffering ability may contribute to the lysis of the endosomes. 
 
The sigmoidal curves obtained for the most representative proton resonances (those 
adjacent to the primary amino groups) for the rest of CDs (10 and 32), their 
corresponding models (50 and 51) and bPEI are collected in Figure 40. Similarly to CD 
32, 9 and 50 exhibited a single protonation equilibrium between pH 7 and 11, while for 
the branched derivatives 10 and 51, and additional one was observed below pH 2, 
probably corresponding to the protonation of the tertiary amino group. This pKa value is 
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consistent with that reported for the tertiary amine of tris(2-aminoethyl)amine (ca. 2),220 
which bears structural resemblance to compounds 10 and 51. In any case, variations in 
the protonation state in the 5-to-7 pH range were unnoticed, in contrast to bPEI, 
exhibiting a continuous resonance shift along. 
 
 
Figure 40. pH-Induced chemical shift variations (∆δ, ppm) of the resonances of protons adjacent to 
primary amines from non-amphiphilic polycationic CDs 32 (), 9 () and 10 (), their 
corresponding models 50 (×) and 51 (ӿ) and bPEI (●). The grey-shaded area represents the pH 
range where effective buffering ability may contribute to the lysis of the endosomes. 
 
The pKa values were obtained by plotting according to the Henderson-Hasselbalch 
equation (4), 
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45 + 6 7289:98; 7<+,7<+,; 7+2,98  (4) 
 
in which δacidic and δbasic are the chemical shifts of the observed signal of the fully 
protonated and deprotonated compound, respectively, and linear fitting, as illustrates 
Figure 41. 
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Figure 41. Logarithmic plot according to the Henderson-Hasselbalch equation and linear fitting to 
determine the pKa value of CD-scaffolded polycation 9. 
 
Determination of pKa values of the CD-scaffolded polycations as well as both 
monovalent model compounds was accomplished analogously (Table 3). 
 
Table 3. Determination of pKa values of CD-scaffolded polycations and their corresponding model 
compounds. 
Polycation pKa Corresponding model compound pKa 
32 8.88 -  
9 8.50 50 9.41 
10 1.88, 9.77 51 2.27, 8.81 
 
 
No remarkable differences in the pKa values of compounds 9 and 32. In contrast, the 
pKa value of polycation 10 is considerably higher, though still in the range for primary 
amines.216,221 pKa Values for the model compounds 50 and 51, mimicking a “slice” of their 
analogous multivalent platforms 9 and 10, deviate less than one pKa unit. These results 
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led to the assumption that the multivalent character of CDs does not significantly affect 
the pKa values of its amines. 
In any case, as can be inferred from Figure 40, non-amphiphilic CD-scaffolded 
polycations apparently do not act as proton sponges upon acidification within endosomes 
because they lack pH-buffering capacities in the pH range from 5 to 7. This scenario, 
however, may change when CD-scaffolded polycations are aggregated to each other. 
Hydrophobic modifications of polycationic CDs might be relevant to enhance endosomal 
escape, because they could improve the interactions between vectors. As amphiphilic 
polycationic CDs self-assemble in aqueous environment, precluding 1H NMR-monitored 
pH titration experiments, their buffering capacities were evaluated by potentiometric 
titration. 
 
 
Figure 42. Amphiphilic and non-amphiphilic CD derivatives for potentiometric titration. 
 
Representative amphiphilic and non-amphiphilic CD derivatives differing in their 
polycationic structure were chosen in order to assess the influence of aggregation on 
their buffering capacities (Figure 42). Keeping the dendritic polycationic display of 
compound 10 fixed, amphiphilic derivative 7 additionally bears butanoyl chains on the 
secondary rim. Amphiphilic compound 3 features lower charge density, while acyl chain 
length is similar to that of 7. For comparative purposes, model compounds 50 and 51, 
bPEI and a blank (150 mM NaCl aqueous solution) were also titrated potentiometrically in 
the 9-to-2 pH range. 
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Each compound (0.05 mmol of amino groups) was first treated with diluted NaOH to 
adjust pH to approximately 9, and then the pH of the solution was measured after each 
addition of aliquots of diluted HCl. The results are summarized in Figure 43. In agreement 
with 1H NMR-pH titration experiments, non-amphiphilic CD-scaffolded polycations 10 and 
32 do not buffer pH in the 7-to-5 range, very much alike model compounds 50 and 51, as 
their acid-base titration curves drop down rapidly in this range. In contrast, amphiphilic 
CD derivatives 3 and 7 showed improved buffering capacities in this pH range, requiring 
a larger amount of HCl to drive pH to the acidic region. 
 
 
Figure 43. Potentiometric titration profiles of amphiphilic and non-amphiphilic polycationic CDs as 
well as their respective model compounds and bPEI. The grey-shaded area represents the pH 
range where effective buffering ability may contribute to the lysis of the endosomes. 
 
As shown in Table 4, among all CD derivatives studied, branched paCD 7 exhibited 
the best buffering capacity, although it could not compete with the golden standard bPEI. 
Its linear amphiphilic analog 3 also featured good buffering ability, which clearly 
evidenced that amphiphilicity, and hence self-aggregation, substantially enhances the 
buffering capacity of CD-scaffolded polycations. 
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Table 4. Equivalents of HCl consumed to switch pH from 7 to 5 for amphiphilic and non-amphiphilic 
polycationic CDs as well as their model compounds and bPEI. 
Compound meq of HCl consumed 
3 67 
7 84 
10 34 
32 34 
50 17 
51 <17 
bPEI 134 
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5. Assessment of DNA-paCD complex (CDplex) 
formation and dissociation 
Facile cellular uptake of free DNA via plasma membrane permeation is hindered by 
the size and negative charge of the DNA. Although several studies have shown that 
naked DNA can be introduced into cells the in vivo relevance of these techniques is 
limited. Systemic circulation of free DNA is hindered by nuclease degradation. Thus, 
compaction and masking the negative charge of its polyphosphate backbone constitutes 
a prerequisite for effective DNA delivery. Gene-carrier complex formation is known to 
critically determine gene transfer efficiency. The size of the complex and stability 
significantly depends on the type of cationic structure used, although preparation 
conditions including concentration of DNA, pH, type of buffer, and N/P ratio also affect 
size.55 Moreover, particle size affects the extent to which nanoparticles are taken up and 
are able to transfect cells, as the endocytotic machinery and cell membrane have well-
defined geometries and flexibility that may restrict entry of incompatibly large or small 
particles.222,223 
 
 
Figure 44. Two-step self-assembling mechanism of paCDs in the presence of DNA. 
 
Along with size, surface charge (ζ potential) also critically determines particle fate and 
transfection efficiency. It is generally believed that positively charged nanoparticles 
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perform better for in vitro transfections of cells through their enhanced binding to 
negatively charged proteoglycans on cell surfaces,224,225 though interaction with 
negatively charged serum proteins, could also be a drawback.226 It has been shown that 
paCDs furnish small nanoparticles (CDplexes) with narrow polydispersity upon incubation 
in the presence of pDNA. These CDplexes are spherical and positively charged (av. 30 
mV, Figure 45) with an average size below 100 nm. CDplex formation has been 
hypothesized to take place through a two-step self-assembling mechanism of paCDs in 
the presence of pDNA, as shown in Figure 44.177 
The first step is a rapid and reversible electrostatically driven interaction between 
phosphates and the positively charged amine headgroups of paCDs, during which the 
paCDs act separately in an independent manner. Driven by desolvation, the second 
probably slower and essentially irreversible step involves the fusion and rearrangement of 
the paCDs, thus triggering extensive compactation by hydrophobic interactions.227 
 
 
Figure 45. TEM micrograph of paCD 52:pDNA CDplexes with amplification of the ultrafine structure 
of the particles and a schematic representation of the proposed arrangement of paCDs and the 
DNA double helix. 
 
Transmission electron microscopy (TEM) showed the small size (40 nm) and 
homogeneous distribution of CDplex formulations from thioureido-cysteaminyl paCD 52 
74 Ph.D. Thesis - Iris Pflueger 
 
 
(Figure 45).177 At high magnification, a snail-like ultra-structure was observed, which has 
been attributed to the alternating lamellar arrangements of paCDs and electron-dense 
regions corresponding to the pDNA molecule, similarly to that reported by Pitard and co-
workers (see Figure 12, Chapter 1).81b 
The spontaneous self-assembly of CDplexes may seem very simple in its concept, yet 
could determine their characteristics (stability, biocompatibility, membrane-crossing ability 
etc.) and, thereby, their transfection potential. Control of the hydrophilic/hydrophobic 
balance between the CD primary and secondary faces is therefore crucial for efficient 
pDNA complexation and nanoparticle (CDplex) formation. Among the most important 
parameters that are affected by the molecular architecture of paCDs are complex size 
and uniformity, complex overall charge, as well as its pDNA condensation and 
dissociation capabilities. For a better understanding of the effects of structural variations 
on the molecular construct in the CDplex stability and its physicochemical properties, in 
this Ph.D. Thesis a deep insight on CDplex formation and dissociation capabilities of 
paCDs differing in their hydrophobic/hydrophilic balance was accomplished. 
 
 
Figure 46. Schematic representation of a conventional, 90º dynamic light scattering (DLS) 
instrument.228 
 
First, the DNA-paCD nanoparticles were characterized by dynamic light scattering 
(DLS) in order to determine their average hydrodynamic size and ζ potential. Briefly, the 
DLS technique measures the time-dependent fluctuations in the intensity of scattered 
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light, which occurs because the particles are undergoing random Brownian motion. 
Analysis of these intensity fluctuations enables the determination of the distribution of 
diffusion coefficients of the particles, which can be converted into a size distribution using 
established theories (Figure 46). 
 
 
Figure 47. Schematic representation of zeta potential.229 
 
In general, the surface charges of particles dispersed in an aqueous system modify 
the distribution of the surrounding ions, resulting in a layer around the particle that is 
different to the bulk solution. The ζ potential is the potential at the point in this layer where 
it moves past the bulk solution (slipping plane, Figure 47). ζ Potential is one of the main 
features that determine particle interactions, thus a high zeta potential will confer stability, 
i.e. the solution or dispersion will resist aggregation. ζ Potential measurement were 
performed by a technique called M3-PALS, which is a combination of laser Doppler 
velocimetry and phase analysis light scattering (PALS) to measure particle 
electrophoretic mobility. The mobility measured is converted to ζ potential using 
established theories. 
76 Ph.D. Thesis - Iris Pflueger 
 
 
The capability of the polycationic CDs differing in their hydrophobic/hydrophilic 
balance synthesized in this Ph.D. Thesis (Figure 48) to form stable CDplexes with DNA 
(calf thymus) was studied at N/P ratios 5 and 10. This ratio, which represents the ionic 
balance within the complexes, is referred to the number of protonable amino groups (N) 
in the polycationic CD per phosphate (P) of DNA. These N/P ratios were chosen since at 
these proportions the most efficient transfection has been achieved in earlier 
reports.177,181 To avoid premature self-aggregation phenomena, the CD stock solutions 
were prepared in DMSO and further diluted with the DNA solution in a 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer at physiological pH, 
thereby assuring that the final DMSO content never exceeded 1% v/v. 
 
 
Figure 48. Library of polycationic CDs for particle size and ζ potential measurements. 
 
The DLS results showed that all assayed polycationic amphiphilic CDs as well as their 
non-amphiphilic analogs formed compact, ordered and stable nanoparticles with DNA, 
Chapter 2  77 
 
exhibiting rather small hydrodynamic diameters as compared with the polyplexes 
obtained using branched polyethyleneimine (bPEI, 25 kDa), one of the most efficient 
commercial gene-delivery systems (60-90 nm vs. 150 nm; Figure 49).230,231 
 
 
Figure 49. Size (hydrodynamic diameters, bars, nm) and ζ potential (lines, mV) of CDplexes 
determined by dynamic light scattering and M3-PALS analysis, respectively. 
 
Hydrodynamic diameter measurements demonstrated that particle size scarcely 
depends on paCD structure. Even in the case of non-amphiphilic CDs 9 and 10, 
hydrodynamic diameters could be measured in the range of 70 nm, in contrast to our 
previous observations,177 but in agreement with that reported for other non-amphiphilic 
CD-scaffolded polycations.169 Reineke and co-workers demonstrated that structurally-
related non-amphiphilic polycationic CD condense pDNA at N/P 5 into spherical 
nanoparticles in the size range of 80-130 nm. These nanoparticles exhibited near neutral 
to positive zeta potentials (+5 < ζ < +15 mV). 
In particular, non-amphiphilic CD derivatives 9 and 10 exhibited similar hydrodynamic 
diameters to their hexanoylated counterparts (ca. 70 nm). While this result may sound 
counterintuitive, their hydrodynamic diameters do not reflect how nanoparticles are 
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compacted and similar values could still reflect quite different behaviors for any case. The 
proposed two-step compaction process cannot be operating for the formation of this non-
amphiphilic nanoparticles. 
Additionally, narrow populations of cationic nanoparticles were observed in each 
individual experiment, thus indicating rather monodisperse nanoparticles (Figure 50). 
Such remarkable behavior (low particle size and monodispersity) has only been reported 
for a monomolecular condensation process that occurs upon mixing DNA with 
dimerizable, polycationic detergents.84a,232,233 
 
 
Figure 50. Particle size distribution by volume determined by DLS for paCD 8 at N/P 5 (diameter in 
nm). 
 
M3-PALS measurements at both N/P ratios 5 and 10 revealed that ζ potential ranked 
in the range 30-70 mV, amenable values for cell-based assays. ζ potential values did not 
depend on the N/P ratio, which indicated that complex stoichiometry does not significantly 
change upon an increase of the N/P ratio. We hypothesize that excess CD does not 
incorporate into the CDplex nanostructure. Previous results of our research group 
indicated that nanoparticles of non-amphiphilic CDs exhibited zeta potential values close 
to neutrality even at high N/P ratio, although these CDplexes were not stable.177 In sharp 
contrast, ζ potential values of CDplexes of non-amphiphilic CD derivatives 9 and 10 were 
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clearly in a positive range (ca. 40 and 50 mV, respectively, for both N/P ratios), thus 
perfectly fitting within the scope of paCDs. Results reported by Reineke and co-
workers169 support these findings, since they also demonstrated that non-amphiphilic CDs 
were capable of binding and compacting pDNA at N/P 5 into spherical nanoparticles with 
slightly positive zeta potentials. 
Altogether, DLS experiments pointed out that all polycationic CD derivatives 1-10 were 
able to form nanoparticles with DNA, regardless of their hydrophilic/hydrophobic balance. 
All these CDplexes featured remarkably similar hydrodynamic diameters, ζ potentials and 
relatively narrow size distributions. 
These results were contrasted using agarose gel electrophoresis shift assays. Thus, 
paCD:ctDNA  complexes were formulated in the same manner as described before for 
different N/P ratios in the range of 0.5 to 20. Naked ctDNA was used for comparative 
purposes. A decrease of DNA migration up to complete inhibition could be observed at 
different N/P ratios for all tested CD derivatives. Moreover, if DNA is efficiently compacted 
and protected in the CDplexes, it becomes inaccessible to the GelRed™ (Biotium), a 
fluorescent intercalating agent used as staining reagent, as demonstrated by the absence 
of fluorescent staining in the corresponding lanes (Figure 51). 
At N/P ratios higher than 1, DNA charge neutralization and migration were achieved 
with all assayed polycationic CDs, which was indicated by the absence of “free” mobile 
plasmid. However, still an intense GelRed™ stain is visible in most of the cases. At N/P 
ratios higher than 1, however, paCDs bearing acyl chains of different length showed 
essentially different behaviors, thereby evidencing the subtle differences between 
nanoparticles with respect to amphiphilicity. From N/P ratio 2 and up, linear amphiphilic 
CDs 2, 3 and 4, as well as branched analogs 6, 7 and 8 were capable to efficiently 
compact and protect DNA in their CDplexes, which was indicated by the absence of 
fluorescent staining in the corresponding lanes. On the contrary, the CDplexes formulated 
with both acetylated (1 and 5) and non-amphiphilic (9 and 10) derivatives did not compact 
and protect DNA efficiently, since it remained accessible to GelRed™ in the whole range 
of N/P values, including even high N/P ratio 20. 
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Figure 51. Protection of DNA from GelRed™ intercalation at different N/P ratios (0.5-20) by paCDs 
1-8 and their non-amphiphilic analogs 9 and 10. 
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These results clearly evidenced that CD derivatives that bear longer acyl chains cover 
the DNA surface more efficiently. However, no remarkable difference between paCDs 
featuring either four-membered or six-membered acyl chains was detected. When 
comparing the linear and the branched subseries among one another, it has to be kept in 
mind that equal N/P ratios do not correspond to equimolecular ratios. To put it differently, 
for the preparation of CDplexes with a given N/P ratio the number of moles of linear CD 
derivatives required triples that of branched CDs. This is a considerable factor because 
therapeutic doses of non-viral gene delivery systems are related to issues of 
immunogenicity and toxicity. 
Additionally, for paCDs 4 and 6 gel electrophoresis shift assays were accomplished 
using luciferase-encoding pDNA for CDplex formation. Whereas ctDNA used so far 
consists of 13000-20000 base pairs (13-20 kbp), luciferase-encoding pDNA (later used 
for later transfection experiments) is only 5739 bp long. Hence, the question rose whether 
CDplexes formulated with either ctDNA or pDNA would have similar characteristics. 
Indeed, the results obtained for both paCDs in gel electrophoresis shift assays using 
luciferase-encoding pDNA were very similar to those obtained for ctDNA. 
 
 
Figure 52. Schematic representation of the experiment designed for fluorescence tracking of 
CDplex formation and dissociation. 
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To get to the bottom of CDplex assembly, both paCD-DNA complex condensation and 
dissociation characteristics have been investigated by fluorescence spectroscopy 
techniques. For an insight into CDplex formation kinetics, a fluorescence quenching 
assay based upon exclusion of RedSafe™ (iNtRON Biotechnology), a DNA intercalating 
fluorescent dye, has been developed (Figure 52).234 RedSafe™ forms a fluorescent 
complex with DNA, however, when the dye is progressively excluded due to formation of 
CDplexes that are capable of protecting DNA, fluorescence intensity decreases gradually. 
Absence of fluorescence eventually indicates complete DNA compaction. 
 
 
Figure 53. paCD-dependent RedSafe™ displacement assays of different paCDs. 
 
In the title experiment, calf thymus DNA (3 µM in a base-pair basis) was incubated 
with different concentrations of each cationic CD in presence of the fluorescence reporter. 
Fluorescence intensity was monitored relative to [paCD], as depicted in Figure 53 
(excitation at 295 nm and emission at 525 nm). The interactions between DNA and CD-
scaffolded polycations were sufficiently strong, so that they could displace the fluorescent 
dye from the DNA strand, leading to a decrease in the fluorescence intensity of 
RedSafe™. It is worth mentioning that paCD concentration has been chosen as 
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independent variable of the experiment instead of N/P ratios. This facilitates comparison 
on a molar basis between linear and branched CD derivatives, since for the preparation 
of CDplexes with a given N/P ratio the number of moles of linear CD derivatives required 
triples that of branched CDs. 
All paCDs proved to condense DNA at relatively low concentrations. However, those 
furnished with longer acyl chains were far more efficient to exclude the fluorescent 
intercalating agent, thereby reducing the fluorescence intensity. All assayed paCDs 
endowed with branched polycationic domains, i.e. compounds 6, 7 and 8, surpassed 
those with linear aminothioureido segments, i.e. derivatives 1, 2 and 4, clearly pointing 
out their more favorable hydrophobic/hydrophilic balance for CDplex formation. paCD 8 
was the most efficient candidate at condensing DNA, followed by its analogs with shorter 
acyl chains. Branched paCD 6 showed comparable CDplex formation abilities to the 
linear derivative 4. This undoubtedly confirms that tuning the balance of acyl chain length 
and charge density is crucial for efficient DNA complexation. As expected, acetylated 
linear paCD 1 performed worse than all other evaluated amphiphilic CDs. Fluorescent 
dye displacement assays of non-amphiphilic polycationic CDs 9 and 10, however, did not 
match with the other results, since they seemed to displace RedSafe™ from the DNA 
strand at lower concentrations than their amphiphilic analogs (data not shown). As 
discussed before (see CAC measurements), this might be an artifact due to molecular 
inclusion of the fluorescent reporter into the cavity of the CD scaffold. 
Despite extensive studies on the complex formation between nucleic acids and non-
viral gene carriers unpacking of nucleic acids from delivery vectors is also essential to the 
gene delivery process. However, the dissociation mechanisms of most polycationic gene 
vectors are poorly known. The complexes may be dissociated in endosomes, in the 
cytosol or in the nucleus.207 It has been reported that the transfection efficiency of 
polylysine (PLL) gene delivery systems is significantly enhanced by using low-molecular-
weight PLL that can dissociate from DNA more rapidly than high-molecular-weight PLL.235 
Clearly, release of free nucleic acids from vectors is one of the most critical steps to 
determine the efficiency of non-viral gene delivery systems, as nucleic acids that remain 
bound to delivery vectors may be disabled to achieve expression. Thus, a correlation 
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between ease of complex dissociation and increases in transfection efficiency is quite 
evident. 
To assess CDplex dissociation and to compare the relative stability in biological 
media, heparin competitive displacement assays were performed on representative 
paCD-DNA complexes at a complexation ratio of N/P 5. Heparin is an polyanionic 
polysaccharide that is present in the extracellular matrix in many tissues and are found on 
the cell surface.236 Due to its anionic nature, Heparin can dissociate electrostatic 
complexes in a concentration dependent manner, as has been reported previously for 
lipoplexes,237 polyplexes238 and CD-based vectors.169 
 
 
Figure 54. Time-dependent RedSafe™ displacement assays of different polycationic CDs. 
 
To assess the stability of CDplexes towards heparin, pre-formed CDplexes were 
incubated with a given amount of heparin in the presence of RedSafe™ and fluorescence 
increase due to DNA release was monitored for several hours. Four paCDs, all belonging 
to the branched subseries, were assayed, i.e. compounds 6, 7, 8 and 10, with the 
purpose of investigating the influence of acyl chain length on CDplex dissociation kinetics 
(Figure 54). 
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The results indicated that CDplex dissociation kinetics is drastically influenced by acyl 
chain length, thus RedSafe™ fluorescence is far faster recovered when CDs are tailored 
with short acyl chains or even lack them. After exposure to heparin for approximately 30 
min, non-amphiphilic derivative 10 has released DNA completely, whereas its amphiphilic 
analogs with long acyl chains, i.e. 7 and 8, did not show significant complex dissociation 
even after 5 hours. As expected, propanoylated CD 6 exhibited intermediate dissociation 
kinetics. In the case of CD derivative 10 the recovered fluorescence intensity surpassed 
the 100% mark. Since intensities were referenced to the fluorescence intensity derived 
from control free DNA, which is continuously being degraded, delayed DNA release may 
lead to relative higher fluorescence intensity. In conclusion, CDplexes composed of 
paCDs with longer acyl chains are more easily formed, but also very slowly dissociated. 
Though protection from environment is more efficient with long-acyl-chain paCDs, 
transfection efficiency may be hampered by slow DNA-release kinetics, thus requiring a 
fine balance of both features. In this sense, both the charge density and the 
hydrophobic/hydrophilic balance have to be finely tuned for efficient DNA complexation 
and subsequent release. 
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6. Gene transfer capabilities towards COS-7 cell lines 
In collaboration with Dr. Christophe Di Giorgio (Univ. Nice-Sophia Antipolis, France) 
the gene transfer efficiency of CDplexes was evaluated towards COS-7 cells. For this 
purpose, a pDNA containing the gene encoding for luciferase (pTG11236, pCMV-SV40-
luciferase-SV40pA) was used. Luciferase catalyzes the oxidation of luciferin in a light-
emitting process (Scheme 10), being the amount of light produced associated to 
enzymatic activity and, thereby, to gene expression efficiency. In parallel, the total 
amount of proteins produced was also measured to estimate the metabolic activity of the 
transfected cells as compared to non-treated cells and the toxicity of the CDplexes. 
 
 
Scheme 10. Luciferase-catalyzed bioluminescent oxidation of luciferin. 
 
The transfection conditions optimized in previous works were used.177 CDplexes of all 
paCDs 1-8 differing in their hydrophobic/hydrophilic balance as well as their non-
amphiphilic analogs CDs 9 and 10 were evaluated (Figure 55). 
For comparative purposes, the naked pDNA and the commercial carrier JetPEI (22 
kDa, optimal N/P ratio) were used as negative and positive controls, respectively. The 
assays were run with CDplexes formulated at N/P 2, 5 and 10 in serum-containing (10%) 
media. These N/P ratios have been previously shown to achieve the best transfection 
levels while preserving low to moderate toxicity profiles.177 Conversely, despite the 
presence of serum proteins is known to be detrimental for gene transfer with CDplexes,177 
in order to preserve the biological relevance of the results it was decided to perform the 
experiments in its presence. The results, measured as the amount of expressed 
luciferase relative to the total proteins and expressed in a logarithmic scale, are collected 
in Figure 56. 
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Figure 55. Library of polycationic CDs for gene transfer assays. 
 
In agreement with previous observations in serum-devoid medium, non-amphiphilic 
CDs featured negligible gene transfer abilities in these experimental conditions. A barely 
1-order of magnitude luciferase expression increase (as compared to naked pDNA) was 
achieved regardless of the number of cationic groups (7 or 21, for 9 and 10, respectively). 
N/P ratio neither played a relevant role, except for the case of the CDplexes formulated 
with the heptacationic CD 9 at N/P 10, for with a relevant efficiency enhancement was 
measured but at the expense of much higher toxicity. Probably, the poor DNA-
condensing abilities of these CDs are at the origin of their poor performance, although 
other non-amphiphilic cationic CDs have been shown to achieve remarkable efficiencies 
in other cell lines.169 
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Figure 56. Luciferase-encoding gene transfer efficiency (A) and cell viability (B) in COS-7 cells 
treated with CDplexes formed with paCDs 1-8 and their non-amphiphilic counterparts 9 and 10 at 
N/P 2, 5 and 10. Naked pDNA and JetPEI polyplexes were used as negative and positive controls, 
respectively. 
 
Despite their amphiphilic structure, the acetylated and propanoylated paCDs featured 
a similar behavior to the non-amphiphilic CDs. Luciferase expression increases as 
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compared to naked pDNA ranged between 1 to 2 orders of magnitude. Again 
heptacationic paCDs 1 and 2 at the highest N/P ratio (10) exhibited the largest 
efficiencies but also considerable toxicities. In any case, in the best performing 
conditions, luciferase expression resulted more than 3 orders of magnitude lower than 
that achieved with JetPEI. Though acetylated and propanoylated paCDs have been 
shown to efficiently condense and compact DNA at these N/P ratios, the stability of their 
CDplexes is largely compromised in competing media, as illustrated previously. We 
hypothesize that the reason for such poor performance may lay on the fact that serum-
containing media could accelerate the dissociation of these particles, though other 
reasons may be considered. For instance, it has been shown that fusogenic capabilities 
of lipoplexes critically determine their cell membrane-binding and cell uptake abilities.210b 
These capabilities in paCDs equipped with short acyl chains are probably far from 
optimal. 
The experiments with hexanoylated and butanoylated paCDs, however, revealed a 
quite distinct scenario. Both series exhibited much higher transgene expression 
efficiencies, which might be linked to the higher stability of their CDplexes (see preceding 
sections), and an N/P-dependent performance, the highest efficiencies generally 
achieved at N/P 10. In contrast to previously reported observations in serum-devoid 
media,177 heptacationic paCDs resulted more efficient than 21-cationic ones. Even 
considering the paCD-pDNA mass instead of N/P ratio, heptacationic paCDs resulted 
more efficient than their branched counterparts. The branched paCDs 7 and 8, regardless 
of the acyl chain length, featured gradual transgene expression efficiency enhancement 
upon N/P increase and remarkably low cytotoxicities even at N/P 10. Interestingly, the 
CDplexes formulated with the corresponding heptacationic conjugates 3 and 4 resulted 
better performing even at the lowest N/P ratio (2). In this case, efficiency increased only 
mildly with N/P and was handicapped due to cytotoxicity at N/P 10 (as also observed for 
heptacationic CDs with shorter acyl chains).  
A remarkable efficiency decrease was observed for CDplexes formulated with paCD 8 
in the presence of serum. paCD 8 has been previously reported to surpass JetPEI 
efficiency towards COS-7 cells,177 though in 10% serum-containing media, efficiency 
drops by 3 orders of magnitude. It is also noticeable that the performance of its 
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heptacationic analog is only mildly affected by the presence of serum. And, the dramatic 
performance differences between butanoylated and propanoylated paCDs, which may 
arise from the comparatively distinct stability of their CDplexes in biological media, were 
even more astonishing. 
Altogether, these experiments led to the identification of the butanoylated 
heptacationic CD 3 as the best performing candidate, exhibiting luciferase expression 
levels almost equaling that of JetPEI but with a slightly better cytotoxic profile (43% vs. 
19% cell viability for 3 and JetPEI, respectively, at their best N/P ratio). A slightly lower 
but virtually non-toxic performance was achieved at N/P 5 with the same compound. 
These results also highlight that, despite paCD 3 is not the most efficient at DNA 
complexation, dynamics and kinetics of CDplex formation play a critical role in overall 
performance. Unfortunately, performance cannot be anticipated so far, due to the 
complex balance of supramolecular features that should be taken into account. But the 
reported results can be considered as a useful tool to experimentally tune up the carrier 
capabilities towards a particular target. 
  
 
 
 
CHAPTER 3 - DESIGN OF CD-SCAFFOLDED CYCLIC 
POLYAMINE CLUSTERS: ENGINEERING 
OLIGONUCLEOTIDE BINDING PATTERNS IN NON-
VIRAL GENE DELIVERY 
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1. Novel DNA binding motifs at improving the efficiency 
of artificial gene carriers 
A large array of cationic epitopes has been explored as nucleic acid binding elements. 
The topic has been comprehensively reviewed very recently.72a Some of the most 
commonly used are depicted in Figure 57. Amines with different substitution and pH-
dependent ionization degree are by far the most frequently used. Quaternary ammonium 
groups are permanently charged at any pH and consequently devoid of buffering 
capability.86 Amines and ammonium groups are rarely found alone, but combined in the 
most bewildering way to enhance their nucleic acid binding abilities and displayed onto 
polymeric or lipidic platforms aimed at zipping oligonucleotides through multipoint 
concerted interactions. 
 
 
Figure 57. Illustrative examples of some commonly used of cationic headgroups for non-viral gene 
carrier design. 
 
Aimed at exploring the effect of alternative cationic headgroups on paCD-based gene 
carriers, we have turned our attention to cyclic oligoamines, such as cyclen (1,4,7,10-
tetraazacyclododecane) and cyclam (1,4,8,11-tetraazacyclotetradecane), featuring quite 
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unique DNA-binding.239 Cyclen and cyclam are known to form stable complexes with 
transition metal ions.240 Cyclen and its simple N-functionalized derivatives, such as 
DOTA241 (N1,N4,N7,N10-cyclentetraacetic acid) and DOTAM242 (N1,N4,N7,N10-
cyclentetraacetamide, Figure 58) are widely used in the construction of a wide variety of 
functional molecules such as contrast agents for magnetic resonance imaging (MRI),243 
single photon emission computed tomography (SPECT)244 and positron emission 
tomography (PET),245 fluorescent246 and luminescent247 probes and metal sensors.248 
Many studies have also revealed that both cyclen249 and its metal complexes249b,250 may 
behave as artificial nucleases, featuring DNA-cleavage abilities, and protease-like 
catalytic activity.251 Macrocyclic polyamines, e.g. cyclen, cyclam or bicyclam AMD3100252 
(1,1′-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane), Figure 58) 
have also exhibited antitumor and anti-HIV activity.253 
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Figure 58. Structures of cyclen, its derivatives DOTA and DOTAM, cyclam and bicyclam AMD3100. 
 
Metal complexes of cyclam such as AMD3100-64Cu have been shown to be suitable 
PET probes for tracking cancer cells in vivo.254 Furthermore, ADM3100-based lipidic and 
polycationic conjugates have been exploited as cancer cell-targeted non-viral gene 
vectors.252,255 
Several factors may account for the unique oligonucleotide binding capabilities of 
cyclic oligoamines, such as cyclen and cyclam. The preorganization of the cyclic scaffolds 
may influence the phosphate binding capacity in a positive manner. The cyclen moiety is 
composed of repeated ethylenediamine units, comparable to those in PEI, while cyclam 
alternates ethylenediamine and propylenediamine segments. The cyclic arrangement of 
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amino groups in macrocyclic oligoamines exerts an important influence on their pKa 
values (Figure 59).256,257 
 
 
Figure 59. pKa values of cyclic oligoamines. 
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Figure 60. Molecular structures of lipids with cationic cyclen headgroups as gene vectors 
synthesized by Yu and co-workers.239a,259,260 
Chapter 3  95 
 
Considering these features, it is somehow surprising that the use of cyclic oligoamines 
in gene delivery has being barely investigated. To the best of our knowledge, until 2008 
only a single example of cyclen-based gene delivery system was reported, i.e. a dendritic 
polymer with a cyclen core.258 It was only five years ago when application of cyclen as 
DNA binding motif in gene vectors got rolling. Yu and co-workers239b were the first to 
describe a cationic lipid with a protonated cyclen headgroup (Figure 60a), yet this 
imidazolium salt group-containing gene carrier showed very poor transfection efficiency. 
To overcome this drawback, the same research group made a considerable effort and 
synthesized over the years a series of lipids bearing cyclen as cationic 
headgroup239a,259,260 (Figure 60b-l). By systematic modifications of both the hydrophobic 
tail259 and the functional linking group239a,260 gene delivery efficacies could be improved 
dramatically and transfection efficiencies of most cyclen-based cationic lipids surpassed 
that of Lipofectamine 2000™, thus exhibiting similar or slightly lower cytotoxicities than 
the lipoplexes prepared from Lipofectamine 2000™ and illustrating the potential of SAR in 
the improvement of transgene expression efficiency. 
Arbuthnot and co-workers261 reported a cyclen-conjugated cholersteryl derivative 
containing biodegradable carbamate linkers, and lipoplexes containing this lipid proved to 
be non-toxic DNA and siRNA delivery systems (Figure 61). Although cyclen-based 
lipoplexes resulted in efficient siRNA-mediated target gene silencing, almost catching up 
the efficiency of Lipofectamine 2000™, their efficiency was poor for DNA transfection. 
 
 
Figure 61. Molecular structure of the cyclen-conjugated cholersteryl derivative reported by 
Arbuthnot and co-workers.261 
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Nearly at the same time, cyclen-based polymers emerged.262 Yu and co-workers have 
pioneered the field of investigating cyclen-based cationic polymers for gene delivery. 
Initially, a cyclen-based side-chain homopolymer capable of self-assembling in presence 
of pDNA has been prepared by Yu and co-workers,262 however, its transfection efficiency 
has not been reported so far (Figure 62a). 
 
 
Figure 62. Molecular structures of cyclen-based cationic polymers as gene vectors synthesized by 
Yu and co-workers.262,263,264,265 
 
Recently, the same research group has reported a variety of cyclen-based polymeric 
vectors, including reticular cyclen-based polymer (Figure 62b),263 linear cyclen-based 
polyamine (Figure 62c),264 as well as diolglycidyl ether-bridged cyclens (Figure 62d).265 A 
biodegradable disulfide-linked version of the latter has been also reported.266 Almost all 
cyclen-based cationic polymers showed transfection efficiencies close to that of PEI (20 
kDa or 25 kDa) at N/P ratios in the range of 5-15 but reduced cytotoxicities. 
In addition, Jiang and co-workers267 synthesized chitosan grafted with two kinds of 
macrocyclic polyamines, i.e. cyclen and 1,4,7-triazacyclononane (TACN), at either C-2 or 
the C-6 position (Figure 63). They showed that, depending on the functionalization 
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position, physicochemical features could be tailored. Indeed, C-2-grafted chitosanes 
exhibited higher cytotoxicity and transfection efficiency than those grafted at C-6. 
 
 
Figure 63. Structures of chitosan grafted with cyclen or TACN on different positions. 
 
 
Figure 64. Structure of reducible polycationic chelators based on cyclam (The precise attachment 
position of the linker could not be determined. Any of the secondary amines are susceptible to 
modification). 
 
Besides, Oupický and co-workers268 described the first comprehensive report on the 
SAR of cyclam-based polymeric gene vectors (Figure 64). They designed a series of bio-
reducible cyclam-based polycationic Cu(II) chelators (RPCs) aimed at combining gene 
delivery and real-time PET monitoring. The cyclam moieties in the polycations retained 
their ability to form complexes with Cu(II). The presence of disulfide bonds in the 
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polycations resulted in substantially lower cytotoxicity than 25 kDa PEI. RPCs, regardless 
of the presence or the absence of Cu(II) ions, exhibited high transfection activity in vivo. 
With the purpose of disclosing the role of the cationic element in gene delivery, taking 
advantage of the modular design of paCDs, a set of monodisperse paCDs with different 
displays of cyclic oligoamines on the primary has been prepared using “click chemistry” 
methodologies and their physicochemical properties and structure-activity relationships 
have been explored. In particular, this chapter comprises the following aspects: 
• synthesis of CD-scaffolded amphiphilic cyclic polyamine clusters, 
• investigation of their self-assembling capabilities in aqueous environment, 
• evaluation of their pH buffering capacities, 
• assessment of their DNA-condensing abilities,  
• and evaluation of their gene transfer capabilities towards COS-7 and HeLa 
cells. 
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2. Design and synthesis of amphiphilic CD-scaffolded 
cyclic polyamine clusters 
Making use of the face-selective hydroxyl manipulation methodologies and following a 
similar skirt-type arrangement described before (Figure 65), lipophilic segments were 
introduced into the secondary rim of the CD core by esterification with long-chain acyl 
anhydrides in the presence of DMAP, thereby ensuring homogeneous acylation.174 The 
length of the acyl chains is a critical parameter. As has been demonstrated in the 
preceding chapter, compounds furnished with hexanoyl functionalities proved to be the 
most efficient ones concerning self-assembling, DNA-condensing and gene delivery 
capabilities. Consequently, hexanoyl chains were used to construct the hydrophobic 
domain. 
  
 
Figure 65. Schematic representation of the general structure of CD-scaffolded cyclic polyamine 
clusters. 
 
The multiple coupling of the βCD core with the cationic polyamine segments is a 
crucial synthetic step, since very efficient reactions are required to warrant 
monodispersity. In addition to the thiourea-forming used in the preceding chapter, the 
Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 144,169,180 has been exploited. Both 
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reactions have been shown to yield homogeneous conjugates, thereby the choice would 
be conditioned by the nucleic acid binding capabilities of the target structure rather than 
the reactivity itself.  
The synthetic approach comprises the preparation of secondary rim-acylated CD 
building blocks on the one hand, and synthesis of appropriate cyclic polyamine 
derivatives on the other hand.  Synthesis of the CD building blocks involved installation of 
a suitable functional group on the primary rim of the CD core, capable of undergoing 
“click” coupling reactions, and subsequent esterification of the secondary rim, as shown 
in Scheme 11. 
 
 
Scheme 11. Synthesis of lipophilic tail-containing CD building blocks 54180b and 21177. Reagents 
and conditions: a) NaN3, DMF, 80 ºC, 24 h, 88%; b) BocHN(CH2)2SH, Cs2CO3, DMF, 60 ºC, 48 h, 
70%; c) hexanoic anhydride, DMAP, DMF, 70 ºC, 16 h, 78%; d) i, 1:1 TFA-DCM, 2 h; ii, HCl, 99%. 
 
Starting from 11,175 nucleophilic substitution of the bromine atoms by either azide ( 
53)269 or N-Boc-protected cysteamine ( 13)185a took place with excellent yields. 
Subsequent acylation of the secondary hydroxyl groups in the presence of DMAP in DMF 
furnished compounds 54180b and 17177 in good yield. Finally, acidic hydrolysis of the 
carbamate groups of N-Boc protected compound 17 in quantitative yield led to the free 
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amine CD building block 21.177 Although both CD derivatives 54 and 21 could also be 
prepared via an alternative synthetic route, i.e. reversing the order of functionalization of 
the two CD faces, this alternative synthetic requires an additional chromatographic 
purification. 
On the other hand, both cyclen and cyclam are commercial available, though due to 
its expensiveness of the former (226 € per g, Aldrich), it was synthesized following the 
reported methodologies.240 Among the different strategies for the preparation of cyclen 
derivatives (Scheme 12)240, the most straightforward method is the 3+1 type cyclization. 
This approach was used by carrying out a Richman and Atkins condensation270 of linear 
1,7-disodium salt of 1,4,7-tritosyl-1,4,7-triazaheptane 55271 with a biselectrophile, namely 
1,3,5-tritosyl-3-azapentane 56,272 to obtain compound 57273 in good yields (Scheme 13). 
 
 
Scheme 12. Synthetic strategies for cyclen ring formation from acyclic precursors (PG protecting 
group, LG leaving group). 
 
 
Scheme 13. Synthesis of cyclen via a 3+1 type cyclization. Reagents and conditions: a) i, treatment 
of 55 with EtONa in EtOH, reflux, 5 min, 100%; ii, addition of 56 in DMF, 100 ºC, 20 h, 80%; b) i, 
conc. H2SO4, 100 ºC, 72 h; ii, 50% NaOH, 77%. 
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The resulting tetratosylated cyclen derivative 57 underwent H2SO4-mediated 
detosylation followed by alkaline aqueous work-up, yielding cyclen 58 in 77% overall 
yield. It is worth mentioning that final strongly alkaline aqueous work-up is essential, since 
free amine groups are required to successfully perform the posterior disymmetrization of 
the macrocyclic tetraamine. 
Tethering cyclen and cyclam to the CD scaffold requires selective functionalization 
with appropriate reactive groups, i.e. alkyne and isothiocyanate functionalities for click 
coupling to per-azido CD 54180b and per-amino CD 21,177 respectively. The direct 
formation of compound 60 by obviously more straightforward N-monofunctionalization of 
cyclen 58 with propargyl bromide, however, failed to produce the target product due to 
cumbersome purification and poor reaction yields. Although the rather different basicity of 
the four amino groups present in the cyclen ring should allow in principle for selective N-
monofunctionalizations,274 a mixture of products was obtained and cyclen derivative 60 
was isolated in a rather poor 12% yield. 
Alternatively, selective protection of amines prior to N-monoalkylation has been 
considered. The disposition of amino groups on the cyclic scaffold results especially 
favorable for selective protection of amines as tert-butylcarbamates.275 As reported in 
literature, reaction of cyclen with di-tert-butyldicarbonate gives the N-tri-protected product 
in high yield,276 and subsequent N-monoalkylation proceeds smoothly. Therefore, this 
efficient route was employed for the synthesis of cyclic polyamine building blocks 
furnished with alkyne or isothiocyanate functionalities (Scheme 14). 
Selective tri-N-Boc protection of free amine 58 was performed as described in 
literature276 using DCM as solvent instead of chloroform, which proved to afford improved 
yield of tri-N-Boc-cyclen 61 to 76%. Reaction conditions were extrapolated to cyclam 59, 
which could be transformed into the corresponding tri-N-Boc protected macrocyclic 
tetraamine 62 in good yield. 
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Scheme 14. Synthesis of cyclic polyamine building blocks. Reagents and conditions: a) 58, 
propargyl bromide, Et3N, CHCl3, 60 ºC, 24 h, 12%; b) 58 (61) or 59 (62), Boc2O, DCM, 20 h, 
76% (61) or 72% (62); c) 61 (63) or 62 (64), propargyl bromide, Et3N, CH3CN, µw, 120 ºC, 
1 h, 51% (63) or 35% (64); or rt, 72 h, 71% (63) or 67% (64); d) 61, n-1-azido-7-
bromoheptane 65, Et3N, CH3CN, µw, 120 ºC, 1 h, 93%; e) TPP, CS2, dioxane, 3 h, 71%; f) 61 
(69) or 62 (70), 1,6-hexamethylenediisothiocyanate 68, Et3N, DCM, rt, 16 h, 85% (69) or 
90% (70). 
 
As both cyclen and cyclam building blocks would be linked to the CD core by either 
thiourea-forming reaction or by CuAAC reaction, compounds 61 and 62 have been 
furnished with different tethers containing the corresponding anchor groups. In order to 
consecutively perform CuAAC reaction with CD heptaazide 54, compounds 61 and 62 
were N-alkylated with propargyl bromide. In both cases, alkylation reactions proceeded 
slowly at room temperature, although in good yields (71% for 63 and 67% for 64, 
respectively, Scheme 14). Interestingly, µw irradiation significantly shortened reaction 
times, but at the expense of yields. 
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To obtain isothiocyanate-armed cyclen and cyclam derivatives for subsequent 
thiourea-forming reaction with CD heptaamine 21, initially a similar N-alkylation approach 
to that described above was used. Reaction of tri-N-Boc protected cyclen 61 with n-1-
azido-7-bromoheptane 65, prepared by statistic substitution of n-1,7-dibromoheptane, 
under µw irradiation afforded azide 66 in good yield. Aza-Wittig type reaction of azide 66 
with triphenylphosphine-carbon disulfide277 afforded the corresponding isothiocyanate 67. 
Alternatively, cyclic polyamine derivatives 61 and 62 were reacted with an excess of 1,6-
hexamethylenediisothiocyanate 68278 to afford cyclen and cyclam-derived thioureas 69 
and 70, both furnished with a terminal isothiocyanate group on the aliphatic spacer. 
These dissymmetrization reactions proceeded smoothly in excellent yields and formation 
of bis-cyclen derivatives was not observed, provided a sufficiently large excess of 
diisothiocyanate was used (3 eq). 
In order to obtain CD-scaffolded cyclic polyamine clusters, both the CD building blocks 
54 and 21 and the armed cyclen and cyclam derivatives 63, 64, 67, 69 and 70 were then 
coupled by “click chemistry” methodologies (Scheme 15 and Scheme 16). The coupling 
of the CD core with the cyclic oligoamine blocks is not trivial, since coupling reactions are 
to take place at seven positions simultaneously, which requires very efficient procedures 
to warrant monodispersity. 
 
 
Figure 66. Structure of silica-supported heterogeneous catalyst Si-BPA·Cu+. 
 
The sevenfold Cu(I)-catalyzed azide-alkyne cycloaddition reaction between 
heptaazide 54 and alkynes 63 and 64 was accomplished using Si-BPA·Cu+ as solid-
supported catalyst in refluxing 3:1 tBuOH-H2O. Recent results had indicated the efficiency 
of silica-based nanoparticles incorporating bis(pyridyl)amine (BPA) Cu(I) chelating 
adsorbents Si-BPA·Cu+ to catalyze multiple CuAAC couplings180a,279 (Figure 66). 
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Scheme 15. Synthesis of cyclic oligoamine-grafted paCDs 75 and 76 by CuAAC reaction. 
Reagents and conditions: a) 63 (71) or 64 (72), Si-BPA·Cu+, tBuOH-H2O, reflux, 16 h, 97% 
(71) or 84% (72); b) i, 1:1 TFA-DCM, 2 h; ii, HCl, quantitative yield in both cases. 
 
Homogeneous heptatriazoles 71 and 72 were obtained in remarkable yields (97% for 
71 and 84% for 72, respectively, Scheme 15) after purification by flash column 
chromatography. ESI-MS and NMR confirmed homogeneity of both compounds and 
neither ESI-MS nor elemental analysis detected traces of copper ions (Figure 67; see 
Figures S40 and S41 for NMR and Figures S119 and S120 for MS spectra, Supporting 
Information). Although NMR spectra of CD-scaffolded cyclic polyamine clusters 71 and 72 
were recorded at elevated temperatures (60 ºC), line broadening due to restricted 
flexibility of Boc-protected cyclic polyamine segments was evident. 
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Figure 67. ESI-MS (top) and 1H NMR (bottom, 500 MHz, MeOD, 333 K) spectra of compound 71. 
 
All attempts to couple isothiocyanate derivative 67 to heptaamine 21 in a thiourea-
forming reaction failed to furnish the heptabranched product homogeneously. However, 
coupling of isothiocyanate derivatives 69 and 70, respectively, and CD building block 21, 
followed by purification by size exclusion chromatography, afforded monodisperse CD 
derivatives 73 and 74 in excellent yields, i.e. 75% for 73 and 77% for 74, respectively 
(Scheme 16). 
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Scheme 16. Synthesis of cyclic oligoamine-grafted paCDs 77 and 78 by thiourea-forming reaction. 
Reagents and conditions: a) Et3N, DCM, 40 ºC, 72 h; b) 69 (73) or 70 (74), Et3N, DCM, 40 ºC, 
72 h,  75% (73) or 77% (74); c) i, 1:1 TFA-DCM, 2 h; ii, HCl, quantitative yield in both cases. 
 
Homogeneity of both heptathiourea derivatives was confirmed by NMR and ESI-MS, 
as illustrated for 74 in Figure 68 (see Figures S42 and S43 for NMR and Figures S121 
and S122 for MS spectra, Supporting Information). As observed for the heptatriazole 
analogs, NMR spectra of compounds 73 and 74 showed broad signals even at high 
temperatures. 
Final carbamate hydrolysis in compounds 71-74 using TFA-DCM afforded the target 
compounds 75-78 in virtually quantitative yields after lyophilization. 
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Figure 68. ESI-MS (top) and 1H NMR (bottom, 500 MHz, MeOD, 333 K) spectra of compound 74. 
 
The set of CD-scaffolded cyclic polyamine clusters synthesized exhibits structural 
resemblance with the most efficient compounds studied in Chapter 2. Keeping the 
hydrophobic domain on the secondary rim unaltered, the polycationic head has been 
modified by introducing cyclic elements. The number and nature of protonable amino 
groups, however, differ among these compounds. Whereas branched polyamine 
segments contain two primary amines and one tertiary amine, cyclic polyamines possess 
three secondary amino groups in the case of the thiourea-tethered derivatives 77 and 78, 
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and an additional tertiary amino group in the case of triazole-linked paCDs 75 and 76. As 
anticipated by literature, theoretical calculations (MarvinSketch, ChemAxon) predict large 
disparities in pKa values of each amino group, which, as later demonstrated, exert 
important effects on the pH buffering abilities of these compounds (Figure 69). 
 
 
Figure 69. Calculated pKa values for acyclic and cyclic polyamine motifs. 
 
Cyclen derivative 60 has been also exploited as scaffold for further installing additional 
oligoamine branches. Thus, a series of isothiocyanate-armed Boc-protected 
(oligo)amines were prepared according to the sequence depicted in Scheme 17. 
Monotritylation of a terminal amino group and Boc-protection of the remaining amines 
was followed by selective trityl group cleavage. In situ treatment of the resulting 
monoamines with thiophosgene. furnished the target isothiocyanates derived from 
ethylenediamine, diethylenetriamine and spermine (12,186 85,177 and 86, respectively) in 
good overall yields. 
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Scheme 17. Synthesis of aliphatic linear isothiocyanate compounds 22,186 85177 and 86. Reagents 
and conditions: a) EDA (79), DETA (80), spermine (81), TrCl, DCM, 14 h, 89-95%; b) 79 
(82), 80 (83), 81 (84), Boc2O, DCM, 15 h, 86-93%; c) 82 (22), 83 (85), 84 (86) i, 2% 
TFA-DCM, 1.5 h; ii, CSCl2, CaCO3, 1:1 H2O-DCM, 1 h, 73-85%. 
 
 
Scheme 18. Synthesis of cyclen-based multivalent polyamino displays 87-89. Reagents and 
conditions: a) i, 1:1 TFA-DCM, 2 h; ii, HCl, 99%; b) 22 (87), 85 (88), 86 (89), Et3N, DCM, 15 
h, 96% (87), 88% (88), 68% (89). 
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Cyclen derivative 60 was obtained in almost quantitative yield from N-Boc protected 
cyclen 63 by acidic hydrolysis of carbamate groups. Coupling of the title isothiocyanates 
to the cyclen scaffold 60 proceeded smoothly in the presence of Et3N and alkyne-armed 
compounds 87-89 were obtained in good yields (Scheme 18). 
 
 
Scheme 19. CuAAC reaction of CD heptaazide 54 and cyclen-based alkyne 87. Reaction 
conditions are summarized in Table 5. 
 
To finally obtain homogeneous paCDs furnished with extended multivalent patterns 
of polyamino motifs, both the amphiphilic CD building block 54 and the cyclen-based 
multivalent polyamino displays 87-89 were then to be coupled by triazole-forming 
methodology. Unfortunately, this synthetic step turned out to be tricky. Taking 
advantage of the reaction conditions optimized before for the preparation of cyclen and 
cyclam-containing paCDs 75-78, in a first attempt the reaction between CD heptaazide 
derivative 54 and alkyne 87 was carried out in the same conditions used to couple the 
Boc-protected cyclen derivative 63 (Si-BPA·Cu+ in refluxing 3:1 tBuOH-H2O, Scheme 
19; Entry 1 in Table 5), but the reaction did not run to completion as denoted by NMR or 
ESI-MS. Integration of characteristic 1H NMR signals of the coupling adduct indicated a 
conversion of ca. 12%. Similar results were obtained for the coupling of the other two 
isothiocyanates 88 and 89, most probably the presence the thiourea tethers playing a 
role in catalyst inactivation. A variety of reaction conditions, including the use of different 
Cu(I) sources, solvents, reaction temperatures and times were explored, though none of 
them led to homogeneous conjugates. Conversion rates were estimated by integration 
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of characteristic 1H NMR signals (Table 5) after isolation of the reaction products by size 
exclusion chromatography. 
 
Table 5. Reaction conditions employed for CuAAC reaction of heptaazide 54 and cyclen-based 
alkyne 87 (1.1 eq relative to azide) shown in Scheme 19. The conversion rate was estimated by 
integration of characteristic 1H NMR signals of the purified products. (For entry 5 µw irradiation was 
used.) 
Entry Solvent Catalyst T (ºC) t (h) Conversion 
1 
tBuOH-H2O 
3:1 
Si-BPA·Cu+ 
(30 mg/mmol 87) 85 14 12% 
2 
tBuOH-H2O 
3:1 
CuI 
(0.2 eq relative to 87) 85 16 25% 
3 anh. DMF (EtO)3P·CuI (0.2 eq relative to 87) 85 16 5% 
4 anh. DMF (EtO)3P·CuI (0.2 eq relative to 87) 100 3 8% 
5 
tBuOH-H2O 
3:1 
CuI (0.2 eq relative to 87) + 
TBTA (0.2 eq relative to 87) 60 1 36% 
6 
tBuOH-H2O 
3:1 
CuI (0.2 eq relative to 87) + 
DIPEA (10 eq relative to 87) 85 15 30% 
 
 
Scheme 20. CuAAC reaction of model glucopyranoside 91 with cyclen derivatives 63 and 87. 
Reagents and conditions: CuI (0.2 eq relative to alkyne), 3:1 tBuOH-H2O, rt, 1 h. 
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To probe the origin of such impaired reactivity a series of experiments were carried 
out. Firstly, 6-azido-6-deoxy-2,3,4-tri-O-methyl-α-D-glucopyranoside 91280 was used as 
model compound in order to study its capacity to undergo CuAAC reaction with both tri-N-
Boc protected cyclen 63 and thiourea-functionalized analog 87 (Scheme 20). 
 
 
Figure 70. 1H NMR spectra (500 MHz, MeOD, 323 K) of cyclen derivative 63 in absence (A) and in 
presence (B) of 1 eq CuI. 
 
When CuI was used in catalytic amounts, i.e. 0.2 eq relative to alkyne, coupling of 
derivative 63 proceeded smoothly. In the case of cyclen derivative 87 no reaction took 
place under the same conditions, pointing to the Cu(I) complexing ability of the thiourea 
groups as the origin of catalyst inactivation. However, addition of excess CuI resulted in 
reaction completion at a rate similar to that observed for tri-N-Boc protected cyclen 63. 1H 
NMR spectra of both compounds 63 and 87 were recorded in absence and in presence of 
equimolar amounts of CuI (Figure 70 and Figure 71). Whereas the 1H NMR spectrum of 
cyclen derivative 63 remained unaltered upon addition of CuI, in the case of thiourea-
derived cyclen 87 a drastic change in its 1H NMR spectrum could be observed. This 
alteration clearly indicated complexation of Cu(I) ions by thiourea moieties present on the 
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cyclen framework. Addition of a second equivalent of CuI did not further alter the 1H NMR 
spectrum. 
 
 
Figure 71. 1H NMR spectra (500 MHz, MeOD, 323 K) of cyclen derivative 87 in absence (A) and in 
presence (B) of 1 eq CuI. 
 
Interaction of thiourea moieties with metals, in particular with copper,281 is well 
documented in literature,282 nevertheless, this issue has apparently been unnoticed when 
performing CuAAC chemistry in the presence of thioureas before.283 It has to be kept in 
mind, however, that conditions for coupling thiourea-derived cyclen 87 to an azide involve 
a critical complexity. The presence of three thiourea groups organized in a favorable 
manner on the cyclic scaffold makes compound 87 an efficient ligand for Cu(I). The 
complexation of Cu(I) by thiourea moieties, in turn, inactivates the metal for catalysis. 
Moreover, spatial proximity of the alkyne group to the three thiourea elements present on 
the cyclen scaffold further complicates CuAAC reaction, as Cu(I) needs to react with the 
alkyne to promote reaction. 
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In an attempt to overcome this drawback we have explored the use of Cu(I)-ligands 
that compete with thiourea moieties without compromising its catalytic activity. Among 
readily available Cu(I)-ligands TPP284 and tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA)285 (Figure 72) were chosen, and their potential to compete with 
thiourea-derived cyclen for Cu(I) chelation was investigated by NMR. 
 
 
Figure 72. Structure of tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA). 
 
Figure 73. Selected region of the 1H NMR spectra (500 MHz, MeOD, 323 K) of cyclen derivative 87 
in absence (A) and in presence of 1 eq of CuI and 1 eq of TBTA (B) and 1 eq of CuI and 4 eq TPP 
(C). 
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As shown in Figure 73, TBTA and TPP exhibited rather different affinities towards 
Cu(I). Whereas the 1H NMR spectrum of cyclen derivative 87 changed considerably when 
1 eq CuI and TBTA, respectively, were added, its 1H NMR spectrum remained unaltered 
upon addition of 1 eq CuI in the presence of 4 eq TPP. These findings indicated that 87 is 
a stronger chelator for Cu(I) than TBTA, but TPP can compete with it. Moreover, TPP has 
shown remarkable reaction rate enhancing activity of Cu(I) species in CuAAC.284 
 
Table 6. Reaction conditions employed for CuAAC reaction of model glucopyranoside 91 and 
cyclen-based alkyne 87 (1.1 eq relative to azide) under µw irradiation at 85 ºC (results for reactions 
carried out at rt or under thermal heating are not shown). 
Entry Catalyst Catalyst load (eq to alkyne) Solvent 
Rate 
1 
Cu(PPh3)2I 
93 
0.0 
tBuOH-H2O very slow 
2 MeCN slow 
3 toluene slow 
4 
0.1 
tBuOH-H2O moderate 
5 MeCN very fast 
6 toluene moderate 
7 
0.2 
tBuOH-H2O moderate 
8 MeCN very fast 
9 toluene fast 
10 
Cu(PPh3)3I 
94 
0.01 
tBuOH-H2O very slow 
11 MeCN slow 
12 toluene slow 
13 
0.1 
tBuOH-H2O moderate 
14 MeCN fast 
15 toluene moderate 
16 
0.2 
tBuOH-H2O moderate 
17 MeCN very fast 
18 toluene fast 
 
 
However, care must be taken using TPP in CuAAC due to the potential competence of 
Staudinger reaction.286 A variety of simple phosphine coordination complexes exist,287,288 
and they are often used in clicking reactions in organic solvents, in which cuprous salts 
have limited solubility. In this regard, in this Ph.D. Thesis two Cu(I)-TPP complexes, 
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namely Cu(PPh3)2I (93)289 and Cu(PPh3)3I  (94)290 have been synthesized. To identify the 
optimal reaction conditions, various solvents (MeCN, toluene and 3:1 tBuOH-H2O) and 
catalyst loads ranging from 0.01 eq to 0.2 eq (relative to alkyne), were screened for both 
catalysts. Furthermore, the influence of temperature and µw irradiation on the reaction 
rate has been examined. TLC was used to qualitatively evaluate the reaction progress 
(Table 6). 
 
 
Scheme 21. Synthesis of paCDs 97-99 furnished with functionalized multivalent cyclen platforms. 
Reagents and conditions: a) 87 (90), 88 (95), 89 (96), Cu(PPh3)2I 93, MeCN, µw, 85 ºC, 2.5 
h, 75% (90), 50% (95), 31% (96); b) i, 1:1 TFA-DCM, 2 h; ii, HCl, quantitative yield in all 
cases. 
 
The exhaustive screening of reaction conditions revealed that the best results could 
be obtained when the CuAAC reaction was performed in MeCN under µw irradiation at 85 
ºC and 0.1 eq of Cu(PPh3)2I 93 was employed as catalyst. Yet, substitution of this 
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phosphine complex by Cu(PPh3)3I 94 did not vary the reaction rate significantly, probably 
because various species coexist in the reaction mixture. 
Once established these optimal reaction conditions, the triazole-forming clicking 
reaction of both the lipophilic tail-containing CD building block and the cyclen-based 
multivalent polyamino displays was tackled (Scheme 21). 
Application of these conditions to the coupling of cyclen alkynes 87-89 to CD scaffold 
54, though TLC initially indicated acceptable reaction progress, did not yield fully 
homogeneous products. In the case of CD derivative 90, conversion was estimated in 
approximately 85%, according to the integration of characteristic 1H NMR signals, 
whereas reaction with more complex cyclen derivatives 88 and 89 resulted in slightly 
lower average substitution patterns (ca. 80% for 95 and 73% for 96; see Figures S54-S56 
for NMR spectra, Supporting Information). ESI-MS spectra of the crude samples are 
compatible with these conclusions. Nevertheless, final acidic hydrolysis of the carbamate 
protecting groups of heterogeneous compounds 90, 95 and 96 took place without any 
difficulty. 
Despite their heterogeneity, it appeared of interest to explore the self-assembling 
capabilities of these compounds, therefore the carbamate protecting groups were cleaved 
using the conventional conditions to quantitatively furnish the CD-scaffolded cyclic 
polyamine clusters 97-99. Unfortunately, these studies could not be concluded within the 
frame of this Ph.D. Thesis. 
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3. Assessment of self-assembling and pH buffering 
capabilities of cyclen/cyclam-grafted paCDs in 
aqueous environment 
Aimed at gaining insight into the relationship between structure and self-organizing 
capabilities of the CD-scaffolded cyclic polyamine clusters, their critical aggregation 
concentration and pH buffering abilities were measured accordingly to the methods 
reported in the preceding chapter. The study was focused on paCDs 75-78, which were 
critically compared to hexanoylated and butanoylated paCDs described in the preceding 
chapter (Figure 74). 
 
 
Figure 74. Series of paCDs decorated with cyclic (cyclen and cyclam) and acyclic oligoamines. 
 
First, the influence of the hydrophobic/hydrophilic balance on the self-assembling 
capabilities in aqueous environment has been examined. Their critical aggregation 
concentrations in aqueous environment are summarized in Table 7. For comparative 
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purposes, CACs of hexanoylated paCDs 4 and 8 with acyclic polycationic elements have 
been included in this table. 
 
Table 7. Critical aggregation concentrations in aqueous environment of cyclen/cyclam-grafted 
paCDs 75-78 and paCDs 4 and 8 with acyclic cationic elements. 
paCD with cyclic 
amines 
CAC (µM) paCD with acyclic 
amines 
CAC (µM) 
75 2.92 4 0.94 
76 2.85 8 2.79 
77 0.54   
78 0.38   
 
 
All paCDs studied in this chapter are furnished with the same hexanoyl chains; 
therefore, possible differences in their hydrophobic/hydrophilic balance would derive 
exclusively from different polycationic heads. Results, however, showed that CACs of 
hexanoylated paCDs bearing cyclic or acyclic polycationic elements did not significantly 
vary, and all of them were in the range from 0.4 µM to 2.9 µM. This indicated that 
hexanoyl chains were able to counterbalance arrays of seven (paCD 4), 21 (paCDs 8, 77 
and 78) and 28 (paCDs 75 and 76) cationic groups on the primary rim respectively, 
leading to low CACs in all cases. CAC values do not apparently depend on type of cyclic 
oligoamine (cyclen or cyclam), but on the type of tether, aggregation taking place for 
thiourea-linked conjugated at lower concentrations than for the corresponding triazole-
tethered analogs. However, it is unclear whether this is solely due to the nature of the 
tether or to the number of protonable nitrogen atoms in each series. 
Buffering capacities of cyclen/cyclam-grafted paCDs 75-78 in the pH range from 5 to 7 
were evaluated by potentiometric titration, and compared to that of paCDs 3 and 7 
furnished with acyclic cationic elements. The potentiometric titration studies were 
conducted over a pH range of 9-2. Additionally, model compounds 104-107, featuring 
identical cationic domains as their CD-scaffolded analogs, were synthesized (Figure 75). 
Their protonation profiles were determined by acid-base titration and compared to 50 and 
51. 
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Figure 75. Monovalent model compounds used for potentiometric acid-base titrations. 
 
 
Figure 76. Potentiometric titration profiles of monovalent model compounds 50, 51, 104-107. 
Titrations of NaCl and bPEI solutions are included for comparative purposes. The grey-shaded area 
represents the pH range where effective buffering ability may enhance lysis of the endosomes. 
 
The results are summarized in Figure 76. Similar to model compounds 50 and 51, 
whose acid-base titration curves drop down rapidly in the pH range between 7 and 5, 
triazole-bearing model compounds 104 and 105 apparently are devoid of buffering 
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capabilities in this range. In contrast, thiourea-tethered models 106 and 107 showed a 
certain buffering capability in this pH range. 
The potentiometric titration profiles of cyclen/cyclam-grafted paCDs 75-78 as well as 
paCDs 3 and 7 furnished with acyclic cationic elements are shown in Figure 77. All 
paCDs exhibited buffering capacities in the pH range from 7 to 5. Whereas buffering 
capacities of triazole-bearing paCDs 75 and 76 resembled those of paCDs 3 and 7, 
cyclen/cyclam-grafted paCDs 77 and 78 furnished with thiourea linkers presented 
considerably improved buffering abilities in this pH range. 
 
 
Figure 77. Potentiometric titration profiles of cyclen/cyclam-grafted paCDs 75-78, and paCDs 3 and 
7 with acyclic cationic elements. Titrations of NaCl and bPEI solutions are included for comparative 
purposes. The grey-shaded area represents the pH range where effective buffering ability may 
enhance lysis of the endosomes. 
 
To study the buffering capacities of paCDs 75-78 and their respective model 
compounds 104-107 in a more detailed manner, for each compound the equivalents of 
HCl consumed to switch pH from 7 to 5 have been quantified. A comparison of the results 
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with those obtained for paCDs 3 and 7 and their corresponding model compounds 50 and 
51 is shown in Table 8. 
 
Table 8. Equivalents of HCl consumed to switch pH from 7 to 5 for paCDs 3, 7 and 75-78, their 
respective model compounds (50, 51, 104-107) and bPEI. 
Compound meq of HCl consumed 
3 67 
7 84 
50 17 
51 <17 
75 67 
76 34 
77 168 
78 118 
104 <17 
105 <17 
106 50 
107 50 
bPEI 134 
 
 
The buffering capacities of all paCDs in the pH range 7-5 were better than those of 
their respective monovalent model compounds, which may indicate that either the 
multivalency of CD platform or their aggregation abilities improve their buffering capacity. 
The more favorable protonation profiles of monovalent models 106 and 107, as 
compared to all other model compounds, suggest that incorporation of cyclic polyamine 
groups into the CD scaffold via a thiourea tether adjacent to a flexible aliphatic spacer 
may result in improved buffering capabilities. Indeed, among all CD derivatives studied, 
cyclen/cyclam-grafted paCDs 77 and 78 furnished with thiourea linkers presented the 
best buffering capacities, catching up with the golden standard bPEI. Although slightly 
lower, the buffering capabilities of triazole-bearing paCDs 75 and 76 were similar to those 
of paCDs 3 and 7. Regarding the type of cyclic polyamine element, i.e. cyclen vs. cyclam, 
the cyclen motif evidently enhances buffering capacity. For cyclic polyamines grafted to 
the CD scaffold via triazole or thiourea linkers, cyclen derivatives 75 and 77 showed 
higher buffering capacities than their cyclam-grafted analogs 76 and 78, respectively. 
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4. Assessment of DNA-condensing capabilities of 
cyclen/cyclam-grafted paCDs 
To study the influence of cyclic polyamine headgroups on DNA-condensing 
capabilities the CDplex formation capabilities of paCDs 75-78 were critically compared to 
paCDs grafted with acyclic oligoamines (Figure 78). First, the paCD-DNA nanoparticles 
were characterized by dynamic light scattering (DLS) in order to determine their average 
hydrodynamic size and ζ potential using ctDNA at N/P ratios 5 and 10. 
 
 
Figure 78. Library of cyclen/cyclam-grafted paCDs (75-78) and paCDs synthesized in Chapter 2 
used for comparative purposes (3, 4, 7 and 8). 
 
The DLS results showed that all assayed cyclen/cyclam-grafted paCDs formed 
compact and stable nanoparticles with ctDNA that, with the exception of compound 75 at 
N/P ratio 10, exhibited rather small hydrodynamic diameters as compared with the 
polyplexes obtained from 25 kDa bPEI (80-100 nm vs. 150 nm; Figure 79). 
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Figure 79. Size (hydrodynamic diameter, bars, nm) and ζ potential (lines, mV) of CDplexes of 
paCDs 75-78 determined by DLS and M3-PALS analysis, respectively (for comparative purposes, 
CDplexes of paCDs 4 and 8 are included). 
 
Hydrodynamic diameter measurements indicated that modifications of the molecular 
structure of paCDs did not influence particle size significantly. Moreover, the N/P ratio did 
scarcely affect particle hydrodynamic diameter. Although nanoparticles of paCD 
derivative 75 exhibited an extraordinary large hydrodynamic diameter at N/P ratio 10, in 
general no substantial difference between analogous cyclen and cyclam-derived paCDs 
could be disclosed. Furthermore, the nature of the linking element marginally affected 
particle size, since paCDs 75 and 76 furnished with rigid and short methylene triazole 
segments and their respective analogs 77 and 78 bearing long and flexible aliphatic 
tethers and thiourea groups led to CDplex nanoparticles of almost the same size. These 
facts suggest that, despite their architectural disparity, the overall hydrophilic/hydrophobic 
balance is barely altered. 
Similar to the results obtained for acyclic oligoamines, narrow populations of cationic 
nanoparticles were observed in each individual experiment, thus indicating rather 
monodisperse nanoparticles (Figure 80). Such remarkable behavior (relatively low 
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particle size and polydispersity) makes CD-scaffolded cyclic polyamine clusters suitable 
candidates for artificial gene carriers. 
 
 
Figure 80. Particle size distribution by volume determined by DLS for ctDNA:78 CDplexes 
formulated at N/P 5 (diameter in nm). 
 
M3-PALS measurements at both N/P ratios 5 and 10 revealed that ζ potential of 
CDplexes formulated with cyclen/cyclam-grafted paCDs 75-78 ranked in the range 40-60 
mV, amenable values for cell-based assays. ζ Potential values were marginally depended 
on the N/P ratio, thus indicating that complex stoichiometry does not change significantly 
upon an increase of the N/P ratio. We hypothesize that excess paCD does not 
incorporate into the CDplex nanostructure. ζ Potential of CDplexes formulated with 
paCDs 4 and 8, however, were slightly higher than those with cyclen/cyclam-grafted 
paCDs (50-80 mV for paCDs 4 and 8 vs. 40-60 mV for paCDs 75-78, respectively). 
Altogether, DLS experiments pointed out that cyclen/cyclam-grafted paCDs 75-78 
were able to form stable nanoparticles with DNA. These nanoparticles all featured 
remarkably similar hydrodynamic diameters, positive ζ potentials and relatively narrow 
size distributions. 
Subsequently, their capabilities to compact and protect DNA were investigated by 
submitting the cyclen or cyclam-grafted paCDs 75-78 to agarose gel electrophoresis shift 
0
2
4
6
8
10
12
14
1 10 100 1000 10000
Vo
lu
m
e 
(%
)
Size (d.nm)
Size Distribution by Volume
Chapter 3  127 
 
assays. Therefore, paCD:ctDNA complexes were formulated in the same manner as 
described before for different N/P ratios in the range of 1 to 10. Naked ctDNA was used 
for comparative purposes. Complete inhibition of DNA migration indicated complex 
formation, whereas absence of fluorescent staining denoted efficient compaction and 
protection of DNA in the CDplexes of the corresponding lanes (Figure 81). 
At N/P ratios 1 or higher, formation of the respective CDplexes was achieved for all 
assayed paCDs, which was indicated by the absence of “free” mobile plasmid. Starting 
from N/P ratio 2, both cyclen and cyclam grafted paCDs were in addition capable to 
efficiently compact and protect DNA in their CDplexes. Although cyclen and cyclam 
moieties exhibit different spatial orientation of the cationic amino groups, no appreciable 
difference in their DNA-condensing capabilities could be inferred and efficient covering of 
the DNA surface by both cyclen and cyclam grafted paCDs has been clearly evidenced. 
 
 
Figure 81. paCD-mediated protection of ctDNA from GelRed™ intercalation at different N/P ratios 
(1-10) for cyclen/cyclam-grafted paCDs 75-78 and paCDs with acyclic polycationic elements 3, 4, 7 
and 8. 
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However, when triazole bearing paCDs 75 and 76 were compared with their thiourea 
analogs 77 and 78, respectively, a remarkable difference became apparent. Whereas 
triazole paCDs 75 and 76 were only capable of efficiently compacting and protecting DNA 
at N/P ratios 5 or higher, thiourea derivatives 77 and 78 already turned DNA inaccessible 
to the GelRed™ intercalating agent at N/P ratio 2. This difference might be attributed to 
the superior ability of thiourea segments to complement electrostatic phosphate binding 
via hydrogen-bonding interactions as compared to triazole tethers. Interestingly, the 
additional protonable nitrogen atom in the triazole-linked series, as compared to the 
thiourea-tethered one, does not compensate the beneficial effects added by the thiourea 
moieties. The presumably low pKa value of the additional tertiary amine in the triazole-
derived paCDs does not seem to favor DNA compaction and protection.256,257 
Compared to the library of paCDs prepared in Chapter 2, which differ in the length of 
the lipophilic chain and are furnished with either 7 or 21 protonable amino groups, cyclen 
or cyclam-grafted paCDs exhibited DNA compactation and protection capabilities similar 
to those of linear and branched paCDs bearing butanoyl or hexanoyl chains on the 
secondary rim. At N/P ratio 1 cyclen and cyclam-derived paCDs showed slightly better 
compactation capabilities as they completely inhibited DNA migration, while linear paCDs 
3 and 4 as well as branched paCDs 7 and 8, respectively, still demonstrated partial DNA 
migration. Nonetheless, regarding DNA protection, the most efficient paCDs prepared in 
Chapter 2 performed as well as cyclen or cyclam-derived paCDs, as all of them efficiently 
compacted and protected DNA at N/P ratios 2 or 5 at most. 
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5. Gene transfer capabilities towards COS-7 and HeLa 
cell lines 
Similarly to that reported in the preceding chapter, the gene transfer efficiency of 
CDplexes formed from cyclic amine-grafted paCDs was evaluated using the luciferase-
encoding gene (pTG11236, pCMV-SV40-luciferase-SV40pA) as reporter towards COS-7 
and HeLa cell lines.  
The experiments towards COS-7 cells were developed using in-house facilities to 
comparatively assess the performance of triazole-tethered paCDs 75 and 76 and 
thiourea-tethered CDs 77 and 78 (Figure 82) in the absence of serum. JetPEI and naked 
pDNA were included as positive and negative controls, respectively. In addition, paCD 8, 
furnished with a cluster of acyclic oligoamines,177 was also included in the experiments as 
positive control (Figure 82). 
 
 
Figure 82. Library of cyclen/cyclam-grafted paCDs 75-78 and acyclic reference paCD 8 screened 
as pDNA carriers towards COS-7 and HeLa cell lines. 
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Previous results indicated that paCD 8 CDplexes formulated at N/P 10 mediate 
comparable luciferase expression levels to JetPEI in COS-7 cells, up to six orders of 
magnitude higher than the corresponding naked pDNA.177 75- and 76-pDNA CDplexes 
paralleled the efficiency of both positive controls at the same N/P (N/P 10, Figure 83), 
though luciferase expression levels dropped by 3 and 4 orders of magnitude at the lower 
N/P ratio assayed (N/P 5, data not shown). No differences due to cyclic oligoamine 
structure (cyclen vs. cyclam) were noticed. In stark contrast, thiourea-tethered paCDs 77 
and 78 resulted far less efficient than their triazole-tethered counterparts. Though 
similarly performing at low N/P, they did not showed the efficiency boost at N/P 10. 
The dramatic change in transgene expression efficiency due to both N/P ratio and 
structure highlights the relevance of architectural parameters on the formation of paCD-
pDNA complexes and their stability. In all cases, the lowest N/P ratio assayed is far 
enough to condense pDNA into nanoparticles of similar size and ζ potential where pDNA 
is isolated from the media, as shown in the preceding sections. Quite remarkably, despite 
thiourea-tethered paCDs 77 and 78 exhibited the largest pH buffering capabilities, this 
feature does not seem to contribute much to their performance. Conversely, triazole-
linked paCDs 75 and 76 displayed critical aggregation concentrations significantly lower 
than their thiourea counterparts, which may furnish their CDplexes with different 
capabilities to interact with their environment. Though these structural effects would 
require further investigation, due to time constraints, a deeper insight could not be 
included into this Ph.D. Thesis. 
Conversely, experiments in the presence of serum-containing media (10%) masked all 
the above commented differences in gene transfer efficiencies (Figure 83, data for N/P 5 
not shown). In this scenario, neither N/P ratio (5 or 10) nor paCD architecture significantly 
affected the performance of CDplexes. While in the case of thiourea-tethered paCDs 
similar levels of luciferase expression were measured, the triazole-tethered paCDs 
resulted approximately 100-fold less efficient. 
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Figure 83. Luciferase-encoding gene transfer efficiency (A) and cell viability (B) in COS-7 cells 
treated with CDplexes formed with cyclen/cyclam-grafted paCDs 75-78 and the acyclic counterpart 
8 at N/P 10. Naked pDNA and JetPEI polyplexes were used as negative and positive controls, 
respectively. 
 
In collaboration with Prof. P. Midoux (Univ. of Orleans, France), cyclen- and cyclam-
granted paCDs have been further tested in HeLa cells, and their gene carrier 
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performance comparatively assessed against PTG, a cationic histidine-grafted αCD 
derivative featuring remarkable transfection capabilities towards different cell lines.291 
Experiments were run using virtually non-toxic CDplex formulations at N/P 5 in serum-
containing media (10%). The results were consistent with those observed for COS-7 
cells. In these conditions, performance of cyclen- and cyclam-grafted paCDs 75-78 is 2 to 
3 orders of magnitude lower than that measured for the acyclic oligoamine derivative 8, 
which is only marginally less efficient that PTG at its optimal N/P (6) (Figure 84). As 
observed for COS-7 cells, there is no apparent correlation between paCD structure and 
gene transfer capabilities, which might indicate that the presence of serum may affect 
CDplex stability. As previously described, CDplexes formed from thiourea-containing 
paCDs may better tolerate this media,177,180a which could explain the better performance 
of the cyclam-grafted thioureido derivative 78 as compared with the rest of the cyclic 
oligoamine series. Nevertheless, additional experimental evidences should be gathered 
to fully support this hypothesis. 
  
 
Figure 84. Luciferase-encoding gene transfer efficiency in HeLa cells treated with CDplexes formed 
with cyclen/cyclam-grafted paCDs 75-78 at N/P 5. PTG and the acyclic paCD analog 8 CDplexes at 
N/P 6 and 5, respectively, were used as positive controls. 
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CHAPTER 4 - SOLID-PHASE ASSISTED SELECTIVE 
FUNCTIONALIZATION OF MULTIVALENT SCAFFOLDS. 
APPLICATION TO SELECTIVE 
MONOFUNCTIONALIZATION OF CYCLODEXTRINS 
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1. Strategies towards selective functionalization of 
cyclodextrins: scope and limitations 
Selective methodologies for the functionalization of cyclodextrin framework either by 
chemical292 or enzymatic293 protocols have enabled the development of a plethora of 
applications for CDs.294 In addition to their utility in the design of self-assembling devices 
for drug and gene delivery (already covered in the previous chapters), selective 
functionalization strategies permitted the development of artificial enzymes,295 sensors,296 
catalysts,297 drugs,298 drug carriers,299 or molecular machines.300 However, it is somehow 
curious that, despite the myriad of applications, only a handful of regioselective synthetic 
methodologies are available for hydroxyl differentiation in CDs. The reason for this 
scantiness lies in the challenge of differentiating a certain functional group among a 
dense display of them. Most of these selective functionalization methodologies take 
advantage of the CD scaffolding or molecular inclusion capabilities to force a preferential 
orientation between the CD and CD-modifying reagent. Despite their undeniable utility, 
these strategies often require a tight matching between CD and reagent pairs, thereby 
their CD architectural scope being very restrictive. 
As illustrated in the previous chapters, the design of CD-based gene carriers has been 
facilitated by the use of synthetic routes that take advantage of CD facial anisotropy.1 
Making use of straightforward perfunctionalization approaches, CD-based facial 
amphiphiles exhibiting remarkable self-assembling, DNA-condensing and gene delivery 
capabilities were obtained. However, installing additional functionalities onto the CD 
platform at selected positions requires a cumbersome synthetic effort. Despite previous 
reports have demonstrated the interest of grafting bioactive elements onto amphiphilic 
CD scaffolds (e.g. biorecognizable saccharide epitopes for targeted delivery), the 
methodological arsenal is still limited and synthetic schemes are cumbersome183a,296f,299 
or do not provide with homogeneous conjugates.183b On the other hand, installation of an 
additional functionality on the gene delivery vehicle, such as a PET or SPECT imaging 
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moiety, or a fluorescent probe for optical imaging could deliver a theranostic device, an 
emerging concept permitting simultaneous diagnostic and therapy.301 
In native CDs there exist three types of hydroxyl groups attached to the C-6, C-2 and 
C-3 positions of the α-D-glucopyranosyl unit, respectively. Those at the C-6 position are 
the most basic and sterically accessible, those at the C-2 position are the most acidic, 
and those at the C-3 position are the least accessible.302 These subtle reactivity 
differences allow for relatively straightforward chemoselective differentiation among the 
three types of hydroxyls,292 but it is much more challenging to regioselectively 
differentiate between groups of the same type because of their identical chemical 
reactivity. A considerable amount of work has been invested in the search for methods to 
enable site selective functionalization of CDs. In general, methods for selective 
modification of CD can be divided into three categories:292 (i) the “long” method, involving 
a series of more or less straightforward protection and deprotection steps; (ii) the “clever” 
method, where the supramolecular features of CD are often exploited to get the desired 
product by the shortest route; (iii) the “sledgehammer” method, where indiscriminate 
(statistical) reaction leads to complex product mixtures and then the desired product is 
painstakingly separated from other isomers and homologues, e.g. by chromatographic 
methods. 
Among the “clever” methods for regioselective CD manipulation, the most successful 
ones are those taking advantage of a preferential approach and orientation of the CD-
modifying reagent. In this way, the reaction outcome can be significantly restricted as 
compared to that statistically expected. An illustrative example of this kind of approach is 
the Cu(II)-complex directed regioselective mono-p-tosylation at the C-6 position of 
CDs.303 Using p-tosyl chloride  as a reagent, 6I-O-tosylation of βCD is commonly 
achieved, either in pyridine304 or with water305 as solvent. Acyl transfer from 1-(p-
toluenesulfonyl)imidazole in water is a valuable alternative procedure,306 though 
regioselectivity is poor with these procedures. A significant improvement was described 
by Defaye and co-workers taking advantage of the sandwich-type chelate that βCD and 
Cu(II) ions form in aqueous alkaline solution (Scheme 22).307 This complex controls the 
orientation of tosyl chloride upon inclusion into the βCD cavity, promoting regioselective 
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6I-O-tosylation in excellent yields.303 Mono C-6-tosylated βCD is a handy entry to 
selectively monofunctionalized CDs, since the tosyl group can be readily displaced by a 
variety of nucleophiles. 
 
 
Scheme 22. Schematic representation of βCD and its inclusion complex-mediated transformation 
into the mono-C-6-O-tosyl derivative. 
 
Taking advantage of the rigidity of the different CD scaffolds, some innovative 
strategies have also being devised to functionalize several selected hydroxyls at the 
same time.308 For instance, using sterically hindered tritylating reagents (method A in 
Figure 85) Knowles and co-workers managed to selectively obtain a C-6I,III,V-tri-tritylated 
αCD derivative long ago.309 
Alternatively, bifunctional reagents have been also exploited to regioselectively 
produce otherwise inaccessible CD functionalization patterns (method B in Figure 85). 
Carefully selecting the geometry of bis-sulfonyl or bis-acyl chlorides, Tabushi and co-
workers prepared the first examples of capped CDs.310 The concept has been refined 
later with the use of other bis-tritylating311 or alkylating reagents312 which selectively react 
with two selected hydroxyl groups of the CD according to the length and geometry of the 
tether. This cap-assisted synthetic strategy313 has mainly been developed on βCD. The 
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geometry of selected arene disulfonyl chlorides controls very efficiently the 
regiochemistry to selectively furnish AB, AC, or AD isomers (Figure 86).314 For example, 
biphenyl-based capping reagents preferentially give AD isomers, benzophenone-based 
reagents lead to AC isomers, and 1,3-benzenedisulfonyl chlorides give AB isomers. 
 
 
Figure 85. General methods for difunctionalization of CDs.308 
 
 
Figure 86. 6-Disulfonated βCDs: the regioselectivity depends on the choice of sulfonylating 
reagents. 
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Matt and co-workers315 employed 1,3-bis[bis(4-tert-butylphenyl)chloromethyl]benzene 
("bis-trityl dichloride", Figure 87) as regioselective capping reagent for the preparation of 
A,B-bridged α- and βCD derivatives.311a Taking advantage of this bulky protecting group, 
selectively tetrafunctionalized CD derivatives could also be accessed.311b,316 
 
 
Figure 87. Capping reagents "bis-trityl dichloride" and α,α’-dibromo o-xylene for regioselective CD 
functionalization. 
 
Small capping reagents based on phosphines, sulfides316,317 and sulfates318 have also 
been proven suitable intermediates for the preparation of tri-differentiated CD derivatives. 
Though most of these capping reagents were designed for primary rim hydroxyl 
differentiation, remarkably efficient procedures have also been envisioned for secondary 
hydroxyls. An in-house-developed methodology permits the straightforward preparation of 
2I,3I-O-capped CDs by incorporation of the o-xylene group (Figure 87) to the vicinal diol 
system presents a remarkable efficiency.312 
But probably the strategy that has demonstrated the greatest potential for tailored 
manipulation of CD topology is the one based on the regioselective DIBAL-H-mediated 
dealkylation pioneered by Sinaÿ and Sollogoub (method C in Figure 85).319 In a series of 
excellent contributions, these authors have rationalized the action of DIBAL-H over per-
O-alkylated CD derivatives implementing strategies to use this reagent as a molecular 
scalpel to sequentially rip off selected protecting groups (mostly benzyls) with astonishing 
regioselectivity.308 For example, in the cases of α- and βCDs, only benzyl group(s) 
attached to O-6 positions of the A and D units are cleaved, the selectivity probably being 
enhanced by the steric collapse at the primary rim due to the volume of the protecting 
groups and the reagent (Scheme 23). The reaction is proposed to proceed in two steps, 
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the first deprotection alleviating the steric crowding around the primary rim of the CD 
scaffold and determining the orientation of the aluminum species, thereby, and selectivity 
at the farthest possible site.319b 
 
 
Scheme 23. Regioselective DIBAL-H promoted double debenzylation reaction pioneered by Sinaÿ 
and Sollogoub. 
 
Sinaÿ and Sollogoub latter found that similar conditions can be applied to sequentially 
rip off methyl groups from permethylated CDs, predominately at the secondary rim.320 
Very recently, Ling and co-workers321 showed that DIBAL-H can also be used to promote 
diametrically opposed di-O-desilylations of primary silyl ethers on CD derivatives, 
following a similar deprotection pattern as the related O-debenzylations. In further 
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refinement of this methodology, DIBAL-H has been used to synthesize triply and 
quadruply O-debenzylated CD derivatives in gram quantities.322 These precisely oriented 
deprotections allow for the preparation of orthogonally protected, multisubstituted CDs in 
an efficient manner.308,323 Besides, the DIBAL-H mediated deprotection reactions are very 
sensitive to concentration, and it is therefore possible to delineate reaction conditions to 
produce mainly monodeprotected compounds. 
Such “clever” approaches have been mastered to furnish extraordinary selectivities, 
but their applications are often limited to tight-matching CD-reagent pairs and this fact my 
seriously limit their scope. Thus, development of tools to widen the accessible CD 
architectural scope would result in an excellent complement for these strategies. 
Orienting the CD-reagent pair and preventing an additional reagent species to react 
the same CD molecule is crucial for the success of selective derivatization strategies. 
While executing this control is inherently difficult in solution, it might be easier with a 
reagent displayed on a solid support. In this regard, solid phase organic synthesis 
presents a very valuable tool. On a solid support, it is reasonably feasible to display 
functional or reactive elements within a predetermined distance among them by tailoring 
support loading and swelling. Despite this advantage, the use of solid supports for the 
selective functionalization of CDs has been scarcely explored. Indeed, solid-support-
assisted synthesis has been already shown to successfully produce single-site 
functionalized 2-nm gold nanoparticles.324 But implementation towards CD 
monofunctionalization has only been reported very recently by Di Fabio and co-
workers.325 They demonstrated that a solid-supported reagent can be used to graft a 
single label onto a series of CD scaffolds via phosphodiester linkages (Scheme 24). Only 
moderate yields were reported, probably due to either a suboptimal reagent display on 
the solid support or reaction conditions. Moreover, the precise functionalization site 
(primary or secondary rim) was not disclosed and final HPLC purification was required. 
Aiming at refining this concept, in this Ph.D. Thesis a solid phase-assisted 
methodology has been developed that permits versatile and regioselective modification of 
CD platforms. The strategy exploits a solid matrix to display the complementary reagent 
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functionalities sufficiently far from each other to prevent CDs from reacting through more 
than one site (Scheme 25). 
 
 
Scheme 24. Regioselective solid phase synthesis of monofunctionalized CDs using standard 
phosphotriester chemistry. Reagents and conditions: a) i, 1H-tetrazole, 30 min, rt; ii, I2, Py, H2O, 5 
min, rt; b) 20% piperidine in DMF, 5 min, rt (3 times); c) i, αCD, βCD, MeβCD or HPβCD, MSNT, 
overnight, rt; ii, NH4OH  conc., 1 h, 50 ºC. 
 
 
Scheme 25. Schematic representation of the solid support-assisted “catch-and-release” protocol for 
site selective CD functionalization. 
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For such a purpose, we have implemented an experimental setup permitting (i) the 
covalent capture of a fully symmetric CD derivative through a single position by a solid-
supported reagent, (ii) eventual “on-bead” orthogonal elaboration of the remaining 
functional groups, and (iii) a final chemoselective release of the dissymmetric CD 
conjugate from the solid support in a sort of one-pot “catch-and-release” process. This 
strategy would allow for easily producing complex CD functionalization patterns in one 
pot and without any purification step. 
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2. Implementation of the Catch-and-Release concept for 
regioselective monofunctionalization of multivalent 
scaffolds 
Based on the pioneering works of Merrifield326 in 1963, the concept of solid phase 
synthesis revolutionized peptide and nucleotide chemistry and more than twenty years 
ago it set the stage for combinatorial chemistry.327 This now widely applied technique 
uses a polymeric matrix or other solid material to temporarily support a substrate, which is 
then taken through a synthetic sequence and subsequently cleaved back into solution.  
Among a wide variety of alternative methods to classic solid phase synthesis, i.e. 
application of solid phase reagents,328 catalysts329 and scavenging techniques,328b a 
hybrid methodology that combines the concept of solid phase synthesis with the idea of 
polymer-supported scavenging reagents has seen increased interest in polymer-assisted 
synthesis. Pioneered by Ley and Baxendale, this so-called “catch-and-release” 
methodology328b,330 allows the selective trapping of specific species onto a functionalized 
support. After filtrating and washing to remove soluble by-products, this species may 
either be released in pure form from the support or subjected to further transformations 
by adding new reaction partners in solution. Alternatively, these reactants can 
simultaneously modify the substrate while cleaving it from the support.331 
The chemical reactivity for the “catch-and-release” process is not a trivial choice. For 
this particular case, the versatility of the Staudinger reaction332 between organic azides 
and phosphines has been considered (Figure 88). Staudinger reaction occurs in virtually 
any solvent to chemoselectively give iminophosphorane species in mild conditions and 
good yields. Moreover, it is relatively feasible to install such functional groups on 
conventional solid-phase synthesis matrixes and control the distance among them to 
prevent a single CD from reacting through more than a single site. For such scenario, a 
series of azido-functionalized compounds and phosphines were selected (Figure 89). 
Secondary face-per-O-methylated CD 110 was chosen to prevent the potential 
interference of secondary hydroxyls with the “catch-and-release" process. It is well known 
that methyl groups on the secondary face are stable under a wide variety of reaction 
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conditions, hence heptakis(6-azido-6-deoxy-2,3-di-O-methyl)cyclomaltoheptaose 110180a 
represents an ideal candidate for probing the utility of the “catch-and-release” concept for 
regioselective CD modification. 
 
 
Figure 88. Formation of the corresponding iminophosphorane by Staudinger reaction between an 
organic azide and TPP. 
 
 
Figure 89. Structures of azides 91, 109 and 110 and phosphines 116, 119 and TPP investigated to 
optimize the Staudinger reaction. 
 
Simpler surrogates 91 and 109 were also included as test compounds (Figure 89). 
Model monosaccharide methyl 6-azido-6-deoxy-2,3,4-tri-O-methyl-α-D-glucopyranoside 
91280 bears only one azido group and was used incipiently to optimize solution and on-
bead Staudinger reaction conditions. The distance between the two azido groups of 
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model disaccharide α,α’-trehalose 109 is smaller than the maximum distance between 
azido groups of CD 110, which makes it a suitable model compound to study selective 
capture through a single position by a solid-supported reagent. 
Different model phosphines have been explored for solution phase kinetics studies 
(Figure 89). Compounds 116 and 119 are electron-poor and electron-rich analogs of TPP 
that should feature reduced and enhanced reactivity, respectively, as compared to TPP. 
An appropriate derivative of the best-performing phosphine would be then coupled to the 
solid support. 
Provided the reactive groups are displayed sufficiently distant on the support, the CD 
adduct would be reacted by a single position, being the rest too far away to further react. 
Once the CD derivative is covalently captured by the solid-supported reagent through a 
single position, the formed iminophosphorane tether might be later released from the 
solid matrix chemoselectively in the form of e.g. an amine, iso(thio)cyanate or (thio)urea. 
In addition, iminophosphorane reactivity333 is orthogonal to other azide-involving 
reactions, such as the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction,144 
which would enable further “on-bead” derivatization of the remaining functional groups. 
To optimize the experimental conditions for solid phase-assisted synthesis, first the 
iminophosphorane formation in solution with model monosaccharide 91 and a set of 
aromatic phosphines has been studied. In particular, compounds 116 and 119 as well as 
TPP were chosen as model phosphines for solution phase kinetics studies. Their 
corresponding precursors 112334 and 118, respectively (Scheme 26 and Scheme 27) are 
furnished with a carboxylic acid anchor group that later on enables coupling onto glycine-
loaded aminomethylated polystyrene (AM-PS) resin by conventional peptide coupling 
techniques. However, as a consequence of the electron-withdrawing character of the 
carbonyl group directly attached to the aromatic ring, phosphine 112 should present 
decreased electron-donating capabilities. As this may decrease iminophosphorane 
formation rates, the more electron-rich phosphine 118 has alternatively been synthesized. 
With the purpose of gaining an insight into kinetics of solution phase iminophosphorane 
formation, derivatives 112 and 118 were transformed into the corresponding 
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benzylamides 116 and 119, respectively, thus mimicking their ultimate form when 
attached to the solid support. 
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Scheme 26. Synthesis of phosphine 116. Reagents and conditions: a) PHPh2, Et3N, Pd(OAc)2, 
degassed MeCN, reflux, 12 h, 68%; b) K2CO3, MeI, 0 ºC, 1 h, 98%; c) PHPh2, Cs2CO3, CuI, 
degassed toluene, reflux, 17 h, 70%; d) aq. KOH, MeOH, reflux, 12 h, 99%; e) P(=O)HPh2, Et3N, 
Pd(OAc)2, MeCN, reflux, 12 h, 21%; f) HSiCl3, dry toluene, reflux, 14 h, 97%; g) BnNH2, DIPEA, 
TBTU, DMF, rt 20 h, 83%. 
 
4-(Diphenylphosphino)benzoic acid 112 was obtained via different synthetic pathways, 
as can be seen in Scheme 26. Direct Pd(II) acetate-catalyzed cross coupling of aryl 
iodide 111 with diphenylphosphine proceeded only in moderate yields, yet attempts to 
obtain the desired compound via alternative reaction sequences did not lead to higher 
yields. Nevertheless, carboxylic acid derivative 112 could be converted smoothly into the 
corresponding benzylamide 116. Electron-rich phosphine carboxylic acid 118 was 
prepared in a very similar way by direct cross coupling and was then reacted with 
benzylamine to give phosphine 119 in good yield (Scheme 27). 
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Scheme 27. Synthesis of phosphine 119. Reagents and conditions: a) PHPh2, Et3N, Pd(OAc)2, 
degassed MeCN, reflux, 12 h, 93%; b) BnNH2, DIPEA, TBTU, DMF, rt 20 h, 59%. 
 
To evaluate the reactivity of phosphines 116, 119 and TPP towards model 
monosaccharide 91, the Staudinger reaction was monitored by 31P NMR (Scheme 28). 
Therefore, reactions were performed under nitrogen atmosphere in NMR tubes using 
anhydrous solvents to prevent hydrolysis of the formed iminophosphorane. Different 
solvents, such as DCM, DMF and 1,4-dioxane, were tested and reactions were carried 
out at either room temperature or 40 ºC. Typically 50 µmol of phosphine were mixed with 
2 eq of azide 91 and 31P NMR spectra of the reaction mixture were recorded every 10 
min. Once the iminophosphorane had formed quantitatively, which could be observed by 
complete disappearance of the phosphine peak at ca. -6 ppm and the newly formed peak 
at ca. 9 ppm, water was added to the reaction mixture to hydrolyze the 
iminophosphorane, yielding the corresponding amine and phosphine oxide (peak at ca. 
26 ppm, Figure 90). 
 
 
Scheme 28. Formation of the corresponding iminophosphoranes 120-122 by Staudinger reaction 
between model monosaccharide 91 and phosphines 116, 119 and TPP, respectively. 
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As depicted exemplarily in Figure 90, quantitative conversion to the corresponding 
iminophosphorane 122 was observed within 2.5 h when 1 eq of 119 was mixed with 2 eq 
of azide 91 at rt in anhydrous DMF. Hydrolysis of iminophosphorane 122 took place 
quantitatively within 2-2.5 h when water was added to the reaction mixture. 
 
 
Figure 90. Monitoring of Staudinger reaction between phosphine 119 (1 eq) and azide 91 (2 eq) for 
5 h at rt in anhydrous DMF by 31P NMR (121 MHz, C6D6). The peak at ca. -6 ppm corresponds to 
phosphine 119; the one at ca. 9 ppm to iminophosphorane 122, and the one at ca. 26 ppm to 
phosphine oxide derived from 119. (a) phosphine 119 alone (reference); (b) phosphine 119 + azide 
91, 30 min; (c) phosphine 119 + azide 91, 2.5 h, (d) phosphine 119 + azide 91 + 10% H2O, after 30 
min; (e) phosphine 119 + azide 91 + 10% H2O, after 2.5 h. 
 
The results of the NMR-monitored kinetics studies of the formation of 
iminophosphoranes 120-122 are summarized in Figure 91. Reaction with TPP at rt 
indicated relatively fast kinetics with a reaction half-life of 20-30 min ( series) in all 
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assayed solvents. The reaction rate of electron-lacking phosphine 116 was definitely 
slower (t½ 80 min in 1,4-dioxane,  series). Conversely, electron-rich phosphine 119 fully 
recovered performance of TPP, being the most appropriate choice to build on the solid-
support. Moreover, the reaction rate could be significantly increased at 40 ºC (t½ 6 min in 
DMF,  series) with negligible iminophosphorane hydrolysis after several hours provided 
anhydrous conditions were preserved. The optimal performance together with good resin 
swelling capabilities supported the choice of DMF as solvent for the assays on the solid 
support. 
 
 
Figure 91.  Iminophosphorane formation kinetics from azide 91 with phosphines 116, 119 and TPP 
monitored by 31P NMR. 
 
Once the appropriate phosphine structure as well as the optimal solvent and reaction 
temperature have been determined, the next step comprised the synthesis of the resin-
supported phosphine reagent. The choice of an appropriate solid matrix is an important 
issue and several aspects have to be considered. In this regard, aminomethylated 
polystyrene resin (AM-PS, 0.39 mmol·g-1, 1% DVB) has been chosen as solid matrix. 
Aminomethylated polystyrene is a versatile resin that is readily modified by conventional 
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peptide coupling reactions. It is chemically and mechanically stable and tolerates 
elevated reaction temperatures without losing functional efficiency. Moreover, it presents 
good swelling capabilities in DMF (5-10 mL·g-1), which makes it compatible with 
Staudinger reaction conditions on the one hand, and on the other hand allows for 
controlling the distance between reactive centers. 
To obtain solid-supported phosphine 123, the resin was first loaded with N-Fmoc-
protected glycine using conventional peptide coupling reagents TBTU and Et3N (Scheme 
29). By this means, optimal resin loading could be confirmed by spectrophotometric 
quantification of dibenzofulvene (DBF) released from the matrix upon treatment with 
either piperidine335 or DBU (1,8-diazobicyclo[5.4.0]undec-7-ene).336 Subsequent 
deprotection of the glycine amino group with 20% v/v piperidine in DMF was monitored by 
colorimetric off-bead assays, e.g. the Kaiser test.337 Final coupling of carboxylic acid 118 
onto glycine-loaded polystyrene by DIC-mediated activation under inert atmosphere, 
afforded the polymer-supported phosphine 123. 
 
 
Scheme 29. Synthesis of resin-supported phosphine 123. Reagents and conditions: a) 
FmocGlyOH, TBTU, Et3N, DMF, rt, 15 h; b) 20% v/v piperidine in DMF, rt, 20 min; c) 118, DIC, 
DMAP, DMF, dry DCM, rt, 15 h. 
 
Gel-phase 31P NMR was employed to confirm successful coupling of phosphine 118 to 
the resin. As shown in Figure 92, only a single peak showed up at ca. -8 ppm, which was 
in agreement with solution phase 31P NMR spectra of phosphines (ca. -6 ppm). Absence 
of a downfield-shifted signal (ca. 26 ppm) corresponding to phosphine oxide species 
indicated that polymer-supported phosphine 123 is stable in the absence of moisture and 
oxygen. 
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Figure 92. Gel-phase31P NMR spectrum of polymer-supported phosphine 123 (121 MHz, C6D6). 
 
Gel-phase 31P NMR was also used for kinetics studies of Staudinger reaction between 
resin-supported phosphine 123 and model monosaccharide 91. The reaction was 
performed at room temperature and at 40 ºC in DMF in an analogous manner to solution 
phase reactions described before (Figure 93). 31P NMR-monitored kinetics studies 
revealed a significantly slower reaction rate at room temperature (t½ 8 h) than the 
corresponding reactions in solution, which can be attributed to the fact that in solid phase 
synthesis reaction kinetics is diffusion controlled due to restricted permeability of the 
reactants. The hindered diffusion of the reactants in the NMR tube due to geometrical 
restrictions may further decelerate the reaction rate. Moreover, nitrogen formation during 
the reaction creates bubbles within the resin, which also hampers diffusion. Nevertheless, 
by increasing reaction temperature to 40 ºC practical rates were obtained for resin-
supported phosphine 123 (t½ 50 min,   series). 
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Figure 93. 31P NMR-assisted comparison of iminophosphorane formation kinetics at 40 ºC from 
azide 91 with phosphine 119 and polymer-supported phosphine 123, respectively. 
 
AM-PS is not a rigid matrix, but even at the relatively high loading of 0.39 mmol·g-1, 
and assuming a swelling in the 5-10 mL·g-1 range, average distance between reactive 
centers is estimated in ca. 4 nm. This interphosphine distance was calculated supposing 
an even distribution in fully swollen resins. From the total number of functional groups in a 
given resin volume, the volume per phosphine group and, therefore, the average distance 
between them was calculated. By molecular modeling using ChemBio3D (ChemBioOffice 
package, CambridgeSoft) maximum distances between the azido groups in α,α’-
trehalose 109 and βCD 110 have been determined (Figure 94). Results showed that the 
maximum distance between the azido groups is 0.75 nm for α,α’-trehalose 109 and 1.3 
nm for βCD 110, respectively. The interphosphine distance in polymer 123 is three-fold 
larger than the maximum distance between the azido groups in βCD 110, which points 
out its suitability for site-selective CD functionalization, since reagent functionalities on 
the solid support are situated sufficiently far from each other to prevent CDs from reacting 
through more than one site. 
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Figure 94. Molecular modeling of α,α’-trehalose 109 (bottom) and βCD 110 (top), with indication of 
the inter-azide distances in their more stable conformations. 
 
The established conditions for solid-phase-assisted Staudinger reaction were first 
tested for model monosaccharide 91 (Scheme 30). Indeed, treating resin 123 with 2 eq of 
azide 91 overnight at 40 ºC in anhydrous DMF under N2 resulted in virtually complete 
consumption of the supported phosphine. Premature hydrolysis of the iminophosphorane 
was not detected, as resin washings only contained the excess of azide. Final hydrolysis 
with 10% H2O-DMF overnight at 40 ºC afforded 6-aminoglucoside 124 in 89% yield. 
Analytical and spectroscopic data of crude methyl 6-amino-6-deoxy-2,3,4-tri-O-methyl-α-
D-glucopyranoside 124 matched with that of an authentic sample prepared in solution 
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(see experimental section, Figure S74 for NMR spectra and Figures S145 and S146 for 
MS spectra, Supporting Information). 
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Scheme 30. Solid support-assisted synthesis of 6-aminoglucoside 124. Reagents and conditions: 
a) 123 (0.5 eq), anh. DMF, 40 ºC, overnight; b) 10% H2O-DMF, 40 ºC, overnight, 89%. 
 
However, α,α’-trehalosediazide 109 and βCD heptaazide 110 appeared to be more 
demanding substrates, since only minute amounts were captured by resin 123 under the 
same conditions. This may be attributed to size-dependent diffusion rates, or the higher 
polarity of larger molecules, which hampers accessibility to non-polar PS resin. Higher 
“catch” temperatures increased reactivity but reduced selectivity. As evidenced by ESI-
MS, even diazide 109, featuring a maximum inter-azide distance of 0.75 nm (Figure 94), 
was doubly-bound by two phosphine moieties, despite the much larger average resin 
inter-phosphine distance. Hydrolytic release of the supported diiminophosphorane 
afforded α,α’-trehalosediamine 125. An increase in temperature probably enhanced resin 
backbone mobility which in turn reduced the effective inter-phosphine distance. A similar 
effect was observed with more flexible supports (e.g. PEGA resin).338 
To overcome this drawback, we set our sights on microwave irradiation, as we 
hypothesized that the larger microwave-absorption capability of DMF (as compared to 
non-polar PS-resin) could selectively increase reagent diffusion and reactivity inside the 
resin vs. resin backbone mobility. Indeed, microwave-assisted heating revealed a 
completely different scenario to thermal conditions. Catch efficiency increased up to 90% 
(estimated from the recovered azide) after irradiating resin 123 swollen in a DMF solution 
of either 109 or 110 at 60 ºC (2 × 10 min, 40 W) under N2 (Scheme 31 for 109 and 
Scheme 32 for 110). 
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Scheme 31. Solid support-assisted synthesis of monoamine 126. Reagents and conditions: a) 123 
(0.5 eq), anh. DMF, µw, 60 ºC, 2 x 10 min; b) 10% H2O-DMF, 40 ºC, overnight, 52%. 
 
 
Scheme 32. Solid support-assisted synthesis of monoamine 127. Reagents and conditions: a) 123 
(0.5 eq), anh. DMF, µw, 60 ºC, 2 x 10 min; b) 10% H2O-DMF, 40 ºC, overnight, 79%. 
 
Hydrolytic release of the supported iminophosphoranes afforded the target mono-
reduced adducts (52% and 79% yields for 126 and 127, respectively) virtually devoid of 
over-reduced adducts as denoted by ESI-MS and RP-HPLC (Figure 95 and Figure 96; 
see Figures S76-S77 for NMR spectra and Figures S148-S151 for MS spectra, 
Supporting Information). 
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Figure 95. ESI-MS spectrum (top) and HPLC trace (bottom) of crude monoamine 126. 
 
 
Figure 96. ESI-MS spectrum (top) and HPLC trace (bottom) of crude monoamine 127. 
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To tap the full potential of the “catch-and-release” concept, the flexibility of 
iminophosphorane chemistry333 was also exploited to produce alternative CD 
functionalization patterns. Aza-Wittig-type reaction of the resin-bound CD 
iminophosphorane with CS2 furnished isothiocyanate 128 in 86% yield (Scheme 33). 
 
 
Scheme 33. Solid support-assisted synthesis of monoisothiocyanate 128. Reagents and 
conditions: a) 123 (0.5 eq), anh. DMF, µw, 60 ºC, 2 x 10 min; b) CS2, µw, 60 ºC, 2x10 min, 86%. 
 
Although a clean HPLC trace was observed, a minor peak for diisothiocyanate 
conjugates was identified by ESI-MS (Figure 97). While the average inter-phosphine 
distance in resin 123 is estimated in ca. 4 nm (much larger than the largest between 
azido groups in CD 110, see Figure 94), resin backbone mobility is a parameter that 
cannot be easily measured. It is feasible that such distance is not large enough to 
completely prevent from doubly-capturing a certain amount of CD 110, as resin backbone 
mobility reduces inter-phosphine distance. Curiously, such over-reactivity was not 
observed in the case of amine 127, despite the similar catch conditions. We reasoned 
that iminophosphorane hydrolysis may occur at a slower rate due to shrinking of the high 
hydrophobic PS resin in the presence of water,339 thereby increasing the chance for 
doubly-linked CD units to remain bound to the matrix. This type of self-sorting mechanism 
that efficiently furnished monoamine 127 in excellent yields and purity, however, does not 
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operate in other cases. The CS2-DMF cocktail swells the PS resin much better, facilitating 
the release of all bound material, including mono- and bis-iminophosphoranes. 
 
 
Figure 97. ESI-MS spectrum (top) and HPLC trace (bottom) of crude monoisothiocyanate 128. 
 
In order to minimize this drawback, a resin with larger inter-phosphine distance has 
been prepared. Thus, AM-PS resin was acylated with a 9:1 mixture of Boc- and Fmoc-
protected glycine and the Boc groups were transformed into inert acetyl groups. 
Phosphine was then installed onto the remaining amino groups, resulting in a ten-fold 
diluted matrix, resin-supported phosphine 129, with ca. 40 µmol·g-1 loading and 7-9 nm 
inter-phosphine average distance, calculated in an analogous manner to that described 
before. 
To probe the performance of this support, we made use of an intermolecular aza-
Wittig type reaction of immobilized iminophosphorane with a heterocumulene, i.e. 
isothiocyanate, to construct a carbodiimide functionality, which is a useful precursor of a 
variety of functional groups.340 CD 110 was sequentially loaded on and cleaved by 3-
methoxypropylisothiocyanate 130341 to release a carbodiimide that in situ added water to 
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furnish the corresponding urea 131 in 76% yield with undetectable trace of 
difunctionalized adducts (Scheme 34; see Figure S79 for NMR spectra and Figure S154 
for MS spectrum of compound 131, Supporting Information). 
 
 
Scheme 34. Solid support-assisted synthesis of monourea 131. Reagents and conditions: a) 129 
(0.5 eq), anh. DMF, µw, 60 ºC, 2x10 min; b) i, 3-methoxypropylisothiocyanate 130, µw, 60 ºC, 2 x 
10 min; ii, AcOH-washed silica gel, MeOH, 5 min, 86%. 
 
To push forward this strategy and taking advantage of the greater selectivity of resin 
129, on-bead manipulation of the solid-supported CD has been taken into account. The 
iminophosphorane tether should, in principle, remain unaffected by the conditions for 
CuAAC reaction. Actually, treating the supported CD iminophosphorane with an excess 
of a terminal alkyne, namely N-Boc-protected propargylamine, in the presence of catalytic 
CuI, followed by CS2-mediated release, afforded the bifunctional CD derivative 132 in 
remarkable 59% yield without any purification step (Scheme 35). 
The NMR spectrum of this conjugate is far too complex to assess purity and even 
identity, but RP-HPLC trace and ESI-MS spectra of the crude product doubtlessly 
confirmed both (Figure 98; see Figure S80 for its 1H NMR spectrum, Supporting 
Information). 
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Scheme 35. Solid support-assisted synthesis of heterobifunctional CD derivative 132. Reagents 
and conditions: a) 129 (0.5 eq), anh. DMF, µw, 60 ºC, 2x10 min; b) i, N-Boc propargylamine, CuI, 
DIPEA, µw, 80 ºC, 2 x 10 min; ii, CS2, µw, 60 ºC, 2 x 10 min, 59%. 
 
 
Figure 98. ESI-MS spectrum (top) and HPLC trace (bottom) of the crude heterobifunctional CD 
132. 
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It is worth mentioning that crude heterobifunctional CD 132 neither exhibited 
detectable traces of hydrolysis products, nor diisothiocyanate conjugates, but completion 
of the CuAAC reaction. Production of such CD functionalization patterns, despite being 
feasible, is far from obvious using conventional solution phase techniques. Although only 
βCD manipulation has been carried out, it is reasonable that this methodology would be 
suited for other CDs and macromolecular scaffolds. 
 
 

  
 
 
 
CONCLUSIONS 
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The results obtained in this Ph.D. Thesis have led to the following conclusions: 
 
1. Taking advantage of the rim anisotropy of the basket-shaped βCD structure, two 
libraries of monodisperse polycationic amphiphilic cyclodextrins (paCDs) with a precise 
and controlled arrangement of functional elements were prepared, endowing these 
macromolecular systems with tailored self-assembling capabilities in aqueous 
environment in the presence of nucleic acids. The flexible and diversity-oriented synthetic 
strategy was based on the sequential installation of a cationic cluster on the primary rim 
of the CD scaffold and acylation of the secondary hydroxyls. Systematic manipulation of 
the molecular structure of paCDs allowed for fine-tuning architectural parameters such as 
cationic density and display, the nature and flexibility of the tether or the acyl chain 
length, thereby maintaining C7-symmetry of facial amphiphilic βCD derivatives. In 
particular, two series of paCDs were elaborated: (i) a library of paCDs furnished with 
acyclic cationic domains and featuring subtle disparities in their hydrophilic/hydrophobic 
balance, and (ii) a library of paCDs decorated with cyclic (preorganized) oligoamines as 
alternative cationic headgroups. 
 
2. The correlation between amphiphilic CD structure and self-assembling capabilities 
in aqueous environment (in terms of the critical aggregation concentrations (CACs) of 
paCDs) was found to be very intimate. Self-assembling was considerably affected by the 
volume of the hydrophobic domain and the positive charge density, CACs progressively 
decreasing with increasing amphiphilicity of the CD conjugates. Conversely, the self-
assembling capabilities of cyclic oligoamine-grafted paCDs resembled those of paCDs 
with acyclic polycationic elements and lipophilic tails of the same length. 
 
3. 1H NMR-pH titration experiments of non-amphiphilic polycationic CDs indicated that 
these non-aggregating polycationic CDs lack pH buffering capabilities in the pH range 
from 5 to 7, as pKa values of their primary amines ranged around 9, whereas their tertiary 
amines exhibited very low pKa values of ca. 2. In stark contrast, their amphiphilic analogs 
revealed a completely different behavior. Potentiometric titration profiles clearly 
Conclusions  165 
 
evidenced that amphiphilicity-induced self-aggregation substantially enhances the 
buffering capacity of CD-scaffolded polycations in the 5-to-7 pH range. Interestingly, the 
buffering potential is intimately dependent on the structure of the oligoamine display. 
Moreover, incorporation of cyclic oligoamine groups into the CD scaffold further improved 
paCD pH buffering capabilities in this pH range. The nature of the cyclic oligoamine motif 
and the type (primary, secondary, of tertiary amine) and the nature and flexibility of the 
tether (thiourea or triazole) considerably affects such buffering capacities. 
 
4. DLS experiments pointed out that all polycationic CD derivatives were able to form 
small, positively charged nanoparticles with calf thymus DNA (ctDNA), regardless of their 
hydrophilic/hydrophobic balance or the nature of their polar headgroup. All these 
nanoparticles (CDplexes) featured remarkably similar hydrodynamic diameters, ζ 
potentials and relatively narrow size distributions. Gel electrophoresis and fluorescence 
quenching assays evidenced that the amphiphilic character and the 
hydrophilic/hydrophobic balance of paCDs play an important role in terms of DNA 
condensing and protecting capabilities. Despite their similar nanoparticle sizes and 
surface charges, CDplexes derived from more amphiphilic paCDs efficiently protected 
nucleic acids from the environment at N/P ratios at which less amphiphilic derivatives only 
attained DNA charge neutralization. No appreciable difference in the DNA-condensing 
capabilities of paCDs depending on the nature of their cationic headgroups could be 
inferred. Fluorescence tracking of CDplex dissociation promoted by heparin showed that 
CDplex dissociation kinetics is drastically influenced by the balance between the lipophilic 
domain and the polar headgroups. CDplexes composed of more amphiphilic paCDs are 
more easily formed, but also very slowly dissociated. 
 
5. The transfection efficiency of the CDplexes towards COS-7 and HeLa cell lines was 
investigated in vitro both in the absence and in presence of serum, and was found to be 
intimately dependent on architectural features. More stable CDplexes formulated with 
paCDs bearing more lipophilic tails and lower charge density resulted the best performing 
candidates in serum-containing medium, exhibiting luciferase expression levels almost 
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equaling that of JetPEI but with considerably better cytotoxic profiles. Despite their 
enhanced pH buffering capacities, CDplexes formulated with CD-scaffolded cyclic 
oligoamine clusters were slightly less efficient than their acyclic counterparts, irrespective 
of the cyclic amine structure or the nature of the tether. These results highlighted the 
relevance of DNA complexation capabilities of paCDs for efficient gene delivery, but also 
clearly indicated that dynamics and kinetics of CDplex formation and, especially, 
dissociation might play a critical role in overall performance. 
 
6. A conceptually novel approach to the selective functionalization of CDs was 
developed. The strategy exploited a solid matrix to display the complementary reagent 
functionalities sufficiently far from each other to prevent a single CD species from 
reacting through more than one site. Using a "catch-and-release" process based on the 
Staudinger reaction and controlling the average distance between the reactive centers 
displayed on the solid support, complex CD functionalization patterns could be easily 
produced in one pot and without any purification step. 
 
  
 
 
 
EXPERIMENTAL PART 
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1. General Methods 
All reagents and solvents used in this Ph.D. Thesis were purchased from commercial 
sources and used without further purification, unless otherwise specified. 
Thin layer chromatography (TLC) was performed on aluminum sheets coated with 
Silica Gel 60 F245 (layer thickness 0.25 mm, E. Merck), with visualization by UV light (λ 
254 nm) and by charring with 10% ethanolic H2SO4, 0.1% ethanolic ninhydrin, 3% 
ethanolic phosphomolybdic acid, or Mostain reagent (5% w/v ammonium molybdate(VI) 
tetrahydrate, 0.1% w/v ceric sulfate hydrate in 10% aq. H2SO4). 
Flash column chromatography was carried out on Silica Gel 60 (E. Merck, 230- 400 
mesh). 
Size exclusion chromatography (SEC) was performed on cross-linked dextran gel 
Sephadex LH-20 and Sephadex G-25 (GE Healthcare) using degassed MeOH and H2O, 
respectively, as eluents, with inline UV monitoring at 254 nm. A Pharmacia Biotech Pump 
P-1 was used as peristaltic pump. 
Microwave-assisted synthesis was carried out using a Biotage Initiator Microwave 
Synthesizer in sealed glass vials. 
Optical rotation data were recorded at 20 °C in a 1 dm tube on a Perkin-Elmer 141 MC 
Polarimeter, using the D-line of a sodium lamp (λ 589 nm). Samples were dissolved in 
DCM or MeOH at concentrations in a range of 0.2 to 1% w/v. 
IR spectra were recorded on a Bruker FTIR Vector 22 spectrometer. Samples were 
dissolved either in MeOH or in DCM, and applied on either KBr or NaCl windows. 
Electrospray ionization mass spectrometry (ESI-MS) was done on a Bruker 
Esquire600 instrument. Typically, samples were dissolved at low µM concentrations in 
appropriate volumes of deionized MeCN, MeOH, H2O or mixtures thereof and injected 
directly at a flow rate of 120 µL/h using a Cole-Palmer syringe pump. 
Elemental analyses were performed either on a Leco CHNS-932 instrument or on a 
Leco TruSpec CHN elemental analyzer. 
1H, 13C and 31PNMR spectra were recorded on Bruker AVANCE 300(300 MHz), Bruker 
AVANCE DRX 400 (400 MHz) and Bruker AVANCE DRX 500 (500 MHz) NMR 
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spectrometers. CDCl3, MeOD, DMSO-d6 and D2O were used as deuterated solvents. 2D 
COSY (Correlated Spectroscopy), 1D TOCSY (Totally Correlated Spectroscopy) and 
HMQC (Heteronuclear Multiple-Quantum Correlation) experiments were employed to 
assist NMR assignments. NMR data are reported as follows: chemical shift (ppm), 
multiplicity (s = singlet, bs = broad singlet, d = doublet, dd = doublet of doublets, t = 
triplet, bt = broad triplet, q = quartet, m = multiplet), peak integration and coupling 
constant J (Hz). NMR experiments in non-deuterated solvents were performed using a 
sealed capillary containing an appropriate deuterated solvent to assist field lock. 
Gel phase 31P NMR was used to confirm successful attachment of the phosphino 
compounds to the resin. For this purpose, approximately 50 mg of resin were transferred 
under nitrogen atmosphere to a NMR tube and were then allowed to swell in dry DMF. A 
thin glass capillary containing a small amount of deuterated solvent (C6D6 or D2O) was 
placed into the NMR tube in order to provide deuterium lock signal. KH2PO4 (1 % w/v) 
was added to D2O capillaries as internal standard (6 ppm). 31P NMR chemical shift of 
reduced phosphino compounds was about -6 ppm, whereas their oxidized analogues 
were shifted to lower field (approximately 27 ppm). Additionally, 31P NMR was used to 
carry out kinetics studies concerning Catch-and-Release reactions (see Chapter 4), 
following the same procedures as described above. 
Analytical reversed-phase high performance liquid chromatography (RP-HPLC) was 
performed on a Waters® 2695 Separations Module using an analytical HPLC Scharlau 
column Kromaphase 100 C18 5 µm 150 x 3 mm (ref. 070B53Y803) column with a flow 
rate of 1 mL·min-1. Evaporative Light Scattering (ELS) detection (Waters® 2420 ELS) was 
used. The ELS detector was operating under the following conditions: N2 gas pressure, 
27 psi; gain, 1; nebulizer control heater level, 75%, and drift tube temperature, 60 ºC. All 
RP-HPLC runs were carried out at 30 ºC using buffers A (0.1 % v/v formic acid in H2O) 
and B (0.1 % v/v formic acid in MeCN) filtered prior to use according to the following 
sequence: 1 min isocratic 0 % B, 9 min gradient to 100 % B, 6 min isocratic 100 % B, 2 
min gradient to 0 % B and 2 min isocratic 0 % B (Figure 99). Samples were dissolved in 
acetonitrile at a concentration of 20 mg/mL and the injection volume ranged from 5 to 40 
µL. The resulting chromatograms were processed using Empower Pro Software (2002). 
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Figure 99. Gradient profile used for RP-HPLC. 
 
 
1.1. General Methods for Synthesis in Solution Phase 
 
Acetylation reactions were carried out in a mixture of Ac2O-Py (1:1, 10 mL per gram of 
compound) at 0 °C, allowing the reaction mixture to warm up to rt overnight. Then, the 
reaction mixture was poured into H2O/ice and extracted with DCM. The organic layer was 
washed successively with 2 M aq. H2SO4 and a saturated aqueous solution of NaHCO3. 
Finally, the organic phase was dried over Na2SO4, filtered and evaporated under reduced 
pressure. In general, the crude product was then purified by flash column 
chromatography. 
Deacetylation reactions were performed under Zemplén conditions.342 Briefly, to a 
solution of the corresponding compound in MeOH, methanolic NaOMe (0.1 eq per mole 
acetate) was added and the reaction mixture was stirred at rt for approximately 5 h. After 
neutralization with ion exchange resin Amberlite IR-120 (H+), the reaction mixture was 
filtered and the solvent evaporated. 
Hydrolysis of carbamate protecting groups was achieved by treating the compounds 
with a 1:1 mixture of DCM and TFA at rt for two hours. After reaction completion, the 
solvents were co-evaporated several times with H2O. To obtain the compounds as their 
corresponding hydrochloride salts, the resulting residue was freeze-dried from 0.1 N aq. 
HCl. 
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In order to hydrolyze carbamate protecting groups belonging to amphiphilic CD 
derivatives which are sensitive to acidic hydrolysis, compounds were treated with 
anhydrous TFA at rt for 5 min and then freeze-dried immediately from 0.1 N aq. HCl, 
yielding the compounds as their corresponding hydrochloride salts. 
 
 
1.2. General Methods for Solid-Phase Synthesis 
 
Aminomethyl polystyrene (AM-PS) resin (PL-AMS resin, 0.39 mmol/g, 75-150 µm) was 
purchased from Polymer Laboratories (ref. 1464-3749). Solid-phase organic chemistry 
was performed in disposable plastic syringes fitted with sintered Teflon filters (pore size 
10 µm) purchased from Bola (ref. N1616-20) or microwave reactor vials. 
Attachment of amino acids to the amine-functionalized resin was achieved by pre-
activation of the carboxylic acid functionality. Therefore, the resin was placed in the 
plastic syringe and allowed to swell in DMF for 20 min, which was carefully added from 
the top and removed from the bottom by vacuum suction. Meanwhile, 3 eq (relative to the 
resin nominal loading) of the N-protected amino acid were dissolved in a minimum 
amount of DMF and Et3N (4 eq) and TBTU (2.9 eq) were sequentially added. The mixture 
was stirred for approximately 5 min until complete dissolution of TBTU. Then, the solution 
was added to the swollen resin and the mixture was incubated at rt overnight. The resin 
was washed with DMF (6 x 2 min) and DCM (4 x 2 min). After the final wash, the resin 
was dried in vacuum to a constant weight. The substitution of the resin was estimated 
from the weight gain of the resin. Completion of the reaction was ensured by negative 
Kaiser test (see below).337 
Solid-phase reaction monitoring was accomplished by colorimetric off-bead assays. To 
detect primary amines, a small sample of the resin (1 - 2 mg) was removed and submitted 
to the Kaiser test,337 which consists in solid-supported amino group derivatization with 
ninhydrin to afford the characteristic Riemann’s purple complex. In a complementary 
manner, bromophenol blue (4,4'-(1,1-dioxido-3H-2,1-benzoxathiole-3,3-diyl)bis(2,6-
dibromophenol)) provided a reliable test for the detection of both primary and secondary 
amines on the solid support. Although less sensitive than the Kaiser test, deprotonation of 
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the reagent by free amino groups present on the resin imparts a characteristic blue 
coloration.343 
To monitor free carboxylic acid moieties on the resin the malachite green test was 
employed.344 Therefore, a few beads of the resin were sampled and washed several 
times with DMF and MeOH. The beads were transferred to a test tube, and 1 mL of a 
0.025 % w/w solution of malachite green oxalate in ethanol was added, followed by 1 
drop of Et3N. The mixture was allowed to stand at rt for 2 min and then the solution was 
decanted and the beads were washed several times with MeOH or EtOH until washes 
were colorless. A dark green coloration of the beads indicated that free acid moieties 
were present. 
Loading measurements to determine the resin substitution grade usually involve 
treatment of a known quantity of Fmoc-loaded resin with piperidine in DMF and 
measuring spectrophotometrically the amount of the dibenzofulvene (DBF)-piperidine 
adduct released.335 However, the accuracy of this approach is moderate, as the values 
obtained do not always correspond with the nominal values. This discrepancy may be a 
consequence of the equilibrium between piperidine and DBF (Scheme 36). 
 
 
Scheme 36. Equilibrium of DBF and piperidine. 
 
Therefore, piperidine was substituted by a base which cannot undergo Michael addition 
to DBF.336 The base of choice was 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU). 
Approximately 5 mg of resin were weighed into a vial and 2 mL of DMF were added. The 
suspension was allowed to stand at rt for 30 min and then 40 µL of DBU were added, 
affording a solution of 2 % v/v DBU in DMF. This mixture was incubated at rt for another 
30 min and diluted with MeCN to 10 mL. 200 µL of this solution were then transferred to 
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another vial and diluted with MeCN to 2.5 mL. A reference solution was prepared in the 
same manner but without addition of the resin. To quantify Fmoc loading, 1 mL of the 
reference solution was transferred to one of a matched pair of 1 cm quartz glass 
cuvettes. The second cuvette was filled with 1 mL of the sample solution. A UV 
spectrometer was set to zero at 294 nm on the reference solution, and the absorbance of 
the sample solution was measured. The loading was calculated using equation (5). 
Alternatively, the quantitation could be performed at 304 nm and calculated using 
equation (6). 
 
6%=>? (@@AB CDEF ('"GH )IJK H@ =  
L ×NKI.NK
@F ('"GH  (5) 
 
6%=>? (@@AB CDEF ('"GH )OPK H@ =  
L ×NQO.JQ
@F ('"GH  (6) 
 
Removal of Fmoc protecting groups was performed with 20% v/v piperidine in DMF 
(approximately 10 mL/g resin). The mixture was allowed to incubate at rt for 20 min 
before rinsing the resin with DMF (6 x 2 min) and DCM (4 x 2 min). 
Removal of Boc protecting groups was accomplished by suspending the resin in 50% 
v/v TFA in DCM, using 1 mL of TFA-DCM per gram of resin. The mixture was allowed to 
incubate at rt for 1 h, followed by rinsing the resin with DCM (4 x 2 min) and 5% v/v Et3N 
in DCM (1 mL/g resin) to remove TFA. 
Acetylation of solid-supported amino groups was achieved by pre-swelling the resin 
in DMF and subsequent adding acetic anhydride (10 eq relative to the resin amine 
loading) and pyridine (10 eq relative to the resin amine loading). The mixture was 
incubated at rt for 1 h, followed by rinsing the resin with DMF (6 x 2 min) and DCM (4 x 2 
min). 
Attachment of phosphinocarboxylic acids to the amine-functionalized resin was 
accomplished under nitrogen atmosphere in order to prevent phosphine oxidation. The 
resin was placed in a plastic syringe and washed several times with dry DMF (6 x 2 min) 
and dry DCM (4 x 2 min), which were carefully added through a septum fixed on the top 
of the syringe and removed from the bottom by purging with nitrogen gas through the 
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septum. Phosphino carboxylic acids were pre-activated. Therefore, 2.1 eq (relative to the 
resin amine loading) of the phosphine carboxylic acid were dissolved under nitrogen 
atmosphere in a minimum amount of dry DCM, and DMAP (2.1 eq) and DIC (2.1 eq) were 
added. The mixture was stirred for approximately 5 min. Subsequently, the solution was 
added to the resin and the mixture was allowed to incubate at rt overnight. Then, the 
resin was washed under nitrogen atmosphere with dry DCM (6 x 2 min). After the final 
wash, the resin was dried in vacuum to a constant weight. The resin was stored under an 
inert nitrogen atmosphere to avoid phosphine oxidation. 
Formation of resin-supported iminophosphoranes (Catch) was accomplished under 
N2 atmosphere in order to prevent hydrolysis of the iminophosphorane compounds. A 
portion of the phosphine-functionalized resin was placed in a plastic syringe and dry and 
degassed DMF (ca.8 mL per g resin) was added through a septum fixed on the top of the 
syringe. The resin was allowed to swell in DMF for 30 min at rt. Meanwhile, 1.2 eq or 2 eq 
respectively (relative to the resin phosphine loading) of the corresponding azide were 
dissolved in the minimum amount of dry DMF under N2. Subsequently, the solution was 
added to the resin and the mixture was incubated at 40 ºC overnight. Evolution of N2 
during the reaction indicated the progression of the reaction. The resin was then washed 
with dry DMF (5 x 2 min) under N2 to remove unreacted starting material and eventual 
byproducts. The combined filtrates were concentrated and freeze-dried in order to 
determine catch efficiency. 
Alternatively, formation of resin-supported iminophosphoranes was also accomplished 
under microwave irradiation. In this case, the reaction mixture was heated in a sealed 
glass vial under microwave irradiation at 60 ºC for two cycles of 10 min (ca. 40 W) with 
intermediate shaking to ensure complete homogenization. The resin was then washed 
with dry DMF (5 x 2 min) under N2 to remove unreacted starting material or undesired 
byproducts. The combined filtrates were concentrated and freeze-dried in order to 
determine catch efficiency. 
Cleavage of resin-supported iminophosphoranes by hydrolysis to yield an amine 
(Release, procedure A) was accomplished immediately after completion of the Catch 
reaction step. The iminophosphorane-loaded resin was swollen in 10% H2O in DMF 
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(approximately 8 mL per g resin) and heated either thermally to 40 ºC overnight or under 
microwave irradiation to 60 ºC (2 x 10 min, ca. 40 W). Then, the resin was filtered and 
washed with DMF (6 x 2 min) to extract the released amine. The combined filtrates were 
concentrated and freeze-dried in order to determine reaction yield and product purity. 
Cleavage of resin-supported iminophosphoranes by reaction with CS2 to yield an 
isothiocyanate (Release, procedure B) was accomplished immediately after completion 
of the Catch reaction step. The iminophosphorane-loaded resin was swollen in 10% CS2 
in dry DMF (approximately 8 mL per g resin) under N2 and heated under microwave 
irradiation to 60 ºC (2 x 10 min, ca. 40 W). Then, the resin was filtered and washed with 
DMF (6 x 2 min) to obtain the released isothiocyanate. The combined filtrates were 
concentrated and freeze-dried in order to determine reaction yield and product purity. 
Cleavage of resin-supported iminophosphoranes by reaction with an 
isothiocyanate to yield a urea (Release, procedure C) was done immediately after 
completion of the Catch reaction step. The iminophosphorane-loaded resin was swollen 
in a solution of 3-methoxypropylisothiocyanate 130341 (5 eq) in dry DMF (approximately 8 
mL per g resin) under N2 and heated under microwave irradiation to 60 ºC (2 x 10 min, 40 
W). Then, the resin was filtered and washed with DMF (6 x 2 min) to obtain the released 
carbodiimide. To transform the carbodiimide into a urea derivative, the combined filtrates 
were concentrated, the residue was dissolved in MeOH and a catalytic amount of AcOH-
washed silica gel was added. Then, the reaction mixture was stirred at rt for 5 min and 
the solvents were then co-evaporated twice with water and the resulting urea was freeze-
dried in order to determine reaction yield and product purity. 
CuAAC “click” reaction in solid phase prior to cleavage of resin-supported 
iminophosphoranes was done on the remaining free azido groups of polyazide 
compounds after formation of the resin-supported iminophosphorane. The 
iminophosphorane-loaded resin was swollen in a solution of N-Boc-propargylamine (2 eq 
per remaining solid-supported azido group), DIPEA (2.5 eq), and CuI (0.1 eq) in dry DMF 
(approximately 8 mL per g resin) under N2 and heated under microwave irradiation to 80 
ºC (2 x 10 min, 70 W). The resin was carefully washed as in the catch phase to remove 
the remaining excess of reagents in solution. The resin was then swollen in 10% CS2 in 
DMF and the product was released as described in Procedure B. The combined filtrates 
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were concentrated and freeze-dried in order to determine reaction yield and product 
purity. 
1.3. General Methods for Characterization of paCDs 
 
The critical aggregation concentration (CAC) was determined using an established 
technique based on the dependence of the fluorescence spectrum of pyrene on the 
microenvironment.205 This extremely hydrophobic probe is preferentially incorporated in 
the inferior of supramolecular aggregates. The onset of supramolecular aggregate 
formation can be observed in a shift of its fluorescence excitation spectrum at an 
emission wavelength of 375 nm. In the concentration range of aqueous solutions, a shift 
of the excitation band in the 335 nm region toward higher wavelengths confirms the 
incorporation of pyrene in the hydrophobic interior of aggregates. 
CAC measurements were performed on a Varian Cary Eclipse Fluorescence 
Spectrophotometer. Fluorescence measurements were carried out at an emission 
wavelength of 375 nm (emission and excitation slits fixed at 5 nm). The ratio of the 
fluorescence intensities at excitation wavelengths of 339 (I339) and 335 (I335) nm was used 
to quantify the shift of the broad excitation band. 
A pyrene stock solution (1 mM in THF) was diluted with Milli-Q water to give a final 
concentration of 0.6 µM. This pyrene solution was subsequently used to prepare stock 
solutions of amphiphilic CDs (500 µM). These CD stock solutions were diluted with 0.6 
µM pyrene solution in order to yield solutions varying in CD concentration from 500 to 
2.56·10-4 µM. The samples were allowed to equilibrate for 1 h at 37 °C prior to 
fluorescence measurement. To determine aggregate stability, selected samples were 
incubated at rt for 5 days and one month, respectively, prior to fluorescence 
measurement. Finally, the critical aggregation concentrations were determined from the 
crossover point when representing Log[CD] vs. I339/I335 ratio. 
pKa and pH-buffering capability determination was done by 1H NMR-pH titration and 
by potentiometric titration. For the 1H NMR-pH titration an acidic solution A containing 60 
µL compound stock solution (10-70 mM in H2O), 60 µL D2O, 600 µL stock solution NaCl 
(0.2 M, in H2O-D2O 9:1, 1% MeCN), 120 µL stock solution HCl (100 mM in H2O) and 360 
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µL H2O, as well as a basic solution B, consisting of 125 µL compound stock solution, 125 
µL D2O, 1.25 mL stock solution NaCl, 250 µL stock solution NaOH and 750 µL H2O, were 
prepared. Determination of the pKa values of the compounds was performed by titrating 
the acidic solution A (500 µL, compound concentration 0.5 mM in 9:1 H2O-D2O) with the 
basic solution B and monitoring the induced chemical shifts of certain proton nuclei 
adjacent to pH-active groups (∆δobs) by 1H NMR spectroscopy at 25 ºC. The MeCN in 
solution A was used as internal reference. The dissociation constants of PEI were also 
determined as indicated for paCDs, starting from a 200 mM stock solution. The pH value 
of the solution was measured after every addition of solution B and just before the 
spectrum acquisition. To record the spectra, the water peak was suppressed using a 
phase-shift presaturation technique. The ionization equilibrium of a protonated amine is 
given by equation (7), 
 
*3R  * + 3R (7) 
         
whose equilibrium constant Ka is expressed as 
 
45 = SD
TU[L]
[LDT]  (8) 
 
or 
 
45 = 3 + 6 [LD
T]
[L]  (9) 
 
Plotting δobs as a function of pH yielded sigmoidal curves for each compound. The pKa 
values were obtained by plotting according to the Henderson-Hasselbalch equation (10), 
 
3 = 45 + 6 7289:98; 7<+,7<+,; 7+2,98   (10) 
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in which δacidic and δbasic are the chemical shifts of the observed signal of the fully 
protonated and deprotonated compound, respectively, and linear fitting. 
 
To determine the buffering capacity of cationic compounds, acid-base titration studies 
were conducted over a pH range of 2-10. Each compound (0.05 mmol of amino groups) 
was dissolved in 1 mL of 150 mM NaCl aqueous solution, and 0.088 N aq. NaOH 
(standardized using 2% w/v aq. potassium hydrogen phthalate) was added to adjust pH 
to 10. Aliquots (10 µL for each) of 0.084 N aq. HCl (titrated with 0.088 N aq. NaOH) were 
added, and the solution pH was measured with a Basic 20 pH-meter (Crison) after each 
addition. A blank (150 mM aq. NaCl) was used under the same experimental conditions. 
By plotting µL of 0.084 N aq. HCl added vs. pH, the acid-base titration profile of each 
compound was represented. 
 
 
1.4. General Methods for Characterization of CDplexes 
 
For the preparation of complexes formulated from CD derivatives and DNA two 
different plasmids were used; DNA sodium salt from calf thymus (ctDNA, Sigma-Aldrich, 
ref. D3664), a highly polymerized DNA (10-15 million Da) which contains both double 
stranded and single stranded forms, being double stranded DNA the predominant form, 
and the luciferase-encoding plasmid pTG11236 (pCMVSV40-luciferase-SV40pA),345 
which is a plasmid of 5739 bp (base pairs). The latter was utilized for transfection assays 
whereas studies of physicochemical properties were carried out using commercially 
available DNA. 
The quantities of compound used were calculated according to the desired DNA 
concentration, the N/P ratio, the molecular weight and the number of protonable nitrogen 
atoms in the corresponding cationic CD or cationic polymeric or CD reference (JetPEI 
(22kDa), bPEI or PTG). In particular, DNA concentrations applied were 0.06 mg·mL-1 (i.e. 
180 µM phosphate) for gel electrophoresis, 0.58 mg·mL-1 (i.e. 1.75 µM phosphate) for 
critical aggregation concentration determination, 0.02 mg·mL-1 (i.e. 60 µM phosphate) for 
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nanoparticle size, polydispersity index (PDI) and ζ potential measurements, 0.002 
mg·mL-1 (i.e. 6 µM phosphate) for fluorimetric pDNA-paCD-binding studies, 0.004 mg·mL-
1
 (i.e. 12 µM phosphate) for heparin competitive displacement assays and 5 µg·mL-1 (i.e. 
15 µM phosphate) for in vitro transfection experiments. 
For the preparation of CDplexes, typically pDNA was diluted in HEPES (20 mM, pH 7.4) 
to the desired final concentration as specified above, and then the desired amount of CD 
derivative was added from a stock solution in DMSO (typically 10 mM). The resulting 
mixture was vortexed thoroughly and the complexes were incubated for one hour prior to 
subjecting them to characterization or transfection experiments. 
Nanoparticle size, polydispersity index (PDI) and ζ potential were determined by 
Dynamic Light Scattering (DLS).228 The average diameter that is measured in DLS is a 
value that refers to how a particle diffuses within a fluid so it is referred to as a 
hydrodynamic diameter. The diameter that is obtained by this technique is the diameter of 
a hypothetical rigid sphere that has the same translational diffusion coefficient as the 
particle. Thus, the average particle size calculated in this manner corresponds to the 
apparent size of solvated particles. It is important to note that this mean size is an 
intensity mean. It is not a mass or number mean because it is calculated from the signal 
intensity. Furthermore, a dispersion width parameter is given, known as the polydispersity 
index (PDI). 
CDplexes were prepared as previously described according to the desired pDNA 
concentration (60 µM phosphate) at N/P ratios 5 and 10.CDplex average sizes were 
measured using a Zetasizer Nano (Malvern Instruments) with the following settings: 
sampling time, automatic; number of measurements, 3 per sample; medium viscosity, 
1.054 cP; refractive index, 1.33; scattering angle, 173°; λ 633 nm; temperature, 25 °C. 
Data were analyzed making use of the multimodal number distribution software included 
in the instrument. Results are presented as volume distribution of the major population by 
the mean diameter and its standard deviation. 
ζ-Potential is a parameter that can be related to the surface electric charge of 
nanoparticles.229 The net charge at the particle surface affects the distribution of ions in 
the surrounding interfacial region, resulting in an increased concentration of counter ions 
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close to the surface. Thus, an electrical double layer exists around each particle. ζ 
Potential is the potential difference between the diffuse region and the stationary layer of 
fluid attached to the dispersed particle. To determine ζ potential, two techniques are 
combined: Electrophoresis and Laser Doppler Velocimetry, being electrophoretic mobility 
the measured parameter (Laser Doppler Electrophoresis). 
ζ Potential measurements on CDplexes were accomplished on the same Zetasizer Nano 
instrument applying “mixed-mode measurement” phase analysis light scattering (M3-
PALS). M3-PALS consists of both slow field reversal and fast field reversal 
measurements, hence the name “mixed-mode measurement”; it improves accuracy and 
resolution. The following settings were applied: sampling time, automatic; number of 
measurements, 3 per sample; medium viscosity, 1.054 cP; medium dielectric constant, 
80; temperature, 25 °C. 
Before each series of experiments, performance of the instrument was calibrated with 
either 90 nm monodisperse latex beads (Coulter) for DLS or with DTS 50 standard 
solution (Malvern) for ζ potentials. 
Agarose gel electrophoresis was run in 0.8% (w/w) agarose gel in TAE buffer ( 1:1:1 
Tris/acetate/EDTA) and stained with GelRed™ (Biotium, 7.5 µL 10000x in 160 mL TAE). 
CDplexes were prepared as previously described according to the desired ctDNA 
concentration (180 µM phosphate) at N/P ratios ranging from 0.5 to 20. The samples 
were prepared by mixing 18 µL of each CDplex formulation and 2 µL of loading buffer (6x; 
5 mL glycerol, 250 µL TAE 40x, 1 mL bromophenol blue and 2.75 mL H2O). Bromophenol 
blue is a negatively charged dye and thus moves in the same direction as DNA during 
electrophoresis. This color marker is used to monitor the process on the gel, although 
DNA may move more rapidly than bromophenol blue. The samples were submitted to 
electrophoresis for approximately 20 min under 150 V. Finally, DNA was visualized after 
photographing (λ 302 nm) using an Alphaimager Mini UV transilluminator (Cell 
Biosciences). 
CDplex formation and dissociation was monitored by fluorescence quenching of an 
intercalating agent. Experiments were performed on a Varian Cary Eclipse Fluorescence 
Spectrophotometer using ctDNA (5 µg, [bp] = 3.0 µM). For CDplex formation studies a 
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solution of intercalating agent RedSafe™ (iNtRON Biotechnology, 2.5 µL 20 000x in 50 
mL HEPES 20 mM, pH 7.4) was prepared. Fluorescence emission was measured in a 
range from 450 to 570 nm, exhibiting RedSafe™ an emission maximum at 525 nm (λex 
295 nm, emission and excitation slits 5 nm). Fluorescence emission of the buffer solution 
was taken as reference. When ctDNA was added to the RedSafe™ buffer solution (final 
concentration 3 µM bp), the fluorescence reading of the RedSafe™-DNA solution 
increased drastically. Subsequently, from CD derivative stock solutions in DMSO (50-
1000 µM) µL portions were added to the RedSafe™-DNA solution in order to obtain 
ascending N/P ratios from0.1 to 10 approximately. These N/P ratios correspond to CD 
concentrations ranging from ca. 0.03 to 8.6 µM. Fluorescence emission was recorded 
after each addition and equilibration (5 min) and as N/P ratio increases fluorescence 
intensity decreases, indicating the DNA condensation and subsequent dye exclusion by 
CDplex formation. Portions of the CD stock solution were added until no further decrease 
in fluorescence intensity could be observed. 
To assess CDplex dissociation and to compare the relative stability, competitive 
displacement assays were performed on CDplexes at an N/P ratio of 5 using heparin. 
The effect of heparin on the stability of CDplexes was evaluated by means of the change 
in relative fluorescence intensity obtained with the fluorescence probe RedSafe™ 
(iNtRON Biotechnology, 20000x). Starting from a CDplex solution in HEPES (20 mM, pH 
7.4, RedSafe™ 1x) containing a DNA concentration of 3.0 µM (base pairs) and the 
corresponding volume of a CD stock solution in DMSO (50-1000 µM), a volume of 150 µL 
of this solution was added to the wells of a 96-well plate. Then, different volumes of 
heparin stock solutions (100-10000 µg/mL in HEPES 20 mM, pH 7.4) were added to each 
well and after taking to a final volume of 250 µL, final heparin concentrations in the range 
of 5-2000 µg/mL were obtained. The samples were incubated for 10 min at rt prior to 
fluorescence measurement. Finally, time-dependent fluorescence intensity was 
measured with a Varian Cary Eclipse Fluorescence Spectrophotometer equipped with a 
microplate reader as indicated above. Naked DNA and bPEI as references were 
processed in a similar manner as indicated for the CDplexes. 
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1.5. Evaluation of the Gene Transfer Capabilities of CDplexes 
 
In vitro transfection experiments were performed in COS-7 and HeLa cells. Twenty-
four hours before transfection, cells were grown at a density of 2·104 cells per well in 96-
well plates in Dulbelcco’s modified Eagle’s culture medium (DMEM; Gibco-BRL) 
containing 10% fetal calf serum (FCS; Sigma), 10 mg·mL-1 gentamycin for HeLa cells, or 
100 units per mg penicillin and 100 mg·mL-1 streptomycin for COS-7 cells, in a wet (37 
ºC) and 5 % CO2 containing air atmosphere. The above-described CD:pDNA (pTG11236) 
complexes, JetPEI:pDNA polyplexes and PTG:pDNA complexes were diluted to 100 µL 
in DMEM or in DMEM supplemented with 10% FCS so as to have 0.5 µg of pDNA in the 
well (15 µM phosphate). The culture medium was removed and replaced by these 100 µL 
of the complexes. After 4 and 24 h, DMEM (50 and 100 µL) supplemented with 30% and 
10% FCS, respectively, were added. After 48 h, the transfection was stopped, the culture 
medium was discarded, and the cells were washed twice with PBS (100 µL) and lysed 
with lysis buffer (50 µL; Promega, Charbonnires, France). The lysates were frozen at -32 
ºC before the analysis of luciferase activity. This measurement was performed using a 
luminometer (GENios PRO, Tecan France S.A.) in dynamic mode, for 10 s on the lysis 
mixture (20 µL) and using the “luciferase” determination system (Promega) in 96-well 
plates. The total protein concentration per well was determined by the BCA test (Pierce, 
Montluçon, France). Luciferase activity was calculated as fg of luciferase per mg of 
protein. The percentage of cell viability was calculated as the ratio of the total protein 
amount per well of the transfected cells relative to that measured for untreated cells. The 
data were calculated from three or four repetitions in two fully independent experiments 
(formulation and transfection). 
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2. Starting Materials 
The following starting materials were prepared as described previously in literature: 
 Heptakis(6-bromo-6-deoxy)cyclomaltoheptaose 11175 
 Heptakis(6-bromo-6-deoxy-2,3-di-O-hexanoyl)cyclomaltoheptaose 12174 
 Heptakis[6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy]cyclomaltoheptaose 13177 
 2-(tert-Butoxycarbonylamino)ethylisothiocyanate 22186 
 2-[Bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethylisothiocyanate 23177 
 Heptakis(6-aminoethylthio)cyclomaltoheptaose 32185a 
 Heptakis(6-azido-6-deoxy)cyclomaltoheptaose 53269 
 Heptakis(6-azido-6-deoxy-2,3-di-O-hexanoyl)cyclomaltoheptaose 54180b 
 1,4,7-Tritosyl-1,4,7-triazaheptane 55271 
 1,3,5-Tritosyl-3-azapentane 56272 
 1,4,7,10-Tetratosyl-1,4,7,10-tetraazacyclododecane 57273 
 1-(Prop-2-ynyl)-1,4,7,10-tetraazacyclododecane trihydrochloride 60274 
 1,4,7-Tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane 61276b 
 1,4,8-Tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 62346 
 1,6-Hexamethylenediisothiocyanate 68278 
 2-[N-(tert-Butoxycarbonyl)-N-[2-(tert-butoxycarbonylamino)ethyl]amino]ethyl 
isothiocyanate 85177 
 Methyl 6-azido-6-deoxy-2,3,4-tri-O-methyl-α-D-glucopyranoside 91280 
 Bis(triphenylphosphine)copper(I)iodide 93289 
 Tris(triphenylphosphine)copper(I)iodide 94290 
 6,6’-Diazido-6,6’-dideoxy-α,α’-trehalose 108269 
 Heptakis(6-azido-6-deoxy-2,3-di-O-methyl)cyclomaltoheptaose 110180a 
 4-(Diphenylphosphino)benzoic acid 112334 
 Methyl 4-iodobenzoate 113347 
 Methyl 4-(diphenylphosphino)benzoate 114348 
 4-(Diphenylphosphoryl)benzoic acid 115349 
 3-Methoxypropylisothiocyanate 130341 
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3. New Compounds 
 
3.1. New Compounds synthesized in Chapter 2 
 
 
 
Heptakis[2,3-di-O-acetyl-6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy]cyclo-
maltoheptaose (14). Compound 13177 (1.03 g, 0.46 mmol) was acetylated using acetic 
anhydride as acetylating agent according to a standard procedure described before. The 
crude product was purified by flash column chromatography (40:1  20:1 DCM-MeOH) 
to yield compound 14 as a white powder (1.04 g, 80%). 
Rf = 0.80 (20:1 DCM-MeOH). [α]D = +18.9 (c = 1.0 in DCM). 
1H NMR (500 MHz, CDCl3, 313 K, Figure S1): δ = 5.39 (bs, 7H, NHBoc), 5.28 (t, 7H, J2,3 = 
J3,4 = 9.4 Hz, H-3), 5.15 (d, 7H, J1,2 = 3.9 Hz, H-1), 4.84 (dd, 7H, H-2), 4.20 (m, 7H, H-5), 
3.82 (t, 7H, J4,5 = 9.4 Hz, H-4), 3.63 (bq, 14H, 3JH,H = 6.5 Hz, CH2NHBoc), 3.16 (dd, 7H, 
J5,6a = 2.1 Hz, J6a,6b = 11.6 Hz, H-6a), 3.06 (dd, 7H, J5,6b = 6.0 Hz, H-6b), 2.82 (m, 14H, 
CH2Scyst), 2.06, 2.02 (2 s, 21H each, COCH3), 1.42 (s, 63H, (C(CH3)3). 
13C NMR (75.5 MHz, CDCl3, 313 K, Figure S1): δ = 171.1, 169.8 (2 CO ester), 156.4 (CO 
carbamate), 97.1 (C-1), 79.7 (C-4), 79.4 (CCH3), 71.7 (C-3), 71.3 (C-2), 70.9 (C-5), 40.6 
(CH2NHBoc), 34.1 (CH2Scyst, C-6), 28.9 (C(CH3)3), 21.2 (COCH3). 
ESI-MS (Figure S81): m/z 1442.0 [M + 2 Na]2+, 2861.7 [M + Na]+. 
Elemental analysis calculated (%) for C119H189N7O56S7: C 50.36, H 6.71, N 3.45; found: C 
50.21, H 6.46, N 3.35. 
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Heptakis[6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy-2,3-di-O-propanoyl]-
cyclomaltoheptaose (15). To a solution of 13177 (1.0 g, 0.44 mmol) in dry DMF (30 mL) 
under nitrogen atmosphere, DMAP (2.28 g, 18.7 mmol, 3 eq) and propanoic anhydride 
(3.2 mL, 24.9 mmol, 4 eq) were added at 0 ºC. The reaction mixture was allowed to warm 
to rt and stirred overnight. Then, MeOH (130 mL) was added and the reaction mixture 
was further stirred for 1 h. The solvents were removed under reduced pressure, and 
subsequently H2O (60 mL) was added to the reaction mixture which was then extracted 
with DCM (4 x 60 mL). The organic layer was successively washed with 1 N aq. HCl (2 x 
50 mL) and a saturated aqueous solution of NaHCO3 (50 mL), dried over Na2SO4, filtered 
and reduced in vacuum. The crude product was purified by flash column chromatography 
(1:2  1:1 EtOAc-petroleum ether) to yield 15 (0.98 g, 73%). 
Rf = 0.29 (20:1 DCM-MeOH). [α]D = +85.7 (c = 1.0 in DCM). 
1H NMR (500 MHz, CDCl3, Figure S2): δ = 5.45 (bs, 7 H, NHBoc), 5.28 (t, 7H, J2,3 = J3,4 = 
8.9 Hz, H-3), 5.12 (d, 7H, J1,2 = 3.9 Hz, H-1), 4.84 (dd, 7H, H-2), 4.20 (m, 7H, H-5), 3.80 
(t, 7H, J4,5 = 8.6 Hz, H-4), 3.35 (bq, 14H, 3JH,H = 6.5 Hz, CH2NHBoc), 3.17 (dd, 7H, J5,6a = 
2.1 Hz, J6a,6b = 11.7 Hz, H-6a), 3.07 (dd, 7H, J5,6b = 5.9 Hz, H-6b), 2.79, 2.77 (2 dt, 14H, 
2JH,H = 13.4 Hz, 3JH,H = 6.7 Hz, CH2Scyst), 2.47-2.20 (m, 28H, CH2CO), 1.47 (s, 63H, 
C(CH3)3), 1.12 (2 t, 42H, 3JH,H = 7.5 Hz, CH3). 
13C NMR (125.7 MHz, CDCl3, Figure S2): δ = 174.1, 172.6 (2 CO ester), 156.0 (CO 
carbamate), 96.8 (C-1), 79.4 (C(CH3)3), 79.0 (C-4), 71.3 (C-5), 70.7 (C-3), 70.2 (C-2), 
40.4 (CH2NHBoc), 33.8 (CH2Scyst, C-6), 28.5 (C(CH3)3), 27.3, 27.2 (CH2CO), 8.9 (CH3). 
ESI-MS (Figure S82): m/z 1540.3 [M + 2 Na]2+, 3057.0 [M + Na]+. 
Elemental analysis calculated (%) for C133H217N7O56S7: C 52.64, H 7.21, N 3.23, S 7.40; 
found: C 52.64, H 7.27, N 3.20, S 7.69. 
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Heptakis[2,3-di-O-butanoyl-6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy]cyclo-
maltoheptaose (16). To a solution of 13177 (1.21 g, 0.54 mmol) in dry DMF (40 mL) under 
nitrogen atmosphere, DMAP (2.77 g, 22.7 mmol, 3 eq) and butanoic anhydride (4.9 mL, 
30.2 mmol, 4 eq) were added at 0 ºC. The reaction mixture was allowed to warm to rt and 
stirred overnight. Then, MeOH (150 mL) was added and the reaction mixture was further 
stirred for 1 h. The solvents were removed under reduced pressure, and subsequently 
H2O (70 mL) was added to the reaction mixture which was then extracted with DCM (4 x 
70 mL).The organic layer was successively washed with 1 N aq. HCl (2 x 60 mL) and a 
saturated aqueous solution of NaHCO3 (60 mL), dried over Na2SO4, filtered and reduced 
in vacuum. The crude product was purified by flash column chromatography (1:3  1:1 
EtOAc-petroleum ether) to yield 16 as a white powder (1.36 g, 78%). 
Rf = 0.31 (20:1 DCM-MeOH). [α]D = +101.6 (c = 1.0 in DCM). 
1H NMR (500 MHz, CDCl3, Figure S3): δ = 5.47 (bs, 7 H, NHBoc),5.29 (t, 7H, J2,3 = J3,4 = 
8.8 Hz, H-3), 5.14 (d, 7H, J1,2 = 3.9 Hz, H-1), 4.82 (dd, 7H, H-2), 4.19 (m, 7H, H-5), 3.81 
(t, 7H, J4,5 = 8.6 Hz, H-4), 3.34 (bq, 14H, 3JH,H = 6.5 Hz, CH2NHBoc), 3.16 (dd, 7H, J5,6a = 
2.1 Hz, J6a,6b = 11.8 Hz, H-6a), 3.07 (dd, 7H, J5,6b = 5.8 Hz, H-6b), 2.79, 2.77 (2 dt, 14H, 
2JH,H = 13.1 Hz, 3JH,H = 6.6 Hz, CH2Scyst), 2.42-2.14 (m, 28H, CH2CO), 1.63 (m, 28H, 
CH2CH3), 1.47 (s, 63H, C(CH3)3), 0.98, 0.94 (2 t, 42H, 3JH,H = 7.5 Hz, CH3). 
13C NMR (125.7 MHz, CDCl3, Figure S3): δ =173.2, 171.6 (2 CO ester), 156.0 (CO 
carbamate), 96.5 (C-1), 79.3 (C(CH3)3), 78.8 (C-4), 71.3 (C-5), 70.4 (C-3), 70.1 (C-2), 
40.4 (CH2NHBoc), 35.9, 35.7 (CH2CO), 33.8 (CH2Scyst, C-6), 28.5 (C(CH3)3), 18.1 
(CH2CH3), 13.6, 13.5 (CH3). 
ESI-MS (Figure S83): m/z 1638.4 [M + 2 Na]2+, 3253.4 [M + Na]+. 
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Elemental analysis calculated (%) for C147H245N7O56S7: C 54.65, H 7.64, N 3.03, S 6.95; 
found: C 54.81, H 7.34, N 2.87, S 6.97. 
 
 
 
Heptakis[6-(2-tert-butoxycarbonylaminoethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclo-
maltoheptaose (17).177 To a solution of 13177 (1.27 g, 0.57 mmol) in dry DMF (30 mL) 
under nitrogen atmosphere, DMAP (2.91 g, 23.8 mmol, 3 eq) and hexanoic anhydride 
(7.3 mL, 31.7 mmol, 4 eq) were added at 0 ºC. The reaction mixture was allowed to warm 
to rt and stirred overnight. Then, MeOH (80 mL) was added and the reaction mixture was 
further stirred for 2 h. The solvents were removed under reduced pressure, and 
subsequently H2O (70 mL) was added to the reaction mixture which was then extracted 
with DCM (2 x 70 mL).The organic layer was successively washed with H2O (2 x 50 mL), 
2 N aq. H2SO4 (3 x 50 mL) and a saturated aqueous solution of NaHCO3 (3 x 50 mL), 
dried over Na2SO4, filtered and reduced in vacuum. The crude product was purified by 
flash column chromatography (1:3  1:2EtOAc-petroleum ether) to yield 17 as a white 
powder (1.49 g, 73%). 
Rf = 0.45 (1:2 EtOAc-petroleum ether). [α]D =+84.1 (c = 0.9 in CHCl3). 
1H NMR (500 MHz, CDCl3, 323 K, Figure S4): δ = 5.45 (m, 7 H, NHBoc), 5.25 (t, 7 H, J2,3 
= J3,4 = 9.5 Hz, H-3), 5.08 (d, 7 H, J1,2 = 3.5 Hz, H-1), 4.76 (dd, 7 H, H-2), 4.12 (ddd, 7 H, 
J4,5 = 9.5 Hz, J5,6b = 5.5 Hz, J5,6a = 2.5 Hz, H-5), 3.77 (t, 7 H, H-4), 3.30, 3.29 (2 t, 14 H, 
3JH,H = 6.5 Hz, CH2NHBoc), 3.10 (dd, 7 H, J6a,6b = 14.0 Hz, H-6a), 3.02 (dd, 7 H, H-6b), 
2.74, 2.72 (2 dt, 14 H, 2JH,H = 13.5 Hz, 3JH,H = 7.0 Hz, CH2Scyst), 2.38-2.11 (m, 28 H, 
CH2CO), 1.57 (m, 28 H, CH2CH2CO), 1.42 (bs, 63 H, C(CH3)3), 1.30 (m, 56 H, CH3CH2, 
CH3CH2CH2), 0.89, 0.87 (2 t, 42 H, 3JH,H  = 7.0 Hz, CH3). 
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13C NMR (125.7 MHz, CDCl3, 323 K, Figure S4): δ = 173.2, 171.6 (CO ester), 155.9 (CO 
carbamate), 96.7 (C-1), 79.2 (C(CH3)3), 78.8 (C-4), 71.4 (C-5), 70.6 (C-3), 70.3 (C-2), 
40.5 (CH2NHBoc), 34.0 (C-6, CH2CO), 33.9 (CH2Scyst), 33.8 (CH2CO), 31.5, 31.3 
(CH3CH2CH2), 28.5 (C(CH3)3), 24.4, 24.3 (CH2CH2CO), 22.3, 22.2 (CH3CH2), 13.8 (CH3). 
ESI-MS (Figure S84): m/z 1835.6 [M + 2 Na]2+. 
Elemental analysis calculated (%) forC175H301N7O56S7: C 58.00, H 8.37, N 2.71; found: C 
57.79, H 8.19, N 2.50. 
 
 
 
Heptakis[2,3-di-O-acetyl-6-(2-aminoethylthio)-6-deoxy]cyclomaltoheptaose hepta-
hydrochloride (18). Treatment of compound 14 (304 mg, 0.11 mmol) with TFA following 
the procedure described in the general methods gave pure compound 18 in virtually 
quantitative yield (326 mg). 
[α]D = +51.7 (c = 1.0 in H2O). 
1H NMR (500 MHz, MeOD, 313 K, Figure S5): δ = 5.41 (t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 
5.25 (d, 7 H, J1,2 = 3.3 Hz, H-1), 4.84 (dd, 7 H, H-2), 4.11 (m, 7 H, H-5), 3.96 (t, 7 H, J4,5 = 
9.5 Hz, H-4), 3.26 (m, 21 H, CH2NH2, H-6a), 3.10-2.98 (m, 21H, H-6b, CH2Scyst), 2.13, 
2.10 (2 s, 21 H each, COCH3). 
13C NMR (125.7 MHz, MeOD, 313 K, Figure S5): δ = 172.1, 172.0 (2 CO ester), 98.1 (C-
1), 80.0 (C-4), 73.9 (C-3), 72.3 (C-2), 72.0 (C-5), 40.7 (CH2NH2), 34.9 (C-6), 31.9 
(CH2Scyst), 21.3, 21.1 (COCH3). 
ESI-MS (Figure S85): m/z 713.2 [M + H]3+, 1069.1 [M + 2 H]2+, 2138.1 [M + H]+. 
Elemental analysis calculated (%) for C84H140Cl7N7O42S7.H2O: C 41.85, H 5.94, N 4.07, S 
9.31; found: C 41.70, H 5.49, N 3.81, S 8.92. 
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Heptakis[6-(2-aminoethylthio)-6-deoxy-2,3-di-O-propanoyl]cyclomaltoheptaose 
heptahydrochloride (19). Treatment of heptacarbamate 15 (307 mg, 0.10 mmol) with 
TFA following the standard procedure described in the general methods, followed by 
freeze-drying from a 0.1 N aq. HCl solution, gave pure compound 19 in quantitative yield 
(262 mg). 
[α]D = +59.2 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, Figure S6): δ = 5.42 (t, 7H, J2,3 = J3,4 = 9.5 Hz, H-3), 5.26 (d, 
7H, J1,2 = 3.6 Hz, H-1), 4.85 (dd, 7H, H-2), 4.15 (m, 7H, H-5), 3.99 (t, 7H, J4,5 = 9.0 Hz, H-
4), 3.30 (t, 14H, 3JH,H = 7.0 Hz, CH2NH2), 3.19-3.12 (m, 21H, H-6a, CH2Scyst), 3.07 (m, 7H, 
H-6b), 2.51-2.30 (m, 28H, CH2CO), 1.15 (2 t, 42H, 3JH,H = 7.5 Hz, CH3). 
13C NMR (125.7 MHz, MeOD, Figure S6): δ = 173.9, (2 CO ester), 96.4 (C-1), 78.2 (C-4), 
72.4 (C-5), 70.5 (C-3), 70.4 (C-2), 38.9 (CH2NH2), 33.2 (C-6), 30.3 (CH2Scyst), 27.1, 26.9 
(CH2CO), 7.9 (CH3). 
ESI-MS (Figure S86): m/z 1167.4 [M + 2 H]2+, 2333.9 [M + H]+. 
Elemental analysis calculated (%) for C98H168Cl7N7O42S7.7H2O: C 43.35, H 6.76, N 3.61, 
S 8.27; found: C 43.42, H 6.53, N 3.72, S 7.90. 
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Heptakis[6-(2-aminoethylthio)-2,3-di-O-butanoyl-6-deoxy]cyclomaltoheptaose 
heptahydrochloride (20). Treatment of heptacarbamate 16 (300 mg, 93 µmol) with TFA 
following the standard procedure described in the general methods, followed by freeze-
drying from a 0.1 N aq. HCl solution, gave pure compound 20 in quantitative yield (258 
mg). 
[α]D = +65.0 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, 313 K, Figure S7): δ = 5.40 (t, 7H, J2,3 = J3,4 = 9.3 Hz, H-3), 
5.22 (d, 7H, J1,2 = 3.5 Hz, H-1), 4.83 (dd, 7H, H-2), 4.14 (m, 7H, H-5), 3.94 (t, 7H, J4,5 = 
8.7 Hz, H-4), 3.32-3.26 (m, 21H, CH2NH2, H-6a), 3.13-2.98 (m, 21H, H6-b, CH2Scyst), 
2.49-2.25 (m, 28H, CH2CO), 1.67 (m, 28H, CH2CH3), 0.98, 0.99 (2 t, 42H, 3JH,H = 7.4 Hz, 
CH3). 
13C NMR (125.7 MHz, MeOD, 313 K, Figure S7): δ = 173.0, 172.8 (2 CO ester), 96.5 (C-
1), 78.4 (C-4), 72.5 (C-5), 70.4 (C-3), 70.1 (C-2), 39.0 (CH2NH2), 35.7, 35.5 (CH2CO), 
33.3 (C-6), 30.4 (CH2Scyst), 17.8 (CH2CH3), 12.6 (CH3). 
ESI-MS (Figure S87): m/z 1265.6 [M + 2 H]2+, 2530.1 [M + H]+. 
Elemental analysis calculated (%) for C112H196Cl7N7O42S7·7H2O: C 46.20, H 7.27, N 3.37, 
S 7.71; found: C 45.89, H 6.91, N 3.19, S 7.63. 
 
 
Experimental Part  191 
 
 
 
Heptakis[6-(2-aminoethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose 
heptahydrochloride (21). Treatment of heptacarbamate 17 (664 mg, 0.18 mmol) with 
TFA following the standard procedure described in the general methods, followed by 
freeze-drying from a 0.1 N aq. HCl solution, gave pure compound 21 in virtually 
quantitative yield (583 mg). 
[α]D = +72.6 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, Figure S8): δ = 5.37 (t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 5.16 (d, 
7 H, J1,2 = 3.5 Hz, H-1), 4.79 (dd, 7 H, H-2), 4.07 (bt, 7 H,J5,6a = J5,6b = 6.5 Hz, H-5), 3.90 
(t, 7 H,J4,5 = 9.0 Hz, H-4), 3.22 (d, 7 H,J6a,6b = 13.0 Hz, H-6a), 3.21 (bt, 14 H, 3JH,H = 7.0 
Hz, CH2NH2), 3.04 (dd, 7H, H-6b), 3.02, 2.94 (2 dt, 14 H, 2JH,H = 14.5 Hz, 3JH,H = 7.5 Hz, 
CH2Scyst), 2.47–2.21 (m, 28 H, CH2CO), 1.62 (m, 28H, CH2CH2CO), 1.33 (m, 56H, 
CH3CH2, CH3CH2CH2), 0.92, 0.91 (2 t, 42 H,3JH,H = 7.0 Hz, CH3). 
13C NMR (125.7 MHz, MeOD, Figure S8): δ = 174.4, 174.3 (CO), 98.2 (C-1), 80.0 (C-4), 
74.0 (C-5), 71.8 (C-2), 71.3 (C-3), 40.2 (CH2NH2), 35.2, 35.0 (CH2CO), 34.4 (C-6), 32.6, 
32.5 (CH3CH2CH2), 31.7 (CH2Scyst), 25.6, 25.5 (CH2CH2CO), 23.6, 23.5 (CH3CH2), 14.4, 
14.3 (CH3). 
ESI-MS (Figure S88): m/z 975.5 [M + 3 H]3+, 1462.6 [M + 2 H]2+. 
Elemental analysis calculated (%) for C140H252Cl7N7O42S7: C 52.91, H 7.99, N 3.09; found: 
C 52.66, H 7.84, N 2.98. 
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Heptakis[2,3-di-O-acetyl-6-(2-(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)ethyl-
thio)-6-deoxy]cyclomaltoheptaose (24). To a solution of compound 18 (125 mg, 42 
µmol) and Et3N (102 µL, 0.73mmol, 2.5 eq) in DCM (3 mL) a solution of 2-(tert-
butoxycarbonylamino)ethyl-isothiocyanate 22186 (71 mg, 0.35 mmol, 1.2 eq) in DCM (2 
mL) was added drop wise. The reaction mixture was stirred overnight at rt. The solvent 
was evaporated under reduced pressure and the residue was purified by flash column 
chromatography (40:1DCM-MeOH) to yield compound 24 as a white powder (140 mg, 
94%). 
Rf = 0.69 (9:1 DCM-MeOH). [α]D = +69.0 (c = 0.4 in CHCl3). 
1HNMR (500 MHz, CDCl3, 313 K, Figure S9): δ = 7.20, 7.01 (2 bs, 14 H, NHCS), 5.44 
(bs, 7 H, NHBoc), 5.24 (t, 7 H, J2,3 = J3,4 = 8.8 Hz, H-3), 5.10 (d, 7 H, J1,2 = 3.6 Hz, H-1), 
4.78 (dd, 7 H, H-2), 4.17 (m, 7 H, H-5), 3.75 (t, 7 H, J4,5 = 8.5 Hz, H-4), 3.74, 3.58 (2 bs, 
28 H, CH2NHCS), 3.29 (m, 14 H, 3JH,H = 5.6 Hz, CH2NHBoc), 3.21 (bd, 7 H, J6a,6b = 13.0 
Hz, H-6a), 3.03 (dd, 7 H, J5,6b = 7.6 Hz, H-6b), 2.94, 2.82 (2m, 14 H, CH2Scyst), 2.05, 2.00 
(2 s, each 21 H, COCH3), 1.42 (s, 63 H, C(CH3)3). 
13C NMR (125.7 MHz, CDCl3, 313 K, Figure S9): δ = 182.6 (CS), 171.0, 169.6 (2 CO 
ester), 157.2 (CO carbamate), 97.2 (C-1), 80.2 (C-4), 79.7 (CCH3), 72.0 (C-3), 71.3 (C-2), 
70.9 (C-5), 45.4, 45.0 (CH2NHCS), 40.5 (CH2NHBoc), 34.1 (CH2Scyst), 33.3 (C-6), 28.9 
(C(CH3)3), 21.0 (COCH3). 
ESI-MS (Figure S89): m/z 1221.0 [M + 3 K]3+, 1820.5 [M + 2 K]2+. 
Elemental analysis calculated (%) for C140H231N21O56S14: C 47.32, H 6.55, N 8.28, S 
12.63; found: C 47.41, H 6.62, N 8.15, S 12.48. 
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Heptakis[6-(2-(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)ethylthio)-6-deoxy-
2,3-di-O-propanoyl]cyclomaltoheptaose (25). To a solution of compound 19 (100 mg, 
39 µmol) and Et3N (94 µL, 0.68 mmol, 2.5 eq) in DCM (2 mL) a solution of 2-(tert-
butoxycarbonylamino)ethylisothiocyanate 22186 (66 mg, 0.32 mmol, 1.2 eq) in DCM (1 
mL) was added drop wise. The reaction mixture was stirred overnight at rt. Once 
evaporated the solvent under reduced pressure, the residue was purified by flash column 
chromatography (40:1  15:1 DCM-MeOH) to yield compound 25 as an off-white powder 
(108 mg, 75%). 
Rf = 0.19 (20:1 DCM-MeOH). [α]D = +73.9 (c = 1.0 in DCM). 
1H NMR (500 MHz, CDCl3, Figure S10): δ = 7.25 (2 bs, 14H, NHCS), 5.63 (bs, 7H, 
NHBoc), 5.27 (t, 7H, J2,3 = J3,4 = 8.5 Hz, H-3), 5.11 (d, 7H, J1,2 = 2.7 Hz, H-1), 4.82 (dd, 
7H, H-2), 4.20 (m, 7H, H-5), 3.78 (t, 7H, J4,5 = 8.2 Hz, H-4), 3.73, 3.61 (2 m, 28H, 
CH2NHCS), 3.30 (bs, 14H, CH2NHBoc), 3.22 (bd, 7H, J6a,6b = 13.1 Hz, H-6a), 3.04 (m, 
7H, H-6b), 2.95, 2.83 (2 m, 14H, CH2Scyst), 2.42-2.17 (m, 28H, CH2CO), 1.45 (s, 63H, 
C(CH3)3), 1.12, 1.10 (2 t, 42H, 3JH,H = 7.5 Hz, CH3). 
13C NMR (125.7 MHz, CDCl3, 313 K, Figure S10): δ = 182.3 (CS), 174.1, 173.1 (2 CO 
ester), 157.3 (CO carbamate), 96.7 (C-1), 79.0 (C(CH3)3), 78.3 (C-4), 71.8 (C-5), 70.8 (C-
3), 70.4 (C-2),43.8 (CH2NHCS), 39.6 (CH2NHBoc), 33.7 (C-6), 32.7 (CH2Scyst), 27.6 
(C(CH3)3), 27.1, 27.0 (CH2CO), 8.0 (CH3). 
ESI-MS (Figure S90): m/z 1286.3 [M + 2 Na + K]3+, 1897.8 [M + 2 Na]2+, 1917.5 [M + Na 
+ K]2+. 
Elemental analysis calculated (%) for C154H259N21O56S14: C 49.33, H 6.96, N 7.84, S 
11.97; found: C 49.25, H 7.17, N 7.55, S 11.93. 
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Heptakis[2,3-di-O-butanoyl-6-(2-(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)-
ethylthio)-6-deoxy]cyclomaltoheptaose (26). To a solution of compound 20 (81 mg, 29 
µmol) and Et3N (71 µL, 0.51 mmol, 2.5 eq) in DCM (2 mL) a solution of 2-(tert-
butoxycarbonylamino)ethylisothiocyanate 22186 (49 mg, 0.24 mmol, 1.2 eq) in DCM (1 
mL) was added drop wise. The reaction mixture was stirred overnight at rt. Then, the 
solvent was evaporated under reduced pressure and the resulting residue was purified by 
flash column chromatography (40:1  15:1 DCM-MeOH) to yield compound 26 as an off-
white powder (97 mg, 84%). 
Rf = 0.20 (20:1 DCM-MeOH). [α]D = +38.5 (c = 1.0 in DCM). 
1H NMR (500 MHz, MeOD, 313 K, Figure S11): δ = 5.36 (t, 7H, J2,3 = J3,4 = 8.2 Hz, H-3), 
5.19 (d, 7H, J1,2 = 2.7 Hz, H-1), 4.83 (dd, 7H, H-2), 4.23 (m, 7H, H-5), 3.96 (t, 7H, J4,5 = 
8.0 Hz, H-4), 3.77, 3.60 (2 m, 28H, CH2NHCS), 3.28 (m, 21H, CH2NHBoc, H-6a), 3.20 
(dd, 7H, J5,6a = 4.1 Hz, J6a,6b = 9.8 Hz, H-6b), 2.97, 2.93 (2 m, 14H, CH2Scyst), 2.46-2.23 
(m, 28H, CH2CO), 1.67 (m, 28H, CH2CH3), 1.47(s, 63H, C(CH3)3), 1.00, 0.97 (2 t, 42H, 
3JH,H = 7.2 Hz, CH3). 
13C NMR (125.7 MHz, 313 K, MeOD, Figure S11): δ = 182.2 (CS), 173.1, 172.0 (2 CO 
ester), 157.3 (CO carbamate), 96.5 (C-1), 79.0 (C(CH3)3), 78.2 (C-4), 71.9 (C-5),70.5 (C-
3), 70.3 (C-2), 43.9 (CH2NHCS), 39.6 (CH2NHBoc), 35.7, 35.6 (CH2CO), 33.7 (C-6), 32.7 
(CH2Scyst), 27.6 (C(CH3)3), 17.9, 17.8 (CH2CH3), 12.7 (CH3). 
ESI-MS (Figure S91): m/z 1995.6 [M + 2 Na]2+, 3966.6 [M + Na]+. 
Elemental analysis calculated (%) for C168H287N21O56S14: C 51.13, H 7.33, N 7.45, S 
11.38; found: C 51.34, H 7.36, N 7.48, S 11.29. 
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Heptakis[6-(2-(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)ethylthio)-6-deoxy-
2,3-di-O-hexanoyl]cyclomaltoheptaose (27). To a solution of compound 21 (150 mg, 
47 µmol) and Et3N (115 µL, 0.83 mmol, 2.5 eq) in DCM (3 mL) a solution of 2-(tert-
butoxycarbonylamino)ethylisothiocyanate 22186 (80 mg, 0.40 mmol, 1.2 eq) in DCM (2 
mL) was added drop wise. The reaction mixture was stirred overnight at rt. Once 
evaporated the solvent under reduced pressure, the resulting residue was purified by 
flash column chromatography (40:1   20:1DCM-MeOH) to yield compound 27 as an off-
white powder (166 mg, 81%). 
Rf = 0.53 (9:1 DCM-MeOH). [α]D = +78.4 (c = 1.05 in DCM). 
1H NMR (500 MHz, CDCl3, 313 K, Figure S12): δ = 7.19, 7.00 (2 bs, 14 H, NHCS), 5.46 
(bs, 7 H, NHBoc), 5.25 (t, 7 H, J2,3 = J3,4 = 8.8 Hz, H-3), 5.08 (d, 7 H, J1,2 = 3.7 Hz, H-1), 
4.76 (dd, 7 H, H-2), 4.15 (m, 7 H, H-5), 3.75 (t, 7 H, J4,5 = 8.8 Hz, H-4), 3.72 (m, 14 
H,CH2CH2Scyst), 3.58 (m, 14 H, CH2NHCS), 3.29 (m, 14 H, CH2NHBoc), 3.20 (bd, 7 H, 
J6a,6b = 13.4 Hz, H-6a), 3.04 (dd, 7 H, J5,6b = 4.8 Hz, H-6b), 2.93, 2.81 (2 dt, 14 H, 2JH,H = 
13.3 Hz, 3JH,H = 6.6 Hz, CH2Scyst), 2.38-2.11 (m, 28 H, CH2CO), 1.56 (m, 28 H, 
CH2CH2CO), 1.42 (s, 9 H, C(CH3)3), 1.24 (m, 56 H, CH3CH2, CH3CH2CH2), 0.90, 0.87 (2 
t, each 21 H, 3JH,H = 7.1 Hz, CH3). 
13C NMR (125.7 MHz, CDCl3, 313 K, Figure S12): δ = 182.0 (CS), 173.4, 171.6 (2 CO 
ester), 156.9 (CO carbamate), 96.7 (C-1), 79.8 (C(CH3)3), 79.0 (C-4), 71.5 (C-5), 70.5 (C-
3), 70.4 (C-2), 44.6 (CH2NH), 43.8 (CH2CH2Scyst), 40.0 (CH2NHBoc), 34.0 (CH2CO), 33.8 
(C-6), 32.9 (CH2Scyst), 31.4, 31.2 (2 CH3CH2CH2), 28.5 (C(CH3)3), 24.4, 24.3 (2 
CH2CH2CO), 22.3 (CH3CH2), 13.8 (CH3). 
ESI-MS (Figure S92): m/z 1468.5 [M + 3 Na]3+, 2191.2 [M + 2 Na]2+. 
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Elemental analysis calculated (%) forC196H343N21O56S14: C 54.26, H 7.97, N 6.78; found: 
C 54.10, H 7.84, N 6.67. 
 
 
 
Heptakis[2,3-di-O-acetyl-6-(2-(N’-(2-(N,N-di-(2-(N-tert-butoxycarbonylamino)ethyl)-
amino)ethyl)thioureido)ethylthio)-6-deoxy]cyclomaltoheptaose (28). To a solution of 
compound 18 (92 mg, 31 µmol) and Et3N (74, µL, 0.54 mmol, 2.5 eq) in DCM (3 mL) a 
solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethylisothiocyanate 23177 (100 
mg, 0.26 mmol, 1.2 eq) in DCM (2 mL) was added drop wise. The reaction mixture was 
stirred overnight at rt. After evaporation of the solvent under reduced pressure, the 
residue was purified by flash column chromatography (40:1 DCM-MeOH) to yield 
compound 28 as a white powder (141 mg, 95%). 
Rf = 0.58 (9:1 DCM-MeOH). [α]D = +51.0 (c = 0.98 in DCM). 
1H NMR (500 MHz, MeOD, 333 K, Figure S13): δ = 5.37 (t, 7 H, J2,3 =  J3,4 = 9.0 Hz, H-3), 
5.21 (d, 7 H, J1,2 = 3.6 Hz, H-1), 4.83 (dd, 7 H,H-2), 4.20 (m, 7 H, H-5), 3.98 (t, 7 H, J4,5 = 
8.8 Hz, H-4), 3.80 (bt, 14 H, 3JH,H = 6.4 Hz, CH2CH2Scyst), 3.58 (bt, 14 H,3JH,H = 6.4 Hz, 
NCH2CH2NHCS), 3.29 (m, 7 H, H-6a), 3.17 (t, 35 H, H-6b, CH2NHBoc), 2.96 (m, 14 H, 
CH2Scyst), 2.76 (bt, 14 H, 3JH,H = 6.1 Hz,  NCH2CH2NHCS), 2.27 (bt, 28 H, 3JH,H = 6.1 Hz, 
CH2CH2NHBoc), 2.11, 2.10 (2 s, 42 H, COCH3), 1.47 (s, 126 H, C(CH3)3). 
13C NMR (75.5 MHz, CDCl3, 313 K, Figure S13): δ = 184.8 (CS), 172.9, 171.6 (2 CO 
ester), 158.8 (CO carbamate), 99.0 (C-1), 81.6 (CCH3), 81.5 (C-4), 73.0 (C-5, C-3, C-2), 
56.7 (CH2CH2NHBoc), 56.3 (NCH2CH2NHCS), 44.6 (CH2CH2Scyst), 41.0 
(NCH2CH2NHCS, CH2NHBoc), 36.0 (C-6), 35.3 (CH2Scyst), 30.6 (C(CH3)3), 23.0, 22.9 
(COCH3). 
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ESI-MS (Figure S93): m/z 1656.6 [M + Na + 2 K]3+, 2456.8 [M + 2 Na]2+, 2472.2 [M + 2 
K]2+, 2463.4 [M + 2 Cl]2-. 
Elemental analysis calculated (%) for C203H357N35O70S14: C 50.20, H 7.41, N 10.09, S 
9.24; found: C 50.01, H 7.22, N 9.81, S 8.94. 
 
 
 
Heptakis[6-(2-(N’-(2-(N,N-di-(2-(N-tert-butoxycarbonylamino)ethyl)amino)ethyl)thio-
ureido)ethylthio)-6-deoxy-2,3-di-O-propanoyl]cyclomaltoheptaose (29). To a solution 
of compound 19 (95 mg, 37 µmol) and Et3N (90 µL, 0.64 mmol, 2.5 eq) in DCM (2 mL) a 
solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethylisothiocyanate 23177 (120 
mg, 0.31 mmol, 1.2 eq) in DCM (1 mL) was added drop wise. The reaction mixture was 
stirred overnight at rt. After evaporation of the solvent under reduced pressure, the 
residue was purified by flash column chromatography (40:1  15:1 DCM-MeOH) to yield 
compound 29 as an off-white powder (114 mg, 62%). 
Rf = 0.64 (9:1 DCM-MeOH). [α]D = +37.8 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S14): δ = 5.36 (t, 7H, J2,3 = J3,4 = 8.7 Hz, H-3), 
5.18 (d, 7H, J1,2 = 3.3 Hz, H-1), 4.83 (dd, 7H, H-2), 4.25 (m, 7H, H-5), 3.97 (t, 7H, J4,5 = 
8.3 Hz, H-4), 3.81 (bt, 14H, CH2CH2Ccyst), 3.56 (bt, 14H, NCH2CH2NHCS), 3.23 (m, 42H, 
H-6a, H-6b, CH2NHBoc), 2.96 (m, 14H, CH2Scyst), 2.74 (t, 14H, 3JH,H = 6.0 Hz, 
NCH2CH2NHCS), 2.64 (t, 28H, 3JH,H = 6.0 Hz, CH2CH2NHBoc), 2.50-2.27 (m, 28H, 
CH2CO), 1.48 (s, 126H, C(CH3)3), 1.15, 1.13 (2 t, 42H, 3JH,H = 7.7 Hz, CH3). 
13C NMR (125.7 MHz, MeOD, 313 K, Figure S14): δ = 182.3 (CS), 174.0, 173.1 (2 CO 
ester), 157.1 (CO carbamate), 96.7 (C-1), 78.9 (C(CH3)3), 78.4 (C-4), 71.8 (C-5), 70.8 (C-
3), 70.4 (C-2), 54.3 (CH2CH2NHBoc), 53.3 (NCH2CH2NHCS), 44.0 (CH2CH2Scyst), 42.0 
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(NCH2CH2NHCS), 38.6 (CH2NHBoc), 33.8 (C-6), 33.0 (CH2Scyst), 27.7 (C(CH3)3), 27.1, 
27.0 (CH2CO), 8.1, 8.0 (CH3). 
ESI-MS (Figure S94): m/z 1723.8 [M + 3 K]3+, 2550.2 [M + 2 Na]2+, 2558.3 [M + Na + K]2+, 
2543.4 [M + Cl - H]2-. 
Elemental analysis calculated (%) for C217H385N35O70S14: C 51.57, H 7.68, N 9.70, S 8.88; 
found: C 51.18, H 7.67, N 9.23, S 8.99. 
 
 
 
Heptakis[2,3-di-O-butanoyl-6-(2-(N’-(2-(N,N-di-(2-(N-tert-butoxycarbonylamino)-
ethyl)amino)ethyl)thioureido)ethylthio)-6-deoxy]cyclomaltoheptaose (30). To a 
solution of compound 20 (100 mg, 36 µmol) and Et3N (87 µL, 0.63 mmol, 2.5 eq) in DCM 
(2 mL) a solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethylisothiocyanate 
23177 (117 mg, 0.30 mmol, 1.2 eq) in DCM (1 mL) was added drop wise. The reaction 
mixture was stirred overnight at rt. Then, the solvent was evaporated under reduced 
pressure and the resulting residue was purified by flash column chromatography (40:1  
15:1DCM-MeOH) to give compound 30 (139 mg, 74%). 
Rf = 0.63 (20:1 DCM-MeOH). [α]D = +38.1 (c = 0.99 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S15): δ = 5.36 (t, 7H, J2,3 = J3,4 = 8.7 Hz, H-3), 
5.17 (d, 7H, J1,2 = 3.7Hz, H-1), 4.83 (dd, 7H, H-2), 4.23 (m, 7H, H-5), 3.97 (t, 7H, J4,5 = 8.3 
Hz, H-4), 3.81 (t, 14H, 3JH,H = 6.5 Hz, CH2CH2Ccyst), 3.56 (m, 14H, NCH2CH2NHCS), 3.29 
(m, 7H, H-6a), 3.21 (dd, 7 H, J5,6b= 5.0 Hz, J6a,6b = 14.3 Hz, H-6b), 3.16 (t, 28 H, 3JH,H = 
6.5 Hz,CH2NHBoc), 2.96 (m, 14H, CH2Scyst), 2.74 (t, 14H, 3JH,H = 6.5 Hz, 
NCH2CH2NHCS), 2.53 (t, 28H, 3JH,H = 6.5 Hz, CH2CH2NHBoc), 2.47-2.23 (m, 28H, 
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CH2CO), 1.67 (m, 28H, CH2CH3), 1.48 (s, 126H, C(CH3)3), 1.01, 0.98 (2 t, 42H, 3JH,H = 7.5 
Hz, CH3). 
13C NMR (125.7 MHz, MeOD, 313 K, Figure S15): δ = 173.1, 172.1 (2 CO ester), 157.1 
(CO carbamate), 96.6 (C-1), 79.1 (C(CH3)3), 78.3 (C-4), 72.0 (C-5), 70.7 (C-3), 70.3 (C-
2), 54.3 (CH2CH2NHBoc), 53.5  (NCH2CH2NHCS), 44.1 (CH2CH2Scyst), 41.9 
(NCH2CH2NHCS), 38.4 (CH2NHBoc), 35.8, 35.6 (CH2CO), 34.0 (C-6), 33.0 (CH2Scyst), 
27.7 (C(CH3)3), 17.9, 17.8 (CH2CH3), 12.7 (CH3). 
ESI-MS (Figure S95): m/z 1772.9 [M + 3 Na]3+, 2647.9 [M + 2 Na]2+. 
Elemental analysis calculated (%) for C231H413N35O70S14: C 52.85, H 7.93, N 9.34, S 8.55; 
found: C 52.77, H 7.95, N 9.36, S 8.38. 
 
 
 
Heptakis[6-(2-(N’-(2-(N,N-di-(2-(N-tert-butoxycarbonylamino)ethyl)amino)ethyl)thio-
ureido)ethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (31). To a solution 
of compound 21 (68 mg, 21 µmol) and Et3N (52 µL, 0.37 mmol, 2.5 eq) in DCM (1.5 mL) 
a solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethylisothiocyanate 23177 (70 
mg, 0.18 mmol, 1.2 eq) in DCM (1 mL) was added drop wise. The reaction mixture was 
stirred overnight at rt. After evaporation of the solvent under reduced pressure, the 
resulting residue was purified by flash column chromatography (40:1  15:1 DCM-
MeOH) yielding compound 31 (84 mg, 71%). 
Rf = 0.65 (9:1 DCM-MeOH). [α]D = +57.4 (c = 1.0 in DCM). 
1H NMR (300 MHz, CDCl3, 313 K, Figure S16): δ = 7.22, 7.16 (2 bs, 14 H, NHCS), 5.29 
(t, 7 H, J2,3 = J3,4 = 9.2 Hz, H-3), 5.24 (bs, 14 H, NHBoc), 5.08 (d, 7 H, J1,2 = 3.5 Hz, H-1), 
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4.77 (dd, 7 H, H-2), 4.17 (m, 7 H, H-5), 3.83 (t, 7 H, J4,5 = 9.2 Hz, H-4), 3.77 (m, 14 H, 
CH2CH2Scyst), 3.54 (m, 14 H, NCH2CH2NHCS), 3.15 (m, 42 H, H-6a, H-6b, CH2NHBoc), 
2.87 (m, 14 H, CH2Scyst), 2.67 (bt, 14 H, 3JH,H = 5.5 Hz, NCH2CH2NHCS), 2.58 (bt, 28 H, 
3JH,H = 5.2 Hz, CH2CH2NHBoc), 2.43-2.11 (m, 28 H, CH2CO), 1.60 (m, 28 H, CH2CH2CO), 
1.44 (s, 126 H, C(CH3)3), 1.30 (m, 56 H, CH2CH3, CH2CH2CH3), 0.91, 0.89 (2 t, 42 H, 
3JH,H = 7.8 Hz, CH3). 
13C NMR (75.5 MHz, CDCl3, 313 K, Figure S16): δ = 182.8 (CS), 173.8, 172.0 (2 CO 
ester), 156.9 (CO carbamate), 97.0 (C-1), 79.8 (C(CH3)3), 79.0 (C-4), 71.8 (C-5), 70.9 (C-
3, C-2), 55.1 (CH2CH2NHBoc), 54.0 (NCH2CH2NHCS), 44.5 (CH2CH2Scyst), 42.9 
(NCH2CH2NHCS), 39.5 (CH2NHBoc), 34.4, 34.2 (CH2CO, C-6), 33.6 (CH2Scyst), 31.8, 
31.7 (2 CH2CH2CH3), 28.9 (C(CH3)3), 24.8, 24.7 (2 CH2CH2CO), 22.7 (CH2CH3), 14.2 
(CH3). 
ESI-MS (Figure S96): m/z 1880.7 [M + 3 H]3+, 2820.3 [M + 2 H]2+. 
Elemental analysis calculated (%) forC259H469N35O70S14: C 55.13, H 8.38, N 8.69; found: 
C 54.76, H 8.21, N 8.50. 
 
 
 
Heptakis[2,3-di-O-acetyl-6-(2-(N’-(2-aminoethyl)thioureido)ethylthio)-6-deoxy]cyclo-
maltoheptaose heptahydrochloride (1). Treatment of compound 24 (50 mg, 14 µmol) 
with anhydrous TFA (100 µL) at rt for 5 min, followed by freeze-drying immediately from a 
0.1 N aq. HCl solution afforded pure compound 1 in virtually quantitative yield (43 mg). 
[α]D = +35.2 (c = 0.5 in MeOH). 
1H NMR (500 MHz, DMSO-d6, 333 K, Figure S17): δ = 8.12 (bs, 14 H, NH2), 7.97, 7.75 (2 
bs, 14 H, NHCS), 5.22 (t, 7H, J2,3 = J3,4 = 9.0 Hz, H-3), 5.11 (d, 7H, J1,2 = 3.7 Hz, H-1), 
4.73 (dd, 7H, H-2), 4.14 (m, 7H, H-5), 3.90 (t, 7H, J4,5 = 8.8 Hz, H-4), 3.72, 3.63 (2 bq, 
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28H, CH2NHCS), 3.12 (m, 14H, H-6a, H-6b), 3.02 (bt, 14H, CH2NH2), 2.82 (m, 14H, 
CH2Scyst), 2.02, 2.00 (2s, 42H, COCH3). 
13C NMR (100.6 MHz, DMSO-d6, 323 K, Figure S17): δ = 183.2 (CS), 170.5, 169.7 (2 CO 
ester), 97.0 (C-1), 78.8 (C-4), 71.6 (C-5), 70.8 (C-2, C-3), 44.0, 41.7 (CH2NHCS), 38.8 
(CH2NH2), 33.7 (C-6), 32.8 (CH2Scyst), 21.0 (COCH3). 
ESI-MS (Figure S97): m/z 713.8 [M + 4 H]4+, 951.7 [M + 3 H]3+, 1426.7 [M + 2 H]2+. 
Elemental analysis calculated (%) for C105H182Cl7N21O42S14: C 40.58, H 5.90, N 9.46, S 
14.44; found: C 40.54, H 6.15, N 9.33, S 14.79. 
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Heptakis[6-(2-(N’-(2-aminoethyl)thioureido)ethylthio)-6-deoxy-2,3-di-O-propanoyl]-
cyclomaltoheptaose heptahydrochloride (2). Treatment of heptacarbamate 25 (35 mg, 
9.3 µmol) with anhydrous TFA (90 µL) at rt for 5 min, followed by freeze-drying 
immediately from a 0.1 N aq. HCl solution yielded pure compound 2 (28 mg, 90%). 
[α]D = +36.9 (c = 0.5 in MeOH). 
1H NMR (500 MHz, DMSO-d6, 333 K, Figure S18): δ = 8.11 (bs, 14 H, NH2),7.96, 7.75 (2 
bs, 14 H, NHCS), 5.24 (t, 7H, J2,3 = J3,4 = 8.9 Hz, H-3), 5.10 (d, 7H, J1,2 = 3.4 Hz, H-1), 
4.74 (dd, 7H, H-2), 4.16 (m, 7H, H-5), 3.91 (t, 7H, J4,5 = 8.6 Hz, H-4), 3.71, 3.64 (2 bq, 
28H, CH2NHCS), 3.12 (m, 14H, H-6a, H-6b), 3.02 (bt, 14H, CH2NH2), 2.83 (m, 14H, 
CH2Scyst), 2.37-2.20 (m, 28H, CH2CO), 1.04, 1.03 (2 t, 42H, 3JH,H = 7.5 Hz, CH3). 
13C NMR (125.7 MHz, DMSO-d6, 323 K, Figure S18): δ = 183.2 (CS), 173.7, 172.9 (2 CO 
ester), 96.9 (C-1), 78.7 (C-4), 71.7 (C-5), 70.9 (C-3), 70.6 (C-2),43.1, 41.7, (CH2NHCS), 
38.9 (CH2NH2),33.8 (C-6), 32.8 (CH2Scyst),27.2 (CH2CO), 9.1 (CH3). 
ESI-MS (Figure S98): m/z 762.7 [M + 4 H]4+, 1017.6 [M + 3 H]3+, 1525.5 [M + 2 H]2+, 
3048.8 [M + H]+. 
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Elemental analysis calculated (%) for C119H210Cl7N21O42S14: C 43.26, H 6.41, N 8.90, S 
13.59; found: C 43.34, H 6.33, N 8.84, S 13.34. 
 
 
 
Heptakis[6-(2-(N’-(2-aminoethyl)thioureido)ethylthio)-2,3-di-O-butanoyl-6-deoxy]-
cyclomaltoheptaose heptahydrochloride (3). Treatment of heptacarbamate 26 (88 mg, 
22 µmol) with anhydrous TFA (0.5 mL) at rt for 5 min, followed by freeze-drying 
immediately from a 0.1 N aq. HCl solution yielded pure compound 3 in quantitative yield 
(78 mg). 
[α]D = +34.3 (c = 0.5 in MeOH). 
1H NMR (500 MHz, DMSO-d6, 333 K, Figure S19): δ = 8.15 (bs, 14 H, NH2), 7.97, 7.75 (2 
bs, 14H, NHCS), 5.26 (t, 7H, J2,3 = J3,4 = 8.8 Hz, H-3), 5.11 (d, 7H, J1,2 = 3.0 Hz, H-1), 4.73 
(dd, 7H, H-2), 4.17 (m, 7H, H-5), 3.91 (t, 7H, J4,5 = 8.9 Hz, H-4), 3.73, 3.65 (2 bq, 28H, 
CH2NHCS), 3.11 (m, 14H, H-6a, H-6b), 3.03 (bt, 14H, CH2NH2), 2.84 (m, 14H, CH2Scyst), 
2.34, 2.22 (2 m, 28H, CH2CO), 1.57 (m, 28H, CH2CH3), 0.92, 0.89 (2 t, 42H, 3JH,H = 7.4 
Hz, CH3). 
13C NMR (125.7 MHz, DMSO-d6, 333 K, Figure S19): δ = 183.4 (CS), 172.8, 171.8 (2 CO 
ester), 96.7 (C-1), 78.6 (C-4), 71.6 (C-5), 70.7, 70.5 (C-3, C-2), 44.2, 43.1 (CH2NHCS), 
39.0 (CH2NH2), 35.8, 35.7 (CH2CO), 34.1 (C-6), 32.9 (CH2Scyst), 18.1, 18.0 (CH2CH3), 
13.7 (CH3). 
ESI-MS (Figure S99): m/z 812.5 [M + 4 H]4+, 1082.4 [M + 3 H]3+, 1623.1 [M + 2 H]2+, 
3245.1 [M + H]+. 
Elemental analysis calculated (%) for C133H238Cl7N21O42S14: C 45.63, H 6.85, N 8.40, S 
12.82; found: C 45.51, H 7.01, N 8.35, S 12.57. 
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Heptakis[6-(2-(N’-(2-aminoethyl)thioureido)ethylthio)-6-deoxy-2,3-di-O-hexanoyl]-
cyclomaltoheptaose heptahydrochloride (4). Treatment of compound 27 (56 mg, 13 
µmol) with anhydrous TFA (100 µL) at rt for 5 min, followed by freeze-drying immediately 
from a 0.1 N aq. HCl solution yielded pure compound 4 in quantitative yield (50 mg). 
[α]D = + 80.7 (c = 1.0 in DMSO). 
1H NMR (500 MHz, DMSO-d6, 333 K, Figure S20): δ = 8.08 (bs, 14 H, NH2), 7.92, 7.72 (2 
bs, 14 H, NHCS), 5.21 (t, 7 H, J2,3 = J3,4 = 8.8 Hz, H-3), 5.05 (d, 7 H, J1,2 = 2.9 Hz,H-1), 
4.67 (dd, 7H, H-2), 4.12 (m, 7 H, H-5), 3.85 (t, 7 H, J4,5 = 8.8 Hz, H-4), 3.68 (m, 14 H, 
CH2NHCS), 3.59 (m, 14 H, CH2CH2Scyst), 3.10 (d, 14 H, H-6a, H-6b), 2.98 (t, 14 H,3JH,H = 
6.3 Hz, CH2NH2), 2.79, 2.77 (2 dt, 14 H, 2JH,H = 13.5 Hz, 3JH,H = 7.0 Hz, CH2Scyst), 2.35-
2.11 (m, 28 H, CH2CO), 1.50 (m, 28 H, CH2CH2CO), 1.24 (m, 56 H, CH3CH2, 
CH3CH2CH2), 0.84, 0.83 (2 t, 42 H, 3JH,H = 7.1 Hz, CH3). 
13C NMR (125.7 MHz, DMSO-d6, 333 K, Figure S20): δ = 183.4 (CS), 172.9, 171.9 (2 
CO), 96.7 (C-1), 78.5 (C-4), 71.5 (C-5), 70.7 (C-3, C-2), 44.2 (CH2CH2Scyst), 41.7 
(CH2NHCS), 39.0 (CH2NH2), 34.0 (CH2CO), 33.7 (C-6), 32.9 (CH2Scyst), 31.3, 31.1 (2 
CH3CH2CH2), 24.3, 24.2 (2 CH2CH2CO), 22.2 (CH3CH2), 14.0 (CH3). 
ESI-MS (Figure S100): m/z 910.2 [M + 4 H]4+, 1213.4 [M + 3 H]3+, 1819.2 [M + 2 H]2+. 
Elemental analysis calculated (%) forC161H294Cl7N21O42S14: C 49.67, H, 7.61, N 7.56; 
found: C 49.27, H 7.30, N 7.32. 
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Heptakis[2,3-di-O-acetyl-6-(2-(N’-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thioureido)-
ethylthio)-6-deoxy]cyclomaltoheptaose tetradecahydrochloride (5). Treatment of 
compound 28 (50 mg, 10 µmol) with anhydrous TFA (100 µL) at rt for 5 min, followed by 
freeze-drying immediately from a 0.1 N aq HCl solution afforded pure compound 5 in 
quantitative yield (41 mg). 
[α]D = +25.1 (c = 0.5 in MeOH). 
1H NMR (500 MHz, 10:1 MeOD-D2O, 333 K, Figure S21): δ = 5.33 (t, 7H, J2,3 = J3,4 = 8.8 
Hz, H-3), 5.21 (d, 7H, J1,2 = 3.6 Hz, H-1), 4.83 (dd, 7H, H-2), 4.20 (m, 7H, H-5), 3.96 (t, 
7H, J4,5 = 8.6 Hz, H-4), 3.88 (bt, 14H, CH2CH2Scyst), 3.78 (bt, 14H, NCH2CH2NHCS), 3.39 
(m, 28H, CH2NH2), 3.33-3.18 (m, 56H, H-6a, H-6b, CH2CH2NH2, NCH2CH2NHCS), 2.95 
(m, 14H, CH2Scyst), 2.10, 2.08 (2s, 42H, COCH3). 
13C NMR (100.6 MHz,15:1 MeOD-D2O, 323 K, Figure S21): δ = 182.9 (CS), 171.3, 170.6 
(2 CO ester), 96.7 (C-1), 78.7 (C-4), 72.1 (C-5), 70.9 (C-3, C-2), 52.7 (NCH2CH2NHCS), 
51.1(CH2CH2NH2), 44.1 (CH2CH2Scyst), 40.4 (NCH2CH2NHCS), 36.4 (CH2NH2), 33.7 (C-
6), 32.7 (CH2Scyst), 19.9, 19.8 (COCH3). 
ESI-MS (Figure S101): m/z 691.7 [M + 5 H]5+, 864.6 [M + 4 H]4+, 1152.7 [M + 3 H]3+, 
1728.7 [M + 2 H]2+. 
Elemental analysis calculated (%) for C133H259Cl14N35O42S14: C 40.28, H 6.58, N 12.36, S 
11.32; found: C 40.10, H 6.66, N 12.56, S 11.32. 
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Heptakis[6-(2-(N’-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thioureido)ethylthio)-6-
deoxy-2,3-di-O-propanoyl]cyclomaltoheptaose tetradecahydrochloride (6). 
Treatment of compound 29 (100 mg, 19.8 µmol) with anhydrous TFA (0.5 mL) at rt for 5 
min, followed by freeze-drying immediately from a 0.1 N aq HCl solution afforded pure 
compound 6 in quantitative yield (82 mg). 
[α]D = +33.2 (c = 0.25 in MeOH). 
1H NMR (500 MHz, 10:1 MeOD-D2O, 323 K, Figure S22): δ = 5.32 (t, 7H, J2,3 = J3,4 = 8.6 
Hz, H-3), 5.18 (d, 7H, J1,2 = 3.5 Hz, H-1), 4.84 (dd, 7H, H-2), 4.21 (m, 7H, H-5), 3.96 (t, 
7H, J4,5 = 8.3 Hz, H-4), 3.77 (bt, 14H, CH2CH2Ccyst), 3.72 (bt, 14H, NCH2CH2NHCS), 3.23 
(m, 42H, H-6a, H-6b, CH2NH2), 3.00 (t, 28H, 3JH,H = 5.9 Hz, CH2CH2NH2), 2.94 (m, 14H, 
CH2Scyst), 2.89 (t, 14H, 3JH,H = 5.9 Hz, NCH2CH2NHCS), 2.49-2.27 (m, 28H, CH2CO), 
1.13, 1.11 (2 t, 42H, 3JH,H = 7.5 Hz, CH3). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 323 K, Figure S22): δ = 182.2 (CS), 174.9, 173.7 
(2 CO ester), 96.6 (C-1), 78.3 (C-4), 72.0 (C-5), 70.9 (C-3), 70.4 (C-2), 52.2 
(NCH2CH2NHCS), 51.0 (CH2CH2NH2), 44.1 (CH2CH2Scyst), 40.8 (NCH2CH2NHCS), 36.8 
(CH2NH2), 33.9 (C-6), 32.7 (CH2Scyst), 27.2 (CH2CO), 8.2, 8.1 (CH3). 
ESI-MS (Figure S102): m/z 931.1 [M + H + 3 Na]4+, 1239.9 [M + 3 Na]3+, 1827.3 [M + 2 
H]2+. 
Elemental analysis calculated (%) for C147H287Cl14N35O42S14·7H2O: C 41.17, H 7.07, N 
11.43, S 10.47; found: C 40.93, H 6.89, N 11.35, S 10.22. 
 
206 Ph.D. Thesis - Iris Pflueger 
 
 
 
 
Heptakis[6-(2-(N’-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thioureido)ethylthio)-2,3-di-
O-butanoyl-6-deoxy-]cyclomaltoheptaose tetradecahydrochloride (7). Treatment of 
compound 30 (63 mg, 12 µmol) with anhydrous TFA (200 µL) at rt for 5 min, followed by 
freeze-drying immediately from a 0.1 N aq HCl solution afforded pure compound 7 in 
virtually quantitative yield (51 mg). 
[α]D = +30.0 (c = 0.5 in MeOH). 
1H NMR (500 MHz, 10:1MeOD-D2O, 333 K, Figure S23): δ = 5.33 (t, 7H, J2,3 = J3,4 = 8.6 
Hz, H-3), 5.20 (d, 7H, J1,2 = 3.6 Hz, H-1), 4.86 (dd, 7H, H-2),4.20 (m, 7H, H-5), 3.97 (t, 7H, 
J4,5 = 8.4 Hz, H-4), 3.84 (bt, 14H, CH2CH2Ccyst), 3.80 (bq, 14H, NCH2CH2NHCS), 3.35 (t, 
28H, 3JH,H = 6.2 Hz, CH2NH2), 3.29 (m, 14H, H-6a, H-6b), 3.24 (t, 28H, 3JH,H = 7.4 Hz, 
CH2CH2NH2), 3.11 (t, 14H, 3JH,H = 6.4 Hz, NCH2CH2NHCS), 2.96 (m, 14H, CH2Scyst), 
2.46-2.24 (m, 28H, CH2CO), 1.66 (m, 28H, CH2CH3), 1.00, 0.96 (2 t, 42H, 3JH,H = 7.5 Hz, 
CH3). 
13C NMR (100.6 MHz, 10:1MeOD-D2O, 323 K, Figure S23): δ = 173.6, 172.3 (2 CO 
ester), 96.5 (C-1), 78.2 (C-4), 72.0 (C-5), 70.6 (C-3), 70.3 (C-2), 52.4 (NCH2CH2NHCS), 
51.2 (CH2CH2NH2), 44.1 (CH2CH2Scyst), 40.9 (NCH2CH2NHCS), 36.9 (CH2NH2), 35.7, 
35.6 (CH2CO), 33.9 (C-6), 32.7 (CH2Scyst), 18.0, 17.9 (CH2CH3), 12.7 (CH3). 
ESI-MS (Figure S103): m/z 978.3 [M+ H+ 3 Na]4+, 1283.2 [M + 3 H]3+. 
Elemental analysis calculated (%) for C161H315Cl14N35O42S14: C 44.36, H 7.28, N 11.25, S 
10.30; found: C 44.54, H 7.44, N 11.36, S 10.55. 
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Heptakis[6-(2-(N’-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thioureido)ethylthio)-6-
deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose tetradecahydrochloride (8). Treatment 
of compound 31 (84 mg, 15 µmol) with anhydrous TFA (100 µL) at rt for 5 min, followed 
by freeze-drying immediately from a 0.1 N aq HCl solution afforded pure compound 8 in 
quantitative yield (70 mg). 
[α]D = +48.2 (c = 0.67 in MeOH). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 313 K, Figure S24): δ = 5.27 (t, 7 H, J2,3 =  J3,4 = 8.6 
Hz, H-3), 5.13 (d, 7 H, J1,2 = 3.7 Hz, H-1), 4.82 (dd, 7 H, H-2), 4.14 (m, 7 H, H-5), 3.89 (t, 
7 H, J4,5 = 8.6 Hz, H-4), 3.73 (m, 28 H, CH2CH2Scyst, NCH2CH2NHCS), 3.25 (t, 28 H, 3JH,H 
= 6.2 Hz, CH2NH2), 3.14 (m, 14 H, H-6a, H-6b), 3.14 (t, 28 H, CH2CH2NH2), 2.97 (t, 14 H, 
3JH,H = 6.5 Hz, NCH2CH2NHCS), 2.90 (m, 14 H, CH2Scyst), 2.50-2.15 (m, 28 H, CH2CO), 
1.60 (m, 28 H, CH2CH2CO), 1.30 (m, 56 H, CH2CH3, CH2CH2CH3), 0.91, 0.89 (2 t, 42 H, 
3JH,H = 7.8 Hz, CH3). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 313 K, Figure S24): δ = 183.5 (CS), 175.0, 173.4 
(2 CO ester), 98.1 (C-1), 80.1 (C-4), 73.1 (C-5), 71.9 (C-3) , 71.5 (C-2), 53.5 
(NCH2CH2NHCS), 52.3 (CH2CH2NH2), 45.4 (CH2CH2Scyst), 42.1 (NCH2CH2NHCS), 38.1 
(CH2NH2), 35.2 (C-6), 35.0 (CH2CO), 33.9 (CH2Scyst), 32.3, 32.2 (2 CH2CH2CH3), 25.4, 
25.3 (2 CH2CH2CO), 23.2, 23.1 (2 CH2CH3), 14.2 (CH3). 
ESI-MS (Figure S104): m/z 849.2 [M + 5 H]5+, 1061.2 [M + 4 H]4+, 1414.4 [M + 3 H]3+, 
2120.7 [M + 2 H]2+. 
Elemental analysis calculated (%) for C189H371N35O42S14Cl14: C 47.78, H 7.87, N 10.32; 
found: C 47.45, H 7.34, N 10.35. 
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Heptakis[6-(2-(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)ethylthio)-6-deoxy]-
cyclomaltoheptaose (33). Saponification of compound 24 (214 mg, 60 µmol) was 
accomplished according to the procedure described in the general methods yielding 
compound 33 as an off-white powder (175 mg, 98%). 
Rf = 0.50 (10:1:1 MeCN-H2O-NH4OH). [α]D = +34.9 (c = 0.24 in MeOH). 
1HNMR (500 MHz, MeOD, 323 K, Figure S25): δ = 4.99 (d, 7 H, J1,2 = 3.4 Hz, H-1), 4.05 
(m, 7 H, H-5), 3.81 (t, 7 H, J2,3 = J3,4 = 9.3 Hz, H-3), 3.73, 3.58 (2 bs, 28 H, CH2NHCS), 
3.50 (m, 14 H, H-2, H-4), 3.26 (m, 21 H, H-6a, CH2NHBoc), 2.98 (m, 7 H, H-6b), 2.92 (m, 
14 H, CH2Scyst), 1.46 (bs, 63 H, C(CH3)3). 
13C NMR (125.7 MHz, MeOD, 323 K, Figure S25): δ = 183.7 (CS), 158.6 (CO), 104.1 (C-
1), 86.4 (C-4), 80.6 (C(CH3)3), 74.5 (C-3), 74.4 (C-2), 73.5 (C-5), 45.3, 45.2 (CH2NHCS), 
41.2 (CH2NHBoc), 35.0 (CH2Scyst), 33.8 (C-6), 29.1 (C(CH3)3). 
ESI-MS (Figure S105): m/z 1504.9 [M + 2 Na]2+. 
Elemental analysis calculated (%) for C112H203N21O42S14: C 45.37, H 6.90, N 9.92; found: 
C 45.11, H 6.69, N 9.80. 
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Heptakis[6-(2-(N’-(2-(N,N-di-(2-(N-tert-butoxycarbonylamino)ethyl)amino)ethyl)thio-
ureido)ethylthio)-6-deoxy]cyclomaltoheptaose (34). Saponification of compound 28 
(242 mg, 50 µmol) was accomplished according to the procedure described in the 
general methods yielding compound 34 as an off-white powder (211 mg, 99%). 
Rf = 0.36 (10:1:1 MeCN-H2O-NH4OH). [α]D = +33.3 (c = 0.8 in MeOH). 
1HNMR (500 MHz, MeOD, 313 K, Figure S26): δ = 4.96 (d, 7 H, J1,2 = 3.5 Hz, H-1), 4.03 
(m, 7 H, H-5), 3.79 (t, 7 H, J2,3 = J3,4 = 8.8 Hz, H-3), 3.74 (bt, 14 H, CH2CH2Scyst), 3.51 (m, 
28 H, H-2, H-4, NCH2CH2NHCS), 3.24 (m, 7 H, J6a,6b = 14.3 Hz, J5,6a = 1.8 Hz, H-6a), 
3.12 (bt, 14 H, 3JH,H = 6.0 Hz, CH2NHBoc), 2.97 (m, 7 H, J5,6b = 5.9 Hz, H-6b), 2.87 (m, 14 
H, CH2Scyst), 2.69 (bt, 14 H, 3JH,H = 5.6 Hz, NCH2CH2NHCS), 2.59 (bt, 28 H, 
CH2CH2NHBoc), 1.44 (bs, 126 H, C(CH3)3). 
13C NMR (125.7 MHz, MeOD, 313 K, Figure S26): δ = 183.6 (CS), 158.5 (CO), 104.1 (C-
1), 86.2 (C-4), 80.3 (C(CH3)3), 74.5 (C-3), 74.4 (C-2), 73.6 (C-5), 55.7 (CH2CH2NHBoc), 
54.8 (NCH2CH2NHCS), 45.3 (CH2CH2Scyst), 43.6 (NCH2CH2NHCS), 40.1  (CH2NHBoc), 
34.9 (C-6), 34.2 (CH2Scyst), 29.1 (C(CH3)3). 
ESI-MS (Figure S106): m/z 1438.6 [M + H + 2 Na]3+, 2146.8 [M + H + Na]2+. 
Elemental analysis calculated (%) for C175H329N35O56S14: C 49.24, H 7.77, N 11.48; found: 
C 49.25, H 7.71, N 11.37. 
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Heptakis[6-(2-(N’-(2-aminoethyl)thioureido)ethylthio)-6-deoxy]cyclomaltoheptaose 
heptahydrochloride (9). Treatment of compound 33 (40 mg, 13 µmol) with anhydrous 
TFA (100 µL) at rt for 5 min, followed by freeze-drying immediately from a 0.1 N aq. HCl 
solution afforded pure compound 9 in quantitative yield (34 mg). 
[α]D = +46.5 (c = 0.5 in H2O). 
1HNMR (500 MHz, D2O, 333 K, Figure S27): δ = 5.42 (d, 7 H, J1,2 = 3.1 Hz, H-1), 4.25 (bt, 
7 H, J4,5 = 9.1 Hz, H-5), 4.20 (t, 7 H, J2,3 = J3,4 = 9.1 Hz, H-3), 4.14 (t, 14 H, 3JH,H = 6.0 Hz, 
CH2CH2NH2), 3.99 (bs, 14 H, CH2NHCS), 3.96 (dd, 7 H, H-2), 3.87 (t, 7 H, H-4), 3.55 (t, 
14 H, 3JH,H = 6.0 Hz, CH2NH2), 3.52 (bd, 7 H, J6a,6b = 13.8 Hz, H-6a), 3.28 (dd, 7 H, J5,6b = 
7.8 Hz, H-6b), 3.21 (t, 14 H, 3JH,H = 6.9 Hz, CH2Scyst). 
13C NMR (125.7 MHz, D2O, 333 K, Figure S27): δ = 182.8 (CS), 101.6 (C-1), 84.1 (C-4), 
73.6 (C-3), 72.5 (C-2), 72.0 (C-5), 44.3, 41.6 (CH2NHCS), 39.8 (CH2NH2), 34.1 (C-6), 
32.4 (CH2Scyst). 
ESI-MS (Figure S107): m/z 755.8 [M + 3 H]3+, 1132.9 [M + 2 H]2+, 2264.5 [M + H]+. 
Elemental analysis calculated (%) for C77H154Cl7N21O28S14: C 36.71, H 6.16, N 11.68, S 
17.82; found: C 36.48, H 5.95, N 11.44, S 17.49. 
 
 
 
 
 
Heptakis[6-(2-(N’-(2-(N,N-di-(2-aminoethyl)amino)ethyl)thioureido)ethylthio)-6-
deoxy]cyclomaltoheptaose tetradecahydrochloride (10). Treatment of compound 34 
(105 mg, 25 µmol) with anhydrous TFA (200 µL) at rt for 5 min, followed by freeze-drying 
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immediately from a 0.1 N aq. HCl solution afforded pure compound 10 in virtually 
quantitative yield (82 mg). 
[α]D = +20.3 (c = 1.0 in H2O). 
1HNMR (500 MHz, D2O, 333 K, Figure S28): δ = 5.46 (d, 7 H, J1,2 = 3.3 Hz, H-1), 4.30 (m, 
7 H, H-5), 4.26 (t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 4.09 (m, 28 H, NCH2CH2NHCS, 
CH2CH2Scyst),  4.02 (dd, 7 H, H-2), 3.98 (t, 7 H, H-4), 3.65 (m, 28 H, CH2NH2), 3.52 (m, 35 
H, CH2CH2NH2, H-6a), 3.40 (m, 21 H, H-6b, CH2Scyst), 3.29 (m, 14 H, NCH2CH2NHCS). 
13C NMR (75.5 MHz, D2O, 333 K, Figure S28): δ = 181.9 (CS), 102.2 (C-1), 84.8 (C-4), 
73.3 (C-3), 72.4 (C-2, C-5), 53.4 (NCH2CH2NHCS), 50.9 (NCH2CH2NHCS), 44.2 
(CH2CH2Scyst), 39.8 (CH2NH2), 35.2 (CH2CH2NH2), 33.8 (C-6), 32.4 (CH2Scyst). 
ESI-MS (Figure S108): m/z 717.5 [M + 4 H]4+, 956.7 [M + 3 H]3+, 1434.5 [M + 2 H]2+.  
Elemental analysis calculated (%) forC105H231Cl14N35O28S14: C 37.34, H 6.89, N 14.52; 
found: C 37.01, H 6.67, N 14.22. 
 
 
 
1-(2-(tert-Butoxycarbonylamino)ethyl)-3-butyl-2-thiourea (48). To a solution of 1-
butylamine (25 µL, 0.25 mmol) and Et3N (86 µL, 0.62 mmol, 2.5 eq) in DCM (1.5 mL) a 
solution of 2-(tert-butoxycarbonylamino)ethylisothiocyanate 22186 (50 mg, 0.25 mmol, 1 
eq) in DCM (0.5 mL) was added drop wise. The reaction mixture was stirred for 4 h at rt. 
Then, the solvent was evaporated under reduced pressure and the resulting residue was 
purified by flash column chromatography (1:1 EtOAc-petroleum ether) to yield compound 
48 (66 mg, 97%). 
Rf = 0.50 (1:1 EtOAc-petroleum ether). 
1H NMR (300 MHz, MeOD, Figure S29): δ = 3.55 (m, 2 H, CSNHCH2CH2NHBoc), 3.42 
(m, 2 H, CSNHCH2CH2CH2), 3.23 (t, 2 H, 3JH,H = 6.0 Hz, CH2NHBoc), 1.58 (m, 2 H, 
CSNHCH2CH2CH2), 1.45 (s, 9 H, C(CH3)3), 1.38 (m, 2 H, CSNHCH2CH2CH2), 0.96 (t, 3 
H, 3JH,H = 6.8 Hz, CH3). 
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13C NMR (75.5 MHz, CDCl3, Figure S29): δ = 181.5 (CS), 157.8 (CO carbamate), 80.2 
(C(CH3)3), 43.7, 43.6 (CH2NHCS), 39.8 (CH2NHBoc), 30.8 (CSNHCH2CH2CH2), 28.3 
(C(CH3)3), 20.0 (CSNHCH2CH2CH2), 13.7 (CH3). 
ESI-MS (Figure S109): m/z 276.2 [M + H]+, 298.2 [M + Na]+, 314.3 [M + K]+. 
Elemental analysis calculated (%) for C12H25N3O2S: C 52.33, H 9.15, N 15.26, S 11.64; 
found: C 52.72, N 15.67, H 9.16, S 11.50. 
 
 
 
1-[2-(Bis(2-(tert-butoxycarbonylamino)ethyl)amino)ethyl]-3-butyl-2-thiourea (49). To 
a solution of 1-butylamine (7.7 µL, 77 µmol) and Et3N (27 µL, 0.19 mmol, 2.5 eq) in DCM 
(1.5 mL) a solution of 2-[bis(2-(tert-butoxycarbonylamino)ethyl)amino]ethylisothiocyanate 
23177 (30 mg, 77 µmol, 1 eq) in DCM (0.5 mL) was added drop wise. The reaction mixture 
was stirred overnight at rt. Then, the solvent was evaporated under reduced pressure and 
the resulting residue was purified by flash column chromatography (1:1 EtOAc-petroleum 
ether) to yield compound 49 (33 mg, 91%). 
 Rf = 0.18 (1:1 EtOAc-petroleum ether). 
1H NMR (300 MHz, MeOD, Figure S30): δ = 3.50 (m, 4 H, CH2NHCS), 3.12 (t, 4 H, 3JH,H = 
6.0 Hz, CH2NHBoc), 2.68 (t, 2 H, 3JH,H = 6.1 Hz, CSNHCH2CH2N), 2.58 (t, 4 H, 3JH,H = 6.0 
Hz, NCH2CH2NHBoc), 1.58 (m, 2 H, CSNHCH2CH2CH2), 1.46 (s, 18 H, C(CH3)3), 1.39 
(m, 2 H, CSNHCH2CH2CH2), 0.96 (t, 3 H, 3JH,H = 7.3 Hz, CH3). 
13C NMR (75.5 MHz, CDCl3, Figure S30): δ = 183.0 (CS), 157.2 (CO carbamate), 80.1 
(C(CH3)3), 56.0 (CH2CH2NHBoc, NCH2CH2NHCS), 44.4 (CH2NHCS), 39.0 (CH2NHBoc), 
31.9 (CSNHCH2CH2CH2), 28.9 (C(CH3)3), 20.4 (CSNHCH2CH2CH2), 14.3 (CH3). 
ESI-MS (Figure S110): m/z 462.5 [M + H]+, 468.5 [M + Li]+, 484.5 [M + Na]+, 500.4 [M + 
K]+, 496.3 [M + Cl]-. 
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Elemental analysis calculated (%) for C21H43N5O4S: C 54.63, H 9.39, N 15.17, S 6.95; 
found: C 54.23, H 9.48, N 15.11, S 6.87. 
 
 
 
1-(2-Aminoethyl)-3-butyl-2-thiourea hydrochloride (50). Treatment of compound 48 
(31 mg, 0.11 mmol) with TFA following the procedure described in the general methods, 
followed by freeze-drying from a 0.1 N aq. HCl solution, gave pure compound 50 in 
almost quantitative yield (23 mg, 96%). 
1H NMR (300 MHz, MeOD, Figure S31): δ = 3.87 (t, 2 H, 3JH,H = 6.0 Hz, 
CSNHCH2CH2NH2), 3.44 (m, 2 H, CSNHCH2CH2CH2), 3.18 (t, 2 H, 3JH,H = 6.0 Hz, 
CH2NH2), 1.58 (m, 2 H, CSNHCH2CH2CH2), 1.40 (m, 2 H, CSNHCH2CH2CH2), 0.96 (t, 3 
H, 3JH,H = 7.3 Hz, CH3). 
13C NMR (75.5 MHz, D2O, Figure S31): δ = 180.0 (CS), 43.5 (CSNHCH2CH2NH2), 41.1 
(CSNHCH2CH2CH2), 39.3 (CH2NH2), 30.0 (CSNHCH2CH2CH2), 19.4 (CSNHCH2CH2CH2), 
13.0 (CH3). 
ESI-MS (Figure S111): m/z 176.1 [M + H]+. 
Elemental analysis calculated (%) for C7H18ClN3S: C 39.70, H 8.57, N 19.84, S 15.14; 
found: C 39.93, H 8.84, N 19.46, S 14.76. 
 
 
1-[2-(Bis(2-aminoethyl)amino)ethyl]-3-butyl-2-thiourea dihydrochloride (51). 
Treatment of compound 49 (33 mg, 71 µmol) with TFA following the procedure described 
in the general methods, followed by freeze-drying from a 0.1 N aq. HCl solution, gave 
pure compound 51 in quantitative yield (24 mg). 
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1H NMR (300 MHz, MeOD, Figure S32): δ = 3.67 (t, 2 H, 3JH,H = 6.3 Hz, CSNHCH2CH2N), 
3.43 (m, 2 H, CSNHCH2CH2CH2), 3.13 (t, 4 H, 3JH,H = 6.0 Hz, CH2NH2), 2.89 (t, 4 H, 3JH,H 
= 6.1 Hz, NCH2CH2NH2), 2.80 (t, 2 H, 3JH,H = 6.2 Hz, CSNHCH2CH2N), 1.56 (m, 2 H, 
CSNHCH2CH2CH2), 1.38 (m, 2 H, CSNHCH2CH2CH2), 0.95 (t, 3 H, 3JH,H = 7.3 Hz, CH3). 
13C NMR (75.5 MHz, D2O, Figure S32): δ = 181.0 (CS), 53.9 (NCH2CH2NHCS), 50.3 
(CH2CH2NH2), 38.9 (CH2NHCS), 33.7 (CH2NH2), 30.1 (CSNHCH2CH2CH2), 19.4 
(CSNHCH2CH2CH2), 13.0 (CH3). 
ESI-MS (Figure S112): m/z 262.3 [M + H]+. 
Elemental analysis calculated (%) for C11H29Cl2N5S: C 39.51, H 8.74, N 20.95, S 9.59; 
found: C 39.88, H 8.79, N 20.57, S 9.50. 
 
 
3.2. New Compounds synthesized in Chapter 3 
 
 
 
1,4,7-Tris(tert-butoxycarbonyl)-10-propargyl-1,4,7,10-tetraazacyclododecane (63).350 
A solution of 1,4,7-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane 61276b (1.0 g, 
2.12 mmol), propargyl bromide solution 80% in toluene (0.68 mL, 6.35 mmol, 3 eq) and 
Et3N (0.88 mL, 6.35 mmol, 3 eq) in MeCN (11 mL) was stirred at rt for 48 h. Then, 
additional portions of propargyl bromide solution 80% in toluene (0.68 mL, 6.35 mmol, 3 
eq) and Et3N (0.88 mL, 1.35 mmol, 3 eq) were added and the suspension was stirred at rt 
for another 24 h. The resulting suspension was filtered and the solid residue extracted 
with DCM (2 x 5 mL). The combined filtrates were concentrated to dryness. The resulting 
residue was purified by flash column chromatography (1:1 EtOAc-petroleum ether) to 
give 63 (0.77 g, 71%). 
Rf = 0.64 (1:1 EtOAc-petroleum ether). 
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1H NMR (500 MHz, CDCl3, 333 K, Figure S33): δ = 3.58 (bs, 2H, CH2C≡CH), 3.54 (t, 4H, 
3JH,H = 5.0 Hz, H-3, H-5), 3.40 (m, 8H, H-2, H-6, H-8, H-12), 2.90 (m, 4H, H-9, H-11), 2.26 
(bs, 1H, C≡CH), 1.48, 1.47 (2 s, 27H, C(CH3)3). 
13C NMR (125.7 MHz, CDCl3, 333 K, Figure S33): δ = 156.1 (CO), 80.1 (C(CH3)3), 79.7 
(C≡CH), 76.2 (C≡CH), 53.5 (C-9, C-11), 50.0 (C-8, C-12), 47.8 (C-3, C-5), 47.6 (C-2, C-
6), 40.8 (CH2C≡CH), 28.9, 28.7 (C(CH3)3). 
ESI-MS (Figure S113): m/z 511.4 [M + H]+, 533.4 [M + Na]+, 549.3 [M + K]+. 
Elemental analysis calculated (%) forC26H46N4O6: C 61.15, H9.08, N 10.97; found: C 
61.22, H 9.22, N 10.67. 
Alternatively, this reaction was also carried out under microwave irradiation: A solution of 
1,4,7-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane 61276b (240 mg, 0.51 
mmol), propargyl bromide solution 80% in toluene (0.16 mL, 1.53 mmol, 3 eq) and Et3N 
(0.21 mL, 1.53 mmol, 3 eq) in MeCN (3 mL) was heated under microwave irradiation at 
120 ºC for 0.5 h (40W). Then, additional portions of propargyl bromide solution 80% in 
toluene (0.16 mL, 1.53 mmol, 3 eq) and Et3N (0.21 mL, 1.53 mmol, 3 eq) were added and 
the suspension was heated under microwave irradiation at 120 ºC for another 0.5 h. The 
resulting suspension was filtered and the solid residue extracted with DCM (2 x 1 mL). 
The combined filtrates were concentrated to dryness. The resulting residue was purified 
by column chromatography (1:1 EtOAc-petroleum ether) to give 63 (132 mg, 51%). 
 
 
 
1,4,8-Tris(tert-butoxycarbonyl)-11-propargyl-1,4,8,11-tetraazacyclotetradecane (64). 
A solution of 1,4,8-tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 62346 (250 
mg, 0.50 mmol), propargyl bromide solution 80% in toluene (0.16 mL, 1.50 mmol, 3 eq) 
and Et3N (0.20 mL, 1.50 mmol, 3 eq) in MeCN (3 mL) was stirred at rt for 48 h. Then, 
additional portions of propargyl bromide solution 80% in toluene (0.16 mL, 1.5 mmol, 3 
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eq) and Et3N (0.20 mL, 1.5 mmol, 3 eq) were added and the suspension was stirred at rt 
for another 24 h. The resulting suspension was filtered and the solid residue extracted 
with DCM (2 x 1 mL). The combined filtrates were concentrated to dryness. The resulting 
residue was purified by flash column chromatography (95:5DCM-MeOH) to yield 64 (181 
mg, 67%). 
Rf = 0.69 (9:1 DCM-MeOH). 
1H NMR (500 MHz, CDCl3, 333 K, Figure S34): δ = 3.41-3.24 (m, 4 H, H-2, H-3), 3.38 (d, 
2 H, 4JH,H = 2.0 Hz, CH2C≡CH), 3.33 (m, 2 H, H-9), 3.32 (t, 2 H, 3JH,H = 6.0 Hz, H-14), 
3.28 (m, 4 H, 3JH,H = 7.0 Hz, H-5, H-7), 2.68 (bt, 2 H, 3JH,H = 5.5 Hz, H-10), 2.51 (bt, 2 H, 
3JH,H = 6.0 Hz, H-12), 2.14 (m, 1 H, C≡CH), 1.90 (m, 2 H, 3JH,H = 7.0 Hz, H-6), 1.69 (m, 2 
H, 3JH,H = 6.0 Hz, H-13), 1.45, 1.44 (2 s, 27 H, C(CH3)3). 
13C NMR (125.7 MHz, CDCl3, 333 K, Figure S34): δ = 155.8, 155.5 (CO), 79.5, 79.4 
(C(CH3)3), 78.1 (C≡CH), 73.1 (C≡CH), 52.7 (C-10), 51.2 (C-12), 47.7, 47.4, 47.3, 47.1, 
46.7, 45.1 (C-2, C-3, C-5, C-7, C-9, C-14), 42.3 (CH2C≡CH), 28.9 (C-6), 28.4 (C(CH3)3), 
26.7 (C-13). 
ESI-MS (Figure S114): m/z 539.4 [M + H]+, 561.4 [M + Na]+, 577.3 [M + K]+. 
Elemental analysis calculated (%) for C28H50N4O6: C 62.43, H 9.35, N 10.40; found: C , H 
, N. 
Alternatively, this reaction was also carried out under microwave irradiation: A solution of 
1,4,8-tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 62346 (243 mg, 0.49 
mmol), propargyl bromide solution 80% in toluene (0.16 mL, 1.48 mmol, 3 eq) and Et3N 
(0.20 mL, 1.48 mmol, 3 eq) in MeCN (2.5 mL) was heated under microwave irradiation at 
120 ºC for 0.5 h. Then, additional portions of propargyl bromide solution 80% in toluene 
(0.16 mL, 1.48 mmol, 3 eq) and Et3N (0.20 mL, 1.48 mmol, 3 eq) were added and the 
suspension was heated under microwave irradiation at 120 ºC (40 W) for another 0.5 h. 
The resulting suspension was filtered and the solid residue extracted with DCM (2 x 1 
mL). The combined filtrates were concentrated to dryness. The resulting residue was 
purified by flash column chromatography (95:5 DCM-MeOH) to give 64 (92 mg, 35%). 
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1-Azido-7-bromoheptane (65). To a solution of 1,7-dibromoheptane (1.19 g, 4.61 mmol) 
in DMSO (2 mL) was added NaN3 (0.12 g, 1.85 mmol, 0.4 eq) and the reaction mixture 
was stirred at rt for 5 h. Then, water was added (15 mL) and the reaction mixture was 
extracted with Et2O (3 x 10 mL). The organic layer was washed with brine (2 x 10 mL), 
dried over Na2SO4, filtered and evaporated to dryness. Solvents were evaporated and the 
resulting residue was purified by flash column chromatography (petroleum ether  1:9 
Et2O-petroleum ether) to yield 65 (353 mg, 35%), together with 620 mg (52%) of 
recovered starting material. 
Rf = 0.23 (petroleum ether). 
1H NMR (500 MHz, CDCl3, Figure S35): δ = 3.41 (t, 2 H, 3JH,H = 7.0 Hz, H-7), 3.26 (t, 2 H, 
3JH,H = 7.0 Hz, H-1), 1.86 (m, 2 H, 3JH,H = 7.0 Hz, H-6), 1.60 (m, 2 H, 3JH,H = 7.0 Hz, H-2), 
1.45 (m, 2 H, 3JH,H = 7.0 Hz, H-5), 1.41-1.35 (m, 2 H, H-3), 1.37-1.31 (m, 2 H, H-4). 
13C NMR (125.7 MHz, CDCl3, Figure S35): δ = 51.5 (C-1), 33.9 (C-7), 32.7 (C-6), 28.8 (C-
2), 28.4 (C-5), 28.1 (C-3), 26.7 (C-4). 
IR (NaCl): 2096 (N3) cm-1. 
Elemental analysis calculated (%) for C7H14N3Br: C 38.20, H 6.41, N 19.09; found: C 
38.49, H 6.12, N 18.74. 
 
 
 
1-(7-Azido-n-hept-1-yl)-4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclo-
dodecane (66). A suspension of 1,4,7-tris(tert-butoxycarbonyl)-1,4,7,10-
tetraazacyclododecane 61276b (300 mg, 0.63 mmol), compound 65 (182 mg, 0.83 mmol, 
1.3 eq) and K2CO3 (114 mg, 0.83 mmol, 1.3 eq) in MeCN (5 mL) was heated under 
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microwave irradiation at 140 ºC for 2 h. Then, additional portions of 65 (182 mg, 0.83 
mmol, 1.3 eq) and K2CO3 (114 mg, 0.83 mmol, 1.3 eq) were added and the suspension 
was heated under microwave irradiation at 140 ºC (60 W) for another 2 h. The resulting 
suspension was filtered and the solid residue extracted with DCM (2 x 1 mL). The 
combined filtrates were concentrated to dryness. The resulting residue was purified by 
flash column chromatography (1:1 EtOAc-petroleum ether) to give 66 (357 mg, 93%). 
Rf = 0.40 (2:1 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, 323 K, Figure S36): δ = 3.50, 3.43 (2m, 8 H, H-5, H-6, H-8, H-
9), 3.28-3.20 (m, 4 H, H-3, H-11), 3.21 (t, 2 H, 3JH,H = 7.0 Hz, H-7’), 2.60 (m, 4 H, H-2, H-
12), 2.47 (t, 2 H, 3JH,H = 8.0 Hz, H-1’), 1.56 (m, 2 H, 3JH,H = 7.0 Hz, H-6’), 1.48 (m, 2H, H-
2’), 1.45, 1.43 (2 s, 27 H, C(CH3)3), 1.33 (m, 4H, H-3’, H-5’), 1.24 (m, 2H, H-4’). 
13C NMR (125.7 MHz, CDCl3, 323 K, Figure S36): δ = 155.9, 155.7 (CO), 79.5, 79,3 
(C(CH3)3), 57.7 (C-2, C-12), 54.2 (C-1’), 53.1 (C-7’), 49.9, 48.2 (C-5, C-6, C-8, C-9), 48.0 
(C-3, C-11), 29.2 (C-3’), 29.0 (C-6’), 28.8, 28.6 (C(CH3)3), 27.8 (C-4’), 26.8 (C-5’), 24.3 
(C-2’). 
IR (NaCl): 2096 (N3) cm-1. 
ESI-MS (Figure S115): m/z 612.4 [M + H]+, 634.4 [M + Na]+, 650.3 [M + K]+. 
Elemental analysis calculated (%) for C30H57N7O6: C 58.89, H 9.39, N 16.03; found: C 
58.98, H 9.43, N 15.71. 
 
 
 
1-(7-Isothiocyanato-n-hept-1-yl)-4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraaza-
cyclododecane (67). To a solution of 66 (177 mg, 0.29 mmol), in dioxane (4 mL) under 
N2, was added TPP (91 mg, 0.35 mmol, 1.2 eq) and the reaction mixture was stirred at rt 
for 15 min. Then, CS2 (0.17 mL, 2.89 mmol, 10 eq) was added and the reaction mixture 
was stirred at rt for 16 h. The reaction was concentrated to dryness. The resulting residue 
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was purified by flash column chromatography (1:4  1:2 EtOAc-petroleum ether) to give 
67 (130 mg, 71%). 
Rf = 0.67 (1:1 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, 333 K, Figure S37): δ = 3.51, 3.35 (2m, 8 H, H-5, H-6, H-8, H-
9), 3.46 (t, 2 H, 3JH,H = 6.5 Hz, H-7’), 3.24 (m, 4 H, H-3, H-11), 2.61 (m, 4 H, H-2, H-12), 
2.54 (m, 2 H, H-1’), 1.67 (m, 2 H, 3JH,H = 7.0 Hz, H-6’), 1.44, 1.42 (2 s, 27 H, C(CH3)3), 
1.43-1.36 (m, 2H, H-2’), 1.33 (m, 4H, H-3’,H-5’), 1.26 (m, 2H, H-4’). 
13C NMR (125.7 MHz, CDCl3, 333 K, Figure S37): δ = 155.8, 155.4 (CO), 131.1 (NCS), 
79.4, 79,2 (C(CH3)3), 54.6 (C-2, C-12), 53.0 (C-1’), 49.8, 47.7 (C-5, C-6, C-8, C-9), 48.1 
(C-3, C-11), 45.0 (C-7’), 29.9 (C-6’), 28.7 (C-3’), 28.6, 28.5 (C(CH3)3), 27.6 (C-4’), 26.5 
(C-5’), 24.2 (C-2’). 
IR (NaCl): 2171, 2096 (NCS) cm-1. 
ESI-MS (Figure S116): m/z 628.3 [M + H]+, 650.3 [M + Na]+, 666.3 [M + K]+. 
Elemental analysis calculated (%) for C31H57N5O6S: C 59.30, H 9.15, N 11.15, S 5.11; 
found: C 59.19, H 9.03, N 10.94, S 4.79. 
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N-[4,7,10-Tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododec-1-yl]-N’-(6-isothio-
cyanato-n-hex-1-yl)thiourea (69). To a solution of 1,6-hexamethylenediisothiocyanate 
68278 (0.56 g, 2.79 mmol, 3 eq) and Et3N (0.39 mL, 2.79 mmol, 3 eq) in DCM (12 mL), a 
solution of 1,4,7-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane 61276b (0.44 g, 
0.93 mmol) in DCM (6 mL) was added drop wise. The reaction mixture was then stirred at 
rt for 16 h. Solvents were evaporated and the resulting residue was purified by flash 
column chromatography (1:2 EtOAc-petroleum ether) to yield 69 (531 mg, 85%). 
Rf = 0.59 (1:1 EtOAc-petroleum ether). 
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1H NMR (500 MHz, CDCl3, 313 K, Figure S38): δ = 5.80 (bs, 1 H, NH), 3.82 (m, 4 H, H-2, 
H-12), 3.61 (m, 2 H, H-1’), 3.49 (m, 4 H, H-3, H-11), 3.48 (t, 2 H, 3JH,H = 6.5 Hz, H-6’), 
3.38 (m, 8 H, H-5, H-6, H-8, H-9), 1.69 (m, 2 H, H-5’), 1.62 (m, 2 H, 3JH,H = 7.0 Hz, H-2’), 
1.45, 1.44 (2 s, 27 H, C(CH3)3), 1.43 (m, 2 H, H-4’), 1.40 (m, 2 H, H-3’). 
13C NMR (125.7 MHz, CDCl3, 313 K, Figure S38): δ = 182.9 (CS), 156.9, 156.7 (CO), 
130.5 (NCS), 80.5, 80.4 (C(CH3)3), 53.6 (C-2, C-12), 50.4 (C-5, C-6, C-8, C-9), 50.0 (C-3, 
C-11), 45.8 (C-1’), 45.1 (C-6’), 30.0 (C-5’), 29.2 (C-2’), 28.6 (C(CH3)3), 26.4 (C-3’), 26.2 
(C-4’). 
IR (NaCl): 2181, 2105 (NCS) cm-1. 
ESI-MS (Figure S117): m/z 673.3 [M + H]+, 695.3 [M + Na]+, 711.3 [M + K]+. 
Elemental analysis calculated (%) for C31H56N6O6S2: C 55.33, H 8.39, N 12.49, S, 9.53; 
found: C 55.48, H 8.75, N 12.43, S 9.18. 
 
 
 
N-[4,8,11-Tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradec-1-yl]-N’-(6-
isothiocyanato-n-hex-1-yl)thiourea (70). To a solution of 1,6-
hexamethylenediisothiocyanate 68278 (120 mg, 0.65 mmol, 3 eq) and Et3N (90 µL, 0.65 
mmol, 3 eq) in DCM (3 mL), a solution of 1,4,8-tris(tert-butoxycarbonyl)-1,4,8,11-
tetraazacyclotetradecane 62346 (108 mg, 0.22 mmol) in DCM (1 mL) was added drop wise 
and then the reaction mixture was stirred at rt for 16 h. Solvents were evaporated and the 
resulting residue was purified by flash column chromatography (1:2  1:1 EtOAc-
petroleum ether) to yield 70 (139 mg, 90%). 
Rf = 0.43 (1:1 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, 313 K, Figure S39): δ = 6.82 (m, 1 H, NH), 3.93 (m, 2 H, H-
14), 3.62 (m, 2 H, H-1’), 3.57 (m, 2 H, H-2), 3.47 (t, 2 H, 3JH,H = 7.0 Hz, H-6’), 3.41-3.34 
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(m, 4 H, H-9, H-10), 3.31 (m, 4 H, H-3, H-12), 3.34-3.23 (m, 4 H, H-5, H-7), 1.86 (m, 2 H, 
3JH,H = 6.5 Hz, H-13), 1.74 (m, 2 H, 3JH,H = 7.0 Hz, H-6), 1.67 (m, 2 H, 3JH,H = 7.0 Hz, H-
5’), 1.65 (m, 2 H, 3JH,H = 7.0 Hz, H-2’), 1.43, 1.42, 1.41 (3 s, 27 H, C(CH3)3), 1.40 (m, 2 H, 
H-4’), 1.38 (m, 2 H, H-3’). 
13C NMR (125.7 MHz, CDCl3, 313 K, Figure S39): δ = 182.1 (CS), 156.1, 156.0, 155.0 
(CO), 130.5 (NCS), 80.9, 80.1, 80.0 (C(CH3)3), 53.6 (C-2), 50.5 (C-14), 48.5 (C-9, C-10), 
47.1 (C-3), 46.7 (C-5, C-7), 46.2 (C-12), 46.4 (C-1’), 45.1 (C-6’), 29.9 (C-5’), 28.8 (C-6), 
28.7 (C-2’), 28.5, 28.4 (C(CH3)3), 28.0 (C-13), 26.4 (C-3’), 26.3 (C-4’). 
IR (NaCl): 2180, 2103 (NCS) cm-1. 
ESI-MS (Figure S118): m/z 701.6 [M + H]+, 723.7 [M + Na]+, 739.6 [M + K]+. 
Elemental analysis calculated (%) for C33H60N6O6S2: C 56.54, H 8.63, N 11.99, S 9.15; 
found: C 56.20, H 8.52, N 11.86, S 9.22. 
 
 
 
Heptakis[6-(4-(4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecyl-1-
methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (71). 
To a solution of heptakis(6-azido-6-deoxy-2,3-di-O-hexanoyl)cyclomaltoheptaose 54180b 
(80 mg, 30 µmol) and 63 (117 mg, 0.23 mmol, 1.1 eq) in tBuOH-H2O (3:1, 4 mL) the 
silica-supported Cu(I) catalyst Si-BPA·Cu+180a (7 mg, 30 mg per mmol of alkyne) was 
added and the reaction mixture was refluxed for 16 h. Then, the solvent was removed 
under reduced pressure, the residue was taken in DCM (4 mL), and the catalyst was 
filtered. After evaporation of the solvent, the residue was purified by flash column 
chromatography (30:1  9:1 DCM-MeOH) to yield compound 71 (182 mg, 97%). 
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Rf = 0.55 (9:1 DCM-MeOH). [α]D = +13.8 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, 333 K, Figure S40): δ = 8.05 (bs, 7H, CHtriazole), 5.55-5.35 (m, 
14H, H-1, H-3), 5.06-4.78 (m, 14H, H-6), 4.74 (m, 7H, H-2), 4.58 (m, 7H, H-5), 4.02 (m, 
14H, CH2triazole), 3.70-3.52 (m, 35H, H-4, H-6’, H-8’), 3.52-3.33 (m, 56H, H-3’, H-5’, H-9’, 
H-11’), 2.82-2.56 (m, 28H, H-2’, H-12’), 2.53-2.19 (m, 28H, CH2CO), 1.65 (m, 
28H,CH2CH2CO), 1.50, 1.46 (2s, 189H, C(CH3)3), 1.43-1.29 (m, 56H, CH2CH2CH3), 0.95 
(m, 42H, CH3). 
13C NMR (125.7 MHz, MeOD, 333 K, Figure S40): δ = 172.9, 171.9 (CO ester), 156.0 
(CO carbamate), 141.1 (Ctriazole), 126.9 (CHtriazole), 96.7 (C-1), 79.6 (C(CH3)3), 77.2 (C-4), 
70.1 (C-3), 69.9 (C-2, C-5), 53.8 (C-2’, C-12’), 50.3 (C-6), 49.4-47.5 (C-3’, C-5’, C-9’, C-
11’), 46.3(C-6’, C-8’), 42.6 (CH2triazole), 33.5, 33.7 (CH2CO), 31.2, 31.0 (CH2CH2CH3), 
27.8, 27.7 (C(CH3)3), 24.1 (CH2CH2CO), 22.0 (CH2CH3), 12.9 (CH3). 
ESI-MS (Figure S119): m/z 3150.9 [M + 2 Na]2+. 
Elemental analysis calculated (%) for C308H525N49O84: C 59.11, H 8.45, N 10.97; found: C 
59.33, H 8.50, N 10.73. 
 
 
 
Heptakis[6-(4-(4,8,11-tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecyl-1-
methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (72). 
To a solution of heptakis(6-azido-6-deoxy-2,3-di-O-hexanoyl)cyclomaltoheptaose 54180b 
(68 mg, 25 µmol) and 64 (105 mg, 0.19 mmol, 1.1 eq) in tBuOH-H2O (3:1, 4 mL) the 
silica-supported Cu(I) catalyst Si-BPA·Cu+180a (6 mg, 30 mg per mmol of alkyne) was 
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added and the reaction mixture was refluxed for 16 h. Then, the solvent was removed 
under reduced pressure, the residue was taken in DCM (4 mL), and the catalyst was 
filtered. After evaporation of the solvent, the residue was purified by flash column 
chromatography (95:5 DCM-MeOH) to yield compound 72 (136 mg, 84%). 
Rf = 0.58 (9:1 DCM-MeOH). [α]D = +10.2 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, 333 K, Figure S41): δ = 8.00 (bs, 7 H, CHtriazole), 5.55 (m, 7 H, 
H-1), 5.50 (t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 4.93 (m, 14 H, H-6), 4.74 (dd, 7 H, J1,2 = 3.0 
Hz, H-2), 4.57 (m, 7 H, H-5), 3.89 (bd, 7 H,2JH,H = 12.5 Hz, CH2-a-triazole), 3.83 (bd, 7 H, 
CH2-b-triazole), 3.57 (bt, 7 H, J4,5 = 9.5 Hz, H-4), 3.48-3.31 (m, 84 H, H-3’, H-5’, H-7’, H-9’, H-
10’, H-12’), 2.69 (m, 14 H, H-2’), 2.49 (m, 14 H, H-14’), 2.46-2.18 (m, 28 H, CH2CO), 1.95 
(m, 14 H, H-6’), 1.75 (m, 14 H, H-13’), 1.62 (m, 28 H, CH2CH2CO), 1.49, 1.48, 1.46 (3s, 
189 H, C(CH3)3), 1.42-1.30 (m, 56 H, CH2CH2CH3), 0.94 (m, 42 H, CH3). 
13C NMR (125.7 MHz, MeOD, 333 K, Figure S41): δ = 172.8, 171.9 (CO ester), 156.1, 
155.9, 155.8 (CO carbamate), 142.8 (Ctriazole), 126.4 (CHtriazole), 96.7 (C-1), 79.7, 79.6 
(C(CH3)3), 77.1 (C-4), 70.2 (C-5), 69.9 (C-2, C-3), 52.6 (C-2’), 51.3 (C-14’), 50.3 (C-6), 
47.6 (CH2triazole), 47.1, 46.8, 46.6, 45.5, 45.1, 41.9 (C-3′, C-5′, C-7′, C-9′, C-10′, C-12′), 
33.8, 33.5 (CH2CO), 31.2, 31.0 (CH2CH2CH3), 28.6 (C-6’), 27.7, 27.6, 27.5 (C(CH3)3), 
26.5 (C-13’), 24.1 (CH2CH2CO), 22.0 (CH2CH3), 12.9 (CH3). 
ESI-MS (Figure S120): m/z 2174.7 [M + 3 Na]3+, 3250.5 [M + 2 Na]2+. 
Elemental analysis calculated (%) for C322H553N49O84: C 59.91, H 8.63, N 10.63; found: C 
60.08, H 8.61, N 10.51. 
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Heptakis{6-[2-(N’-(N’-(4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododec-
1-yl)-thioureido-n-hex-1-yl)thioureido)ethylthio]-6-deoxy-2,3-di-O-hexanoyl}cyclo-
maltoheptaose (73). To a solution of compound 21 (61 mg, 19 µmol) and Et3N (0.02 mL, 
0.15 mmol, 1.1 eq) in DCM (4 mL) 69 (100 mg, 0.15 mmol, 1.1 eq) was added and the 
reaction mixture was stirred in a sealed reaction vial at 40 ºC for 72 h assuring that pH 
value was maintained at 9. Then, solvents were evaporated under reduced pressure and 
the resulting residue was purified by size exclusion chromatography in MeOH to yield 73 
(109 mg, 75%). 
Rf = 0.50 (95:5 DCM-MeOH). [α]D = +43.3 (c = 1.0 in DCM). 
1H NMR (500 MHz, MeOD, 333 K, Figure S42): δ = 5.34 (t, 7 H, J2,3 = J3,4 = 8.5 Hz, H-3), 
5.19 (d, 7 H, J1,2 = 3.0 Hz, H-1), 4.85 (dd, 7 H, H-2), 4.22 (m, 7 H, H-5), 3.95 (t, 7 H, J4,5 = 
8.5 Hz, H-4), 3.89 (m, 28 H, H-2’, H-12’), 3.80 (m, 14 H, CH2Ncyst), 3.65 (t, 14 H, 3JH,H = 
7.0 Hz, H-1’’), 3.57 (m, 28 H, H-3’, H-11’), 3.50 (m, 56 H, H-5′, H-6′, H-8′, H-9′), 3.49 (m, 
14 H, H-6’’), 3.30 (m, 7 H, H-6a), 3.20 (dd, 7 H, J6a,6b = 14.0 Hz, J5,6b = 6.5 Hz, H-6b), 2.96 
(m, 14 H, CH2Scyst), 2.50-2.24 (m, 28 H, CH2CO), 1.64 (m, 56 H, H-2’’, H-5’’, CH2CH2CO), 
1.52, 1.51 (2 s, 189 H,C(CH3)3), 1.44 (m, 28 H, H-3’’, H-4’’), 1.43-1.30 (m, 56 H, 
CH2CH2CH3), 0.95 (m, 42 H, CH3). 
13C NMR (125.7 MHz, MeOD, 333 K, Figure S42): δ = 182.6, 182.0 (CS), 173.3, 172.0 
(CO ester), 157.2, 156.8 (CO carbamate), 96.9 (C-1), 80.6, 80.5 (C(CH3)3), 78.7 (C-4), 
71.9 (C-5),70.7 (C-3), 70.3 (C-2), 52.7 (C-2’, C-12’), 50.2, 49.9 (C-5′, C-6′, C-8′, C-9′), 
49.5 (C-3′, C-11′), 45.8 (C-1′′), 44.0, 43.9 (C-6′′, CH2NCyst), 34.0 (C-6), 33.8, 33.7 
(CH2CO), 32.9 (CH2Scyst), 31.2, 31.1 (CH2CH2CH3), 29.0, 28.9 (C-2′′, C-5′′),27.7, 27.6 
(C(CH3)3), 26.5 (C-3′′, C-4′′), 24.2 (CH2CH2CO), 22.1, 22.0 (CH2CH3), 13.1, 12.9 (CH3). 
ESI-MS (Figure S121): m/z 2567.8 [M + 3 Na]3+, 3839.4 [M + 2 Na]2+. 
Elemental analysis calculated (%) for C357H637N49O84S21: C 56.17, H 8.41, N 8.99, S 8.82; 
found: C 56.29, H 8.16, N 8.99, S 8.46. 
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Heptakis{6-[2-(N’-(N’-(4,8,11-tris(tert-butoxycarbonyl)-1,4,8,11-
tetraazacyclotetradec-1-yl)-thioureido-n-hex-1-yl)thioureido)ethylthio]-6-deoxy-2,3-
di-O-hexanoyl}cyclomaltoheptaose (74). To a solution of compound 21 (59 mg, 19 
µmol) and Et3N (0.02 mL, 0.14 mmol, 1.1 eq) in DCM (4 mL), 70 (100 mg, 0.14 mmol, 1.1 
eq) was added and the reaction mixture was stirred in a sealed reaction vial at 40 ºC for 
72 h assuring that pH value was maintained at 9. Then, solvents were evaporated under 
reduced pressure and the resulting residue was purified by size exclusion 
chromatography in MeOH to yield 74 (111 mg, 77%). 
Rf = 0.49 (95:5 DCM-MeOH). [α]D = +34.1 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, 333 K, Figure S43): δ = 5.34 (t, 7 H, J2,3 = J3,4 = 8.5 Hz, H-3), 
5.19 (d, 7 H, J1,2 = 3.3 Hz, H-1), 4.85 (dd, 7 H, H-2), 4.21 (m, 7 H, H-5), 3.95 (t, 7 H, J4,5 = 
8.5 Hz, H-4), 3.85 (m, 14 H, H-2’), 3.81 (m, 14H, H-14′), 3.80 (m, 14 H, CH2Ncyst),3.65 (t, 
14H, 3JH,H = 7.0 Hz, H-1′′), 3.56 (m, 14H, H-3′), 3.51, 3.45 (2m, 28H, H-9′, H-10′), 3.50 (m, 
14H, H-6′′), 3.44 (m, 14H, H-12′), 3.43-3.37 (m, 28H, H-5′, H-7′), 3.30 (m, 7 H, H-6a), 3.20 
(m, 7 H, H-6b), 2.96 (m, 14 H, CH2Scyst), 2.51-2.23 (m, 28 H, CH2CO), 1.93 (m, 14H, H-
13′), 1.84 (m, 14H, H-6′), 1.66 (m, 56H, H-2′′, H-5′′, CH2CH2CO), 1.50 (s, 189 H, 
C(CH3)3),1.45 (m, 28H, H-3′′, H-4′′), 1.43-1.31 (m, 56H, CH2CH2CH3), 0.95 (m, 42 H, 
CH3). 
13C NMR (125.7 MHz, MeOD, 333 K, Figure S43): δ = 182.0, 181.5 (CS), 173.3, 172.0 
(CO ester), 156.4, 155.9 (CO carbamate), 96.9 (C-1), 80.3, 80.0 (C(CH3)3), 78.8 (C-4), 
71.9 (C-5), 70.7 (C-3), 70.3 (C-2), 50.4 (C-2’), 49.5 (C-14′), 49.0, 48.3 (C-9′, C-10′, C-
12′),47.2 (C-3′), 46.6 (C-5′, C-7′), 45.9 (C-1′′), 44.1, 43.9 (C-6′′, CH2NCyst), 34.0 (C-6), 
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33.8, 33.7 (CH2CO), 32.9 (CH2Scyst), 31.2, 31.1 (CH2CH2CH3), 29.0, 28.9 (C-2′′, C-5′′), 
28.0 (C-6′), 27.7, 27.6 (C(CH3)3), 27.0 (C-13′), 26.5 (C-3′′, C-4′′), 24.2 (CH2CH2CO), 22.1, 
22.0 (CH2CH3), 13.1, 12.9 (CH3). 
ESI-MS (Figure S122): m/z 1991.1 [M + 2 Na + 2 K]4+, 2646.5 [M + Na + 2 K]3+, 3957.8 
[M + 2 K]2+. 
Elemental analysis calculated (%) for C371H665N49O84S21: C 56.91, H 8.56, N 8.77; found: 
C 56.88, H 8.94, N 8.54. 
 
 
 
Heptakis[6-(4-(1,4,7,10-tetraazacyclododecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-
deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose henicosahydrochloride (75). 
Treatment of compound 71 (80 mg, 13 µmol) with TFA following the procedure described 
in the general methods, followed by freeze-drying from a 0.1 N aq. HCl solution, gave 
pure compound 75 in virtually quantitative yield (63 mg, 99%). 
[α]D = +20.0 (c = 1.0 in 1:1 MeOH-H2O). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 333 K, Figure S44): δ = 8.27 (bs, 7H, CHtriazole), 5.53 
(m, 14H, H-1, H-3), 4.95 (m, 14H, H-6), 4.70 (dd, 7H, J2,3 = 10.0 Hz, J1,2 = 3.3 Hz, H-2), 
4.60 (m, 7H, H-5), 4.06 (m, 14H, CH2triazole), 3.69 (t, 7H, J3,4 = J4,5 = 9.5 Hz, H-4), 3.35 (m, 
56H, H-3′, H-5′, H-9′, H-11′), 3.24 (m, 28H, H-6′, H-8′), 3.02 (m, 28H, H-2′, H-12′), 2.54-
2.16 (m,28H, CH2CO), 1.63 (m, 28H, CH2CH2CO), 1.36 (m, 56H, CH2CH2CH3), 0.93 (m, 
42H, CH3). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 333 K, Figure S44): δ = 173.4, 172.1 (CO ester), 
141.3 (Ctriazole), 127.7 (CHtriazole), 96.8 (C-1), 77.3 (C-4), 70.2 (C-2), 70.1 (C-5), 69.8 (C-3), 
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50.4 (C-6), 48.0 (C-2’, C-12’), 46.9 (CH2triazole), 44.3 (C-5′, C-9′), 43.0 (C-3′, C-11′), 41.2 
(C-6′, C-8′), 33.8 (CH2CO), 31.2, 31.1 (CH2CH2CH3), 24.2 (CH2CH2CO), 22.1, 22.0 
(CH2CH3), 12.9 (CH3). 
ESI-MS (Figure S123): m/z 1065.8 [M + 3 Na + K]4+, 1420.5 [M + 3 K]3+, 2115.5 [M + 2 
K]2+. 
Elemental analysis calculated (%) for C203H378N49O42Cl21: C 49.54, H 7.74, N 13.94; 
found: C 49.54, H 7.39, N 13.62. 
 
 
 
Heptakis[6-(4-(1,4,8,11-tetraazacyclotetradecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-
deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose henicosahydrochloride (76). 
Treatment of compound 72 (60 mg, 9 µmol) with TFA following the procedure described 
in the general methods, followed by freeze-drying from a 0.1 N aq. HCl solution, gave 
pure compound 76 in virtually quantitative yield (47 mg, 99%). 
[α]D = +15.0 (c = 1.0 in 1:1 MeOH-H2O). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 333 K, Figure S45): δ = 8.24 (bs, 7H, CHtriazole), 5.56 
(m, 7H, H-1), 5.55 (t, 7H, J2,3 = J3,4 = 9.5 Hz, H-3), 4.96 (m, 14H, H-6), 4.68 (dd, 7H, J1,2 = 
3.0 Hz, H-2), 4.63 (m, 7H, H-5), 4.15 (d, 7H, 2JH,H = 15.0 Hz, CH2-a-triazole), 4.08 (d, 7H, 
CH2-b-triazole), 3.71 (t, 7H, J4,5 = 9.5 Hz, H-4), 3.56-3.35 (m, 28H, H-9’, H-10’), 3.40 (m, 14H, 
H-7′), 3.36 (m, 14H, 3JH,H = 6.0 Hz, H-12′), 3.31 (m, 14H, H-3′), 3.24 (m, 14H, H-5′), 3.06 
(m, 14H, H-2′), 2.99 (m, 14H, H-14′), 2.49-2.13 (m, 28H, CH2CO), 2.22 (m, 14H, H-6′), 
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2.02 (m, 14H, H-13′), 1.65 (m, 28H, CH2CH2CO), 1.35 (m, 56H, CH2CH2CH3), 0.93 (bt, 
42H, 3JH,H = 7.0 Hz, CH3). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 333 K, Figure S45): δ = 173.6, 172.3 (CO ester), 
139.6 (Ctriazole), 128.5 (CHtriazole), 96.8 (C-1), 77.2 (C-4), 70.4 (C-2), 70.0 (C-5), 69.7 (C-3), 
50.4 (C-6), 50.2 (C-14’), 48.7 (C-2′), 45.4 (C-5′), 44.9 (CH2triazole), 44.7, 44.4 (C-9′, C-10′), 
43.6 (C-3′), 43.0 (C-12’), 41.6 (C-7’), 33.7 (CH2CO), 31.2, 31.1 (CH2CH2CH3), 24.2, 24.1 
(CH2CH2CO), 22.1 (C-6’), 22.0 (CH2CH3), 21.7(C-13), 13.1 (CH3). 
ESI-MS (Figure S124): m/z 2212.1 [M + 2 Cl]2-, 4387.3 [M + Cl]-. 
Elemental analysis calculated (%) for C217H385N49O42: C 59.88, H 8.92, N 15.77; found: C 
59.98, H 9.01, N 15.56. 
 
 
 
Heptakis{6-[2-(N’-(N’-(1,4,7,10-tetraazacyclododec-1-yl)thioureido-n-hex-1-
yl)thioureido)ethylthio]-6-deoxy-2,3-di-O-hexanoyl}cyclomaltoheptaose 
henicosahydrochloride (77). Treatment of compound 73 (47 mg, 6 µmol) with TFA 
following the procedure described in the general methods, followed by freeze-drying from 
a 0.1 N aq. HCl solution, gave pure compound 77 in virtually quantitative yield (40 mg, 
99%). 
[α]D = +26.7 (c = 1.0 in MeOH). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 333 K, Figure S46): δ = 5.32 (t, 7H, J2,3 = J3,4 = 9.5 
Hz, H-3), 5.18 (d, 7H, J1,2 = 3.5 Hz, H-1), 4.85 (dd, 7H, H-2), 4.19 (m, 7H, H-5), 4.07 (m, 
28H, H-2’, H-12’), 3.93 (t, 7H, J4,5 = 8.5 Hz, H-4), 3.78 (m, 14H, CH2Ncyst), 3.67 (t, 14H, 
3JH,H = 7.0 Hz, H-1′′), 3.47 (m, 14H, H-6′′), 3.44 (m, 28H, H-6′, H-8′), 3.33 (m, 56H, H-3′, 
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H-5′, H-9′, H-11′), 3.32 (m, 7H, H-6a), 3.18 (m, 7H, H-6b), 2.95 (m, 14H, CH2Scyst), 2.49-
2.24 (m, 28H, CH2CO), 1.81-1.58 (m, 56H, H-2′′, H-5′′, CH2CH2CO), 1.43 (m, 28H, H-3′′, 
H-4′′), 1.41-1.30 (m, 56H, CH2CH2CH3), 0.94 (m, 42H, CH3). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 333 K, Figure S46): δ = 183.4, 181.5 (CS), 173.7, 
172.3 (CO ester), 96.9 (C-1), 78.9 (C-4), 71.9 (C-5), 70.7 (C-3), 70.3 (C-2), 50.6 (C-2′, C-
12′), 46.9 (C-5′, C-9′), 46.4 (C-1′′), 44.7 (C-3′, C-11′), 44.6 (C-6′′), 44.4 (C-6′, C-8′), 44.0 
(CH2Ncyst), 34.0 (C-6), 33.8 (CH2CO), 32.8 (CH2Scyst), 31.2, 31.0 (CH2CH2CH3), 28.8, 28.5 
(C-2′′, C-5′′), 26.4 (C-3′′, C-4′′), 24.2 (CH2CH2CO), 22.0 (CH2CH3), 13.2, 13.0 (CH3). 
ESI-MS (Figure S125): m/z 1383.9 [M + 4 H]4+, 1875.9 [M + Na + 2 K]3+, 2797.9 [M + Na 
+ K]2+. 
Elemental analysis calculated (%) forC252H469N49O42S21: C 54.72, H 8.55, N 12.41, S 
12.17; found: C 54.64, H 8.84, N 12.66, S 12.06. 
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Heptakis{6-[2-(N’-(N’-(1,4,8,11-tetraazacyclotetradec-1-yl)thioureido-n-hex-1-yl)thio-
ureido)ethylthio]-6-deoxy-2,3-di-O-hexanoyl}cyclomaltoheptaose henicosahydro-
chloride (78). Treatment of compound 74 (111 mg, 14 µmol) with TFA following the 
procedure described in the general methods, followed by freeze-drying from a 0.1 N aq. 
HCl solution, gave pure compound 78 (90 mg, 97%). 
[α]D = +37.6 (c = 1.0 in 1:1 MeOH-H2O). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 333 K, Figure S47): δ = 5.32 (t, 7H, J2,3 = J3,4 = 8.5 
Hz, H-3), 5.18 (m, 7H, H-1), 4.85 (bd, 7H, H-2), 4.29 (m, 14H, H-2’), 4.20 (m, 7H, H-5), 
3.93 (m, 7H, H-4), 3.92 (m, 14H, H-14′), 3.78 (m, 14 H, CH2Ncyst), 3.65 (t, 14H, 3JH,H = 7.0 
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Hz, H-1′′), 3.59-3.49 (m, 28H, H-9′, H-10′), 3.53 (m, 14H, H-3′), 3.50, 3.32 (2m, 28H, H-5′, 
H-7′), 3.47 (m, 14H, H-6′′), 3.34 (m, 14H, H-12′), 3.29 (m, 7 H, H-6a), 3.20 (m, 7 H, H-6b), 
2.95 (m, 14 H, CH2Scyst), 2.50-2.23 (m, 28 H, CH2CO), 2.28 (m, 14H, H-6′), 2.24 (m, 14H, 
H-13′), 1.73-1.58 (m, 56H, H-2′′, H-5′′, CH2CH2CO), 1.41 (m, 28 H, H-3′′, H-4′′), 1.40-1.29 
(m, 56H, CH2CH2CH3), 0.94 (m, 42H, CH3). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 333 K, Figure S47): δ = 182.8, 181.6 (CS), 173.7, 
172.3 (CO ester), 96.9 (C-1), 78.8 (C-4), 71.9 (C-5), 70.7 (C-3), 70.3 (C-2), 48.2 (C-2’), 
47.8 (C-14′), 46.3 (C-1′′), 45.0 (C-5′, C-7′), 44.5 (C-3′), 44.1 (C-6′′), 44.0 (C-12′, CH2NCyst), 
42.4, 42.2 (C-9′, C-10′), 34.0 (C-6), 33.8 (CH2CO), 32.9 (CH2Scyst), 31.2, 31.0 
(CH2CH2CH3), 28.8, 28.6 (C-2′′, C-5′′), 26.4 (C-3′′, C-4′′), 24.2 (CH2CH2CO), 23.8 (C-13′), 
22.0 (CH2CH3), 21.6 (C-6′), 13.2, 13.0 (CH3). 
ESI-MS (Figure S126): m/z 1443.5 [M + 2 H + 2 Na]4+, 1933.5 [M + 3 Na]3+. 
Elemental analysis calculated (%) for C266H518N49O42S21Cl21: C 49.20, H 8.04, N 10.57, S 
10.37; found: C 49.21, H 8.29, N 10.50, S,10.17. 
 
 
 
N-Tritylspermine (81). To a solution of spermine (2 g, 9.88 mmol) in dry DCM (20 mL) 
under nitrogen atmosphere triphenylmethyl chloride (276 mg, 0.99 mmol, 0.1 eq) was 
added in small portions at 0 ºC. The reaction mixture was allowed to warm to rt and 
stirred overnight. Then, the reaction mixture was washed with H2O (2 x 15 mL). The 
organic layer was dried over Na2SO4, filtered and the solvent was removed under 
reduced pressure to yield compound 81 (416 mg, 95 % on the basis of tripehnylpmethyl 
chloride). The unreacted spermine was reused for another reaction cycle after 
concentrating the aqueous layer to dryness . 
1H NMR (500 MHz, CDCl3, Figure S48): δ = 7.48 (d, 6 H, 3JH,H = 7.5 Hz, Har-2), 7.26 (t, 6 
H, 3JH,H = 7.5 Hz, Har-3), 7.17 (t, 3 H, 3JH,H = 7.5 Hz, Har-4), 2.73 (t, 2 H, 3JH,H = 7.3 Hz, H-
1), 2.67 (m, 4 H, H-3, H-8), 2.61 (m, 4 H, H-4, H-7), 2.21 (t, 2 H, 3JH,H = 7.2 Hz, H-10), 
1.67 (m, 2 H, H-9), 1.61 (m, 2 H, H-2), 1.51 (m, 9 H, H-5, H-6, NH, NH2). 
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13C NMR (125.7 MHz, MeOD, Figure S48): δ = 146.2, 128.7, 127.8, 126.2 (Ph), 70.9 
(CPh3), 50.0 (C-4, C-7), 48.6, 47.9 (C-3, C-8), 42.2 (C-10), 40.6 (C-1), 33.8 (C-2), 31.0 
(C-9), 28.0, 27.9 (C-5, C-6). 
ESI-MS (Figure S127): m/z 445.5 [M + H]+. 
Elemental analysis calculated (%) for C29H40N4·2H2O: C 72.46, H 9.23, N 11.66; found: C 
72.69, H 9.07, N 11.73. 
 
 
N1-(3-tert-Butoxycarbonylaminopropyl)-N4-(3-(tritylamino)propyl)bis(N1,N4-tert-
butoxycarbonyl)butane-1,4-diamine (84). To a solution of compound 81 (157 mg, 0.35 
mmol) in DCM (5 mL) was added drop wise a solution of di-tert-butyl dicarbonate (255 
mg, 1.17 mmol, 3.3 eq) in DCM (5 mL). The reaction mixture was stirred at rt overnight. 
Then, solvents were evaporated under reduced pressure and the resulting residue was 
purified by flash column chromatography (1:2 EtOAc-petroleum ether) yielding compound 
84 as a white solid (301 mg, 86%). 
Rf = 0.42 (1:2 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, Figure S49): δ = 7.48 (d, 6 H, 3JH,H = 7.4 Hz, Har-2), 7.27 (t, 6 
H, 3JH,H = 7.4 Hz, Har-3), 7.18 (t, 3 H, 3JH,H = 7.4 Hz, Har-4), 5.32, 4.80 (2 bs, 1 H each, 
NHTr, NHBoc), 3.27-3.12 (m, 10 H, H-3, H-4, H-7, H-8, H-10), 2.14 (m, 2 H, H-1), 1.69 
(m, 4 H, H-2, H-9), 1.54 (m, 4 H, H-5, H-6), 1.46 (bs, 18 H, C(CH3)3), 1.42 (bs, 9 H, 
C(CH3)3). 
13C NMR (125.7 MHz, CDCl3, Figure S49): δ = 156.1, 155.5 (CO), 146.2, 128.6, 127.8, 
126.2 (Ph),79.5, 79.2, 78.8 (C(CH3)3), 70.9 (CPh3), 46.8, 46.4 (C-4, C-7), 45.1, 43.9 (C-3, 
C-8), 41.1 (C-1), 37.4 (C-10), 30.3 (C-2), 29.4 (C-9), 28.5 (C(CH3)3), 26.0, 25.6 (C-5, C-
6). 
ESI-MS (Figure S128): m/z 745.6 [M + H]+, 767.5 [M + Na]+, 743.5 [M – H]-, 779.6 [M + 
Cl]-. 
Elemental analysis calculated (%) for C44H64N4O6: C 70.94, H 8.66, N 7.52; found: C 
70.91, H 8.90, N 7.52. 
232 Ph.D. Thesis - Iris Pflueger 
 
 
 
 
 
 
 
 
4,9,13-Tris(tert-butoxycarbonyl)-4,9,13-triazatridecyl-1-isothiocyanate (86). 
Compound 84 (229 mg, 0.23 mmol) was treated with a solution of 2% TFA in DCM (5 mL) 
at rt for 1.5 h. Then, the solvent was removed to yield crude 1,4,9-tris(tert-
butoxycarbonyl)spermine which subsequently was suspended in a 1:1 mixture of H2O-
DCM (5 mL). CaCO3 (232 mg, 2.32 mmol, 10 eq) was added and the mixture was 
vigorously stirred for a few minutes. The suspension was then cooled to 0 ºC, CSCl2 (27 
µL, 0.35 mmol, 1.5 eq) was added and the reaction mixture was further stirred for 1 h. 
The organic phase was decanted, the solvent was evaporated and the resulting residue 
was purified by flash column chromatography (1:2 EtOAc-petroleum ether) to yield 
compound 86 (92 mg, 73%). 
Rf = 0.34 (1:2 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, Figure S50): δ = 5.29 (NHBoc), 3.56 (t, 2 H, 3JH,H = 6.5 Hz, H-
1), 3.30 (t, 2 H, 3JH,H = 6.6 Hz, H-10), 3.20, 3.11 (2 m, 8 H, H-3, H-4, H-7, H-8), 1.92 (m, 2 
H, H-9), 1.66 (m, 2 H, H-2), 1.50 (m, 4 H, H-5, H-6), 1.47 (bs, 18 H, C(CH3)3), 1.44 (s, 9 
H, C(CH3)3). 
13C NMR (125.7 MHz, CDCl3, Figure S50): δ = 155.8, 155.2 (CO), 130.4 (NCS), 79.6, 
79.3, 78.6(C(CH3)3), 47.3 (C-1), 46.6, 46.0 (C-4, C-7), 43.9, 42.6 (C-3, C-8), 37.4 (C-10), 
28.8 (C-2), 28.2 (C(CH3)3), 25.7 (C-9), 25.3 (C-5, C-6). 
ESI-MS (Figure S129): m/z 567.5 [M + Na]+, 583.4 [M + K]+, 543.4 [M – H]-, 579.5 [M + 
Cl]-. 
Elemental analysis calculated (%) for C26H48N4O6S: C 57.33, H 8.88, N 10.28, S 5.89; 
found: C 57.53, H 8.99, N 9.95, S 6.01. 
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1,4,7-Tris(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)-10-propargyl-1,4,7,10-
tetraazacyclododecane (87). To a solution of compound 60274 (135 mg, 0.42 mmol) and 
Et3N (212 µL, 1.53 mmol, 1.2 eq) in DCM (8 mL) a solution of 2-(tert-
butoxycarbonylamino)ethylisothiocyanate 22186 (284 mg, 1.40 mmol, 1.1 eq) in DCM (2 
mL) was added drop wise. The reaction mixture was stirred overnight at rt maintaining pH 
9. After evaporation of the solvent under reduced pressure, the resulting residue was 
purified by flash column chromatography (1:1 EtOAc-petroleum ether) yielding compound 
87 as a white solid (333 mg, 96%). 
Rf = 0.66 (1:1 EtOAc-petroleum ether). 
1H NMR (400 MHz, MeOD, 333 K, Figure S51): δ = 4.04 (m, 4 H, H-3, H-5), 3.89 (m, 8 H, 
H-2, H-6, H-8, H-12), 3.77 (t, 2 H, 3JH,H = 6.0 Hz, H-1’’), 3.71 (bs, 2 H, CH2C≡CH), 3.68 (t, 
4 H, 3JH,H = 6.0 Hz, H-1’), 3.36 (t, 2 H, 3JH,H = 6.1 Hz, H-2’’), 3.28 (t, 4 H, 3JH,H = 6.1 Hz, H-
2’), 2.98 (m, 4 H, H-9, H-11), 2.62 (m, 1 H, C≡CH), 1.46 (s, 27 H, C(CH3)3). 
13C NMR(100.6 MHz, MeOD, 333 K, Figure S51): δ = 183.0, 182.4 (CS), 157.4 (CO), 
79.1 (C(CH3)3), 77.3 (C≡CH), 74.0 (C≡CH), 53.5 (C-9, C-11), 50.5 (C-2, C-3, C-5, C-6, C-
8, C-12), 46.0 (C-1’, C-1’’), 40.4 (CH2C≡CH), 39.8 (C-2’, C-2’’), 27.5 (C(CH3)3). 
ESI-MS (Figure S130): m/z 839.4 [M + Na]+, 855.4 [M + K]+, 815.3 [M – H]-, 851.2 [M + 
Cl]-. 
Elemental analysis calculated (%) for C35H64N10O6S3: C 51.44, H 7.89, N 17.14, S 11.77; 
found: C 51.64, H 7.82, N 16.84, S 11.39. 
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1,4,7-Tris[N’-(2-(N-(tert-butoxycarbonyl)-N-(2-(tert-butoxycarbonylamino)ethyl)-
amino)ethyl)]thioureido-10-propargyl-1,4,7,10-tetraazacyclododecane (88). To a 
solution of compound 60274 (226 mg, 0.71 mmol) and Et3N (355 µL, 2.56 mmol, 1.2 eq) in 
DCM (9 mL) a solution of 2-[N-(tert-butoxycarbonyl)-N-[2-(tert-
butoxycarbonylamino)ethyl]amino]ethyl isothiocyanate 85177 (810 mg, 2.34 mmol, 1.1 eq) 
in DCM (5 mL) was added drop wise. The reaction mixture was stirred overnight at rt 
maintaining pH 9. After evaporation of the solvent under reduced pressure, the resulting 
residue was purified by flash column chromatography (2:1 EtOAc-petroleum ether) 
yielding compound 88 as a white solid (782 mg, 88%). 
Rf = 0.56 (2:1 EtOAc-petroleum ether). 
1H NMR (500 MHz, MeOD, 333 K, Figure S52): δ = 4.03 (m, 4 H, H-3, H-5), 3.85 (m, 8 H, 
H-2, H-6, H-8, H-12), 3.73 (t, 6 H, 3JH,H = 6.1 Hz, H-1’), 3.68 (bs, 2 H, CH2C≡CH), 3.53 (t, 
2 H, 3JH,H = 6.1 Hz, H-2’), 3.47 (t, 4 H, 3JH,H = 6.1 Hz, H-2’), 3.41-3.35 (m, 6 H, H-3’), 3.25, 
3.24 (2 t, 6 H, 3JH,H = 6.2 Hz, H-4’), 2.97 (m, 4 H, H-9, H-11), 2.62 (t, 1 H, 4JH,H = 2.2 Hz, 
C≡CH), 1.50, 1.46 (2 s, 27 H each, C(CH3)3). 
13C NMR (100.6 MHz, MeOD, 333 K, Figure S52): δ = 182.9, 182.4 (CS), 156.8, 156.5 
(CO), 80.1, 78.8 (C(CH3)3), 77.4 (C≡CH), 74.0 (C≡CH), 53.7 (C-9, C-11), 50.5 (C-2, C-3, 
C-5, C-6, C-8, C-12), 46.6 (C-2’, C-3’), 44.2 (C-1’), 40.7 (CH2C≡CH), 39.0 (C-4’), 27.6, 
27.5 (C(CH3)3). 
ESI-MS (Figure S131): m/z 1268.7 [M + Na]+, 1284.6 [M + K]+. 
Elemental analysis calculated (%) for C56H103N13O12S3: C 53.95, H 8.33, N 14.61, S 7.72; 
found: C 53.60, H 7.99, N 14.67, S 7.84. 
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1,4,7-Tris[N’-(3-((4-((3-(tert-butoxycarbonyl)amino)propyl)(tert-butoxycarbonyl)-
amino)butyl)(tert-butoxycarbonyl)amino)propyl)]thioureido-10-propargyl-1,4,7,10-
tetraazacyclododecane (89). To a solution of compound 60274 (27 mg, 83 µmol) and 
Et3N (42 µL, 0.30 mmol, 1.2 eq) in DCM (5 mL) a solution of compound 86 (150 mg, 0.28 
mmol, 1.1 eq) in DCM (2 mL) was added drop wise. The reaction mixture was stirred 
overnight at rt maintaining pH 9. After evaporation of the solvent under reduced pressure, 
the resulting residue was purified by flash column chromatography (1:1 EtOAc-petroleum 
ether) yielding compound 89 as a white solid (105 mg, 68%). 
Rf = 0.38 (2:1 EtOAc-petroleum ether). 
1H NMR (400 MHz, MeOD, 333 K, Figure S53): δ = 4.05 (m, 4 H, H-3, H-5), 3.89 (m, 8 H, 
H-2, H-6, H-8, H-12), 3.71 (bs, 2 H, CH2C≡CH), 3.68 (t, 2 H, 3JH,H = 6.7 Hz, H-1’), 3.60 (t, 
4 H, 3JH,H = 6.7 Hz, H-1’), 3.35 (t, 2 H, 3JH,H = 6.7 Hz, H-3’), 3.26 (m, 22 H, H-3’, H-4’, H-
7’, H-8’), 3.07 (m, 6 H, H-10’), 2.99 (m, 4 H, H-9, H-11), 2.63 (t, 1 H, 4JH,H = 2.3 Hz, 
C≡CH), 1.92 (m, 2 H, H-2’), 1.85 (m, 4 H, H-2’), 1.73 (m, 6 H, H-9’), 1.56 (m, 12 H, H-5’, 
H-6’), 1.50 (s, 9 H, C(CH3)3), 1.49 (s, 18 H, C(CH3)3), 1.48 (s, 27 H, C(CH3)3), 1.46 (s, 27 
H, C(CH3)3). 
13C NMR (100.6 MHz, MeOD, 333 K, Figure S53): δ = 182.6, 182.0 (CS), 156.9, 156.2, 
156.1 (CO), 79.7, 79.6, 78.7 (C(CH3)3), 77.4 (C≡CH), 74.0 (C≡CH), 53.6 (C-9, C-11), 50.8 
(C-2, C-3, C-5, C-6, C-8, C-12), 44.6 (C-3’, C-4’, C-7’, C-8’), 43.2 (C-1’), 40.6 (CH2C≡CH), 
37.8 (C-10’), 29.2 (C-9’), 27.5 (C-2’), 27.5 (C(CH3)3), 25.6 (C-5’, C-6’). 
ESI-MS (Figure S132): m/z 942.4 [M + 2 Na]2+, 1867.0 [M + Na]+, 1843.1 [M – H]-, 1878.0 
[M + Cl]-. 
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Elemental analysis calculated (%) for C89H166N16O18S3: C 57.95, H 9.07, N 12.15; found: 
C 58.17, H 9.23, N 12.48. 
 
 
 
Heptakis[6-(4-(4,7,10-tris(N’-(2-tert-butoxycarbonylaminoethyl)thioureido)-1,4,7,10-
tetraazacyclododecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-hexanoyl]-
cyclomaltoheptaose (90). To a solution of heptakis(6-azido-6-deoxy-2,3-di-O-
hexanoyl)cyclomaltoheptaose 54180b (8.5 mg, 3.2 µmol) and compound 87 (20 mg, 25 
µmol, 1.1 eq) in acetonitrile (0.5 mL) bis(triphenylphosphine)copper(I)iodide 93289 (1.8 
mg, 2.5 µmol, 0.1 eq relative to the alkyne) was added and the reaction mixture was 
heated under microwave irradiation to 85 ºC for 1 h (60 W). Then, the solvent was 
evaporated and the resulting residue was purified by size exclusion chromatography in 
MeOH to yield compound 90 (20 mg, 75%). As determined by integration of characteristic 
1H NMR signals, the average degree of substitution of heterogeneous compound 90 was 
estimated 85%. 
Rf = 0.61 (9:1 DCM-MeOH). [α]D = +19.5 (c = 1.0 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S54): δ = 7.82 (bs, 6 H, CHtriazole), 5.72-4.65 (m, 
35 H, H-1, H-2, H-3, H-6), 4.33-3.52 (m, 126 H, H-4, H-5, CH2triazole, H-1’’,H-3’, H-5’, H-6’, 
H-8’, H-9’, H-11’), 3.52-3.10 (m, 35 H, H-2’’), 3.05-2.63 (m, 24 H, H-2’, H-12’), 2.60-2.09 
(m, 28 H, CH2CO), 1.64 (m, 28 H, CH2CH2CO), 1.46 (bs, 149 H, C(CH3)3), 1.37 (m, 56 H, 
CH3CH2, CH3CH2CH2), 0.95 (m, 42 H, CH3). 
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Heptakis[6-(4-(4,7,10-tris(N’-(2-N-((N-tert-butoxycarbonylaminoethyl)tert-butoxy-
carbonyl)amino)ethyl)thioureido)-1,4,7,10-tetraazacyclododecyl-1-methyl)-1H-1,2,3-
triazol-1-yl)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (95). To a solution of 
heptakis(6-azido-6-deoxy-2,3-di-O-hexanoyl)cyclomaltoheptaose 54180b (5.6 mg, 2.1 
µmol) and compound 88 (20 mg, 16 µmol, 1.1 eq) in acetonitrile (0.5 mL) 
bis(triphenylphosphine)copper(I)iodide 93289 (1.2 mg, 1.6 µmol, 0.1 eq relative to the 
alkyne) was added and the reaction mixture was heated under microwave irradiation to 
85 ºC for 1 h (60 W). Then, the solvent was evaporated and the resulting residue was 
purified by size exclusion chromatography in MeOH to yield compound 95 (12 mg, 50%). 
As determined by integration of characteristic 1H NMR signals, the average degree of 
substitution of heterogeneous compound 95 was estimated 80%. 
Rf = 0.26 (9:1 DCM-MeOH). [α]D = +15.6 (c = 0.6 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S55): δ = 8.10 (bs, 5 H, CHtriazole), 6.40-4.64(m, 
35 H, H-1, H-2, H-3, H-6), 4.39-3.63 (m, 92 H, H-4, H-5, CH2triazole, H-3’, H-5’, H-6’, H-8’, 
H-9’, H-11’), 3.59-3.35 (m, 101 H, H-1’’, H-2’’, H-3’’), 3.25 (m, 34 H, H-4’’), 3.06-2.66 (m, 
22 H, H-2’, H-12’), 2.56-2.17 (m, 28 H, CH2CO), 1.63 (m, 28 H, CH2CH2CO), 1.50, 1.46 (2 
bs, each 151 H, C(CH3)3), 1.37 (m, 56 H, CH3CH2, CH3CH2CH2), 0.95 (m, 42 H, CH3). 
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Heptakis[6-(4-(4,7,10-tris(N’-(-(3-((4-((3-(tert-butoxycarbonyl)amino)propyl)(tert-
butoxycarbonyl)amino)butyl)(tert-butoxycarbonyl)amino)propyl))thioureido)-
1,4,7,10-tetraazacyclododecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-
hexanoyl]cyclomaltoheptaose (96). To a solution of heptakis(6-azido-6-deoxy-2,3-di-O-
hexanoyl)cyclomaltoheptaose 54180b (4.7 mg, 1.8 µmol) and compound 89 (25 mg, 13.6 
µmol, 1.1 eq) in acetonitrile (0.5 mL) bis(triphenylphosphine)copper(I)iodide 93289 (1.0 
mg, 1.4 µmol, 0.1 eq relative to the alkyne) was added and the reaction mixture was 
heated under microwave irradiation to 85 ºC for 1 h (60 W). Then, the solvent was 
evaporated and the resulting residue was purified by size exclusion chromatography in 
MeOH to yield compound 96 (8.4 mg, 31%). As determined by integration of 
characteristic 1H NMR signals, the average degree of substitution of heterogeneous 
compound 96 was estimated 73%. 
Rf = 0.25 (9:1 DCM-MeOH). [α]D = +6.37 (c = 0.4 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S56): δ = 7.85 (bs, 5 H, CHtriazole), 5.70-4.81 (m, 
35 H, H-1, H-2, H-3, H-6), 3.78-3.50 (m, 32 H, H-4, H-5, CH2triazole, H-1’’, H-3’, H-5’, H-6’, 
H-8’, H-9’, H-11’), 3.32-3.20 (m, 122 H, H-3’’, H-4’’, H-7’’, H-8’’), 3.07 (t, 31 H, 3JH,H = 6.4 
Hz, H-10’’), 3.00-2.81 (m, 20 H, H-2’, H-12’), 2.57-2.17 (m, 28 H, CH2CO), 1.98-1.79 (m, 
31 H, H-2’’), 1.72 (m, 31 H, H-9’’), 1.61 (m, 28 H, CH2CH2CO), 1.56 (m, 61 H, H-5’’, H-6’’), 
1.49, 1.46 (2 bs, 414 H, C(CH3)3), 1.37 (m, 56 H, CH3CH2, CH3CH2CH2), 0.95 (m, 42 H, 
CH3). 
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Heptakis[6-(4-(4,7,10-tris(N’-(2-aminoethyl)thioureido)-1,4,7,10-tetraazacyclo-
dodecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-hexanoyl]cyclomalto-
heptaose henicosahydrochloride (97). Treatment of compound 90 (20 mg, 2.4 µmol) 
with TFA following the procedure described in the general methods, followed by freeze-
drying from a 0.1 N aq. HCl solution, gave compound 97 in quantitative yield (15 mg). 
[α]D = +18.3 (c = 0.4 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S57): δ = 7.86 (bs, 6 H, CHtriazole), 5.72-4.61 (m, 
35 H, H-1, H-2, H-3, H-6), 4.42-3.59 (m, 126 H, H-4, H-5, CH2triazole, H-1’’, H-3’, H-5’, H-6’, 
H-8’, H-9’, H-11’), 3.49-3.18 (m, 35 H, H-2’’), 3.07-2.63 (m, 24 H, H-2’, H-12’), 2.62-2.15 
(m, 28 H, CH2CO), 1.65 (m, 28 H, CH2CH2CO), 1.38 (m, 56 H, CH3CH2, 
CH3CH2CH2),0.95 (m, 42 H, CH3). 
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Heptakis[6-(4-(4,7,10-tris(N’-(2-(N-2-aminoethyl)aminoethyl)thioureido)-1,4,7,10-
tetraazacyclododecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-
hexanoyl]cyclomaltoheptaose dotetracontahydrochloride (98). Treatment of 
compound 95 (11 mg, 1.0 µmol) with TFA following the procedure described in the 
general methods, followed by freeze-drying from a 0.1 N aq. HCl solution, gave 
compound 98 in quantitative yield (8.4 mg). 
[α]D = +15.0 (c = 0.6 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S58): δ = 7.85 (bs, 5 H, CHtriazole), 5.66-4.68 (m, 
35 H, H-1, H-2, H-3, H-6), 4.40-3.85 (m, 92 H, H-4, H-5, CH2triazole, H-3’, H-5’, H-6’, H-8’, 
H-9’, H-11’), 3.78-3.40 (m, 134 H, H-1’’, H-2’’, H-3’’, H-4’’), 2.66-2.07 (m, 50 H, CH2CO, 
H-2’, H-12’), 1.65 (m, 28 H, CH2CH2CO), 1.38 (m, 56 H, CH3CH2, CH3CH2CH2), 0.96 (m, 
42 H, CH3). 
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Heptakis[6-(4-(4,7,10-tris(N’-(3-((4-(3-aminopropyl)aminobutyl)aminopropyl))thio-
ureido)-1,4,7,10-tetraazacyclododecyl-1-methyl)-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-
di-O-hexanoyl]cyclomaltoheptaose trishexacontahydrochloride (99). Treatment of 
compound 96 (8 mg, 0.5 µmol) with TFA following the procedure described in the general 
methods, followed by freeze-drying from a 0.1 N aq. HCl solution, gave compound 99 in 
quantitative yield (6 mg). 
[α]D = +7.86 (c = 0.4 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S59): δ = 7.86 (bs, 5 H, CHtriazole), 5.66-4.64 (m, 
35 H, H-1, H-2, H-3, H-6), 4.44-3.44 (m, 32 H, H-4, H-5, CH2triazole, H-1’’, H-3’, H-5’, H-6’, 
H-8’, H-9’, H-11’), 3.28-3.10 (m, 173 H, H-3’’, H-4’’, H-7’’, H-8’’, H-10’’, H-2’, H-12’), 2.52-
1.87 (m, 151 H, CH2CO, H-2’’, H-5’’, H-6’’, H-9’’), 1.65 (m, 28 H, CH2CH2CO), 1.38 (m, 56 
H, CH3CH2, CH3CH2CH2), 0.95 (m, 42 H, CH3). 
 
 
 
1,4,7-Tris(tert-butoxycarbonyl)-10-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,4,7,10-
tetraazacyclododecane (100). To a solution of compound 63 (50 mg, 97.9 µmol) and 
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benzyl azide (19.2 mg, 0.15 mmol, 1.5 eq) in THF (2 mL) 2,6-lutidine (3.5 µL, 29.4 µmol, 
0.3 eq) and CuI·P(OEt)3 (0.5 mg, 1.5 µmol, 1.5 mol-%) were added and the reaction 
mixture was heated under microwave irradiation to 110 ºC for 20 min (60 W). Then, the 
solvent was evaporated and the resulting residue was purified by flash column 
chromatography (95:5 DCM-MeOH) to obtain compound 100 (56 mg, 89%). 
Rf = 0.50 (9:1 DCM-MeOH). 
1H NMR (400 MHz, CDCl3, 323 K, Figure S60): δ = 7.37 (m, 4 H, CHtriazole, Ar), 7.25 (m, 2 
H, Ar), 5.51 (s, 2 H, CH2Ph), 3.88 (s, 2 H, CH2triazole), 3.53, 3.33 (2 m, 12 H, H-2, H-3, H-5, 
H-6, H-8, H-12), 2.67 (m, 4 H, H-9, H-11), 1.49, 1.43 (2 s, 27 H, C(CH3)3). 
13C NMR (100.6 MHz, CDCl3, 323 K, Figure S60): δ = 155.8, 155.4 (CO carbamate), 
143.4 (Ctriazole), 134.8 (Arquaternary), 129.1, 128.7, 127.9 (Ar), 122.7 (CHtriazole), 79.5, 79.2 
(C(CH3)3), 54.9 (C-9, C-11), 54.1 (CH2Ph), 49.8, 47.8 (C-2, C-3, C-5, C-6, C-8, C-12), 
46.1 (CH2triazole), 29.6, 28.7, 28.5 (C(CH3)3). 
ESI-MS (Figure S133): m/z 666.3 [M + Na]+, 682.3 [M + K]+. 
Elemental analysis calculated (%) for C33H53N7O6: C 61.56, H 8.30, N 15.23; found: C 
61.76, H 8.34, N 15.55. 
 
 
 
1,4,8-Tris(tert-butoxycarbonyl)-11-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-
tetraazacyclotetradecane (101). To a solution of compound 64 (30.5 mg, 56.6 µmol) 
and benzyl azide (11.3 mg, 84.9 µmol, 1.5 eq) in THF (2 mL) 2,6-lutidine (2.1 µL, 17.0 
µmol, 0.3 eq) and CuI·P(OEt)3 (0.3 mg, 0.8 µmol, 1.5 mol-%) were added and the 
reaction mixture was heated under microwave irradiation to 110 ºC for 20 min (60 W). 
Then, the solvent was evaporated and the resulting residue was purified by flash column 
chromatography (95:5 DCM-MeOH) to obtain compound 101 (23.6 mg, 62%). 
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Rf = 0.45 (9:1 DCM-MeOH). 
1H NMR (500 MHz, CDCl3, 323 K, Figure S61): δ = 7.37 (m, 4 H, CHtriazole, Ar), 7.29 (m, 2 
H, Ar), 5.52 (s, 2 H, CH2Ph), 3.77 (s, 2 H, CH2triazole), 3.38-3.26 (m, 12 H, H-3, H-5, H-7, 
H-9, H-10, H-12), 2.64 (t, 2 H, 3JH,H = 5.4 Hz, H-2), 2.45 (t, 2 H, 3JH,H = 5.4 Hz, H-14), 1.89 
(m, 2 H, 3JH,H = 6.4 Hz, H-6), 1.71 (m, 2 H, 3JH,H = 6.4 Hz, H-13), 1.47, 1.44 (2 s, 27 H, 
C(CH3)3). 
13C NMR (125.7 MHz, CDCl3, 323 K, Figure S61): δ = 155.7, 155.5 (CO carbamate), 
144.6 (Ctriazole), 134.9 (Arquaternary), 129.1, 128.6, 127.9 (Ar), 122.3 (CHtriazole), 79.5, 79.4 
(C(CH3)3), 54.1 (CH2Ph), 53.2 (C-2), 51.6 (C-14), 49.2 (CH2triazole), 47.6, 47.2, 46.9, 45.6 
(C-3, C-5, C-7, C-9, C-10, C-12), 28.8 (C-6), 28.5, 28.4 (C(CH3)3), 26.8 (C-13).  
ESI-MS (Figure S134): m/z 694.3 [M + Na]+, 710.3 [M + K]+. 
Elemental analysis calculated (%) for C35H57N7O6: C 62.57, H 8.55, N 14.59; found: C 
62.17, H 8.51, N 14.98. 
 
 
 
N-[4,7,10-Tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododec-1-yl]-N’-[6-(N’-
benzyl)thioureido-n-hex-1-yl]thiourea (102). To a solution of benzyl amine (9 µL, 81.7 
µmol, 1.1 eq) and Et3N (10 µL, 81.7 µmol, 1.1 eq) in DCM (3.5 mL) 69 (50 mg, 74.3 µmol) 
was added and the reaction mixture was stirred in a sealed reaction vial at 45 ºC for 24 h 
assuring that pH value was maintained at 9. Then, solvents were evaporated under 
reduced pressure and the resulting residue was purified by flash column chromatography 
(3:2 EtOAc-petroleum ether  45:5:3 EtOAc-EtOH-H2O) to afford 102 (64 g, 88%). 
Rf = 0.65 (2:1 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, 323 K, Figure S62): δ = 7.32 (m, 5 H, Ar), 6.33 (bs, 1 H, 
NHBn), 6.09, 5.83 (2 bs, 2 H, NH), 4.69 (d, 2 H, 3JH,H = 5.4 Hz, CH2Ph), 3.82 (m, 4 H, H-
2, H-12), 3.62 (q, 2 H, 3JH,H = 5.8 Hz, H-1’), 3.50 (m, 4 H, H-3, H-11), 3.46 (m, 2 H, H-6’), 
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3.40 (m, 8 H, H-5, H-6, H-8, H-9), 1.59 (m, 4 H, H-2’, H-5’), 1.47, 1.46 (2 s, 27 H, 
C(CH3)3), 1.35 (m, 4 H, H-3’, H-4’). 
13C NMR (125.7 MHz, CDCl3, 323 K, Figure S62): δ = 183.0, 182.7 (CS), 156.7, 156.6 
(CO carbamate), 137.5 (Arquaternary), 128.7, 127.7, 127.6 (Ar), 80.5, 80.4, 80.3 (C(CH3)3), 
53.5 (C-2, C-12), 50.3 (C-5, C-6, C-8, C-9), 49.9 (C-3, C-11), 48.5 (CH2Ph), 45.6 (C-1’), 
44.3 (C-6’), 29.0, 28.8 (C-2’, C-5’), 28.5, 28.4 (C(CH3)3), 26.3, 26.2 (C-3’, C-4’). 
ESI-MS (Figure S135): m/z 802.4 [M + Na]+. 
Elemental analysis calculated (%) for C38H65N7O6S2: C 58.51, H 8.40, N 12.57, S 8.22; 
found: C, H, N, S. 
 
 
 
N-[4,8,11-Tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradec-1-yl]-N’-[6-(N’-
benzyl)thioureido-n-hex-1-yl]thiourea (103). To a solution of benzyl amine (8.6 µL, 
78.5 µmol, 1.1 eq) and Et3N (10 µL, 78.5 µmol, 1.1 eq) in DCM (3.5 mL) 70 (50 mg, 71.3 
µmol) was added and the reaction mixture was stirred in a sealed reaction vial at 45 ºC 
for 48 h assuring that pH value was maintained at 9. Then, solvents were evaporated 
under reduced pressure and the resulting residue was purified by flash column 
chromatography (3:2 EtOAc-petroleum ether  EtOAc) to afford 103 (48 mg, 83%). 
Rf = 0.16 (1:1 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, 323 K, Figure S63): δ = 7.32 (m, 5 H, Ar), 6.49 (bs, 1 H, 
NHBn), 6.34, 6.11 (2 bs, 2 H, NH), 4.69 (d, 2 H, 3JH,H = 5.3 Hz, CH2Ph), 3.92 (m, 2 H, H-
14), 3.63 (m, 4 H, H-2, H-1’), 3.46 (m, 2 H, H-10), 3.40 (m, 4 H, H-9, H-6’), 3.34 (m, 8 H, 
H-3, H-5, H-7, H-12), 1.88 (m, 2 H, H-13), 1.77 (m, 2 H, H-6), 1.64 (m, 2 H, H-2’), 1.57 (m, 
2 H, H-5’), 1.47 (s, 27 H, C(CH3)3), 1.37 (m, 4 H, H-3’, H-4’). 
13C NMR (125.7 MHz, CDCl3, 323 K, Figure S63): δ = 182.7, 182.1 (CS), 156.0, 155.7, 
155.6 (CO carbamate), 137.6 (Arquaternary), 128.7, 127.6 (Ar), 80.8, 80.1, 80.0 (C(CH3)3), 
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50.4 (C-14), 48.5 (CH2Ph), 47.0 (C-2), 46.6, 46.2, 46.1 (C-3, C-5, C-7, C-9, C-10, C-12), 
44.3 (C-1’, C-6’), 28.8 (C-2’, C-5’), 28.5 (C-6), 28.4, 28.3 (C(CH3)3), 27.9 (C-13), 26.3 (C-
3’, C-4’). 
ESI-MS (Figure S136): m/z 830.5 [M + Na]+. 
Elemental analysis calculated (%) for C40H69N7O6S2: C 59.45, H 8.61, N 12.13; found: C 
59.26, H 9.10, N 11.61. 
 
 
 
1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-1,4,7,10-tetraazacyclododecane 
trihydrochloride (104). Treatment of compound 100 (66 mg, 0.10 mmol) with TFA 
following the procedure described in the general methods, followed by freeze-drying from 
a 0.1 N aq. HCl solution, gave compound 104 in virtually quantitative yield (46 mg). 
1H NMR (400 MHz, 5:1 MeOD-D2O, 333 K, Figure S64): δ = 8.01 (s, 1 H, CHtriazole), 7.39 
(m, 5 H, Ar), 5.63 (s, 2 H, CH2Ph), 3.97 (s, 2 H, CH2triazole), 3.24, 3.06 (2 m, 12 H, H-3, H-
5, H-6, H-8, H-9, H-11), 2.98 (t, 4 H, 3JH,H = 5.6 Hz, H-2, H-12). 
13C NMR (100.6 MHz, 5:1 MeOD-D2O, 333 K, Figure S64): δ = 143.2 (Ctriazole), 135.0 
(Arquaternary), 128.8, 128.4, 127.9 (Ar), 124.1 (CHtriazole), 53.9 (CH2Ph), 48.5 (C-2, C-12), 
47.1 (CH2triazole), 44.8, 42.7, 42.1 (C-3, C-5, C-6, C-8, C-9, C-11). 
ESI-MS (Figure S137): m/z 344.2 [M + H]+. 
Elemental analysis calculated (%) for C18H32Cl3N7: C 62.94, H 8.51, N 28.55; found: C, H, 
N. 
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1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-1,4,8,11-tetraazacyclotetradecane trihydro-
chloride (105). Treatment of compound 101 (23 mg, 34 µmol) with TFA following the 
procedure described in the general methods, followed by freeze-drying from a 0.1 N aq. 
HCl solution, afforded compound 105 in quantitative yield (16 mg). 
1H NMR (400 MHz, 5:1 MeOD-D2O, 333 K, Figure S65): δ = 8.00 (s, 1 H, CHtriazole), 7.41 
(m, 5 H, Ar), 5.63 (s, 2 H, CH2Ph), 3.84 (s, 2 H, CH2triazole), 3.29 (m, 4 H, H-9, H-10), 3.13-
3.03 (m, 8 H, H-3, H-5, H-7, H-12), 2.89 (m, 4 H, H-2, H-14), 2.09 (m, 2 H, 3JH,H = 6.4 Hz, 
H-6), 1.92 (m, 2 H, 3JH,H = 5.4 Hz, H-13). 
13C NMR (100.6 MHz, 5:1 MeOD-D2O, 333 K, Figure S65): δ = 144.6 (Ctriazole), 135.1 
(Arquaternary), 128.9, 128.5, 128.1 (Ar), 123.8 (CHtriazole), 54.2 (CH2Ph), 54.0, 52.6 (C-2, C-
14), 47.1, 46.4 (C-9, C-10), 46.8 (CH2triazole), 46.6, 45.2, 44.0 (C-3, C-5, C-7, C-12), 24.4 
(C-13), 22.7 (C-6). 
ESI-MS (Figure S138): m/z 372.3 [M + H]+, 406.1 [M + Cl]-. 
Elemental analysis calculated (%) for C20H36Cl3N7: C 64.66, H 8.95, N 26.39; found: C, H, 
N. 
 
 
 
N-(1,4,7,10-Tetraazacyclododec-1-yl)-N’-[6-(N’-benzyl)thioureido-n-hex-1-yl]thiourea 
trihydrochloride (106). Treatment of compound 102 (64 mg, 82 µmol) with TFA following 
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the procedure described in the general methods, followed by freeze-drying from a 0.1 N 
aq. HCl solution, afforded compound 106 in quantitative yield (48 mg). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 333 K, Figure S66): δ = 7.34 (m, 5 H, Ar), 4.71 (s, 2 
H, CH2Ph), 4.05 (t, 4 H, 3JH,H = 5.0 Hz, H-2, H-12), 3.65 (t, 2 H, 3JH,H = 7.4 Hz, H-1’), 3.49 
(t, 2 H, 3JH,H = 7.3 Hz, H-6’), 3.42, 3.31 (2 m, 12 H, H-3, H-5, H-6, H-8, H-9, H-11), 1.68 
(m, 2 H, H-2’), 1.61 (m, 2 H, H-5’), 1.38 (m, 4 H, H-3’, H-4’). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 333 K, Figure S66): δ = 186.3 (CS), 130.9, 129.8, 
129.7 (Ar), 53.1 (C-2, C-12), 49.4 (C-1’), 48.9, 46.9 (C-3, C-5, C-6, C-8, C-9, C-11), 47.3 
(CH2Ph), 46.6 (C-6’), 31.2, 31.0 (C-2’, C-5’), 28.8, 28.6 (C-3’, C-4’). 
ESI-MS (Figure S139): m/z 480.3 [M + H]+, 514.1 [M + Cl]-. 
Elemental analysis calculated (%) for C23H44Cl3N7S2: C 46.89, H 7.53, N 16.64, S 10.89; 
found: C, H, N, S. 
 
 
 
N-(1,4,8,11-Tetraazacyclotetradec-1-yl)-N’-[6-(N’-benzyl)thioureido-n-hex-1-
yl]thiourea trihydrochloride (107). Treatment of compound 103 (55 mg, 68 µmol) with 
TFA following the procedure described in the general methods, followed by freeze-drying 
from a 0.1 N aq. HCl solution, afforded compound 107 in quantitative yield (42 mg). 
1H NMR (500 MHz, 5:1 MeOD-D2O, 333 K, Figure S67): δ = 7.34 (m, 5 H, Ar), 4.70 (s, 2 
H, CH2Ph), 4.25 (t, 2 H, 3JH,H = 6.7 Hz, H-2), 3.87 (t, 2 H, 3JH,H = 7.4 Hz, H-14), 3.63 (t, 2 
H, 3JH,H = 7.4 Hz, H-1’), 3.49, 3.30 (2 m, 14 H, H-3, H-5, H-7, H-9, H-10, H-12, H-6’), 2.23 
(m, 4 H, H-6, H-13), 1.67 (m, 2 H, H-2’), 1.60 (m, 2 H, H-5’), 1.38 (m, 4 H, H-3’, H-4’). 
13C NMR (125.7 MHz, 5:1 MeOD-D2O, 333 K, Figure S67): δ = 185.6 (CS), 131.0, 129.8, 
129.7 (Ar), 48.8 (C-2), 47.3 (CH2Ph), 46.9 (C-14), 46.8 (C-1’), 46.5, 45.1, 44.8 (C-3, C-5, 
C-7, C-9, C-10, C-12, C-6’), 28.7, 28.6 (C-2’, C-5’), 26.4 (C-3’, C-4’), 24.3 (C-6, C-13). 
ESI-MS (Figure S140): m/z 508.3 [M + H]+, 542.2 [M + Cl]-. 
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Elemental analysis calculated (%) for C25H48Cl3N7S2: C 48.65, H 7.84, N 15.89, S 10.39; 
found: C, H, N, S. 
 
 
3.3. New Compounds synthesized in Chapter 4 
 
 
 
6,6’-Diazido-6,6’-dideoxy-2,2’,3,3’,4,4’-hexa-O-methyl-α,α’-trehalose (109). To a 
solution of 6,6’-diazido-6,6’-dideoxy-α,α’-trehalose 108269 (0.56 g, 1.31 mmol) in dry DMF 
(15 mL) under N2 atmosphere at 0 ºC NaH (0.63 g, 15.8 mmol, 2 eq, 60% dispersion in 
mineral oil) and methyl iodide (0.98 mL, 15.8 mmol, 2 eq) were sequentially added. The 
reaction mixture was allowed to warm to rt and stirred overnight. Then, the reaction was 
quenched by addition of water (15 mL). The reaction mixture was then concentrated 
under reduced pressure and the residue was taken in DCM (15 mL) and washed with 
water (2 x 15 mL). The organic layer was dried over Na2SO4, filtered and evaporated to 
dryness. The crude product was purified by flash column chromatography (1:2 EtOAc-
petroleum ether) to furnish 109 in 72% yield (0.45 g). 
Rf = 0.41 (1:2 EtOAc-petroleum ether). [α]D = +161.8 (c = 1.0 in MeOH). 
1H NMR (500 MHz, CDCl3, Figure S68): δ = 5.19 (d, 2 H, J1,2 = 3.7 Hz, H-1), 4.07 (ddd, 2 
H, J4,5 = 9.9 Hz, J5,6b = 5.5 Hz, J5,6a = 2.7 Hz, H-5), 3.64, 3.57, 3.48 (3 s, 6 H each, OCH3), 
3.51 (t, 2 H, J2,3 = J3,4 = 9.2 Hz, H-3), 3.45 (m, 4 H, H-6a, H-6b), 3.20 (dd, 2 H, H-2), 3.08 
(dd, 2 H, H-4). 
13C NMR (125.7 MHz, CDCl3, Figure S68): δ = 93.2 (C-1), 82.8 (C-3), 81.6 (C-2), 80.4 (C-
4), 70.5 (C-5), 60.8, 60.7, 58.6 (OCH3), 51.5 (C-6). 
ESI-MS (Figure S141): m/z 499.5 [M + Na]+, 515.5 [M + K]+. 
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Elemental analysis calculated (%) for C18H32N6O9: C 45.37, H 6.77, N 17.64; found: C 
45.32, H 6.66, N 17.41. 
RP-HPLC: tR = 10.5 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
 
 
 
N-Benzyl-4-(diphenylphosphino)benzamide (116). To a solution of 4-
(diphenylphosphino)benzoic acid 112334 (0.68 g, 2.2 mmol) in DMF (20 mL) DIPEA (0.42 
mL, 2.5 mmol, 1.1 eq) and TBTU (0.72 g, 2.2 mmol, 1 eq) were sequentially added. The 
reaction mixture was stirred for 5 min and then benzylamine (0.24 mL, 2.2 mmol, 1 eq) 
was added. The reaction mixture was stirred at rt overnight. The solvent was evaporated 
and the residue was taken in DCM, and successively washed with 1 M aq. HCl, saturated 
aq. NaHCO3, brine and H2O. The organic layer was dried over Na2SO4, filtered and 
evaporated to dryness. The crude product was purified by flash column chromatography 
(1:6  1:3 EtOAc-petroleum ether) to afford 116 as a white solid (729 mg, 83%). 
Rf = 0.55 (1:3 EtOAc-petroleum ether). 
1H NMR (500 MHz, CDCl3, Figure S69): δ =7.75 (d, 2 H, 3JH,H = 7.6 Hz, CHCCONH), 
7.38-7.29 (m, 17 H, Ar), 6.46 (bs, 1 H, NH), 4.66 (d, 2 H, 3JH,H = 5.6 Hz, CH2). 
13C NMR (125.7 MHz, CDCl3, Figure S69): δ = 167.0 (CO), 138.1 (PCCHCHCCONH), 
136.4, 136.3 (CP), 134.4 (CCH2NH), 134.0, 133.8 (PCCH), 133.7, 133.5 
(PCCHCHCCONH), 129.1 (CCONH, CHCHCCH2NH), 128.8 (PCCHCHCH), 128.7, 128.6 
(PCCHCH), 127.9 (CHCCH2NH), 127.7 (CHCHCHCCH2NH), 126.9, 126.8 (CHCCONH), 
44.2 (CH2). 
31P NMR (202.5 MHz, CDCl3, Figure S69): δ = -6.21 (s). 
ESI-MS (Figure S142): m/z 396.4 [M + H]+, 418.4 [M + Na]+, 434.3 [M + K]+, 394.2 [M – 
H]-. 
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Elemental analysis calculated (%) for C26H22NOP: C 78.97, H 5.61, N 3.54; found: C 
78.48, H 5.82, N 3.42. 
 
 
[4-(Diphenylphosphino)phenoxy]acetic acid (118). To a solution of (4-
iodophenoxy)acetic acid 117 (1.39 g, 5 mmol) and Et3N (1.39 mL, 10 mmol, 2 eq) in 
degassed MeCN (30 mL) under N2 Pd(AcO)2 (1.1 mg, 5 µmol, 0.1% eq) and 
diphenylphosphine (0.87 mL, 5 mmol, 1 eq) were sequentially added. The intensely 
orange-red colored reaction mixture was refluxed at 85 °C for 12 h. The volatiles were 
then evaporated and the residue was suspended in water (15 mL), taken to basic pH by 
adding KOH (0.56 g, 10 mmol, 2 eq) and washed with Et2O (3 x 20 mL). The aqueous 
layer was then acidified to pH 2 by addition of 1.8 M HCl and extracted with Et2O (3 x 20 
mL). The collected organic phase was washed with water (15 mL), dried over Na2SO4, 
filtered and evaporated to dryness. The crude product was purified by flash column 
chromatography (1:2  2:1 EtOAc-petroleum ether) to afford 118 as a white solid (1.57 g, 
93%). 
Rf = 0.35 (1% AcOH in 2:1 EtOAc-petroleum ether). 
1H NMR (400 MHz, CDCl3, Figure S70): δ = 9.04 (bs, 1 H, COOH), 7.38-7.28 (m, 12 H, 
Ar), 6.93 (dd, 2 H, 3JH,H = 8.8 Hz, 4JH,P = 0.9 Hz, CHCOCH2COOH), 4.71 (s, 2 H, CH2). 
13C NMR (100.6 MHz, CDCl3, Figure S70): δ = 173.6 (CO), 158.1 (COCH2COOH), 138.5 
(PCCHCHCOCH2COOH), 137.5, 137.4 (CP), 135.8, 135.6 (PCCHCHCOCH2COOH), 
133.6, 133.4 (PCCH), 128.7, 128.6, 128.5 (PCCHCH, PCCHCHCH), 114.9, 114.8 
(CHCOCH2COOH), 64.7 (CH2). 
31P NMR (162 MHz, CDCl3, Figure S70): δ = -7.02 (s). 
ESI-MS (Figure S143): m/z 335.0 [M – H]-. 
Elemental analysis calculated (%) for C20H17O3P: C 71.42, H 5.09; found: C 71.54, H 
5.38. 
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N-Benzyl-[4-(diphenylphosphino)phenoxy]acetamide (119). To a solution of 
compound 118 (100 mg, 0.30 mmol) in DMF (10 mL) DIPEA (54 µL, 0.33 mmol, 1.1 eq) 
and TBTU (96 mg, 0.3 mmol, 1 eq) were sequentially added. The reaction mixture was 
stirred for 5 min and then benzylamine (33 µL, 0.3 mmol, 1 eq) was added. The reaction 
mixture was stirred at rt overnight. The solvent was then evaporated and the residue was 
taken in DCM, washed with 1 M aq. HCl, saturated aq. NaHCO3, brine and H2O. The 
organic layer was dried over Na2SO4, filtered and evaporated to dryness. The crude 
product was purified by flash column chromatography (1:3 EtOAc-petroleum ether) to 
yield 119 as a white solid (75 mg, 59%). 
Rf = 0.23 (1:3 EtOAc-petroleum ether). 
1H NMR (400 MHz, CDCl3, Figure S71): δ = 7.37-7.29 (m, 17 H, Ar), 6.92 (d, 2 H, 3JH,H = 
8.4 Hz, CHCOCH2CONH), 4.59 (m, 3 H, OCH2CO, CONHCHa), 4.57 (m, 1 H, 
CONHCHb). 
13C NMR (75.5 MHz, CDCl3, Figure S71): δ = 167.9 (CO), 157.8 (COCH2CONH), 137.6 
(PCCHCHCOCH2CONH), 135.9, 135.5 (CP), 133.6, 133.4 (PCCHCHCOCH2CONH), 
132.1 (CCH2NH), 128.8, 128.6, 128.5, 127.7 (PCCH, PCCHCH, PCCHCHCH, 
CHCHCCH2NH, CHCCH2NH, CHCHCHCCH2NH), 115.1, 114.8 (CHCOCH2CONH), 67.3 
(OCH2CONH), 43.1 (CONHCH2). 
31P NMR (162 MHz, CDCl3, Figure S71): δ = -7.03 (s). 
ESI-MS (Figure S144): m/z 448.2 [M + Na]+, 464.2 [M + K]+. 
Elemental analysis calculated (%) for C27H24NO2P: C 76.22, H 5.69, N 3.29; found: C 
76.00, H 5.90, N 3.46. 
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Phosphine-functionalized PS resins 123 and 129. Commercially available AM-PS resin 
(2.0 g, 0.39 mmol·g-1) was placed in a plastic syringe and allowed to swell in DMF for 20 
min. Fmoc-Gly-OH (0.70 g, 2.34 mmol, 3 eq) was dissolved in a minimum amount of 
DMF. DIPEA (0.54 mL, 3.12 mmol, 4 eq) and TBTU (0.75 g, 2.34 mmol, 3 eq) were then 
sequentially added to the glycine solution. The mixture was stirred for approximately 5 
min until complete dissolution of TBTU. Then, the solution was added to the swollen resin 
and the mixture was incubated rt overnight. Disappearance of amino groups was 
monitored by Kaiser test.337 The resin was then washed with DMF (6 x 2 min) and DCM 
(4 x 2 min). The resin was finally dried under vacuum to constant weight. Resin 
substitution was estimated to be close to the nominal value (0.39 mmol·g-1) by UV 
determination of the dibenzofulvene released from a portion of resin upon 2% DBU in 
DMF treatment according to standard procedures. 
Fmoc was removed by treating the resin with 20% v/v piperidine in DMF at rt for 20 min, 
followed by rinsing the resin with degassed DMF (6 x 2 min) and degassed DCM (4 x 2 
min) under N2 to prevent oxidation during phosphine coupling.   
To a solution of phosphine 118 (0.54 g, 1.63 mmol, 2.1 eq) in dry and degassed DCM 
under N2 atmosphere DMAP (0.20 g, 1.63 mmol, 2.1 eq) and DIC (0.20 g, 1.63 mmol, 2.1 
eq) were sequentially added. The mixture was stirred for approximately 5 min under N2 
and the solution was subsequently transferred to the resin. After incubation for 16 h, the 
resin was then washed under N2 stream with dry DCM (6 x 2 min) and dried under 
vacuum to constant weight. The resin was stored under an inert atmosphere to prevent 
phosphine oxidation. Successful phosphine incorporation was confirmed by appearance 
of the corresponding resonance at ca. -6 ppm in the 31P NMR spectra. 
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31P NMR (121 MHz, DMF, Figure S72): δ = -7.78 (s). Minute amounts (< 5%) of oxide 
phosphine (signal at ca. 32 ppm) were observed. Final resin loading (due to resin mass 
increase) was estimated in 0.34 mmol·g-1. 
For the synthesis of the diluted version of resin 129, the coupling of the initial amino acid 
was effected using a mixture of Fmoc-Gly-OH and Boc-Gly-OH (1:9 in a molar basis). 
Thus, AM-PS resin (2.0 g, 0.39 mmol·g-1) was treated with mixture of Fmoc-Gly-OH (68 
mg, 0.23 mmol, 0.3 eq), Boc-Gly-OH (0.37 g, 2.1 mmol, 2.7 eq), DIPEA (0.54 mL, 3.12 
mmol, 4 eq) and TBTU (0.75 g, 2.34 mmol, 3 eq) in DMF. After disappearance of amino 
groups, the resin was then washed with DMF (6 x 2 min) and DCM (4 x 2 min). Then Boc 
protecting groups were removed by treatment with a 1:1 mixture of TFA-DCM for 1 h and 
the resin was washed with DCM (4 x 2 min), 5% DIPEA in DCM and neat DCM again (4 x 
2 min). Free amino groups were capped by treating the DMF-swollen resin with a 1:1 
Ac2O-Py mixture (10 eq each) for 1 h. The resin was finally rinsed with DMF (6 x 2 min) 
and DCM (4 x 2 min). Phosphine installation on the diluted resin was effected as 
described for 123. 
31P NMR (121 MHz, DMF, Figure S73): δ = -7.78 (s). Minute amounts (< 5%) of oxide 
phosphine (signal at ca. 32 ppm) were observed. Final resin loading (due to resin mass 
increase) was estimated in 40 µmol·g-1. 
 
 
 
Methyl 6-amino-6-deoxy-2,3,4-tri-O-methyl-α-D-glucopyranoside (124). Amine 124 
was obtained from methyl 6-azido-6-deoxy-2,3,4-tri-O-methyl-α-D-glucopyranoside 91280 
(35 mg, 136 µmol, 2 eq) and resin 123 (0.2 g, 0.34 mmol·g-1) using the catch-and-release 
protocol as described in procedure A (General Methods for Solid-Phase Synthesis) in 
89% yield (14 mg). 
ESI-MS (Figure S145): m/z 236.1 [M + H]+, 258.1 [M + Na]+. 
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Alternatively, compound 124 was prepared in solution as follows: To a mixture of methyl 
6-azido-6-deoxy-2,3,4-tri-O-methyl-α-D-glucopyranoside 91280 (100 mg, 0.38 mmol) and 
Et3N (106 µL, 0.77 mmol, 2 eq) in MeOH (3 mL) was added 1,3-propanedithiol (77 µL, 
0.77 mmol, 2 eq). The reaction mixture was stirred at rt overnight and solvents were 
subsequently evaporated under reduced pressure. The resulting residue was purified by 
flash column chromatography (30:2:1 MeCN-H2O-NH4OH) to yield compound 124 (88 
mg, 98%). 
Rf = 0.19 (30:2:1 MeCN-H2O-NH4OH). [α]D = +41.6 (c = 1.0 in MeOH). 
1H NMR (300 MHz, MeOD, Figure S74): δ = 4.86 (d, 1 H, J1,2 = 3.6 Hz, H-1), 3.59, 3.54, 
3.49, 3.42 (4 s, 3 H each, OCH3), 3.45 (ddd, 1 H, J4,5 = 10.4 Hz, J5,6b = 5.7 Hz, J5,6a = 2.7 
Hz, H-5), 3.39 (m, 1 H, H-3), 3.20 (dd, 1 H, J2,3 = 9.6 Hz, H-2), 2.98 (dd, 1 H, H-6a), 2.59 
(dd, 1 H, J3,4 = 9.0 Hz, H-4), 2.71 (dd, 1 H, J6a,6b = 13.2 Hz, H-6b). 
13C NMR (75.5 MHz, MeOD, Figure S74): δ = 97.0 (C-1), 83.2 (C-3), 81.6 (C-4), 81.3 (C-
2), 71.0 (C-5), 59.6, 59.4, 57.4, 54.1 (OCH3), 42.2 (C-6). 
ESI-MS (Figure S146): m/z 236.1 [M + H]+, 258.2 [M + Na]+, 471.3 [2 M + H]+. 
Elemental analysis calculated (%) for C10H21NO5: C 51.05, H 9.00, N 5.95; found: C 
51.23, H 9.04, N 5.96. 
 
 
 
6,6’-Diamino-6,6’-dideoxy-2,2’,3,3’,4,4’-hexa-O-methyl-α,α’-trehalose (125). To a 
solution of compound 109 (49 mg, 96 µmol) in MeOH (1.5 mL) Pd/C (5 mg, 10% w/w) 
was added. The reaction mixture was stirred at rt for 24 h at 2 bar hydrogen pressure. 
Then, the reaction mixture was filtered over celite to remove the catalyst. The solvent was 
evaporated yielding compound 125 (43 mg, 97%). The crude product was used without 
further purification. 
Rf = 0.15 (10:1:1 MeCN-H2O-NH4OH). [α]D = +33.1 (c = 0.52 in MeOH). 
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1H NMR (500 MHz, CDCl3, Figure S75): δ = 5.14 (d, 2 H, J1,2 = 3.5 Hz, H-1), 3.83 (ddd, 2 
H, J4,5 = 9.6 Hz, J5,6b = 6.1 Hz, J5,6a = 2.8 Hz, H-5), 3.64, 3.58, 3.47 (3 s, 6 H each, OCH3), 
3.55 (t, 2 H, J2,3 = J3,4 = 9.2 Hz, H-3), 3.16 (dd, 2 H, H-2), 3.03 (m, 4 H, H-4, H-6a), 2.81 
(dd, 2 H, J6a,6b = 13.1 Hz, H-6b). 
13C NMR (125.7 MHz, CDCl3, Figure S75): δ = 92.8 (C-1), 83.0 (C-3), 81.8 (C-2), 80.9 (C-
4), 71.9 (C-5), 60.8, 60.5, 58.8 (OCH3), 42.7 (C-6). 
ESI-MS (Figure S147): m/z 425.5 [M +H]+, 447.4 [M + Na]+. 
Elemental analysis calculated (%) for C18H36N2O9: C 50.93, H 8.55, N 6.60; found: C 
50.70, H 8.24, N 6.45. 
RP-HPLC: tR = 5.4 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
 
 
 
6-Amino-6’-azido-6,6’-dideoxy-2,2’,3,3’,4,4’-hexa-O-methyl-α,α’-trehalose (126). 
Compound 126 was obtained from compound 109 (32 mg, 68 µmol, 2 eq) and resin 123 
(0.1 g, 0.34 mmol·g-1) using the catch-and-release protocol as described in procedure A 
(General Methods for Solid-Phase Synthesis) in 52 % yield (8 mg). 
HPLC: tR= 6.3 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
ESI-MS (Figure S148): m/z 451.4 [M + H]+, 473.4 [M + Na]+. 
Alternatively, compound 126 was prepared in solution by statistical reduction of a single 
azido group as follows: To a mixture of compound 109 (100 mg, 0.21 mmol), Et3N (58 µL, 
0.42 mmol, 2 eq) and 1,3-propanedithiol (3 µL, 0.02 mmol, 0.1 eq) in 2-propanol-DMF 
(2:1, 3 mL) was added NaBH4 (8.7 mg, 0.23 mmol, 1.1 eq). The reaction mixture was 
stirred at rt for 4.5 h, and then H2O (1 mL) was added and solvents were evaporated 
under reduced pressure. The resulting residue was purified by flash column 
chromatography (30:2:1 MeCN-H2O-NH4OH) to yield compound 126 (38 mg, 40%). 
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Rf = 0.36 (30:2:1 MeCN-H2O-NH4OH). [α]D = +101.2 (c = 1.0 in MeOH). 
1H NMR (500 MHz, CDCl3, Figure S76): δ = 5.18, 5.17 (2 d, 1 H each, J1,2 = 3.7 Hz, H-1, 
H-1’), 4.09 (ddd, 1 H, J4,5 = 9.9 Hz, J5,6b = 5.2 Hz, J5,6a = 2.7 Hz, H-5’), 3.84 (ddd, 1 H, J4,5 
= 12.8 Hz, J5,6b = 5.8 Hz, J5,6a = 2.7 Hz, H-5), 3.65, 3.64, 3.59, 3.58, 3.49, 3.48 (6 s, 3 H 
each, OCH3), 3.53 (2 t, 1 H each, J2,3 = J3,4 = 9.7 Hz, H-3, H-3’), 3.47-3.42 (m, 2 H, H-6a’, 
H-6b’), 3.20, 3.18 (2 dd, 1 H each, H-2, H-2’), 3.10-3.01 (m, 3 H, H-4, H-4’, H-6a), 2.83 
(dd, 1 H, J6a,6b = 13.5 Hz, H-6b). 
13C NMR (125.7 MHz, CDCl3, Figure S76): δ = 93.1, 93.0 (C-1, C-1’), 83.0, 82.8 (C-3, C-
3’), 81.8, 81.6 (C-2, C-2’), 80.8, 80.4 (C-4, C-4’),71.9 (C-5’), 70.4 (C-5), 60.8, 60.6, 58.7 
(OCH3), 51.5 (C-6’), 42.6 (C-6). 
ESI-MS (Figure S149): m/z 451.5 [M + H]+, 473.4 [M + Na]+. 
Elemental analysis calculated (%) for C18H34N4O9: C 47.99, H 7.61, N 12.44; found: C 
47.67, H 7.54, N 12.35. 
RP-HPLC: tR = 6.3 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
 
 
 
6I-Amino-6II-VII-hexaazido-6I-VII-heptadeoxy-2I-VII,3I-VII-tetradeca-O-methylcyclomalto-
heptaose (127). Monoamine 127 was obtained from heptakis(6-azido-6-deoxy-2,3-di-O-
methyl)cyclomaltoheptaose 110180a (153 mg, 0.1 mmol, 2 eq) and resin 123 (0.15 g, 0.34 
mmol·g-1) using the catch-and-release protocol as described in procedure A (General 
Methods for Solid-Phase Synthesis) in 79% yield (60 mg). 
HPLC: tR = 9.2min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
ESI-MS (Figure S150): m/z 1480.6 [M + H]+, 1502.5 [M + Na]+. 
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Alternatively, compound 127 was prepared in solution by statistical reduction of a single 
azido group as follows: To a solution of heptakis(6-azido-6-deoxy-2,3-di-O-
methyl)cyclomaltoheptaose 110180a (262 mg, 0.17 mmol) in 2-propanol (10 mL) under 
nitrogen atmosphere, Et3N (48 µL, 0.35 mmol, 2 eq), 1,3-propanedithiol (1.75 µL, 17 
µmol, 0.1 eq) and NaBH4 (7.3 mg, 0.19 mmol, 1.1 eq) were added, and the reaction 
mixture was vigorously stirred overnight. The reaction was quenched by addition of water 
(2 mL). The solvent was evaporated under reduced pressure and the residue was diluted 
with DCM (20 mL) and washed with 1 M aq. NaOH (3 x 5 mL). The organic layer was 
dried, filtered and concentrated. The resulting residue was purified by flash column 
chromatography (20:1  9:1 DCM-MeOH) to obtain the starting material and compound 
127 as an amorphous white solid. Yield: 56 mg (23 %) along with unreacted starting 
material (126 mg, 48%). 
Rf = 0.50 (9:1 DCM-MeOH). [α]D = +149.1 (c = 1.0 in DCM). 
1H NMR (500 MHz, MeOD, 333 K, Figure S77): δ =5.27 (d, 1H, J1,2 = 3.7 Hz, H-1II), 5.22-
5.18 (m, 6 H, H-1I,III-VII), 3.95-3.84 (m, 11 H, H-5II-VII, H-6aII-VI), 3.81-3.78 (dd, 1 H, H-6aVII), 
3.77-3.74 (ddd, 1 H, H-5I), 3.70-3.50 (m, 20 H, H-4I-VII, H-3I-VII, H-6bII-VII), 3.66 (m, 21 H, 
OCH3 I-VII), 3.55 (m, 21 H, OCH3 I-VII), 3.26-3.21 (m, 7 H, H-2I-VII), 3.19-3.16 (dd, 1 H, H-
6aI), 3.07-3.02 (dd, 1 H, H-6bI). 
1D-TOCSY (500 MHz, MeOD, H-6aI irradiation): δ =5.21 (d, 1 H, J1,2 = 2.8 Hz, H-1I), 3.75 
(ddd, 1 H, J4,5 = 8.4 Hz, J5,6a = 2.9 Hz, J5,6b = 5.6 Hz, H-5I), 3.58-3.52 (m, 2 H, H-3I, H-4I), 
3.22 (dd, 1 H, J2,3 = 8.6 Hz, H-2I), 3.16 (dd, 1 H, H-6a), 3.04 (dd, 1 H, H-6b, J6a,6b = 14.0 
Hz). 
1D-TOCSY (500 MHz, MeOD, H-2II irradiation): δ =5.25 (d, 1 H, J1,2 = 3.9 Hz, H-1II), 3.92 
(ddd, 1 H, H-5 II), 3.85 (d, 1 H, H-6aII), 3.69 (dd, 1 H, J6a,6b = 14.0 Hz, J5,6b = 4.0 Hz, H-6b 
II), 3.6 (t, 1 H, H-4 II), 3.52 (t, 1 H, J2,3 = J3,4 = 9.1 Hz, H-3 II), 3.23 (dd, 1 H, J2,3 = 9.9 Hz, 
H-2 II). 
13C NMR (125.7 MHz, MeOD, 333 K, Figure S77): δ = 100.6-100.4 (C-1I-VII), 84.0-82.1 (C-
2I-VII,C-3I-VII, C-4I-VII), 73.8-73.2 (C-5I-VII), 62.8-62.4 (OCH3), 60.2-59.9 (OCH3), 54.1-53.9 
(C-6II-VII), 43.9 (C-6I). 
ESI-MS (Figure S151): m/z 1480.7 [M + H]+, 1502.6 [M + Na]+. 
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Elemental analysis calculated (%) for C56H93N19O28: C 45.43, H 6.33, N 17.98; found: C 
45.08, H 6.27, N 17.61. 
RP-HPLC: tR = 9.2 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
 
 
 
6II-VII-Hexaazido-6I-VII-heptadeoxy-6I-isothiocyanato-2I-VII,3I-VII-tetradeca-O-methyl-
cyclomaltoheptaose (128). Monoisothiocyanate 128 was obtained from heptakis(6-
azido-6-deoxy-2,3-di-O-methyl)cyclomaltoheptaose 110180a (153 mg, 0.1 mmol, 2 eq) and 
resin 123 (0.15 g, 0.34 mmol·g-1) using the catch-and-release protocol as described in 
procedure B (General Methods for Solid-Phase Synthesis) in 86% yield (67 mg). 
HPLC: tR= 13.7 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
ESI-MS (Figure S152): m/z 1544.6 [M + Na]+. 
Alternatively, compound 128 was prepared in solution as follows: To a solution of 
compound 127 (50 mg, 34 µmol) in DCM-H2O (1:1, 6 mL), thiophosgene (5 µL, 68 µmol, 
2 eq) and CaCO3 (14 mg, 0.14 mmol, 4 eq) were added and the suspension was 
vigorously stirred at rt for 5 h. The organic layer was diluted with DCM(10 mL) and 
decanted, then dried over Na2SO4, filtered and concentrated. The residue was purified by 
flash column chromatography (3:1 EtOAc-petroleum ether) to give compound 128. Yield: 
29 mg (58 %). 
Rf = 0.55 (4:1 EtOAc-petroleum ether). [α]D = +163.2 (c = 0.9 in DCM). 
1H NMR (500 MHz, CDCl3, Figure S78): δ =5.11-5.08 (m, 7 H, H-1I-VII), 3.97 (dd, 1 H, J6a,5 
= 2.4 Hz, J6a,6b = 14.8 Hz, H-6aI), 3.91 (dd, 1 H, J6a,5 = 5.1 Hz, H-6bI), 3.84-3.65 (m, 7 H, 
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H-5I-VII), 3.84-3.45 (m, 12 H, H-6a,bII-VI), 3.63 (m, 21 H, OCH3 I-VII), 3.55-3.45 (m, 14 H, H-
3I-VII, H-4I-VII), 3.52 (m, 21 H, OCH3I-VII), 3.21-3.15 (m, 7 H, H-2I-VII). 
1D-TOCSY (500 MHz, CDCl3, H-6aI irradiation): δ = 5.10 (s, 1 H, H-1I), 4.04-3.90 (m, 14 
H, H-6aI, H-6bI), 3.60-3.40 (m, 2 H, H-3I, H-4I), 3.22 (m, 1 H, H-2I). 
13C NMR (125.7 MHz, CDCl3, Figure S78): δ = 99.0 (C-1I-VII), 81.9-81.3 (C-2I-VII,C-3I-VII, C-
4I-VII), 71.3 (C-5I-VII), 61.9 (OCH3 I-VII), 59.3 (OCH3 I-VII), 52.2 (C-6I-VII). 
ESI-MS (Figure S153): m/z 1544.7 [M + Na]+. 
Elemental analysis calculated (%) forC57H91N19O28S: C 44.97, H 6.02, N 17.48, S 1.45; 
found: C 44.71, H 5.90, N 17.31, S 1.86. 
RP-HPLC: tR = 13.7min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
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6I-[N’-(3-methoxypropyl)ureido]-6II-VII-hexaazido-6I-VII-heptadeoxy-2I-VII,3I-VII-tetradeca-
O-methylcyclomaltoheptaose (131). Monourea 131 was obtained from heptakis(6-
azido-6-deoxy-2,3-di-O-methyl)cyclomaltoheptaose 110180a (52 mg, 35 µmol, 2 eq) and 
resin 129 (0.5 g, 35 µmol·g-1) using the catch-and-release protocol as described in 
procedure C (General Methods for Solid-Phase Synthesis) in 76% yield (21 mg). 
1H NMR (500 MHz, MeOD, 323 K, Figure S79): δ = 5.29-5.15 (m, 7 H, H-1I-VII), 4.03 (m, 2 
H, CH2O), 3.93-3.80 (m, 14 H, H-5I-VII, H-6aI-VII), 3.67-3.63, 3.56-3.51 (2 m, 45 H, OCH3), 
3.62-3.56 (m, 7 H, H-6bI-VII), 3.61-3.47 (m, 14 H, H-3I-VII, H-4I-VII), 3.24-3.21 (m, 7 H, H-2I-
VII). 
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13C NMR (125.7 MHz, MeOD, Figure S79): δ = 158.0 (CO), 98.2-97.9 (C-1I-VII), 81.8-79.7 
(C-2I-VII, C-3I-VII, C-4I-VII, CH2O), 71.0 (C-5I-VII), 60.6 (OCH3 I-VII), 57.8 (OCH3 I-VII), 51.7 (C-6II-
VII), 42.0 (C-6I, CH2N), 29.7 (CH2CH2CH2). 
ESI-MS (Figure S154): m/z 1617.6 [M + Na]+. 
HPLC: tR = 12.9 min (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
 
 
 
6-II-VII-Hexakis[(N-tert-butoxycarbonylaminomethyl-1H-1,2,3-triazol-1-yl]-6I-VII-
heptadeoxy-6I-isothiocyanato-2I-VII,3I-VII-tetradeca-O-methylcyclomaltoheptaose 
(132). Monoisothiocyanate 132 was obtained from heptakis(6-azido-6-deoxy-2,3-di-O-
methyl)cyclomaltoheptaose 110180a (52 mg, 35 µmol, 2 eq) and resin 129 (0.5 g, 35 
µmol·g-1) using the catch-and-release protocol as described in General Methods for Solid-
Phase Synthesis in 59% yield (25 mg). 
Rf = 0.39 (20:1 DCM-MeOH). [α]D = +121.0 (c = 0.5 in MeOH). 
1H NMR (500 MHz, MeOD, 323 K, Figure S80): δ = 7.89-7.73 (m, 6 H, triazole), 5.48-5.39 
(m, 6 H, H-1II-VII), 5.17 (m, 1 H, H-1I), 4.33 (m, 2 H, H-6aI, H-6bI), 4.24 (m, 7 H, H-5I-VII), 
3.67-3.49 (m, 80 H, H-3I-VII, H-4I-VII, H-6aII-VII, H6bII-VII, CH2NHBoc, OCH3I-VII), 3.11 (m, 6 H, 
H-2I-VII), 1.45, 1.43 (2 s, 9 H each, C(CH3)3), 1.42 (bs, 18 H, C(CH3)3), 1.40, 1.38 (2 s, 9 H 
each, C(CH3)3). 
ESI-MS (Figure S155): m/z 1249.5 [M + 2 Na]2+, 2475.7 [M + Na]+, 2487.8 [M + Cl]-. 
RP-HPLC: tR = 12.8 (according to the RP-HPLC analytical procedure described in the 
General Methods section). 
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